0001144204-14-046802.txt : 20140804 0001144204-14-046802.hdr.sgml : 20140804 20140804165208 ACCESSION NUMBER: 0001144204-14-046802 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140804 DATE AS OF CHANGE: 20140804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-119366 FILM NUMBER: 141013592 BUSINESS ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 BUSINESS PHONE: 617-244-1616 MAIL ADDRESS: STREET 1: 3301 AGRICULTURE DRIVE CITY: MADISON STATE: WI ZIP: 53716 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 10-Q 1 v385092_10q.htm FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[mark one]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number 333-119366

CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE

04-3321804

(State or other jurisdiction of incorporation or organization)

(IRS Employer

Identification No.)

3301 Agriculture Drive

Madison, Wisconsin 53716

(Address of principal executive offices)

(608) 441-8120

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

(Check one):

Large accelerated filer	¨	Accelerated filer	¨

Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares outstanding of the issuer’s common stock as of the latest practicable date: 2,869,739 shares of common stock, $0.00001 par value per share, as of August 1, 2014.

CELLECTAR BIOSCIENCES, INC.

FORM 10-Q INDEX

PART I. FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 4.	Controls and Procedures	19

PART II. OTHER INFORMATION		20

Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 5.	Other Information	21
Item 6.	Exhibits	22

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	June 30, 2014			December 31, 2013
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	1,626,025		$	2,418,384
Restricted cash		55,000			55,000
Prepaid expenses and other current assets		334,979			294,687
Total current assets		2,016,004			2,768,071
FIXED ASSETS, NET		2,185,087			2,360,534
GOODWILL		1,675,462			1,675,462
OTHER ASSETS		12,009			11,872
TOTAL ASSETS	$	5,888,562		$	6,815,939

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Current maturities of notes payable	$	41,330		$	—
Accounts payable and accrued liabilities		1,195,418			1,162,098
Derivative liability		2,840,557			3,359,363
Capital lease obligations		431			1,694
Total current liabilities		4,077,736			4,523,155
LONG-TERM LIABILITIES:
Convertible debt		3,796,781			—
Notes payable, less current maturities		408,670			450,000
Deferred rent		145,993			143,234
Total long-term liabilities		4,351,444			593,234
TOTAL LIABILITIES		8,429,180			5,116,389
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of June 30, 2014 and December 31, 2013		—			—
Common stock, $0.00001 par value; 20,000,000 shares authorized; 2,869,739 shares issued and outstanding at June 30, 2014 and December 31, 2013		29			29
Additional paid-in capital		53,548,170			52,759,089
Deficit accumulated		(56,088,817	)		(51,059,568	)
Total stockholders’ equity (deficit)		(2,540,618	)		1,699,550
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	5,888,562		$	6,815,939

The accompanying notes are an integral part of these financial statements.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2013			2014			2013

COSTS AND EXPENSES:
Research and development	$	1,380,798		$	1,648,838		$	3,096,105		$	3,239,450
General and administrative		959,885			1,073,749			2,046,921			2,195,452
Restructuring costs		204,934			—			221,815			—
Total costs and expenses		2,545,617			2,722,587			5,364,841			5,434,902

LOSS FROM OPERATIONS		(2,545,617	)		(2,722,587	)		(5,364,841	)		(5,434,902	)

OTHER INCOME (EXPENSE):
Gain on revaluation of derivative warrants		573,751			660,341			518,806			666,384
Loss on issuance of derivative warrants		—			—			—			(744,957	)
Interest expense, net		(113,970	)		(2,216	)		(183,214	)		(4,866	)
Total other income (expense), net		459,781			658,125			335,592			(83,439	)
NET LOSS	$	(2,085,836	)	$	(2,064,462	)	$	(5,029,249	)	$	(5,518,341	)
BASIC AND DILUTED NET LOSS PER COMMON SHARE	$	(.73	)	$	(.72	)	$	(1.75	)	$	(2.03	)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE		2,869,739			2,869,739			2,869,739			2,717,966

The accompanying notes are an integral part of these financial statements.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended June 30,
	2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(5,029,249	)	$	(5,518,341	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		188,369			219,968
Stock-based compensation expense		536,216			803,791
Non-cash interest expense related to discount on convertible debt		50,805			—
Loss on disposal of fixed assets		2,268			4,513
Gain on revaluation of derivative warrants		(518,806	)		(666,384	)
Loss on issuance of derivative warrants		—			744,957
Changes in:
Accounts payable and accrued liabilities		33,320			304,484
Prepaid expenses and other current assets		132,115			180,024
Other assets and liabilities		2,622			4,391
Cash used in operating activities		(4,602,340	)		(3,922,597	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of fixed assets		(15,191	)		(92,977	)
Change in restricted cash		—			121,768
Cash (used in) provided by investing activities		(15,191	)		28,791
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes		4,000,000			—
Payments on capital lease obligations		(1,263	)		(1,178	)
Reverse stock split fractional shares		(1,158	)		—
Proceeds from issuance of common stock, net of issuance costs		—			4,975,153
Change in deferred issuance costs		(172,407	)		70,539
Cash provided by financing activities		3,825,172			5,044,514
(DECREASE) INCREASE IN CASH AND EQUIVALENTS		(792,359	)		1,150,708
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD		2,418,384			4,677,545
CASH AND EQUIVALENTS AT END OF PERIOD	$	1,626,025		$	5,828,253
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Fair value of warrants classified as derivative liability	$	—		$	5,720,000
Relative fair value of warrants issued with convertible debt	$	254,024		$	—

The accompanying notes are an integral part of these financial statements.

CELLECTAR BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

Cellectar Biosciences, Inc. (the “Company”) is a biopharmaceutical company developing compounds for the treatment and imaging of cancer. Prior to February 11, 2014, the name of the Company was Novelos Therapeutics, Inc. (“Novelos”). On April 8, 2011, Novelos entered into a business combination (the “Acquisition”) with Cellectar, Inc., a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers.

References in these financial statements and notes to “Cellectar, Inc.” relate to the activities and financial information of Cellectar, Inc. prior to the Acquisition, references to “Novelos” relate to the activities and financial information of Novelos prior to the Acquisition and references to “the Company” or “we” or “us” or “our” relate to the activities and obligations of the combined Company following the Acquisition.

The Company’s headquarters are located in Madison, Wisconsin.

The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.

The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its efforts toward research and development and has, during the six months ended June 30, 2014, generated a net loss of approximately $5,029,000. The Company expects that it will continue to generate operating losses for the foreseeable future. See footnote 12 below for further information regarding the Company’s cash resources. The Company’s ability to execute its operating plan depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The accompanying condensed consolidated balance sheet as of December 31, 2013 has been derived from audited financial statements. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2014, the condensed consolidated statements of operations for the three months and six months ended June 30, 2014 and 2013, the condensed consolidated statements of cash flows for the six months ended June 30, 2014 and 2013 and the related interim information contained within the notes to the condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions, rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments which are of a nature necessary for the fair presentation of the Company’s consolidated financial position at June 30, 2014 and consolidated results of its operations for the three months and six months ended June 30, 2014, and its cash flows for the six months ended June 30, 2014 and 2013. The results for the six months ended June 30, 2014 are not necessarily indicative of future results.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 19, 2014.

Principles of Consolidation — The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

Restricted Cash — The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2014 and December 31, 2013 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.

Goodwill — At June 30, 2014 and December 31, 2013, the balance of goodwill resulted from the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore no changes in goodwill were made during the six months ended June 30, 2014.

Impairment of Long-Lived Assets — Long-lived assets other than goodwill consist of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore, no such impairment occurred during the six months ended June 30, 2014.

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable, convertible debt and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The fair value of convertible debt is equal to the fair value of the underlying common stock, which was approximately $2,556,000 at June 30, 2014. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivative Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 551,365 and 826,365 at June 30, 2014 and December 31, 2013, respectively. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2014 and December 31, 2013, these warrants represented the only outstanding derivative instruments issued or held by the Company.

Development Stage Entity — In previous filings, the Company has reported as a “Development Stage Entity”. However, in June 2014, the Financial Accounting Standards Board (FASB) published an Accounting Standards Update 2014-10 (ASU 2014-10) that removed the development stage entity guidance under Accounting Standards Codification Topic 915 (ASC 915) Development Stage Entities, thereby removing the financial reporting distinction between development stage entities and other reporting entities.

In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.

Presentation and disclosure requirements under ASC 915 are no longer required for the first annual period beginning after December 15, 2014, including interim periods therein. Earlier adoption of the new guidance for ASC 915 is permitted for any annual or interim period for which financial statements have not yet been issued for public business entities. Accordingly, the Company has elected to adopt these changes effective with the filing of this Form 10-Q.

2. FAIR VALUE

In accordance with the Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

	·	Level 1: Input prices quoted in an active market for identical financial assets or liabilities.
	·	Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
	·	Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company had issued warrants to purchase 1,365 shares of common stock prior to the Acquisition (“Legacy Warrants”) that are classified within the Level 2 hierarchy. Additionally, the Company issued warrants to purchase an aggregate of 825,000 common shares in a February 2013 public offering (“February 2013 Public Offering Warrants”). On February 20, 2014, warrants to purchase 275,000 shares of common stock issued in the February 2013 offering expired. The remaining 550,000 warrants are classified within the Level 3 hierarchy.

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2014 and December 31, 2013:

	June 30, 2014
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Legacy Warrants	$	—	$	2,557	$	—	$	2,557
February 2013 Public Offering Warrants		—		—		2,838,000		2,838,000
Total	$	—	$	2,557	$	2,838,000	$	2,840,557

	December 31, 2013
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Legacy Warrants	$	—	$	4,363	$	—	$	4,363
February 2013 Public Offering Warrants		—		—		3,355,000		3,355,000
Total	$	—	$	4,363	$	3,355,000	$	3,359,363

In order to estimate the fair value of the Legacy Warrants considered to be derivative instruments, the Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 6).

In order to estimate the value of the February 2013 Public Offering Warrants considered to be derivative instruments as of June 30, 2014, the Company uses a modified option-pricing model together with assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate of 1.76% (compared with risk-free interest rate of 0.92% as of December 31, 2013), volatility of 108% (compared with 109% as of December 31, 2013), contractual term of 6 years (also 6 years as of December 31, 2013), future financing requirements and dividend rates.

The assumptions used to estimate the value of the February 2013 Public Offering Warrants as of December 31, 2013 include the fair value of the underlying stock, risk free interest rates ranging from 0.07% to 1.27%, volatility ranging from 75% to 115%, the contractual term of the warrants ranging from 0.14 to 4.14 years, future financing requirements and dividend rates. The future financing estimates are based on the Company’s estimates of anticipated cash requirements over the term of the warrants as well as the frequency of required financings based on its assessment of its historical financing trends and anticipated future events. Due to the nature of these inputs and the valuation technique utilized, these warrants are classified within the Level 3 hierarchy.

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

	June 30, 2014			December 31, 2013
Beginning balance – Fair value	$	3,355,000		$	—
Fair value of warrants issued in connection with February 2013 public offering		—			5,720,000
Gain on derivatives resulting from change in fair value		(517,000	)		(2,365,000	)
Ending balance – Fair value	$	2,838,000		$	3,355,000

3. CONVERTIBLE DEBT

On February 5, 2014, the Company entered into a securities purchase agreement with certain accredited investors to sell $4,000,000 in principal amount of convertible debentures and warrants to purchase 400,000 shares of its common stock for an aggregate purchase price of $4,000,000. On February 6, 2014, the Company completed the sale of the debentures and warrants (the “February 2014 Private Placement”).

Debentures

The debentures mature on February 6, 2016 and are convertible at any time at a conversion price of $10.00 per share into an aggregate of 400,000 shares of common stock. The debentures accrue interest at an annual rate of 8%, payable upon redemption or conversion, in cash or shares of the Company’s common stock. During the six months ended June 30, 2014, the Company accrued $128,000 in interest expense, which is included in accrued liabilities as of June 30, 2014. The debenture conversion price and the common stock issuable pursuant to the debentures are subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the debenture holders after such event will be equivalent to the rights of debenture holders prior to such event.

The Company may elect to redeem the debentures prior to the maturity date upon 30-day notice to the holder. In the event of any sale of securities by the Company resulting in aggregate gross proceeds of at least $2,000,000 (a “Subsequent Financing”), the holder shall have the right to require the Company to redeem some or all of the then outstanding principal amount of the debenture, plus all accrued but unpaid interest and other amounts due in respect of the debenture, in an amount equal to the amount of the holder’s investment in the Subsequent Financing, by delivering notice to the Company on or before the consummation date of the Subsequent Financing. If, within 21 months after the issuance of the debentures, the Company raises gross proceeds of at least $8,000,000, in the aggregate, in one or more subsequent financings (the “Minimum Proceeds”), the Company may, by notice given within three trading days after the receipt of the Minimum Proceeds, compel holders to convert all or part of the then outstanding principal amount of the debentures and accrued but unpaid interest and other amounts.

Other than as specifically permitted under in the debentures, as long as any of the debentures remain outstanding, the Company may not, without the consent of holders of a majority in principal amount of the then outstanding debentures: incur any indebtedness for borrowed money; grant any liens on its property or assets; repurchase shares of its common stock or common stock equivalents; repurchase or otherwise acquire any indebtedness; pay cash dividends or distributions on any equity securities; enter into any transaction with any affiliate of the Company which would be required to be disclosed in any public filing with the SEC, unless such transaction is made on an arm’s-length basis and expressly approved by a majority of the disinterested directors of the Company; or enter into any agreement with respect to any of the foregoing. See footnote 12 for discussion of the security interest extended to these debentures as consideration for the consent of the holders to the issuance of the promissory notes in July 2014.

If any event of default occurs, the outstanding principal amount of the debentures, plus accrued but unpaid interest and other amounts owing in respect thereof through the date of acceleration, shall become, at the holder’s election, immediately due and payable in cash. If such amounts are not paid within 5 days after the occurrence of any event of default, interest shall begin to accrue at the lesser of 12% per annum or the maximum rate permitted under applicable law. Events of default consist of: any default in the payment of amounts due and payable that is not cured within three trading days; failure of the Company to observe or perform any other covenant or agreement contained in the Debentures that is not cured within the earlier to occur of five trading days after notice of such failure sent by any holder of debentures or ten trading days after the Company has become aware of such failure; the occurrence of any uncured material default or event of default under the other transaction documents or any other material agreement, lease, document or instrument under which the Company or any of its subsidiaries is obligated; any representations or warranties made in the debentures or other transaction documents being materially false when made; an institution of any voluntary or involuntary bankruptcy or other insolvency proceeding or similar or related events; default on any borrowings in excess of $150,000; the Company’s common stock being ineligible for quotation on a trading market for greater than five trading days; the Company entering into any change in control transaction; the Company’s failure to deliver shares of common stock as required upon conversion of the debentures; or the Company being the subject of a monetary judgment greater than $100,000.

Common Stock Purchase Warrants

The warrants have an exercise price of $20.00 and, if unexercised, expire on February 6, 2019. The warrants are exercisable only following the full or partial conversion of the associated debentures, and in the event of a partial conversion the warrant shall become exercisable only for a proportionate number of the total shares subject to the warrant. In the event any debentures cease to be outstanding prior to the associated warrants becoming exercisable, whether by reason of repayment, prepayment, redemption or otherwise, the associated warrants will automatically terminate.

The warrant exercise price and the number of shares of common stock issuable pursuant to the warrants are subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.

The Company determined that the warrants associated with the convertible debentures meet the requirements for classification as equity. Therefore, the relative fair value of the warrants at the date of issuance of $254,000 has been included as a component of stockholders’ equity. In order to estimate the value of the these warrants the Company used a probability weighted valuation model together with assumptions that considered, among other variables, the fair value of the underlying stock, a risk-free interest rate of 1.52%, a volatility of 110%, a 0% dividend rate, a contractual term of 5 years, and an estimate of the probability that the warrants will become exercisable upon conversion of the associated debt.

Following the allocation of the relative fair value of the warrants to equity, the remaining value of approximately $3,746,000, at the date of issuance, was allocated to the convertible debentures. The resulting discount on the debentures of $254,000 will be accreted to interest expense over the shorter of the time to maturity or conversion. During the six months ended June 30, 2014, the Company recorded approximately $51,000 of non-cash expense related to accretion of the discount on the debentures.

4. REVERSE STOCK SPLIT AND RECAPITALIZATION

At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt. The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected and the corresponding reduction in authorized shares of common stock by filing an appropriate amendment to the Company’s certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on June 6, 2014 and effective at the close of business on June 13, 2014, the second amended and restated certificate of incorporation was amended to effect a 1-for-20 reverse split of the Company’s common stock (the “Listing Reverse Split”) and reduce the number of authorized shares of common stock to 20,000,000 from 150,000,000. All share and per share numbers included in this Form 10-Q give effect to the Listing Reverse Split.

5. STOCKHOLDERS’ EQUITY

Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of June 30, 2014.

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date

February 2014 Private Placement (1)		400,000	$	20.00	February 6, 2019
February 2013 Public Offering (2)		550,000		10.00	February 20, 2018
February 2013 Public Offering – Placement Agents		38,496		12.50	February 4, 2018
November 2012 Private Placement		50,000		25.00	November 2, 2017
June 2012 Public Offering		149,069		25.00	June 13, 2017
December 2011 Underwritten Offering		462,411		12.00	December 6, 2016
April 2011 Private Placement		302,922		15.00	March 31, 2016
Legacy warrants (2)		1,365		10.00	July 27, 2015
Legacy warrants		5,252		321.30	July 27, 2015
Legacy warrants		4,570		1,989.00 - 2,019.60	December 31, 2015
Total		1,964,085

(1)

Warrants issued in connection with the sale of convertible debentures. As described in Note 3, the warrants are only exercisable following conversion of the associated debentures.

(2)

The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as a derivative instrument as described in Note 2.

6. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:

	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013

Employee and director stock option grants:
Research and development	$	47,274	$	106,774	$	110,701	$	212,612
General and administrative		176,581		264,243		360,965		576,282
Restructuring costs		47,853		—		47,853		—
		271,708		371,017		519,519		788,894

Non-employee consultant stock option grants:
Research and development		1,982		3,311		16,697		4,322
General and administrative		—		3,565		—		10,575
		1,982		6,876		16,697		14,897

Total stock-based compensation	$	273,690	$	377,893	$	536,216	$	803,791

In October 2013, the Company granted options to purchase 264,278 shares of common stock in connection with the appointment of its then Acting Chief Executive Officer, including options to purchase 96,278 shares of common stock at $15.00 per share (the “Anti-dilution Option”), exercisable as shares of the Company’s common stock are issued following the exercise of outstanding warrants to purchase up to 96,278 shares of the Company’s common stock, in the ratio of one option share for each 19 shares issued upon warrant exercise. No compensation expense was recognized related to these options as the Company was not able to conclude that the achievement of the performance condition was probable. On February 20, 2014, warrants to purchase 275,000 shares of common stock at an exercise price of $10.00 per share expired unexercised and as a result, the number of shares subject to the Anti-dilution Option was reduced by 14,474 shares, according to its terms.

Assumptions Used In Determining Fair Value

Valuation and amortization method. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).

Volatility. The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Expected term. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.

Forfeitures. The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of 2% and 0% was applied to all unvested options for employees and directors, respectively for the six months ended June 30, 2014 and for the year ended December 31, 2013. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.

The following table summarizes weighted-average values and assumptions used for options granted to employees, directors and consultants in the periods indicated:

	Six Months Ended June 30, 2014			Six Months Ended June 30, 2013
Volatility		108	%		109	%
Risk-free interest rate		1.76	%		0.92	%
Expected life (years)		6.0			6.0
Dividend		0	%		0	%
Weighted-average exercise price	$	7.40		$	14.80
Weighted-average grant-date fair value	$	6.20		$	12.20

Exercise prices for all grants made during the six months ended June 30, 2014 and 2013 were equal to the market value of the Company’s common stock on the date of grant.

Stock Option Activity

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options			Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2013		634,658		$	18.20
Granted		20,000		$	7.40
Canceled		(20,521	)	$	23.17
Forfeited		(14,474	)	$	15.00
Outstanding at June 30, 2014		619,663		$	17.80

Vested, June 30, 2014		264,752		$	29.00		4.04	$	—
Unvested, June 30, 2014		354,911		$	9.20		9.26	$	—
Exercisable at June 30, 2014		264,752		$	29.00		4.04	$	—

The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.

As of June 30, 2014, there was approximately $1,869,000 of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize approximately $1,096,000, $570,000, and $203,000 during 2014, 2015, and 2016, respectively. The Company expects 273,106 unvested options to vest in the future. In addition, there are outstanding options to purchase 81,805 shares of common stock that vest upon the occurrence of future events. The Company was not able to conclude that the achievement of the performance condition is probable; therefore, the Company has not recognized any expense associated with the $418,000 fair value of these awards. Recognition of expense will begin when and if the Company determines that achievement of the performance condition is probable. The weighted-average grant-date fair value of vested and unvested options outstanding at June 30, 2014 was $16.66 and $5.98, respectively.

7. INCOME TAXES

The Company accounts for income taxes in accordance with the liability method of accounting. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, (NOLs) using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the six months ended June 30, 2014 or 2013 because the Company has experienced losses on a tax basis since inception. Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax asset.

The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions. No uncertain tax positions have been identified.

8. NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options and warrants and convertible debt. Since there is a net loss attributable to common stockholders for the six months ended June 30, 2014 and 2013, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

	Six Months Ended June 30,
	2014		2013
Warrants		1,964,085		1,839,123
Stock options		619,663		314,582
Convertible debt		400,000		—

9. COMMITMENTS AND CONTINGENCIES

Litigation

The Company is party to the following legal matter.

BAM Dispute

From its inception through 2010, Novelos was primarily engaged in the development of certain oxidized glutathione-based compounds for application as therapies for disease, particularly cancer. These compounds were originally developed in Russia and in June 2000, Novelos acquired commercial rights from the Russian company (“ZAO BAM”) which owned the compounds and related Russian patents. In April 2005, Novelos acquired worldwide rights to the compounds (except for the Russian Federation) in connection with undertaking extensive development activities in an attempt to secure US Food and Drug Administration (“FDA”) approval of the compounds as therapies. These development activities culminated in early 2010 in an unsuccessful Phase 3 clinical trial of an oxidized glutathione compound (NOV-002) as a therapy for non-small cell lung cancer. After the disclosure of the negative outcome of the Phase 3 clinical trial in 2010, ZAO BAM claimed that Novelos modified the chemical composition of NOV-002 without prior notice to or approval from ZAO BAM, constituting a material breach of the June 2000 technology and assignment agreement. In September 2010, Novelos filed a complaint in Massachusetts Superior Court seeking a declaratory judgment by the court that the June 2000 agreement has been entirely superseded by the April 2005 agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied. ZAO BAM answered the complaint and alleged counterclaims. In August 2011, Novelos filed a motion for judgment on the pleadings as to the declaratory judgment count and all counts of ZAO BAM’s amended counterclaims. On October 17, 2011, the court ruled in favor of Novelos on each of the declaratory judgment claims and dismissed all counts of ZAO BAM’s counterclaim. Judgment in our favor was entered on October 20, 2011. On November 14, 2011 ZAO BAM filed a notice of appeal. On November 1, 2013, ZAO BAM’s appeal was docketed with the Massachusetts Appeals Court. BAM’s appellate brief and the Company’s opposition have been filed with the Appeals Court but oral arguments have not yet been scheduled. On April 14, 2014, BAM filed a motion to modify the record on appeal. The Company has opposed the motion.

We do not anticipate that this litigation matter will have a material adverse effect on the Company’s future financial position, results of operations or cash flows.

10. RESTRUCTURING COSTS

During 2013 the Company had several changes to its board composition and executive management, including the relocation of the Company’s principal executive offices from Newton, Massachusetts to its corporate headquarters in Madison, Wisconsin. During the six months ended June 30, 2014, the Company incurred approximately $222,000 of costs associated with the closure of the executive offices in Newton, Massachusetts and accruals related to severance agreements. This amount has been classified as restructuring costs on the accompanying statement of operations.

In connection with the Acquisition, the responsibilities of the Company’s Vice President of Finance, Chief Financial Officer and Treasurer (CFO) and those of the Director of Financial Reporting were transitioned to the Company’s headquarters in Madison, Wisconsin. As a result, the Company’s relationship with both employees terminated in June 2014. These two employees received lump-sum severance payments totaling approximately $160,000, which is included in the approximately $222,000 restructuring costs presented in the accompanying Condensed Consolidated Statement of Operations. Benefits will continue for these employees for six and four months, respectively, following termination.

In addition, all unvested options held by the former CFO were credited with an additional six months vesting and the vested options held by this employee shall be exercisable for eighteen months following termination. All unvested options held by the former Director of Financial Reporting shall be exercisable for twelve months following termination.

The Company does not anticipate any further costs related to the relocation and restructuring.

11. RELATED PARTY TRANSACTIONS

Jamey Weichert, the Company’s Chief Scientific Officer and principal founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”). During the six months ended June 30, 2014, the Company was invoiced $334,000 by UW, of which $264,000 has been paid, for costs associated with clinical trial agreements. During the six months ended June 30, 2013, the Company made contributions to UW totaling $62,500 for use towards unrestricted research activities.

12. SUBSEQUENT EVENT

The Company and a group of lenders entered into a Note Purchase and Security Agreement dated as of July 29, 2014 providing for borrowing by the Company of up to an aggregate of $1,000,000 upon the issuance of the Company’s secured promissory notes (the “Notes”) bearing interest of 8% per annum and having a stated maturity of 60 days from issuance or the earlier closing of an equity financing with gross proceeds to the Company of $1,000,000. The Notes are secured by a lien on substantially all assets of the Company, now existing or subsequently acquired. The Company borrowed an aggregate of $617,500 at an initial closing on July 29, 2014. Any borrowing of the remaining $382,500 balance of the $1,000,000 is at the option of the lenders. In connection with the entry into the Note Purchase and Security Agreement, the Company obtained the consent of the holders of its outstanding convertible debentures in exchange for the extension of the security interest on all such assets of the Company to the convertible debentures, pari passu with the Notes.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report on Form 10-Q includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those disclosed in the forward-looking statements we make. These important factors include our significant accounting estimates, such as those for amounts due to clinical research organizations, and clinical investigators and the risk factors set forth in our annual report on Form 10-K and below under the caption “Risk Factors”. Although we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the date of this quarterly report.

Overview

Cellectar Biosciences, Inc. (the Company) is a biopharmaceutical company developing compounds for the treatment and imaging of cancer. Prior to February 11, 2014, the name of the Company was Novelos Therapeutics, Inc. (Novelos). On April 8, 2011, Novelos entered into a business combination (the Acquisition) with Cellectar, Inc., a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers.

Our cancer-targeting technology permits selective delivery of a wide range of agents to cancer cells, including cancer stem cells. By attaching different agents to our proprietary PLE cancer-targeting delivery platform, we believe we can engineer product candidates with the potential to both image and treat a wide range of solid tumors. This offers the potential for a paradigm shift in the detection and treatment of cancer by using the same delivery platform for both detecting malignancy and providing efficacy versus all three major drivers of morbidity and mortality in cancer: primary tumors, metastases and stem cell-based relapse.

The Company is currently developing three proprietary product candidates:

I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeting PET imaging agent that we believe has the potential to be the first of its kind for the selective detection of tumors and metastases in a broad range of cancers. Investigator-sponsored Phase 1/2 clinical trials of I-124-CLR1404 are ongoing across solid tumor indications. In March 2014, we commenced enrollment in a Phase 2 clinical trial studying I-124-CLR1404 in the imaging of glioblastoma, a type of glioma. We expect to complete this trial during the first half of 2015, subject to additional funding. In April 2014, the FDA granted I-124-CLR1404 orphan status as a diagnostic for the management of glioma.

I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeting molecular radiotherapeutic that delivers cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells. We believe I-131-CLR1404 also has the potential to be the first therapeutic agent to use phospholipid ether (PLE) analogs to target cancer cells. In November 2013, we completed enrollment in a Phase 1b dose-escalation trial evaluating I-131-CLR1404 in the treatment of patients with advanced solid tumors and the results of the trial were presented to the American Society of Clinical Oncology (ASCO) June 2014 Annual Meeting. Because of the highly radiosensitive nature, clear unmet medical need in the relapse/refractory setting and the potential to receive orphan drug designation, the Company is pursuing multiple myeloma as an initial target indication for future I-131-CLR1404 development and plans to submit an Investigational New Drug Application (IND) with the FDA in 2014.

CLR1502 is a preclinical, small-molecule, cancer-targeting, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. We anticipate filing an IND with the FDA for CLR1502 in 2014.

Together, we believe our compounds have the potential to improve upon current standard of care for the detection, treatment and monitoring of a wide variety of human cancers.

Results of Operations

Research and development expense. Research and development expense consists of costs incurred in identifying, developing and testing, and manufacturing product candidates, which primarily include salaries and related expenses for personnel, costs of our research and manufacturing facility, cost of manufacturing materials and contract manufacturing fees paid to contract research organizations, fees paid to medical institutions for clinical trials, and costs to secure intellectual property. The Company analyzes its research and development expenses based on four categories as follows: clinical projects, preclinical projects, chemistry and manufacturing costs, and general fixed and overhead costs that are not allocated to the functional project costs, including personnel costs, facility costs, related overhead costs and patent costs.

General and administrative expense. General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance and administrative functions. Other costs include insurance, costs for public company activities, investor relations, directors’ fees and professional fees for legal and accounting services.

Six Months Ended June 30, 2014 and 2013

Research and Development. Research and development expense for the six months ended June 30, 2014 was approximately $3,096,000 (comprised of $624,000 in clinical project costs, $177,000 of preclinical project costs, $368,000 of manufacturing and related costs and $1,927,000 in general unallocated research and development costs) compared to approximately $3,239,000 (comprised of $343,000 in clinical project costs, $217,000 of preclinical project costs, $464,000 of manufacturing and related costs and $2,215,000 in general unallocated research and development costs) for the six months ended June 30, 2013. The overall decrease in research and development expense of $143,000, or 4.4%, was due to four primary factors: (1) the restructuring, which reduced compensation-related expenses by approximately $237,000 (included in the $288,000 decrease in general unallocated research and development costs); (2) the $96,000 decrease in manufacturing and related costs in the six months ended June 30, 2014 versus 2013, which was related a decrease in manufacturing materials as a result of the completion of the Phase 1b trial for I-131-CLR1404; (3) the $40,000 decrease in preclinical projects expense, which is primarily attributable to lower spending on studies related to CLR1502; and (4) reduced equipment costs. These lower costs were partially offset by a $281,000 increase in clinical project expense, due primarily to incremental expenses related to the Phase 2 clinical trial studying I-124-CLR1404 in the imaging of glioblastoma.

General and Administrative. General and administrative expense for the six months ended June 30, 2014 was approximately $2,047,000 compared to approximately $2,195,000 in the six months ended June 30, 2013. The approximately $148,000, or 6.7%, decrease is related to lower compensation costs as a result of the restructuring and a decrease in directors fees associated with a reduction in the number of independent directors. The decreases were partially offset by an increase in legal fees.

Restructuring Costs. During the six months ended June, 2014, the Company recorded approximately $222,000 of restructuring expenses related to the closure of the Newton, Massachusetts executive offices. The Company did not incur any restructuring costs in the six months ended June 30, 2013.

Gain on Derivative Warrants. We recorded a gain on derivative warrants of approximately $519,000 in the six months ended June 30, 2014 and a gain on derivative warrants of approximately $666,000 in the six months ended June 30, 2013. These amounts represent the change in fair value, during the respective period, of outstanding warrants which contain “down-round” anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants.

Loss on Issuance of Derivative Warrants. Loss on derivative warrants of approximately $745,000 was recorded in the six months ended June 30, 2013 and represents the amount by which the initial fair value of warrants issued in connection with the February Offering exceeded the net proceeds received from the offering. These warrants are classified as derivative liabilities because they include “down-round” anti-dilution protection. We had no such expense in the six months ended June 30, 2014.

Interest expense, net. Interest expense, net for the six months ended June 30, 2014 consists of approximately $128,000 of interest expense related to the accrual of interest at the stated rate on convertible debentures, approximately $51,000 of non-cash interest expense related to the accretion of the discount on convertible debentures and approximately $4,000 related to the Company’s outstanding debt with the Wisconsin department of Commerce. Interest expense for six months ended June 30, 2013 was driven solely by the notes payable to the Wisconsin Department of Commerce. The increase in interest expense is attributable to the issuance of the convertible debentures issued in the February 2014 Private Placement.

Liquidity and Capital Resources

We have financed our operations since inception primarily through the sale of equity and debt securities. As of June 30, 2014, we had approximately $1,626,000 in cash and cash equivalents. To date, including funds raised by Cellectar, Inc., we have raised capital aggregating approximately $130 million.

During the six months ended June 30, 2014, we reported a net loss of approximately $5,029,000, while using approximately $4,602,000 in cash in operations. This loss included the following non-cash items: an approximately $519,000 gain on the revaluation of derivative warrants, approximately $536,000 in stock-based compensation expense, approximately $188,000 in expense related to depreciation and amortization, and approximately $51,000 of non-cash interest expense related to the accretion of the discount on convertible debt. After adjustment for these non-cash items, other changes in working capital provided cash of $170,000.

During the six months ended June 30, 2014, we purchased approximately $15,000 in fixed assets.

In February 2014, we completed a private placement of convertible debentures and warrants for gross proceeds of $4,000,000. The debentures mature on February 6, 2016 and are convertible at any time at $10.00 per share into 400,000 shares of common stock. In the event of the sale of securities by the Company for minimum proceeds of at least $2,000,000 (“Subsequent Financing”), the holders of the debentures may elect to redeem some or all of the then outstanding principal amount of the debenture, along with accrued but unpaid interest, in an amount equal to the amount of the holder’s investment in the Subsequent Financing.

If, within 21 months of the issuance of the debentures, the Company raises gross proceeds of at least $8,000,000 in aggregate, the Company may require the holders of the debentures to convert all or part of the then outstanding principal amount and accrued but unpaid interest of the debentures. In the event that the holders of the debentures do not convert all of the debentures in a Subsequent Financing, the Company may be required to satisfy the remaining outstanding debt and accrued but unpaid interest with payments in cash.

The accompanying consolidated financial statements have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During the six months ended June 30, 2014, we generated a net loss of approximately $5,029,000 and we expect that we will continue to generate operating losses for the foreseeable future. At June 30, 2014, our consolidated cash balance was approximately $1,626,000. We believe this cash balance, plus the amount (approximately $615,000) raised upon issuance of the Notes in July 2014, is adequate to fund operations through August 2014. Our ability to execute our operating plan beyond that time depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. We have, in the past, successfully completed multiple rounds of financings, but, due to market conditions and other factors, including our development stage, the proceeds we have been able to secure have been less than the amounts we sought to obtain. We plan to actively pursue all available financing alternatives; however, we have not entered into negotiations for any such transactions and there can be no assurance that we will obtain the necessary funding. Other than the uncertainties regarding our ability to obtain additional funding and the repayment of convertible debt obligations, there are currently no known trends, demands, commitments, events or uncertainties that are likely to materially effect our liquidity.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2014. Disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and financial officers, to allow timely decisions regarding required disclosures.

Based on the evaluation of our disclosure controls and procedures as of June 30, 2014 our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were operating effectively.

Change in Internal Control over Financial Reporting

The Company’s management, in connection with its evaluation of internal controls (with the participation of the Company’s principal executive officer and principal financial officer), did not identify any change in internal control over the financial reporting process that occurred during the Company’s second quarter of 2014 that would have materially effected, or would have been reasonably likely to materially effect, the Company’s internal control over financial reporting.

Limitations on Effectiveness of Controls

In designing and evaluating our disclosure controls and procedures, our management recognizes that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part on certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

We will require additional capital in order to continue our operations, and may have difficulty raising additional capital.

We expect that we will continue to generate significant operating losses for the foreseeable future. At June 30, 2014, our consolidated cash balance was approximately $1,626,000. We believe our cash balance at June 30, 2014, plus the proceeds of the Notes issued in July 2014, is adequate to fund operations through August 2014. We will require additional funds to conduct research and development, establish and conduct clinical and preclinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. We plan to actively pursue financing alternatives. However, there can be no assurance that we will obtain the necessary funding in the amounts we seek or that it will be available on a timely basis or upon terms acceptable to us. If we obtain capital by issuing debt or preferred stock, the holders of such securities would likely obtain rights that are superior to those of holders of our common stock.

Our capital requirements and our ability to meet them depend on many factors, including:

the number of potential products and technologies in development;

continued progress and cost of our research and development programs;

progress with preclinical studies and clinical trials;

the time and costs involved in obtaining regulatory clearance;

costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;

costs of developing sales, marketing and distribution channels and our ability to sell our drugs;

costs involved in establishing manufacturing capabilities for clinical trial and commercial quantities of our drugs;

competing technological and market developments;

market acceptance of our products;

costs for recruiting and retaining management, employees and consultants;

costs for educating physicians regarding the application and use of our products;

whether or not we obtain listing on a national exchange and, if not, our prospects for obtaining such listing;

uncertainty and economic instability resulting from terrorist acts and other acts of violence or war; and

the condition of capital markets and the economy generally, both in the U.S. and globally.

We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any necessary additional funds through the issuance of warrants, equity or debt financings or executing collaborative arrangements with corporate partners or other sources, which may be dilutive to existing stockholders or have a material effect on our current or future business prospects. In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other sources, we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves. If we cannot secure adequate financing when needed, we may be required to delay, scale back or eliminate one or more of our research and development programs or to enter into license or other arrangements with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves and commercialize ourselves. In such an event, our business, prospects, financial condition, and results of operations may be adversely affected.

We will require additional funds to conduct research and development, establish and conduct clinical and preclinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.

We have incurred net losses and negative cash flows since inception. We currently have no product revenues, and may not succeed in developing or commercializing any products that will generate product or licensing revenues. We do not expect to have any products on the market for several years. Our primary activity to date has been research and development. In addition, development of our product candidates requires a process of preclinical and clinical testing, during which our product candidates could fail. We may not be able to enter into agreements with one or more companies experienced in the manufacturing and marketing of therapeutic drugs and, to the extent that we are unable to do so, we may not be able to market our product candidates. Whether we achieve profitability or not will depend on our success in developing, manufacturing, and marketing our product candidates. We have experienced net losses and negative cash flows from operating activities since inception and we expect such losses and negative cash flows to continue for the foreseeable future. As of June 30, 2014, we had a stockholders’ deficit of $2,541,000. The net loss for the six months ended June 30, 2014 was approximately $5,029,000, and we may never achieve profitability.

All of the Company’s assets represent collateral security for our outstanding debt.

In July 2014, in connection with the issuance and sale of our 8% promissory notes, we granted a security interest in all of the Company’s assets, now existing or subsequently acquired, as collateral for the Company’s obligations under these notes. Additionally, in connection with obtaining the consent of the holders of our convertible debentures to the incurrence of this additional debt, we extended the security interest in all of our assets to our obligations under the convertible debentures. The creation of a security interest in all assets in favor of the holders of the promissory notes and the convertible debentures may make it more difficult for the Company to obtain trade credit in the future.

Item 5. Other Information

The Company and a group of lenders entered into a Note Purchase and Security Agreement dated as of July 29, 2014 providing for borrowing by the Company of up to an aggregate of $1,000,000 upon the issuance of the Company’s secured promissory notes (the “Notes”) bearing interest of 8% per annum and having a stated maturity of 60 days from issuance or the earlier closing of an equity financing with gross proceeds to the Company of $1,000,000. The Notes are secured by a lien on substantially all assets of the Company,now existing or subsequently acquired. The Company borrowed an aggregate of $617,500 at an initial closing on July 29, 2014. Any borrowing of the remaining $382,500 balance of the $1,000,000 is at the option of the lenders. In connection with the entry into the Note Purchase and Security Agreement, the Company obtained the consent of the holders of its outstanding convertible debentures in exchange for the extension of the security interest on all such assets of the Company to the convertible debentures, pari passu with the Notes.

Item 6. Exhibits

			Incorporation by Reference
Exhibit No.	Description	Filed with this Form 10-Q	Form	Filing Date	Exhibit No.

2.1	Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011		8-K	April 11, 2011	2.1

3.1	Second Amended and Restated Certificate of Incorporation		8-K	April 11, 2011	3.1

3.1.1	Amendment to the Second Amended and restated Articles of Incorporation		8-K	June 13, 2014	3.1

3.2	Amended and Restated By-laws		8-K	June 1, 2011	3.1

10.1	Form of Note Purchase and Security Agreement	X

10.2	Form of 8% Secured Promissory Note	X

10.3	Form of Consent Agreement with Debenture Holders	X

31.1	Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

32.1	Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101	Interactive Data Files	X

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CELLECTAR BIOSCIENCES, INC.

Date: August 4, 2014	By:	/s/ Simon Pedder
		Simon Pedder
		President and Chief Executive Officer

EX-10.1 2 v385092_ex10-1.htm EXHIBIT 10.1

EXHIBIT 10.1

NOTE PURCHASE AND SECURITY AGREEMENT

This Note Purchase and Security Agreement (this “Agreement”) is dated as of July 29, 2014, between Cellectar Biosciences, Inc. (f/k/a Novelos Therapeutics, Inc.), a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, secured promissory notes of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

1.1 Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Notes (as defined herein), and (b) the following terms have the meanings set forth in this Section 1.1:

“Action” shall have the meaning ascribed to such term in Section 3.1(i).

“Additional Note” shall have the meaning ascribed to such term in Section 2.2.

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“Board of Directors” means the board of directors of the Company.

“Closing” means any closing of the purchase and sale of the Notes pursuant to Section 2.1 or Section 2.2.

“Closing Date” means each of the Initial Closing date and the Trading Day on which any Additional Notes are issued and sold to Purchasers pursuant to Section 2.2.

“Collateral” means the Company’s right, title and interest in and to all of its assets and properties, including without limitation the following, whether now owned or hereafter acquired and wherever located: (a) all accounts receivable; (b) all equipment; (c) all fixtures; (d) all general intangibles; (e) all intellectual property of the Company, (f) all inventory; (g) all investment property; (h) all deposit accounts; (i) all shares or other equity interests in its Subsidiaries; (j) all other goods and personal property of the Company, whether tangible or intangible and whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located; (k) all books and records of the Company; and (l) all proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing.

“Commission” means the United States Securities and Exchange Commission.

“Common Stock” means the common stock of the Company, par value $0.00001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.

“Company Counsel” means Foley Hoag LLP with offices located at 155 Seaport Boulevard, Boston, Massachusetts 02210.

“Debentures” means the 8% Convertible Debentures due February 6, 2016 of the Company issued on February 6, 2014.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“GAAP” shall have the meaning ascribed to such term in Section 3.1(g).

“Initial Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Initial Subscription Amount and (ii) the Company’s obligations to deliver the Initial Notes, in each case, have been satisfied or waived.

“Initial Notes” means the Notes issued at the Initial Closing.

“Initial Subscription Amount” means, as to each Purchaser, the aggregate Subscription Amount to be paid for the Initial Notes purchased hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Initial Subscription Amount,” in United States dollars and in immediately available funds.

“Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

“Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).

“Maximum Rate” shall have the meaning ascribed to such term in Section 5.15.

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.

“Purchaser Party” shall have the meaning ascribed to such term in Section 4.5.

“SEC Reports” shall have the meaning ascribed to such term in Section 3.1(g).

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for Notes purchased hereunder at any Closing.

“Subsidiary” means any subsidiary of the Company.

“Trading Day” means a day on which the principal Trading Market is open for trading.

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTC Bulletin Board or any other over-the-counter market on which the Company is listed or quoted for trading (or any successors to any of the foregoing).

“Transaction Documents” means this Agreement, the Notes, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

ARTICLE II.

PURCHASE AND SALE

2.1 Initial Closing. On the Initial Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto or within three Trading Days thereafter, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, the Initial Notes. Each Purchaser shall deliver to an account designated by the Company in writing, via wire transfer, immediately available funds equal to such Purchaser’s Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and the Company shall deliver to each Purchaser its respective Initial Note, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Company Counsel or such other location as the parties shall mutually agree.

2.2 Additional Closing. At any time prior to September 30, 2014, upon the terms and subject to the conditions set forth herein, by written notice from the Company to the Purchasers calling for an additional Closing (which shall be in the Company’s sole discretion), each Purchaser shall have the option, but not the obligation, to purchase an additional Note (each, an “Additional Note”), with the aggregate principal amount of all such additional Notes to be no greater than $1 million less the aggregate principal amount of all Initial Notes. The Company shall allocate any the principal amount of any Additional Notes to the Purchasers on the basis of the principal amount for which each such Purchaser elects to subscribe; provided, that if the Company receives elections to subscribe for Additional Notes having an aggregate principal amount in excess of the principal amount of Additional Notes the Company is permitted to issue and sell pursuant to this Section 2.3, then the Company shall ratably reduce the principal amount of the Additional Note to be issued and sold to each Purchaser based on the principal amount of the Additional Note for which each such Purchaser has elected to subscribe relative to the aggregate amount of all such subscriptions. Each Purchaser shall deliver to an account designated by the Company in writing, via wire transfer, immediately available funds equal to such Purchaser’s Subscription Amount for its Additional Note, which shall be equal to the principal amount of the Additional Note to be purchased by such Purchaser, and the Company shall deliver to each Purchaser its respective Additional Note, as determined pursuant to Section 2.3(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.3 deliverable at such Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.3 and 2.4, the Closing shall occur at the offices of Company Counsel or such other location as the parties shall mutually agree.

2.3 Deliveries.

(a) On or prior to each Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

(i) with respect to the Initial Closing, this Agreement duly executed by the Company;

(ii) a legal opinion of Company Counsel, substantially in the form of Exhibit C attached hereto;

(iii) a Note with a principal amount equal to such Purchaser’s Subscription Amount, registered in the name of such Purchaser; and

(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, as applicable, the following:

(i) with respect to the Initial Closing, this Agreement duly executed by such Purchaser; and

(ii) such Purchaser’s Subscription Amount by wire transfer to the account specified by the Company in writing.

2.4 Closing Conditions.

(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

(i) the accuracy in all material respects on such Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to such Closing Date shall have been performed; and

(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

(b) The respective obligations of the Purchasers hereunder in connection with such Closing are subject to the following conditions being met:

(i) the accuracy in all material respects when made and on such Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein);

(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to such Closing Date shall have been performed; and

(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement.

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

3.1 Representations and Warranties of the Company. Except as set forth in the SEC Reports (as defined below), which SEC Reports shall be deemed a part hereof and shall qualify any representation or otherwise made herein, the Company hereby makes the following representations and warranties to each Purchaser:

(a) Subsidiaries. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith or therewith. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(d) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Notes and the consummation by it of the transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(e) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents.

(f) Issuance of the Notes. The Notes are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, free and clear of all Liens imposed by the Company other than Liens and restrictions on transfer provided for in the Transaction Documents.

(g) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(h) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. No event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, properties, operations, assets or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.

(i) Litigation. Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Notes or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

(j) Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

(k) Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.

(l) Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiaries to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.

(m) Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Notes by the Company to the Purchasers as contemplated hereby.

(n) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Notes, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration under the Investment Company Act of 1940, as amended.

(o) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

(p) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Notes to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities under the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.

(q) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.

(r) No General Solicitation. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Notes by any form of general solicitation or general advertising. The Company has offered the Notes for sale only to the Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

(s) Seniority. As of the Closing Date, no indebtedness or other claim against the Company is senior to the Notes in right of payment, whether with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior only as to the property covered thereby).

(t) Acknowledgment Regarding Purchasers’ Purchase of Notes. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Notes. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

3.2 Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of each Closing Date to the Company as follows (unless as of a specific date therein):

(a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b) Own Account. Such Purchaser understands that the Notes are “restricted securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring the Notes as principal for its own account and not with a view to or for distributing or reselling such Notes or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Notes in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Notes in violation of the Securities Act or any applicable state securities law. Such Purchaser is acquiring the Notes hereunder in the ordinary course of its business.

(c) Purchaser Status. At the time such Purchaser was offered the Notes, it was, and as of the date hereof it is, either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.

(d) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Notes, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Notes and, at the present time, is able to afford a complete loss of such investment.

(e) General Solicitation. Such Purchaser is not purchasing the Notes as a result of any advertisement, article, notice or other communication regarding the Notes published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

(f) Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Notes and the merits and risks of investing in the Notes; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

(g) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, executed any purchases or sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Notes covered by this Agreement. Other than to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).

The Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction contemplated hereby.

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

4.1 Transfer Restrictions.

(a) The Notes may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Notes, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Notes under the Securities Act.

(b) The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Notes in the following form:

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

4.2 Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Notes in a manner that would require the registration under the Securities Act of the sale of the Notes.

4.3 Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

4.4 Use of Proceeds. The Company shall use the net proceeds from the sale of the Notes hereunder for working capital purposes.

4.5 Indemnification of Purchasers. Subject to the provisions of this Section 4.5, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.5 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

4.6 Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. Further, the Company shall not make any payment of principal or interest on the Notes in amounts which are disproportionate to the respective principal amounts outstanding on the Notes at any applicable time. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase or disposition of Securities or otherwise.

4.7 Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Transaction Documents.

ARTICLE V.
COLLATERAL SECURITY

5.1 Collateral Security. As security for the payment of the Company’s obligations hereunder, and as security for the payment of the Company’s obligations under the Debentures, the Company hereby grants to the Purchasers and the holders of Debentures a pari passu security interest in the Collateral. The existence of such security shall not limit any other rights or remedies which Lender may have in the event of a default hereunder. By its signature hereon, the Company hereby agrees file a UCC-1 financing statement and such continuation or amendment statements in all jurisdictions in which such filing is deemed by the Purchasers to be necessary or desirable in order to perfect, preserve and protect the aforesaid security interest. If required by any Purchaser, the Company will execute all documentation necessary for the Purchasers to obtain and maintain perfection of the aforesaid security interests in the Collateral. Upon the payment in full of all amounts owing under the Notes and the Debentures, the Company automatically and unconditionally be released from any liens granted pursuant to this Agreement and shall be permitted to file any required UCC termination statements. The holders of Debentures who are not Purchasers are express third party beneficiaries of this Section 5.1.

ARTICLE VI.

MISCELLANEOUS

6.1 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.

6.2 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

6.3 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2^nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

6.4 Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding a majority in interest of the Notes then outstanding and held by Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

6.5 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

6.6 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Notes, provided that such transferee agrees in writing to be bound, with respect to the transferred Notes, by the provisions of the Transaction Documents that apply to the “Purchasers.”

6.7 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.5, Section 5.1 and this Section 6.7.

6.8 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.5, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

6.9 Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Notes.

6.10 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.

6.11 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

6.12 Replacement of Notes. If any instrument evidencing any Note is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Notes.

6.13 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.

6.14 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

6.15 Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any time hereafter in force, in connection with any claim, action or proceeding that may be brought by any Purchaser in order to enforce any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document, it is expressly agreed and provided that the total liability of the Company under the Transaction Documents for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Transaction Documents is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective date thereof forward, unless such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness evidenced by the Transaction Documents, such excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of handling such excess to be at such Purchaser’s election.

6.16 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents.

6.17 Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.

6.18 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

(Signature Pages Follow)

IN WITNESS WHEREOF, the parties hereto have caused this Note Purchase and Security Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

cellectar biosciences, inc.		Address for Notice:

		3301 Agriculture Drive
		Madison, WI 53716
By:		Fax:
	Name:
	Title:
With a copy to (which shall not constitute notice):

Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
Attn: Paul Bork, Esq.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

[PURCHASER SIGNATURE PAGES TO note PURCHASE and security AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Note Purchase and Security Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: ________________________________________________________________________________

Signature of Authorized Signatory of Purchaser: _________________________________________________________

Name of Authorized Signatory: _______________________________________________________________________

Title of Authorized Signatory: ________________________________________________________________________

Email Address of Authorized Signatory: ________________________________________________________________

Facsimile Number of Authorized Signatory: _____________________________________________________________

Address for Notice to Purchaser:

Address for Delivery of Note to Purchaser (if not same as address for notice):

Subscription Amount: ________________

EIN Number: _______________________

[SIGNATURE PAGES CONTINUE]

EXHIBIT C

OPINION OF COUNSEL TO COMPANY

EX-10.2 3 v385092_ex10-2.htm EXHIBIT 10.2

EXHIBIT 10.2

EXHIBIT A

Original Issue Date: July 29, 2014

$_______________

8% SECURED PROMISSORY NOTE

DUE [60 days from date of issue], 2014

THIS 8% SECURED PROMISSORY NOTE is one of a series of duly authorized and validly issued 8% Secured Promissory Notes of Cellectar Biosciences, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 3301 Agriculture Drive, Madison, WI 53716, designated as its 8% Secured Promissory Notes due 2014 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).

FOR VALUE RECEIVED, the Company promises to pay to ________________________ or its registered assigns (the “Holder”), or shall have paid pursuant to the terms hereunder, the principal sum of $_______________ ON DEMAND of the Holder at any time on or after _________ __, 2014 (the “Maturity Date”) or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate outstanding principal amount of this Note in accordance with the provisions hereof. This Note is subject to the following additional provisions:

Section 1. Definitions. For the purposes hereof, in addition to the terms defined elsewhere in this Note, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b) the following terms shall have the following meanings:

“Bankruptcy Event” means any of the following events: (a) the Company or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) thereof commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Company or any Significant Subsidiary thereof, (b) there is commenced against the Company or any Significant Subsidiary thereof any such case or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Significant Subsidiary thereof is adjudicated insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Significant Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or stayed within 60 calendar days after such appointment, (e) the Company or any Significant Subsidiary thereof makes a general assignment for the benefit of creditors, (f) the Company or any Significant Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment or restructuring of its debts or (g) the Company or any Significant Subsidiary thereof, by any act or failure to act, expressly indicates its consent to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the foregoing.

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

“Note Register” shall have the meaning set forth in Section 2(c).

“Event of Default” shall have the meaning set forth in Section 5(a).

“Late Fees” shall have the meaning set forth in Section 2(d).

“New York Courts” shall have the meaning set forth in Section 6(d).

“Original Issue Date” means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless of the number of instruments which may be issued to evidence such Notes.

“Purchase Agreement” means the Note Purchase and Security Agreement, dated as of July 29, 2014 among the Company and the original Holders, as amended, modified or supplemented from time to time in accordance with its terms.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Subsequent Financing” means the closing of any offering by the Company or a Subsidiary of Common Stock or Common Stock Equivalents for cash consideration, indebtedness or a combination thereof for aggregate gross proceeds of at least $1,000,000.

Section 2. Interest; Repayment; Security.

a) Payment of Interest in Cash. The Company shall pay interest to the Holder on the aggregate outstanding principal amount of this Note at the rate of 8% per annum, which interest shall accrue and become payable in cash at the time the principal amount of this Note shall become payable.

b) Interest Calculations. Interest shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, and shall accrue daily commencing on the date of issue of this Note until payment in full of the outstanding principal, together with all accrued and unpaid interest, and other amounts which may become due hereunder, has been made.

c) Late Fee. All overdue accrued and unpaid interest to be paid hereunder shall entail a late fee at an interest rate equal to the lesser of 12% per annum or the maximum rate permitted by applicable law (the “Late Fees”), whichever is less, which shall accrue daily from the date such interest is due hereunder through and including the date of actual payment in full.

d) Prepayment. Except as otherwise set forth in this Note, the Company may not prepay any portion of the principal amount of this Note without the prior written consent of the Holder.

e) Repayment on Subsequent Financing. All principal, interest and any other obligations owing under this Note shall become immediately due and payable upon a Subsequent Financing.

f) Security. All obligations under this note are secured by the Collateral as set forth in the Purchase Agreement.

Section 3. Registration of Transfers and Exchanges.

a) Different Denominations. This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the Holder surrendering the same. No service charge will be payable for such registration of transfer or exchange.

b) Investment Representations. This Note has been issued subject to certain investment representations of the original Holder set forth in the Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal and state securities laws and regulations.

c) Reliance on Note Register. Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the Company may treat the Person in whose name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither the Company nor any such agent shall be affected by notice to the contrary.

Section 4. Events of Default.

a) “Event of Default” means, wherever used herein, any of the following events (whatever the reason for such event and whether such event shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order, rule or regulation of any administrative or governmental body):

i. any default in the payment of (A) the principal amount of any Note or (B) interest and other amounts owing to a Holder on any Note, as and when the same shall become due and payable (whether on the Maturity Date or by acceleration or otherwise) which default, solely in the case of an interest payment or other default under clause (B) above, is not cured within 3 Business Days;

ii. a material default or event of default (subject to any grace or cure period provided in the applicable agreement, document or instrument) shall occur under the Company’s 8% Convertible Debenture date February 6, 2014;

iii. the Company or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) shall be subject to a Bankruptcy Event.

b) Remedies Upon Event of Default. If any Event of Default occurs, the outstanding principal amount of this Note, plus accrued but unpaid interest and other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder’s election, immediately due and payable in cash at the Mandatory Default Amount. Commencing 5 days after the occurrence of any Event of Default that results in the eventual acceleration of this Note, the interest rate on this Note shall accrue at an interest rate equal to the lesser of 12% per annum or the maximum rate permitted under applicable law. Upon the payment in full of the Mandatory Default Amount, the Holder shall promptly surrender this Note to or as directed by the Company. In connection with such acceleration described herein, the Holder need not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind, and the Holder may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Holder at any time prior to payment hereunder and the Holder shall have all rights as a holder of the Note until such time, if any, as the Holder receives full payment pursuant to this Section 5(b). No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon.

Section 5. Miscellaneous.

a) Notices. Any and all notices or other communications or deliveries to be provided by the Holder hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service, addressed to the Company, at the address set forth above, or such other facsimile number or address as the Company may specify for such purposes by notice to the Holder delivered in accordance with this Section 6(a). Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of the Holder appearing on the books of the Company, or if no such facsimile number or address appears on the books of the Company, at the principal place of business of such Holder, as set forth in the Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time) on any date, (ii) the next Business Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business Day, (iii) the second Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (iv) upon actual receipt by the party to whom such notice is required to be given.

b) Absolute Obligation. Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and accrued interest on this Note at the time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the Company. This Note ranks pari passu with all other Notes now or hereafter issued under the terms set forth herein.

c) Lost or Mutilated Note. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed Note, a new Note for the principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such Note, and of the ownership hereof, reasonably satisfactory to the Company.

d) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Note shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the “New York Courts”). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Note or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of this Note, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

e) Waiver. Any waiver by the Company or the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company or the Holder to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any other occasion. Any waiver by the Company or the Holder must be in writing.

f) Severability. If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company from paying all or any portion of the principal of or interest on this Note as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Note, and the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Holder, but will suffer and permit the execution of every such as though no such law has been enacted.

g) Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder’s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any such breach or any such threatened breach, without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions of this Note.

h) Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day.

i) Headings. The headings contained herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit or affect any of the provisions hereof.

*********************

(Signature Pages Follow)

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed by a duly authorized officer as of the date first above indicated.

	CELLECTAR BIOSCIENCES, inc.

	By:
		Name:
		Title:

Facsimile No. for delivery of Notices:

EX-10.3 4 v385092_ex10-3.htm EXHIBIT 10.3

EXHIBIT 10.3

CONSENT AGREEMENT

This Consent Agreement (this “Agreement”) is dated as of July 29, 2014, between Cellectar Biosciences, Inc. (f/k/a Novelos Therapeutics, Inc.), a Delaware corporation (the “Corporation”), and each undersigned holder of the Corporation’s 8% Convertible Debentures due February 6, 2016 (the “Debentures”).

WHEREAS, the undersigned are holders of Debentures, which Debentures were issued on February 6, 2014 pursuant to that certain Securities Purchase Agreement dated as of February 6, 2014 between the Corporation and the holders of the Debentures (the “Securities Purchase Agreement”), which holders are identified on Exhibit A hereto;

WHEREAS, the Corporation is seeking to issue and sell its promissory notes (the “Promissory Notes”) in aggregate principal amount of up to $1 million in one or more tranches (collectively, the “Bridge Financing”), and the Corporation requires the consent of, and certain approvals from, the holders of a majority in principal amount of the Debentures (the “Majority Holders”); and

WHEREAS, the Corporation desires to provide notice of and the opportunity to participate in the Bridge Financing to each holder of Debentures;

NOW THEREFORE, the parties hereto agree as follows:

1. Certain Defined Terms. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Securities Purchase Agreement.

2. Notice of Bridge Financing. By delivery of this Agreement, notice is hereby given to each holder of the Debentures of the Corporation’s intention to complete the Bridge Financing substantially on the terms set forth in the attached summary on Exhibit B. Each holder of Debentures is hereby offered the opportunity to participate in the initial tranche of the Bridge Financing based on its pro rata portion of $500,000 (such pro rata to be determined based on the principal amount of each Debenture holder’s Debenture relative to the aggregate principal amount of all Debentures). In addition, each holder of Debentures may express interest in participating above such pro rata in the initial tranche of the Bridge Financing. Any such indication of interest shall be provided in writing to the Corporation not later than July 29, 2014, and the holder may provide such indication of interest on its signature page hereto. In the event the initial tranche of the Bridge Financing is over-subscribed, the Corporation shall (1) allocate to each holder of Debentures electing to participate in the Bridge Financing its pro rata portion of $500,000, and (2) allocate to each holder of Debentures expressing interest in participating in excess of its pro rata the amount of such oversubscription; provided that, if the aggregate amounts set forth in all indications of interest exceeds $1 million, the Corporation shall reduce the participation of the over-subscribing holders of Debentures ratably based on the amount of their oversubscriptions. Participation in any subsequent tranche of the Bridge Financing shall be allocated and completed in accordance with, and subject to the terms and conditions of, the definitive documentation executed in connection with the Bridge Financing.

3. Consent of Holders of Debentures. The undersigned holders of Debentures, constituting the Majority Holders, hereby consent in all respects, in accordance with Section 7 of the Debentures, to the Bridge Financing, including without limitation (i) the issuance and sale of Promissory Notes in the aggregate principal amount of up to $1 million on substantially the terms set forth in Exhibit B, (ii) the creation of any lien, security interest or other encumbrance on the assets of the Corporation in connection therewith, and (iii) the repayment of the Promissory Notes in accordance with their terms.

4. Amendment of Securities Purchase Agreement. The undersigned holders of Debentures, having the power to amend the Securities Purchase Agreement on behalf of themselves and all other holders of Debentures, hereby amend the definition of “Exempt Issuance” set forth therein by re-lettering the existing clause “(c)” as clause “(d)” and by inserting a new immediately preceding clause “(c)” as follows: “(c) up to $1 million in aggregate principal amount of promissory notes issued after the date hereof,”.

5. Entire Agreement. This Agreement, the Securities Purchase Agreement, the Debentures, and the exhibits and schedules hereto and thereto, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. Except as expressly modified herein, the Securities Purchase Agreement and the Debentures remain in full force and effect.

6. Choice of Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

7. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

IN WITNESS WHEREOF the undersigned have executed this Consent Agreement as of the date first above written.

THE CORPORATION:

CELLECTAR BIOSCIENCES, INC.

By:

[Debenture holder signature pages follow]

[Debenture Holder SIGNATURE PAGES TO CONSENT AGREEMENT]

IN WITNESS WHEREOF, the undersigned has caused this Consent Agreement to be duly executed by its authorized signatory as of the date first indicated above.

Name of Debenture Holder:

Signature of Authorized Signatory of Purchaser:

Name of Authorized Signatory:

Title of Authorized Signatory:

	The holder declines to participate in the Bridge Financing

	The holder intends to participate in the Bridge Financing

Participation Amount (including oversubscription): $_____________

EXHIBIT A

Debenture Holders

Holder	Principal Amount of Debenture

Greenway Properties, Inc.	$	1,316,250
Hertzberg Family Trust (TD 6/4/96)	$	1,316,250
Venture Investors (ESF IV LP)	$	500,000
ENSO Ventures 2 Limited	$	350,000
MIG Commercial Real Estate, LLC	$	100,000
Marc Vaccaro	$	100,000
WIP-Novelos LLC	$	167,500
Dean S. Woodman	$	100,000
Scheinberg Family Trust	$	50,000
Total	$	4,000,000

EXHIBIT B

Cellectar Biosciences, Inc.

Short-Term Bridge Note

—CONFIDENTIAL—

The purpose of this document is to facilitate the discussion of the terms of a proposed EXTENSION OF DEBT TO the Company (the “Transaction”). The actual terms remain subject to negotiation and the completion of a mutual agreement and definitive documentation. This outline does not constitute a contractual commitment of the Company or the Investor(s) but merely represents a discussion document.

Summary of Terms for Discussion

*Debt Issuer:*	Cellectar Biosciences, Inc. (the “Company”)
*Debt Issue:*	60-Day Secured Bridge Notes (the “ Bridge Notes”)
*Bridge Note Security Interest:*	General Business Security Agreement (GBSA) covering assets of Cellectar Biosciences, Inc. GBSA also to apply to obligations under 8% Debentures assuming $500,000 minimum commitment for Bridge Notes
*Interest:*	8.0% annual paid at maturity or upon repayment.
*Maturity:*	60-days from issuance or simultaneous with the closing of any equity offering of $1,000,000 or greater, whichever event occurs first.
*Required Consent*	Holders of a majority of the outstanding principal amount of the 8% Convertible Debentures issued February 6, 2014, having maturity on February 6, 2016, must consent to the terms and issuance of this Bridge Note.
*Debt Issuance Amount and Timing of Funding*	$500,000 minimum initial commitment. For a period of 30-days from date of execution of definitive documentation, Company will have the right to draw down any amount up to the full amount of the initial commitment by providing a three –day notice to participants. The amount of the draw down will be funded pro-rata by each Bridge Note participant, or greater in the case of oversubscription. Further, for a period of 30-days from the date issuance, participants will have the option to increase their Bridge Notes in amount that in aggregate will not exceed an additional $500,000.
*Events of Default:*	All standard events
*Issuance Date:*	July 29, 2014 or earlier
*Modifications to Terms, Actions to Seek Remedy*	Require consent of the Holders of a majority of the outstanding principal amount of the 60-day Bridge Notes.

EX-31.1 5 v385092_ex31-1.htm EXHBIIT 31.1

Exhibit 31.1

I, SIMON PEDDER, certify that:

I have reviewed this quarterly report on Form 10-Q of Cellectar Biosciences, Inc., a Delaware Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially effected, or is reasonably likely to materially effect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely effect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2014

/s/ Simon Pedder

Simon Pedder

President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 6 v385092_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

I, CHAD KOLEAN, certify that:

I have reviewed this quarterly report on Form 10-Q of Cellectar Biosciences, Inc., a Delaware Corporation;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2014

/s/ Chad Kolean

Chad Kolean

Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 7 v385092_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cellectar Biosciences, Inc. (the “Company”) for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Simon Pedder, President and Chief Executive Officer of the Company, and Chad J. Kolean, Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Simon Pedder
Simon Pedder
President and Chief Executive Officer (Principal Executive Officer)

Date: August 4, 2014

/s/ Chad Kolean
Chad Kolean
Chief Financial Officer (Principal Financial and Accounting Officer)

Date: August 4, 2014

EX-101.INS 8 clrb-20140630.xml XBRL INSTANCE DOCUMENT 0001279704 2013-01-01 2013-06-30 0001279704 2013-01-01 2013-12-31 0001279704 2014-01-01 2014-06-30 0001279704 2014-02-01 2014-02-05 0001279704 2014-02-01 2014-02-20 0001279704 2014-02-05 0001279704 2014-02-20 0001279704 2013-04-01 2013-06-30 0001279704 2014-04-01 2014-06-30 0001279704 2014-06-30 0001279704 2014-08-01 0001279704 2013-10-31 0001279704 2013-12-31 0001279704 2012-12-31 0001279704 2013-06-30 0001279704 us-gaap:FairValueInputsLevel1Member clrb:WarrantOneMember 2014-06-30 0001279704 us-gaap:FairValueInputsLevel2Member clrb:WarrantOneMember 2014-06-30 0001279704 us-gaap:FairValueInputsLevel3Member clrb:WarrantOneMember 2014-06-30 0001279704 clrb:WarrantOneMember 2014-06-30 0001279704 us-gaap:FairValueInputsLevel1Member clrb:February2013PublicOfferingWarrantsMember 2014-06-30 0001279704 us-gaap:FairValueInputsLevel2Member clrb:February2013PublicOfferingWarrantsMember 2014-06-30 0001279704 us-gaap:FairValueInputsLevel3Member clrb:February2013PublicOfferingWarrantsMember 2014-06-30 0001279704 clrb:February2013PublicOfferingWarrantsMember 2014-06-30 0001279704 us-gaap:FairValueInputsLevel1Member 2014-06-30 0001279704 us-gaap:FairValueInputsLevel2Member 2014-06-30 0001279704 us-gaap:FairValueInputsLevel3Member 2014-06-30 0001279704 us-gaap:FairValueInputsLevel1Member clrb:WarrantOneMember 2013-12-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:WarrantOneMember 2013-12-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:WarrantOneMember 2013-12-31 0001279704 clrb:WarrantOneMember 2013-12-31 0001279704 us-gaap:FairValueInputsLevel1Member clrb:February2013PublicOfferingWarrantsMember 2013-12-31 0001279704 us-gaap:FairValueInputsLevel2Member clrb:February2013PublicOfferingWarrantsMember 2013-12-31 0001279704 us-gaap:FairValueInputsLevel3Member clrb:February2013PublicOfferingWarrantsMember 2013-12-31 0001279704 clrb:February2013PublicOfferingWarrantsMember 2013-12-31 0001279704 us-gaap:FairValueInputsLevel1Member 2013-12-31 0001279704 us-gaap:FairValueInputsLevel2Member 2013-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2013-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2012-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2013-01-01 2013-12-31 0001279704 us-gaap:FairValueInputsLevel3Member 2014-01-01 2014-06-30 0001279704 clrb:February2013PublicOfferingWarrantsMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0001279704 clrb:February2013PublicOfferingWarrantsMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0001279704 us-gaap:SubsequentEventMember 2014-02-01 2014-02-05 0001279704 clrb:February2014PipeWarrantsMember 2014-01-01 2014-06-30 0001279704 clrb:February2014PrivatePlacementMember 2014-06-30 0001279704 clrb:February2013PublicOfferingMember 2014-06-30 0001279704 clrb:February2013PublicOfferingPlacementAgentsMember 2014-06-30 0001279704 clrb:NovemberPrivatePlacementMember 2014-06-30 0001279704 clrb:JunePublicOfferingMember 2014-06-30 0001279704 clrb:UnderwrittenOfferingMember 2014-06-30 0001279704 clrb:AprilPrivatePlacementMember 2014-06-30 0001279704 clrb:WarrantTwoMember 2014-06-30 0001279704 clrb:WarrantThreeMember 2014-06-30 0001279704 clrb:February2014PrivatePlacementMember 2014-01-01 2014-06-30 0001279704 clrb:February2013PublicOfferingMember 2014-01-01 2014-06-30 0001279704 clrb:February2013PublicOfferingPlacementAgentsMember 2014-01-01 2014-06-30 0001279704 clrb:NovemberPrivatePlacementMember 2014-01-01 2014-06-30 0001279704 clrb:JunePublicOfferingMember 2014-01-01 2014-06-30 0001279704 clrb:UnderwrittenOfferingMember 2014-01-01 2014-06-30 0001279704 clrb:AprilPrivatePlacementMember 2014-01-01 2014-06-30 0001279704 clrb:WarrantOneMember 2014-01-01 2014-06-30 0001279704 clrb:WarrantTwoMember 2014-01-01 2014-06-30 0001279704 clrb:WarrantThreeMember 2014-01-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember clrb:RestructuringCostsMember 2013-01-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2013-01-01 2013-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember 2013-01-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember clrb:RestructuringCostsMember 2014-01-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2014-01-01 2014-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember 2014-01-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember clrb:RestructuringCostsMember 2013-04-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2013-04-01 2013-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember 2013-04-01 2013-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember clrb:RestructuringCostsMember 2014-04-01 2014-06-30 0001279704 clrb:EmployeeAndDirectorStockOptionMember 2014-04-01 2014-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001279704 clrb:NonEmployeeConsultantStockOptionMember 2014-04-01 2014-06-30 0001279704 clrb:PerformanceBasedMember 2013-10-01 2013-10-31 0001279704 us-gaap:ChiefExecutiveOfficerMember 2013-10-01 2013-10-31 0001279704 us-gaap:ChiefExecutiveOfficerMember 2013-10-31 0001279704 us-gaap:DirectorMember 2013-01-01 2013-12-31 0001279704 clrb:EmployeeMember 2014-01-01 2014-06-30 0001279704 us-gaap:WarrantMember 2013-01-01 2013-06-30 0001279704 us-gaap:StockOptionMember 2013-01-01 2013-06-30 0001279704 us-gaap:ConvertibleDebtMember 2013-01-01 2013-06-30 0001279704 us-gaap:WarrantMember 2014-01-01 2014-06-30 0001279704 us-gaap:StockOptionMember 2014-01-01 2014-06-30 0001279704 us-gaap:ConvertibleDebtMember 2014-01-01 2014-06-30 0001279704 us-gaap:SubsequentEventMember 2014-01-01 2014-06-30 0001279704 us-gaap:SubsequentEventMember 2014-06-30 0001279704 us-gaap:MinimumMember clrb:WarrantThreeMember 2014-06-30 0001279704 clrb:WarrantThreeMember us-gaap:MaximumMember 2014-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>6. STOCK-BASED COMPENSATION</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Accounting for Stock-Based Compensation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended<br/> June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six Months Ended<br/> June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Employee and director stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47,274</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>106,774</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>110,701</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>212,612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>176,581</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>264,243</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>360,965</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>576,282</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restructuring costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47,853</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47,853</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>271,708</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>371,017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>519,519</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>788,894</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Non-employee consultant stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,697</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,322</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,565</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,697</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>14,897</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>273,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>377,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>536,216</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>803,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October 2013, the Company granted options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 264,278</font> shares of common stock in connection with the appointment of its then Acting Chief Executive Officer, including options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 96,278</font> shares of common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.00</font> per share (the “Anti-dilution Option”), exercisable as shares of the Company’s common stock are issued following the exercise of outstanding warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 96,278</font> shares of the Company’s common stock, in the ratio of one option share for each <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19</font> shares issued upon warrant exercise. No compensation expense was recognized related to these options as the Company was not able to conclude that the achievement of the performance condition was probable. On February 20, 2014, warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 275,000</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font> per share expired unexercised and as a result, the number of shares subject to the Anti-dilution Option was reduced by <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,474</font> shares, according to its terms.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Assumptions Used In Determining Fair Value</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Valuation and amortization method</i>. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model.  The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Volatility.</i> The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Risk-free interest rate</i>. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Expected term</i>. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Forfeitures.</i>  The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% was applied to all unvested options for employees and directors, respectively for the six months ended June 30, 2014 and for the year ended December 31, 2013.  Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes weighted-average values and assumptions used for options granted to employees, directors and consultants in the periods indicated:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="74%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six Months Ended<br/> June 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six Months Ended<br/> June 30, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.76</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Dividend</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Weighted-average exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="74%"> <div>Weighted-average grant-date fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Exercise prices for all grants made during the six months ended June 30, 2014 and 2013 were equal to the market value of the Company’s common stock on the date of grant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Stock Option Activity</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Number of<br/> Shares<br/> Issuable Upon<br/> Exercise of<br/> Outstanding<br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Weighted<br/> Average<br/> Remaining<br/> Contracted<br/> Term in<br/> Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>634,658</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>18.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Canceled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20,521)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(14,474)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Outstanding at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>619,663</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Vested, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>264,752</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Unvested, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>354,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Exercisable at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>264,752</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options.  There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2014, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,869,000</font> of total unrecognized compensation cost related to unvested stock-based compensation arrangements.  Of this total amount, the Company expects to recognize approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,096,000</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">570,000</font>, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">203,000</font> during 2014, 2015, and 2016, respectively. The Company expects <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 273,106</font> unvested options to vest in the future.  In addition, there are outstanding options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 81,805</font> shares of common stock that vest upon the occurrence of future events. The Company was not able to conclude that the achievement of the performance condition is probable; therefore, the Company has not recognized any expense associated with the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">418,000</font> fair value of these awards. Recognition of expense will begin when and if the Company determines that achievement of the performance condition is probable. The weighted-average grant-date fair value of vested and unvested options outstanding at June 30, 2014 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16.66</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.98</font>, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1626025

2418384

55000

334979

294687

2016004

2768071

2185087

2360534

1675462

12009

11872

5888562

6815939

1195418

1162098

2840557

3359363

431

1694

4077736

4523155

3796781

408670

450000

145993

143234

4351444

593234

8429180

5116389

53548170

52759089

-56088817

-51059568

-2540618

1699550

5888562

6815939

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Principles of Consolidation</i></b>  The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Restricted Cash</i></b>  The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2014 and December 31, 2013 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Goodwill</i></b>  At June 30, 2014 and December 31, 2013, the balance of goodwill resulted from the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore no changes in goodwill were made during the six months ended June 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Impairment of Long</i></b>-<b><i>Lived Assets</i></b>  Long-lived assets other than goodwill consist of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore, no such impairment occurred during the six months ended June 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Stock-Based Compensation</i></b>  The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, <i> Equity. </i> As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Fair Value of Financial Instruments</i></b>  The guidance under FASB ASC Topic 825, <i>Financial Instruments</i>, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable, convertible debt and long-term obligations.  The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature.  The fair value of convertible debt is equal to the fair value of the underlying common stock, which was approximately $2,556,000 at June 30, 2014. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Derivative Instruments</i></b>  The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks.  However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities.  In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 551,365 and 826,365 at June 30, 2014 and December 31, 2013, respectively. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock.  Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2014 and December 31, 2013, these warrants represented the only outstanding derivative instruments issued or held by the Company.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2014 and December 31, 2013:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div>June 30, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div>Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Legacy Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,557</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,557</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,838,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,838,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,557</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,838,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,840,557</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> December 31, 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="41%"> <div style="CLEAR:both;CLEAR: both">Liabilities:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div style="CLEAR:both;CLEAR: both">Legacy Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div style="CLEAR:both;CLEAR: both">February 2013 Public Offering Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,355,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,355,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,355,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,359,363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="75%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30, <br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,<br/>  2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Beginning balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,355,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Fair value of warrants issued in connection with February 2013 public offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,720,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Gain on derivatives resulting from change in fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(517,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,365,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Ending balance  Fair value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,838,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,355,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.00001

7000

0.00001

20000000

2869739

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three Months Ended<br/> June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six Months Ended<br/> June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Employee and director stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47,274</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>106,774</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>110,701</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>212,612</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>176,581</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>264,243</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>360,965</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>576,282</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restructuring costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47,853</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>47,853</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>271,708</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>371,017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>519,519</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>788,894</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Non-employee consultant stock option grants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,311</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,697</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,322</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,565</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,575</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,982</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,876</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,697</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>14,897</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>273,690</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>377,893</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>536,216</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>803,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of stock option activity is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Number of<br/> Shares<br/> Issuable Upon<br/> Exercise of<br/> Outstanding<br/> Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Weighted<br/> Average<br/> Remaining<br/> Contracted<br/> Term in<br/> Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> Intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>634,658</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>18.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Canceled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(20,521)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>23.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(14,474)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Outstanding at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>619,663</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17.80</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Vested, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>264,752</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Unvested, June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>354,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Exercisable at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>264,752</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>29.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 68%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="3"> <div>Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,964,085</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,839,123</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>619,663</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>314,582</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Convertible debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>400,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

55000

551365

826365

2556000

2557

2838000

2557

2838000

4363

3355000

4363

3355000

0 3355000 5720000 0

-2365000

-517000

2838000

0.0092

0.0007

0.0127

0.0176

1.09

0.75

1.15

1.08

P6Y

P1M20D

P4Y1M20D

P6Y

4000000

400000 4000000 2014-02-05

2016-02-06

10.00

400000

0.08

2000000 8000000

0.12

100000

20.00

2019-02-06 150000 254000

3746000

128000

0.0152

1.1

P5Y

3239450

3096105

1648838

1380798

2195452

2046921

1073749

959885

221815

204934

5434902

5364841

2722587

2545617

-5434902

-5364841

-2722587

-2545617

666384

518806

660341

573751

-744957

-4866

-183214

-2216

-113970

-83439

335592

658125

459781

-5518341

-5029249

-2064462

-2085836

-2.03

-1.75

-0.72

-0.73

2717966

2869739

1964085

400000

550000

38496

50000

149069

462411

302922

1365

5252

4570

2019-02-06 2018-02-20 2018-02-04 2017-11-02 2017-06-13 2016-12-06 2016-03-31 2015-07-27 2015-07-27 2015-12-31

803791

212612

576282

788894

4322

10575

14897

536216

110701

360965

47853

519519

16697

377893

106774

264243

371017

3311

3565

6876

273690

47274

176581

47853

271708

1982

1.09

1.08

0.0092

0.0176

P6Y

14.80

7.40

12.20

6.20

634658

20000

20521

14474

619663

264752

354911

264752

18.20

7.40

23.17

15.00

17.80

29.00

9.20

29.00

P4Y14D

P9Y3M4D

P4Y14D

81805

264278

96278

15.00

0 0.02 1096000 570000 203000 16.66 5.98 273106 418000 14474

10.00

1839123

314582

1964085

619663

400000

219968

188369

0 50805

-4513

-2268

-180024

-132115

304484

33320

-3922597

-4602340

92977

15191

-121768

28791

-15191

4000000

1178

1263

4975153

70539

-172407

5044514

3825172

1150708

-792359

4677545

5828253

5720000 0 0 254024 160000 264000

10-Q false 2014-06-30 2014 Q2 Cellectar Biosciences, Inc. 0001279704 --12-31 Smaller Reporting Company CLRB 2869739

41330

-4391

-2622

0 1158 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Development Stage Entity</i></b>  In previous filings, the Company has reported as a “Development Stage Entity”. However, in June 2014, the Financial Accounting Standards Board (FASB) published an Accounting Standards Update 2014-10 (ASU 2014-10) that removed the development stage entity guidance under Accounting Standards Codification Topic 915 (ASC 915) Development Stage Entities, thereby removing the financial reporting distinction between development stage entities and other reporting entities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Presentation and disclosure requirements under ASC 915 are no longer required for the first annual period beginning after December 15, 2014, including interim periods therein. Earlier adoption of the new guidance for ASC 915 is permitted for any annual or interim period for which financial statements have not yet been issued for public business entities. Accordingly, the Company has elected to adopt these changes effective with the filing of this Form 10-Q.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>4. REVERSE STOCK SPLIT AND RECAPITALIZATION</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt. The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected and the corresponding reduction in authorized shares of common stock by filing an appropriate amendment to the Company’s certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on June 6, 2014 and effective at the close of business on June 13, 2014, the second amended and restated certificate of incorporation was amended to effect a 1-for-20 reverse split of the Company’s common stock (the “Listing Reverse Split”) and reduce the number of authorized shares of common stock to 20,000,000 from 150,000,000. All share and per share numbers included in this Form 10-Q give effect to the Listing Reverse Split.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1-for-20 150000000

275000

1365

550000

825000

334000

62500

2014-07-29

1000000

0.08

P60D

617500

382500

254000

20.00

10.00

12.50

25.00

12.00

15.00

10.00

321.30

1989

2019.60

96278

1869000

19 Warrants issued in connection with the sale of convertible debentures. As described in Note 3, the warrants are only exercisable following conversion of the associated debentures. The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as a derivative instrument as described in Note 2.

EX-101.SCH 9 clrb-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - FAIR VALUE link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - CONVERTIBLE DEBT link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - REVERSE STOCK SPLIT AND RECAPITALIZATION link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - RESTRUCTURING COSTS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - FAIR VALUE (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - FAIR VALUE (Details 1) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - FAIR VALUE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - CONVERTIBLE DEBT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - REVERSE STOCK SPLIT AND RECAPITALIZATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - RESTRUCTURING COSTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - SUBSEQUENT EVENT (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 clrb-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 clrb-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 clrb-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Convertible Debt [Abstract] Debt Disclosure [Text Block] Equity [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Statement Of Financial Position [Abstract] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents CASH AND EQUIVALENTS AT BEGINNING OF PERIOD CASH AND EQUIVALENTS AT END OF PERIOD Restricted Cash and Investments, Current, Total Restricted cash Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total FIXED ASSETS, NET Goodwill GOODWILL Other Assets Noncurrent OTHER ASSETS Assets, Total TOTAL ASSETS Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] CURRENT LIABILITIES: Notes Payable, Current Current maturities of notes payable Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued liabilities Derivative Liability, Current Derivative liability Warrants Capital Lease Obligations, Current Capital lease obligations Liabilities Noncurrent [Abstract] LONG-TERM LIABILITIES: Convertible Debt, Noncurrent Convertible debt Notes Payable, Noncurrent, Total Notes payable, less current maturities Deferred Rent Credit Noncurrent Deferred rent Liabilities, Noncurrent, Total Total long-term liabilities Liabilities, Total TOTAL LIABILITIES Commitments and Contingencies COMMITMENTS AND CONTINGENCIES (Note 9) Stockholders Equity [Abstract] STOCKHOLDERS' EQUITY (DEFICIT): Preferred Stock Value Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of June 30, 2014 and December 31, 2013 Common Stock, Value, Issued Common stock, $0.00001 par value; 20,000,000 shares authorized; 2,869,739 shares issued and outstanding at June 30, 2014 and December 31, 2013 Additional Paid in Capital, Total Additional paid-in capital Retained Earnings (Accumulated Deficit) Deficit accumulated Stockholders Equity Attributable to Parent, Total Total stockholders' equity (deficit) Liabilities and Equity, Total TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Organization, Consolidation and Presentation of Financial Statements [Abstract] Consolidation, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Share-Based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured On Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block] The tabular disclosure of changes in fair market value classified within the Level 3 fair value hierarchy. Schedule Of Stockholders' Equity Note, Warrants Or Rights [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Schedule Of Compensation Cost For Share-Based Payment Arrangements, Allocation Of Share-Based Compensation Costs By Plan [Table Text Block] Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsidiary, Sale of Stock [Axis] Sale of Stock, Name of Transaction [Domain] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items] Net Income (Loss) Attributable to Parent, Total NET LOSS Net loss Certificates of Deposit, at Carrying Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Convertible Debt, Fair Value Disclosures Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Equity Components [Axis] Equity Component [Domain] Warrant One [Member] Legacy Warrants [Member] Legacy Warrants Warrant one Member February 2013 Public Offering Warrants [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Liabilities [Abstract] Liabilities: Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Of Warrants Classified As Derivative Liability Outstanding Beginning balance - Fair value Ending balance - Fair value Represents the fair value of warrants classified as derivative liabilities, outstanding as of the balance date. Fair Value Of Warrants Classified As Derivative Liability Fair value of warrants issued in connection with February 2013 public offering Fair value of warrants classified as derivative liability Represents the fair value of warrants classified as derivative liabilities during the period. Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Gain on derivatives resulting from change in fair value Gain on revaluation of derivative warrants Gain on revaluation of derivative warrants Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Fair Value Assumptions, Risk Free Interest Rate Fair Value Assumptions, Expected Volatility Rate Fair Value Assumptions, Expected Term Debt Conversion [Table] February 2014 PIPE Warrants [Member] Debt Conversion [Line Items] Convertible Debt Convertible Debentures And Warrants To Purchase Common Stock Represents convertible debentures and warrants to purchase common stock, shares as on the reporting date. Payment For Convertible Debentures Represents the payment for convertible debentures during the period. Securities Purchase Agreement, Initiation Date Represents securities purchase agreement, initiation date. Debt Instrument, Maturity Date Debt Instrument, Convertible, Conversion Price Debt Conversion, Converted Instrument, Shares Issued Debt Instrument, Interest Rate, Stated Percentage Gross Proceeds From Sale Of Securities Represents the minimum gross proceeds towards sale of securities. Debt Instrument, Interest Rate, Effective Percentage Payment On Default On Borrowings Represents the payment on default of conversion from debentures to common stock. Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price (in dollars per share) Warrants Exercise Price Warrants Expiration Date Warrants Expiration Date Expiry date of warrants held. Default Value Of Borrowings Represents the amount of default made towards borrowings. Debt Conversion Converted Instrument Value Warrants Issued Relative fair value of warrants issued with convertible debt Represents relative fair value of warrants issued with convertible debt during the reporting period. Debt Conversion, Converted Instrument, Amount Non-Cash Interest Expense Related To Discount On Convertible Debt Non-cash interest expense related to discount on convertible debt Amount of noncash interest expense related to discount on convertible debt. Deposit Liabilities, Accrued Interest Fair Value Assumptions, Expected Dividend Rate Income Statement [Abstract] Operating Costs and Expenses [Abstract] COSTS AND EXPENSES: Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Restructuring Costs, Total Restructuring costs Costs and Expenses, Total Total costs and expenses Operating Income (Loss), Total LOSS FROM OPERATIONS Nonoperating Income Expense [Abstract] OTHER INCOME (EXPENSE): Derivative, Gain (Loss) on Derivative, Net, Total Loss on issuance of derivative warrants Loss on issuance of derivative warrants Interest Income (Expense), Nonoperating, Net Interest expense, net Nonoperating Income (Expense), Total Total other income (expense), net Earnings Per Share, Basic and Diluted, Total BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) Weighted Average Number Of Shares Outstanding, Basic and Diluted SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE (in shares) Class of Warrant or Right [Table] February 2014 Private Placement [Member] February 2013 Public Offering [Member] February 2013 Public Offering - Placement Agents [Member] November Private Placement [Member] November 2012 Private Placement [Member] June Public Offering [Member] June 2012 Public Offering [Member] June Public Offering [Member]. Underwritten Offering [Member] December 2011 Underwritten Offering [Member] Underwritten Offering Member April Private Placement [Member] April 2011 Private Placement [Member] April Private Placement Member Warrant Two [Member] Warrant two member Warrant Three [Member] Warrant three member Consolidation Items [Axis] Consolidation Items [Domain] Intersegment Eliminations [Member] Reportable Legal Entities [Member] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Reportable Subsegments [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number Of Shares Issuable Upon Exercise Of Outstanding Warrants (in shares) Warrants Issued To Purchase Common Stock Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table] Option Indexed to Issuers Equity, Type [Axis] Option Indexed to Issuers Equity, Type [Domain] Employee and Director Stock Option [Member] Employee and director stock option member Non Employee Consultant Stock Option [Member] Non-Employee Consultant Stock Option Grants [Member]. Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] General and Administrative Expense [Member] Restructuring Costs [Member] Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items] Share-based Compensation, Total Total stock-based compensation Stock-based compensation expense Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table] Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected life (years) Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value Schedule of Share-based Compensation, Stock Options, Activity [Table] Share-based Compensation, Stock Options, Activity [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Granted - Number of Shares Issuable Upon Exercise of Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Canceled - Number of Shares Issuable Upon Exercise of Outstanding Options The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options Share Based Compensation Arrangement By Share Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Vested - Number of Shares Issuable Upon Exercise of Outstanding Options EX-101.PRE 13 clrb-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"I^C`/Y@$``,P7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%JVS`8A>\+>P>CVQ$K MDM:N&W%ZL767;:'=`VC6G]C$EH2DMLG;5W;:4DJ6$A;8N8E)+/WGB\`?^,PN MUGU7/%"(K;,5$^64%61K9UJ[K-CONU^3^[MM8ID_(':]ZE3)X3RKQS7!.; MUL?/&8/QG0G#G;\'/.^[SD<36D/%C0[I2O<9@Z\[_NC"ZH]SJW+_D!V4;K%H M:S*NON_S"931!](F-D2I[\KQ6O:ZM2_<>_+'Q9&/%W%DD.'_C8,/Y)`@'`J$ MXPL(QRD(QQD(QU<0CG,0CF\@'&**`H)B5(&B5('B5($B58%B58&B58'B58$B M5H%B5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5HEB5H5B5H5B5H5B5H5B M5H5B5H5B5H5B5O6_S)IR5TI\_/SW!W<<\T%9%].FHWCD%^SMT(^2&QW(W*:0 M6^6C`[R=O8\C=ZXWP?F8V^=`AY_"2[T\[)[X/(A":NFU8-Y5U+XFYN;Z\,!W M33$-W;@ALR.;CUW\_`D``/__`P!02P,$%``&``@````A`+55,"/U````3`(` M``L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24 MFV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A M363X8<'%#U1?````__\#`%!+`P04``8`"````"$`\*#N9/0!``#)%@``&@`( M`7AL+U]R96QS+W=O_4G9E2_HBT%[12 MKRP\@)6X346;1+9AZ=MC%384B?UV#]%<(ME1QI\^C^?YU>FB,FUM=MUK2_-P4>S7)S]N+WW.Y?R1['9]K'( M4=I8FB:E_L;:6#5^[^*DZWV;WZR[L'3J=VW`:PRR^Q"Q6 M=6G"JB8QQ<.ASTO_.WBW7F\K?]=5SWO?IF_6L+^[\!0;[U,.ZL+&I](,4]$> MWY!,LF9C_R(G^Z$KYPK)X;FR')XC.7(]IIR8#KN<;L-.O8_1^DQCKC]DQJ>$ M8>HC69B0')DIRY$9DG.IK.82B2%65D,,Y6B;0]`=OE!VAR^0.Z)=A`4681FU M"*<,*Y_M_N#!<6B/3WBXM?,7IZ\V!PAR@',;H4I)GJ+TY5&Q-##@,V>&J3]8 MN$9RM"$%TU@[<6#>D+HUT!O6YC=#?HMVR1%8"53K0KLN"2/.JQ^@]W M"**0'+[Y0?TX@T``/__`P!02P,$%``&``@````A`'0CS9JB M`P``G@L```\```!X;"]W;W)K8F]O:RYX;6R4EMURHD`0A>^W:M^!XGZ#@.:O MHBG424(M@@NCV>S-%)$Q4D&P`%?S]MM@Q,8A67.E(_;A=/?7#3>WVV4D_>5I M%B9Q5U;/6K+$XUD2A/%+5Y[0NQ^7LI3E?ASX41+SKOS&,_FV]_W;S29)7Y^3 MY%4"@3CKRHL\7UTK2C9;\*6?G24K'L.5>9(N_1R.Z8N2K5+N!]F"\WP9*5JK M=:XL_3"6=PK7Z2D:R7P>SO@PF:V7/,YW(BF/_!SL9XMPEDN(\E? MK6Q_";ZWD2Q%?I:3(,QYT)4[<$PVO/9#NE[UUV$$5Z_TEBXKO2K)<2H%?.ZO MHYQ">GMUJ)?6UK3SXI]%*:8AWV2'H.(H;1_#.$@VQ5^AM&_520<#F_+28QCD M"[C>:K6JWQYX^++(]S^"O(+TRPK"?$&7'`2)R'^1LSXUWUPP1: M6%3=A,Q464JO0_B2FH%:&,$MLC0P;?/,@^'B;3F_P('"[2YQ"H';VRX](E1UX"Z#8K"U30P::J`FC?I M>]`NR(,!"':-&PR<*A#W.>NUD<$`J@*!!]H9]9\C>'(<1K^#H5-/H:Y!`\,' MZ_5HFY7DBO`UZ.BH&YK`H$A3@P0&4A.!_'1]0!K52M1J7@0Z44F'//?#"-=4 MJYD0D!1C6:V9>"XT@T_(3:>653.K#9SMDD,Z.AX7.#29^5`'9Z7CX8'# MEX0P;3J>(#A\20A(K1K?P0W3!6P;1DC$5\?XPN'(3,-&W?<*^$%>BE>KZK$( M!T'GH^5:R&$=W';]OPL6F8&Q0#H=S*!>PJR4A8-WN)D?S>#ELO@HWLY*)I3] MJW7O'P```/__`P!02P,$%``&``@````A`#SLVB36!```AA$``!@```!X;"]W M;W)K$_`F(N)DAR52W>/ M=%9:K?;R3(F3H`*.@#;MM]\Q)H%QVUU^^ZA*XYTW;2'J ME4GFMFGP.A>;HMZMS'_^?IXQTVB[K-YDI:CYROSDK?EM_>LORZ-H7ML]YYT! M%NIV9>Z[[K"PK#;?\RIKY^+`:_AF*YHJZ^"QV5GMH>'9II]4E99CV[Y5945M M*@N+YA$;8KLM,-+S,.O"_W1>']F2MRA\Q5V7-Z]MAEHOJ`"9> MBK+H/GNCIE'EB^^[6C392PFZ/XB;Y2?;_<.%^:K(&]&*;3<'8SX6T. M$04S<\>3EG)1@@/PVZ@*61H0D>RC_WLL-MU^95)_[@4V)8`;+[SMG@MITC3R MM[83U7\*(H,I9<09C,",P0B!H=N3+>5(KRO)NFR];,31@&*!5[6'3)8>68#! MDR#U^K/$GRD$:=+(D[2R,@/3`.=;2,O[V@^6UCM$,A^0Z`K",!*?$!DW:38Y M#8QF"9Z2G@B9-%!TE@4!F&ZD!L'V6X^#WQI>$'V(DN40T M(^DE,3&"Y-"OR)$P%-;$^\#&OD4*<2>(AXGX+I'<)=);!)('CCR>+0FO3(C= M.3F!5A610EA?B(0R.PCU4D.$[S)&-2*9$M0.?6)K(4H1X=#0]<8P(WFPKAZ7 M)V%-GE8WD4*\7E[HA8QIGL53@-@!#5R].*>$8[M^Z&@Q3!%!0L_U1C>0.O\K MZB2LJ:.X\B*%*'7@6DA=#,0*<'OY8\15QT"3'<*(%IKT^F0D"-K8X^F2L"9( M\S=2R"`(XN@3K3?&B`@5H08CO$LE= M(KU%H`(E<&Z9IE!NVA3&;J>RGZ7E4BNS:&!4,CUH')Y69C$B?-^F>B$FB/`( M8[86SA01ON]3-BX9+%1N[P_7*E&'`;0S:%T]&IBKS2.^]65RZ\MT^')8!('K MAMX86BQ);OJ/2U)'!"1):^61//Q!`0_O)H2&^G8?8\1QB):1!`.$48>,*>D[ M:XH1E_FC#2Q0[OJ/"U1GA*E`IO7TB"A&"72],&`713DE?(_!:1JOX`39H-3S MPK$[#OJF-F:,NG0,-!8H]_W'!:I3`A*HN1^1Z4EBYMC,8W2,;N]>K#.^Z_J: MA`0SGNV$CK[QIQH#ZW.Z@K%0>028"'VPS:B#`Q*L.1K)*Q.4;-AOX3-['FAG M@/@"T"PD&"#S0$MXB@%G#L&8_HQ]`4N6QP--L@O.WNFLZE"!)&N*(KB5CJO4 M87X83.IK2/%=)+EO15Y_)R\*2!!>K%1UO577P(HW.Q[SLFR-7+S)JRN%K)Q' MS]?J)T=>C[3QB"S@TG8YGLAKN!RWSA/@%GS(=OR/K-D5=6N4?`NO@LQ#JCIUJOK$O?SZ7I76&VUYP>J531S/MFB=L;RH=RO[ MWW]>'N:VQ45:YVG):KJR/RBWOZY_^[(\LO:5[RD5%F2H^"]$L7)=G>UJE MW&$-K>&;+6NK5,#;=N?RIJ5IW@55I>M[7NQ6:5';F&'1WI.#;;=%1I]9=JAH M+3!)2\M4`'^^+QI^RE9E]Z2KTO;UT#QDK&H@Q:8H"_'1);6M*EM\W]6L33[>7*2OBJQEG&V%`^E<)'K9<^(F+F1:+_,".I"R6RW=KNQ'LGCR M(]M=+SN!_BOHD9^]MOB>'?]HB_Q'45-0&^8D)[!A[%5"O^?R(PAV+Z)?N@G\ MU5HYW::'4OS-CM]HL=L+&'<$'MFRHP5;`S5YD\H=)`O(?.H,>?2]7FL5Z,DDCS++RI[9 M%G3!83YOZS"8+=TWT#13F"?$P&./(3W"!38]):!Q3FE,22`&$6`A.$L[!4R M",C_$(/C=WL%9-"`P,4*($:M`$GB.!@GD%P2N+T",FA`(-3Y40'$J!6(PUFD M)3(4('#FAA+<9M!%#2EHC9&"`B&'(`H3W=YT<$[ M;`&"U!;,'"V1R6"2)Y(14XRTZZLA(`@5\+4^9OT12[QC"48\,=*G7=5'$"J0 M."0Q_K2!F7PF.209L<@S!U1\$/1K/?Q)_MA%#;PITAUB?06"HZ%_2T17SJ8_ M8I&WQ])%#6GHU5=8;E8UU! ME4?0>/=X/\/K2T7;'?V=EB6W,G:0=R\"E/M/^WOAH]_=[/HOX%K6I#OZ9]KN MBII;)=U"J.?,H&Z+%SM\(UC378XV3,"%K'NYAPLXA2N&YP!XRY@XO9%7Q_Y* MO_X)``#__P,`4$L#!!0`!@`(````(0"OE^!=(0,```@)```9````>&PO=V]R M:W-H965TV`"58!(]MIVG^_8QP(.&N4Y:(-^/7+<]YC[*SN7JL2O5`A&:\3[#L> M1K1.><;J?8)__7R:+#"2BM09*7E-$_Q&);Y;?_RP.G+Q+`M*%0*'6B:X4*I9 MNJY,"UH1Z?"&UC"2Y%:$U=@X+,4M'CS/64H? M>'JH:*V,B:`E4<`O"];(SJU*;[&KB'@^-).45PU8[%C)U%MKBE&5+K_L:R[( MKH2Z7_V0I)UW>W%A7[%4<,ESY8"=:T`O:X[=V`6G]2IC4(&.'0F:)_C>7VYC M[*Y7;3Z_&3W*P7J/$?DG*V,R/9D$0'\:AUO7)[L& MI*WK@2BR7@E^1+!6X%&R(7KE^4LP[`HRC^]+?*]"*$V;W&N7!,\Q`G@)77E9 MA\%LY;Y`E.E)L[G4^&/%ME/H#@!>SPC5#1G_'7:'HL4:18>OV3;F!GCW;%/K MN9>**.XE(Q)(:$BBTPK?;7]'I"=!HP<`81#U_@;2:,*!QHIO>TTQ8@23(>/U MM+0XP1#`.9R+QAG-8M;V%?:VQ9A]:X_'WO!S;O*($E*[G5*+;/[CQ.[Z:$+L^/'HLWB[):;/.=U[Y9FT9S2M;K0VD'M^\,CHCTX3?88ZZO2"VVB$+KH1NCB=L% M.7=""VDXZH?..>X15#R&TJ]R`.?!=3@]R88[+W`3E]$8N,BQ5]UPU)\.A@V< M.7G,#EU1L:=;6I82I?R@3Y4I5-S?[0^\^ZG>[*S[&S@(VV/#[0?@(&K(GGXC M8L]JB4J:@Z7GS.%%$.8H,Q>*-^VYL.,*CJ#V:P&_."ALIIX#XIQSU5WHK;K_ M#;/^"P``__\#`%!+`P04``8`"````"$`QKR;M8T%``#C&0``&0```'AL+W=O M$0)=DJV)W9 MTHPT&LWAFA(G00T0`3V]_2QCDMBFM3-2U2;PK85_KQ^S<-??W^N3\\JZOFJ; MC8L6ONNPIFQW57/8N'__]?@M<9U^*)I=<6H;MG$_6.]^W_[\T_JM[9[[(V.# M`QF:?N,>A^&\\KR^/+*ZZ!?MF35P9M]V=3'`U^[@]>>.%;LQJ#YYV/XOV>KRGG1UT3V_G+^5;7V& M%$_5J1H^QJ2N4Y>K'X>F[8JG$^A^1V%17G*/7V;IZZKLVK[=#PM(YXF!SC6G M7NI!INUZ5X$"/NU.Q_8;]P&M*%ZZWG8]3M`_%7OKI<].?VS??NFJW6]5PV"V MH4Z\`D]M^\S1'SM^"(*]6?3C6($_.F?']L7+:?BS??N558?C`.5>@B(N;+7[ M(*PO848AS4(,HVQ/,`#X[=05MP;,2/$^_GVK=L-QXP;18AG[`0+<>6+]\%CQ ME*Y3OO1#6_\K(,0'=4V"IR00,25!<,@<[(F!C+I(,13;==>^.6`6N%1_+KCU MT`H27@2)RU\E?J401L63//`L&S=V'1A\#V5YW88X6GNO,)7EQ&1S)DI4)+\@ M7"W/2RX';GF1&D(O!*\:2+KJ@AF1=7U>H,OP.K%XWGQ-1 MJB)DCFA)Z)R0DBAR`E4.+U,$[C7+XD'@,$E%B&-UD)E@0HE9JD1N)8B5H"9" MT0D#N;]L'-ZX,(FW*F%M])E@DM&3.`ZBU-?DR4`0QTD:J`"1@6408:09F\I` MX@=Q>O.HH@UN+UD;KV%@K2$/4C6&6+MM,L'`,*[SH,U";B6(E:`F0M$9S77: MO9#-JX(QZ;02Q$I0$Z'H1+#0R`4U%W*DU4K.W3I!PJYAC..; ME<:'=ZX`R(]BG2`J@?S8ORV=8PZJ$!CA"-V>H:I`W@C\;\`0GSHCA:)IKSI=ZF8:#IR";(4*S2DCUO*^;Y>]9=O>:NI1I6;(B M9+J48T=ZZUH0V`A MN3;F\QIM*Z^`D43X? M);'VCD60?!Y%4:IUOE0%PD0"%&U8:X3N6VG'*'VEU6ZZ;(),OK4CQ(Y0(Z*J M_:0KLOL6BZ[([-L),JH5>0P(L6>A1D15"QZ\W[>8TVI-Y[Z=H"]]JYP/`J0] M?8ER_C/?*@"LA;?%4)7&NQ'IEKS3MJ*'D6_-,-#:]`P+R%"EW(X0.T*-B*H6 M!J.KO<.V/,KV7H8%9%1K18@]"S4BJEJM'3(OMWRCV&Y;`8EM+^WYGT\9Q,E@ MJ7>M1#FO!?/==7YY$8S\97SK>84HL7HFMXYL3U\G]H!-M?'CT?X9PJ#K69_`?"^;8?+%[ZA?/WWS/8_````__\# M`%!+`P04``8`"````"$`[7$QFX,'```6(@``&0```'AL+W=O'3K[;4W6H;*0]__SP=:S^".`FC\V-=;VCU6G#> M1X?P_/I8_V?G_=6IUY+4/Q_\8W0.'NN_@J3^]]-___/P$<7?D[<@2&M@X9P\ MUM_2].(VF\G^+3CY22.Z!&=H>8GBDY_"U_BUF5SBP#]DG4['IJ%IK>;)#\]U M;L&-[[$1O;R$^Z`?[=]/P3GE1N+@Z*;SX]9`[Z7QA\)-+G6O(6?0SC\#`+ MSP%X&^+$(O`<1=^9='Q@"#HW26\OB\`JKAV"%__]F&ZBCU$0OKZE$&X;9L0F MYAY^]8-D#QX%,PW#9I;VT1$&`']KIY"E!GC$_YE=/\)#^O98-UL-NZV9.LAK MST&2>B$S6:_MWY,T.OV?B[(978T8N1&XYD9TNV$9=KOS%2MF;@6NP@H8O',( M5MX9KM?.#:-CZW;K"Q.!*6?>@.O5RMU#:.6=X2HZMZ4AE/BOG?>$:][3:G1L MVVIUVC"2DHZPBK/QPC7O:!A?=[R36X$\O9HQI0'<&0)=I`'[D`_'U*7AE$Q$ M%\%G'_*^G49;UQRSP@6ZB#S[()S@W'E7$6^V8O*^[?ON*H*MWV+V&PM'%P%D M'X3+S"^O/UU$T&#UXZO+N,E+0E9A^G[J/SW$T4<-RC:D0W+QV4-`=YEE45MX M'*_5YK-B`U6&6?G&S#S6P4]01Q*HD#^>+,UY:/Z`JK;/-5VN@;]7#<1=U?2$ MAA4Q9KB/P0`#CP/YUKIJ="@4PN@(@S$&$PRF&,P$N,T&W78N%.*V"PR6&*PP M6&.PP6"+P4X"30CR-=*P8/]$I)D9%FDQJZX`-T>8[98:@1[5&*JB3Q6FC1)H M4*!I::H=CVK0G89"(28PX@#<=LU+U&505/`M`ZVV+M?`_:X/ M!;1&>I6*?J5B4*GP*A5#H1#+;B3`IT,?5RHFE8III6)6J9@+A1CZ0H!/A[X4 M"M%E)<"G7=:5BDVE8ENIV)4IE%R%7Q5*KK(W;@MZEY<8UNNQ#@_-:SY:!EK) M7:XIRUFNL+,7=-UI65H'975?5AAM6]-0$1W(`J=EM%&Q]N1VW6PA^T/>W('+ M=2)F^U:$LY?^D6S#-FRT-L=RLP7[&&JQFO#F$C=,*Q4SY1;@!.R&.1[RQ).9]N3M^:1M4 M=O?*N@_S1G!325)SD9.-WS3T!EJ]X\HQ3)0Q.!T4QJE\`T/3G09*E)G<'WMP MGC?*RS,M5II6*FW(.Z<\[;E8G09%:-Z#9Z"BT+C!!OK)`1\Y9< MV:-LK;9K%KK)1FDW.@Y:U%NU'39+U8?=3FVWI/T0);EA\U!)[O*7#::&EQ+S MMLE#2(^0/B$#0CQ"AH2,"!D3,B%D2LB,D#DA"T*6A*P(61.R(61+R$XF2G!T MV,U0HO.[F[#,#JI$^-VJF]T,=GOEGS]F&SV,>C>5>-'N4S2@R*-H2-&(HC%% M$XJF%,THFE.TH&A)T8JB-44;BK84[12DQANV1/Y(O)D=-=ZDRG79@0^(E'B3 MRM^[J6[QOG84:$!5'D5#BD84C2F:4#2E:$;1G*(%14N*5A2M*=I0M*6(G0#G MC@9_\7CS$UU^WG(*XM>@%QR/26T?O;/36CAN>7JXXOPHV7&A3H`!Q&'9PAES M=DQ,6JZGSZC%LUS8,Z*V9H8+.\D%W'1AXZ^`6R[L]U"^,%S87B[@I@M[@07< MX8+APH%W'1A-QAX\QH8.)6_^*_!W(]?PW-2.P8OD`=:@QU_QOQ< MGW])HTMV-/<GWU\@_^_"&"33VN`^"6*4O&%W>#Z'QU/_P(``/__`P!0 M2P,$%``&``@````A`-B8U-#0`@``Q@<``!D```!X;"]W;W)K&ULE)5=;YLP%(;O)^T_6+XO7X&DC4*J)E6W29LT3?NX=HP!JQ@C MVVG:?[]CG!`^NK3+!<'PGI?GG&,.J]MG4:$GIC27=8I#+\"(U51FO"Y2_.OG MP]4U1MJ0.B.5K%F*7YC&M^N/'U8'J1YUR9A!X%#K%)?&-$O?U[1D@FA/-JR& M.[E4@AA8JL+7C6(D:X-$Y4=!,/<%X35V#DOU'@^9YYRR>TGW@M7&F2A6$0/\ MNN2-/KD)^AX[0=3COKFB4C1@L>,5-R^M*4:"+K\4M51D5T'>SV%,Z,F[74SL M!:=*:ID;#^Q\!SK-^<:_\<%IOPF"_4GT0]N`[PIE+"?[ROR0A\^,%Z6! M;B>0D,UKF;W<,TVAH&#C18EUHK("`#@BP>W.@(*0YQ1'\&">F3+%L[F7+()9 M"'*T8]H\<&N)$=UK(\4?)PJ/5LYD=C2!_Z-)&'G1=1(F\[==?$?4)GA/#%FO ME#P@V#3P3-T0NP7#)3B?,G,<7:[_2A5RM"9WUB7%"XP@"PWM>5K'0;CRGZ"F M]*C9.`T<.\U(L3TI;"L`KV.$LO497Z_Z"<6*+8KM@F7;N`O]YT9#LNTKBD4G M&9!`A?HDMEHSV$V7B6P0Z'J)Q\$(8>,T<4^3=`1M&MM+B@$CF$P8YV]"VJAV M@W;=B8/9$&'C-'W(.(B'FNU4_5V_G69(.1]13C5G MEP'E?$AYN=%6/*8[;R1'YS1)^X[`$&]_([B+D@$=O'#_7T,;-*:\'B)LG,91 MALGKF$[3K_.XAFZ>NG$CF"K8EE651E3N[:P,H0;=U6Z,WT7M).YNP!AM2,&^ M$57P6J.*Y1`:>`OHH'*#V"V,;-IAMI,&!FA[6L+WDL$$"#P0YU*:T\+.E^X+ MO/X+``#__P,`4$L#!!0`!@`(````(0!T"L&64P<``,PH```9````>&PO=V]R M:W-H965T>;NF.=U-)O5ZEQ^R>ER>\B-\LBVK0];`R^II4I^J/-NT!QWV MDV`ZG4T.67'T4.&NND:CW&Z+=9Z6Z^=#?FQ0I,KW60/MKW?%J3ZK'=;7R!VR MZMOSZ69='DX@\5CLB^9G*^J-#NN[+T_'LLH>]]#O'_YMMCYKMR\&\H=B795U MN6W&(#?!A@[[O)PL)Z#T<+\IH`?&]E&5;U?>9_].AY$W>;AO#?JWR%_JWO^C M>E>^_%85FZ_%,0>WX3J9*_!8EM\,^F5CWH*#)X.C=7L%_JQ&FWR;/>^;O\J7 MW_/B:=?`Y8Z@1Z9C=YN?:5ZOP5&0&0=M,];E'AH`SZ-#84H#',E^M']?BDVS M6WGA;!S-IZ$/^.@QKQM=&$EOM'ZNF_+P'T*^:50G$E@1^&M%_&A\&T3SQ7M4 M0JMR^ZH"@EW\39E8%_IY5@G&PB/QH)MLQ06O;*Y5F3?9P M7Y4O(RA_,*\^968P^7>@?+Y$:&AWT=ZZ9N"S$?EL5%;>W!O!Y:BAT+X_A//; M^\EW*(ZU96)DX+G'1"Z3#'5\ETC/A+G$YM3J@FQ$3JW/C"E6Z'?7>;B$_($0AP1HB$$@G-$8X1,.7UC>`-,#`Q8#%U^Q`$`D2G`,BH41" MN*P5S$'6"S-0Q,C,L!7\V)P6?X.><#R*A1$)SA..#"9V]A9"O M!`/3_I.)/4;&]C^XG=*E`3_G^B\22B0T1SC]7[K]OZX.S$'4AY","&1PGYD'K`G687J96A4&4C&@6<8TP6:MGQ)5U@0G--82F M21^AKBY\,J\F%F#ZFLJ(DA'-(JX=T)B^'4)=&)I.%Z3Z8Q\AK`O_8ED@`<]O M9DHKPB!*1C2+N#Z8W/7^LL"TYI8%#9;F>P,P#9>18#!$N,#7)M/4"K!>B"K: M:49O-7-M,.&K9X-0#AC5G.XO20=C'R&;)L)H.A@57."S#HB(LJ=A3-(LXMI@ MLM?U-F!2U@=.Q?7!9+">#U=.EIC<7#_( M58]]A.SJ$9E[3[IX4"(@P22U&K=M4">'J^[#-R<9S2*N$2:'O=\(3&^N$31D M^ES$:R][8A'T"KZ>F@W,2F45)2.:11Q#@@_%S?8HLGXLR56-+<14<&(1-"2: M+J8DHJ6=AOE"CU9&]^';E<$BKA$D9_(S9G`A7RY)XV,+L0:@CIU-@L6P(&01 M)2.:15P?H,K?/T(""W5#QK)F15V[/A1#@PLQ=$8:$5N(M MNQ<@\^L*-65)[^,LQ)J".F\OUJDLHF1$LXCKATF$/3^$:1?SH[L0T]NW0`R9 MB8RD,J)D1+.(:X0)<]<;@=$/AG]WYQ7.!T9P^1`322`BJ8PH&=$LXAKQH:P: M7,BJPP4((7:$(-+-AE%P8(96XCI2F(1:PX)J*DL MH&1$LXCK!S\P89BCR(0Q^$$A1(@U!)'SA#%,[+*&DA'-(JX=))`*=7$AB"YH$(4-7<8K M_*+4W-+"PQU#B448IU(943)B-I>9MEP^$1J!F\=P2](AKY[R)-_OZ]&Z?#8; MPP+X4JI[M]NT]CDPFW#(^XE_!YN#S`Z?[@/82W;*GO(_LNJI.-:C?;X%R>EX M#JVJ<#<:OFC*4[L1ZK%L8!=9^^\.=@WFL+UH.@9X6Y;-^84Y0;%_```` M__\#`%!+`P04``8`"````"$`_N@OU2('```K(P``&0```'AL+W=O'>D76FUVLLS M34B")H0(Z.F9O]\RQC8N)W8RVGYH.M6GRCY597,"?O[TK3HY7XNF+>OSQO4F M,]]&ZGUY^_NGYHVZ^M,>BZ!R( M<&XW[K'K+NOIM,V/196UD_I2G.$_^[JIL@X^-H=I>VF*;-<[5:>I/YM%TRHK MSRZ+L&[NB5'O]V5>;.O\O2K.'0O2%*>L@_FWQ_+2\FA5?D^X*FN^O%^>\KJZ M0(BW\E1VW_N@KE/EZ\^'<]UD;R?@_\F$&[*)JIS M7DU74XCT\KPK@0%-N],4^XW[ZJU)X+G3E^<^0?^4Q4<[^MMIC_7'+TVY^ZT\ M%Y!MJ!.MP%M=?Z'0SSMJ`N>IYDWZ"OS1.+MBG[V?NC_KCU^+\G#LH-PA,*+$ MUKOOVZ+-(:,09N*'-%)>GV`"\-NI2MH:D)'L6W_]*'?=<>,&T21&-%1#2/- M!T>X7IFNP1'"]B/"54QQL@S#>;1,!D^X2D_39*J3ZI#@G"E8L@53#03&(4[]#3F/H<.N[X@>5&I$RR] MY-%M%L_..E3\@A80YST3A;)<)JXJV4GV7Z%*B93'D$.2V4 M:V)"*&F!VC^>%NJ$TX+F&#.,2,L,;0()^_\H"]AA-4[C#+5;RMUOI\"$4%(` MF]WC*:!..`5H0XH9!DHQZAY4J(1CQ*+@!H-3JF-06&)"*.1AIWZ$V<2N"F!`*<0_V^'&I*7/[OM][H9I'N,,'$&OQD#8CZHID0(Q:7%AN MD[=#B!&BTJ<::-3I=])GRDFY[\W1;2SV&,A4>@$1M1<6`W]K7&*,HO*GT@CQ MMS>^QP05:(O1SHWN0/$`,O)G<<;UYQ89&6T4J3TN,4)4_E0?(?YWM#]353#7 M$7^M_1F(M?_2US?CQ&.(,7UND8$U^E8($7&O15'I0W5^@#[UPJL?Z?+88R!C M^3E$MC^W7)MYKY)3>UQBA*C\J0A"Y;^C_9ET@D*,RJ^UOTE?,<%/O^E#'L?U MYQ896:N_%4)$W&M15/Y4!R'^=[0_4T]J^VO;GTEB#?PY1-:?680J]B-%ZJ^T M+PNIQV-#B:JU'1@N>\QD'$Y<(A,![.(='AS-1VJN$OM M8Q`C1,T%U4Z/YX(I+C476/=[)EDVM`:'R%QPBRQT$$GYVKNE]LC$"%$S0$74 MXQE@TDO-`'H@$7LF?39D@$-D!KA%9D#;'*P08AQ:X>]?D8;VS;'WLJGB`61: M#0(B^`O+;?YV"#%"5/X_I`W]*]I0>R8R@(S\N+,[I7#DY#.F:3!5X,]JC$"%'94]GU M\&9`'Z1K[%&5X@%D9,]%GVP&;I&+(5B@[U>I/3(Q0M0,P`3'&3`_%/`I6JV[ M%V*--(",S%F<<=VY13+7*F^%$./0*F\JN%#E[]@&F4R#*ADT(GU=T@M`"4)4 M$@&1E;Z3+T-XJ](`VAX"!9$&OE!#L)%9G&! MNF@[1#%T46J'$"-$30A598\GA&DY)2$++)I]+@$E7RTG'"(;@EMN.J7VN,0( M4?E3)8;XW[$@F'ZS+`A=Y&G\.43RYQ8#?RN$^":(RI^*+,3_C@7!I)E2?^V1 MF<]`MQ<$UW>2/+<8R%LA9!CW^A)2R%.B8_+FNT"/AF^X@7B9$^NF1#=M=5.J MFXAB4J=Y0[L]^+86WOWCNUB`]Y]X`-&G+J-="FF<1*)$[713JIOH^0,Z!P@/ MCHPD.T_`WDY717,HDN)T:IV\?J=G!6CW"*LXQ_#J4W]DC[UUTA\&P'9_#2]C M=?QK,(,#$?V9!NP1B*,24_$O.*IPR0[%[UES*,^MN MOO3OU]_J#@XI]'\>X5!*`6^V9Q,`[^NZXQ]H$L0QEY?_````__\#`%!+`P04 M``8`"````"$`^9XEY,4#``#0#```&0```'AL+W=OJ![0\+DF1?/ZS%VUM_>R\)X(XSGM-J8SL(V#5*E-,NK\\;\^Z_D M*3`-+G"5X8)69&-^$&Y^V_[ZR_I&V2N_$"(,4*CXQKP(48>6Q=,+*3%?T)I4 M\,N)LA(+N&5GB]>,X*Q)*@O+M6W?*G%>F4HA9%_1H*=3GI*(IM>25$*),%)@ M`>/GE[SFK5J9?D6NQ.SU6C^EM*Q!XI@7N?AH1$VC3,/OYXHR?"R@[G=GB=-6 MN[D9R9=YRBBG)[$`.4L-=%SSL_5L@=)VG>50@;3=8.2T,5^<\!"8UG;=^/-/ M3FZ\]]W@%WH[L#S[D5<$S(9IDA-PI/15HM\S&8)D:Y2=-!/P!S,R%"3K"K./B/`4#`69A>M)I906,`"X&F4N.P,,P>_-YRW/Q&5C M(G_AK6SD`&X<"1=)+B5-([UR03Q>!C+N(`Z$O)OOWY%67C)9S MR9:JHC$EP@)OUXS>#&@T&">OL6Q;)P3!U@TU]LZ?G]D#ODB1%ZFR,2$?*N
2'C@B1[8ZX%(#\1Z(%&!?C7(L[O!-LX>IIE!0;!6 M^I,L.W[YT_7?3K9,@I4^:")O.(:=8N#:-9I&[&>):):(9XEDECA,$0.OP)>^ M5],+0L(;$SJKJQ]YON:18N#Y':-[-$M$LT0\2R2*"-2K"GF>;>L=U2<>OPW< M@1=QWYVO=9),&KKD^)H'.\5,N31+1"TA7\:/\3>K)5:_>4WUW@K.'WKUR43V M82I[X`_L![H_"/;KZ2Z22;H_>A[R[F\'M M%#/50+-$-$O$LT2B"+7,W``%8Y/Z!-(6HO)(G>34H:4D[$SVI"BXD=*K/*6M MH(F[:'>`?$%R6];B.R>$$\8X'CDAG!K&\9T;[C[3V;LA;&-C/G)#V,W&\=@- M85.#N-4-"`Z4-3Z3WS$[YQ4W"G*"4NS%"EXZ3!U)U8V@=7-$.U(!1\GFZP7^ M.1`X&]D+@$^4BO9&/J#[+[+]#P``__\#`%!+`P04``8`"````"$`,:^%>A\& M``!$(```&0```'AL+W=O?ILVK?N6):]`@KG;J,>^_ZRUO6N.)9UWFG-I3S#/_NFK?,>?K8' MO;NT9;X;*M4GW30,5Z_SZJPRA75[CT:SWU=%&3;%>UV>>R;2EJ>\A_9WQ^K2 M7=7JXAZY.F_?WB_?BJ:^@,1K=:KZGX.HJM3%.CN[8?"9MM?NM.I?@-HP3'8'7IGFC:+:C15!97]2.AQ'XHU5VY3Y_/_5_ M-I]I61V./0RW`SVB'5OO?H9E5X"C(*.9#E4JFA,T`#Z5NJ*A`8[D/X;K9[7K MCQO5T3% M'E7@>E4Q-=-SB.,^T!9H]=`AN$XJ=W?$'2O#=:QL>H\W836JP/7:!%];$<.W M5O=["@_HT`^XCB(6>7A@_%$$KM>6@)Y\5'46(4/`A7F?/S^US:<"3S'$0'?) MZ9Q`UB!X.\(@M"C[0N&-"@Y`\'3P6'P\VRYYTC\@E(N1"1@#GS/&Y)GMDA%4 MPBM!8YO>.A(+XFN!Y#[)DA'NDRX)VQ5:FRT9R[&G'NE@Y.0F/#/WNTEAZN:U MC\&UX*M+EN-/-QI\V"X9H;GADK!6+J\2W6!<@V=BQD#GIX&T1"99,D)KTB6Q M4,F6C+F:&L/Y"W/1_?Y2F/-7+-B*!:%8$(D%,2N8NV*[UM3888R26\Q7P`Q, M>HMQ>)WL%O,UDIPQ,+W.C:$+A@W3DOQQII5@:9B-L.U^&3^T,V`,?$Y1(+1R MBQ(A2D0H$:-$@A(I2F0R@O,;O'W<;UIIHT*T3U[:KL>/><`8:,?$B'XSPAFF M7X]XAO!_B"I$*!'/[V&ZMKD2FIF@$NE(/5IE`]1*M'*!&C1((2*2-8(XD0#)FL.N;,YHFJ/--ESWS=2T MDFBTL)4)&",SFA%CI!B^:QC"8(6H1H02,4HD*)&B1"8C.+]A4_NXW[22Z+<0 M#@%C9'XS@L439%]+NU&)""5BE$A0(D6)3$9P=A.8FA_W>Z@E&BYLJX(1DCD^ M(LQRT["6EN,B$8[$.)+@2(HCF13AC:=IRL,3"V')#;(:$8[$.)+@2(HCF13A?:?9R^.^LYR']UU8O`/"(*GO#&&^ M.YHO[--"7"+"D1A'$AQ)<223(KSM-#D2;*69E$4,0"7&1"$=B'$EP),613(KPQH,OHO$6NA\GM)8XP8NYY@A)C6[%^2UN0@+"H.NT[2QFCRU'$-^U M#4]8E<,1D0Q+Q*G<>/D1XQH)CJ0XDDD1WG::4+J"<\ M],$(2<)S.R+CBP#/]1?/08BK1#@2XTB"(RF.T,-8ZLSM3C/GV6$K._NJR_90 M;LO3J5.*YIT>I-(I82J=#GE?+'HX(Y0'YCJX5;XUUW"@L.1#U+3L%9C_ZYC*#E^/ M<%I?PD&9H0&\;YK^^H/>8#K_?_X/``#__P,`4$L#!!0`!@`(````(0"SFBX! M*@,``$P*```9````>&PO=V]R:W-H965TO MGW..Z^/ES7-9D">NM)!53(.13PFO$IF*:A?3W[_NKV:4:,.JE!6RXC%]X9K> MK#Y_6AZD>M0YYX:`0Z5CFAM3+SQ/)SDOF1[)FE?P)I.J9`8>U<[3M>(L;2:5 MA3?V_<@KF:BH=5BHCWC(+!,)OY/)ON25L2:*%\P`O\Y%K5NW,OF(7AH8G>Q:DB>N.&;9:*GD@L%E@*5TSW'K!`@S;@.SR M78AO10BAH$Z0R.6K6YYJ>8M,JL`*`US%"=*>, M_T]VBX)B1,'D(]O:#H!WQS9VR3;GBFC>21P2R-#'25`<4S#O%@YGO:775A.> M:*;=R@W^9DCAL(')*1M6,GQS:[;9PDFP"4_6#V<3EV!M-4.,0PJ'$7@N9\1) M_3R&/4:KF=JMY^/'%6RL(&P$K^\):S1#CD,)AQ";7.TK>WX`XJ9_'?G&MQA8WF$>A/^ME>N,H9I-Y,'[= MQ`[CW&4'*F6TC9OV^1*KG9\PXM"DT3NL3&/ MX03H1KM+P^T8^T5O?(V7B>8ZT+V`7EZS'?_.U$Y4FA0\`TM_=`VGB[*W`?M@ M9-VTUJTTT,6;GSG';`@%7`R'::]M_O&A?* MQY8V#P1?SCT^YUYSV=X^525ZI$(R7D?8M1R,:)WPE-5YA'_]O+\),)**U"DI M>4TC_$PEOMU]_+"]$-K>))Q41$%2Y'; MLA&4I&U25=J>XZSLBK`:&X90O(>#9QE+:,R3S8JN0] M=!41#^?F)N%5`Q0G5C+UW))B5"7AE[SF@IQ*\/WD^B3IN-O%C+YBB>"29\H" M.ML(G7O>V!L;F';;E($#778D:!;A.S<\+K&]V[;U^6K_+RQ51807*VNY=A8NP-&)2G7/-"5& MR5DJ7OTQ(%>+ZDF\%Q+(>"%Q(70]V39"6E\Q462W%?R"X*S`5K(A^N2Y(1!V MALSVO<7_.015FN1.LT1XC1&(E]"5QYT?K+?V(Y0R><'LYYA5,(8<.HAVJWGC M+O#*ZXY3CAU"=PTL];Z@(D-?_VY0)U^#M?QNW[T)`'?OQQOO>Y@C5ILQ))Y# M)B3'.6)`,K*S&-O1;5K`Z;UN2RX.YYO--1&P007N^W94#OW&ICM8Y_F;ACZ4=AH!)@`TV$"4Y.J'JS)'F M2*/17)XI(0EJ@`AHT_[];+-=C$V2PDN3E.7-\KZL!5Y]>R].UEM6-WE5KFVR M<&TK*]-JEY>'M?W/WT\/H6TU;5+NDE-59FO[(VOL;YM??UE=JOJE.699:T&$ MLEG;Q[8]+QVG28]9D32+ZIR5<&5?U472PL_ZX#3G.DMVW:+BY%#7Y4Z1Y*6- M$9;UE!C5?I^GV6.5OA99V6*0.CLE+?!OCOFY^8Q6I%/"%4G]\GI^2*OB#"&> M\U/>?G1!;:M(ES\.954GSR?8]SOQD_0S=O=C%+[(T[IJJGV[@'`.$AWO.7(B M!R)M5KL<=B#2;M79?FU_)\O879K!=ZLY5I??ZGSW1UYFD&VH MDZC`VK^JR^]9?CBV4&X&.Q(;6^X^ M'K,FA8Q"F`5E(E):G8``_+6*7+0&9"1Y[SXO^:X]KFV/+UC@>@3@UG/6M$^Y M"&E;Z6O35L5_""(R%`:A,@A\RB`$ODY<[,G%\-DO7M"0$<:_IN#@=KKL/"9M MLEG5U<6"E@/"S3D1#4R6$%FD!W[ZNT8)I&=*:UG!BD4&/&/00@O0\SX\"([7Q$$`CGXHR9\VSPU7UA2B0&=Z#%&:N.[$)V>D.C) M#2=LUBRKZ0H2@ZGQB6<*8"P!?J>`2OUT6D*>![2FR1M!41\ZPZ`L,GN(D6U' M(@;:;Q97AW#J1@JBTQ1B/:#Y17%1VH?T?+5_26\H_S3T7<:,^L=D"/$\:#VN M!$FG9YC$%_3&[N`K`97T$(.U\SWC
!/O)(3Q2:J3SFN4-9&P.OC&/6XF1 M3><&0>`94QWK$$8]PM38Z/1F^0-!;8>>ZH`71#P(1Y5%R/VAG>409&P1OI&4K<1\EC7D@3$OL8X0 MCU,*H66-SK*)#JW;A&\TU%9BI)+X+(J,LL<&PJ.W7)_.,HD.;9`S1&(K,3)S M'B.^6?58@X"*W&8WRR/HV"-\)9_8 MB/`TK^A6&4E4-Y`TT0BTF1SQO(O16U`(]X#H?3FF`JV_@3%C*K<2HQ$TS.PN M1*=GN(7((__R'5:\,QN/!,Q49XDQQ4,6>F@I*KLZ-<,P)E(;&P\T,R$CX=0P,6N3<'9)9AT+%A#(Q2 M#L;0,!X8=^$AF1@2%,M`N(L'1EP6,:Z40,_A+.N@8^M@(W5&C+P[9;[+1P]Z M,@YBX'$E@O?Q?GPT?N(L9SBZTS2F6Z5KC/DTMY48/*JX_K*A0:Z_;.!Y'9Y( MG9-#]C.I#WG96*=L#U/L+@(8LAI/Z_!'6YV[DZ?GJH53MN[K$4Y5,SB6\G[3\@WQ=# M$DB(0JJ2KENE3IJF?5P[8()5P,AVFO;?[[6=9C7)&,U%@/B\)X^/OUA=/S>U M]T2%9+Q-4>@'R*-MS@O6[E+T\\?=U0)Y4I&V(#5O:8I>J$37ZX\?5@]SG!"0:G]:I@T`,= MNR=HF:*;<+E)$%ZO3#Z_&#W(-_>>K/CALV#%`VLIA`W#I`=@R_FCEMX7^B;JG,(5"P\2>1=LIY#0#P M[35,SPP(A#R;ZX$5JDK1-/:C>3`-0>YMJ51W3%LB+]]+Q9O?5A0>K:S)Y&@" MUZ-)"+BOW)(@JC^/\(V';'I'-+%%FO!#]X,.,`6'9$S]]P"SD6R$/7W.@B4PIJ"4/YM(X6*_P$\>='278NF;B*S07%_"3!@'=BA(S> MSZB+4@3??QF3D[WI1F8EB>D`K'SW$WZZBES]9KS>P8=8W^(/1ZO%+G8P[0;O/FG\T.U.P]4%K<@PK=?\VL9&:@^D27VQP<6$/C,]+B'DYO[^#/7?SA&:?%/>Q9#]M*[(R#8\M\ M7,EF4.+`Z0/US8XS#*?%/;C>JLRLY`BWB)/YM+?.-T,*!RUY#YH6]]!B-Y3, M2H;0AA06S9YH=L_NR(Y^)6+'6NG5M(2=+?#G,)V%/<_L@^*=V9NW7,$Y9&XK M>.V@L'$'/HA+SM7K@SXQ3R\RZS\```#__P,`4$L#!!0`!@`(````(0";N#65 M:5$``(,*`0`4````>&PO&ASAB)E5JE[O(8OBE5)LMS%*KH.DN@KO\/LS0"[@-YB M[_4H?I+]_;\O(C(RLXJBVN/V`#Z(61D17WSG4T1^_R\?KD;%NW(Z&T[&O[FW MM;%YKRC'_*V;PW'O1&DW'YFWLWY>S>O[S\G__C^]EL M7C!V//O-OQZ6O8&L\NR MG%^-OMG>W'SZS55O.+Y7]">+\9QUGSY^S?[8 MG.WKYH,`^VEY,9S-ISUV=-R[*IMO?;U;CD9E?]Z;%J^&DUE_"$7*V1I;[F\T MWPTS[H*=:6_$*X/R0_%OY4WSO:\W-S>WMI^]>+;9VO/N8CIE>'$PG/69XOJWYOC[OC6:MB=(J M;\KI<"(>7H[>]%Z@17C]`/Z?->'X^G?;S4?-X4;*Y8.7,?_NR?'>_G%G?Z_@ M7YV3H\.]G2Y_O-HYVCG>W2\ZO]W?[W:*!V\[>\7]AZVURSYBY9+SJ/GC[MO3 MT_WC;K'3Z3#%MZV?>[/+`AU3]/6/\L^+X;O>")9L[?FT1&R&_7GIKS;G>3,M MKWO#05%^0`7-(+SFG,PO8;E^8/+>;%:VY^U.YG#^[>\<'/X[R/`=K!7'^]WF MZC^]+=.5KQ6T3:T>'.J\.CP^[A_A+,A6VA M:1?3X7S(GB?GQ7@RYQ_7O9O>V:C%BSM]4[KI=T-2K]^?+L#J:-@[&XYLHB:H M>[#NN]Y\^*Y,;[7D=K=W/10F1V5O5A:3L]'P@A&3<8N0=83?LNK1R?$/Z]W] MT]?%K6B8C+%A\R';+0;EV;P)^W&.D#7`F\T2M2O4-4?ME>?WZL/L:">D4.\A>?'@ M&.B+%RV)^_K3QT\?FU-UNB>[__;;DZ.]_=/.U\7^[]X>=G]?/-C;/SCP^ M;$D>$A/V.)N;QKR_N8&EV-R">Z8%4K@HORN>K?&DF+DN[2WFEY/I\"_EX#OX M#-,WG,W$.29JE9XM>L:)&-LR&5M[9Z_LEU=G2.1*7>$:_!9XMC<%T"J@MM>> M/WVQ]NS1BPCQ*@#GQ2^`;F8%H+:X6 M(VSBH/F*\Y#M]'(R&N"%?6W:#_?FP<"'MZCN&B-C)N.8V\G>7/=NBOX/;S"> M^%'E?(A?\,=5BK_%0HESB@=@9S`9C7I3M`TD-Q9J[:@U08O3FO"W1CB)/_O: MI.+/YKLX(O(;`M=]Z1;JHS\+_]+7E^]AZ:NW[6.Y#>]T,>6N8$X.BI,W^Z<[ MW4.,_"JB/KJS"]VV]2>=H,;V__V-W(FVU<*,XV3VW>8/RG?E:'(MCZI)E!_* M<2FO5KJE-[@:CLUKE@EJOFF.P:(O(XC;V)_,5MIX_6031B>A.=712:=3')R> MO,[0U'S'3?KA,8I[OW@0]MG6KC\0XQ1PU;24)C5+*/.,H$=+^KXW51C0,AE' M$RP4(\44/;S_.PX['&.+\)&B![16C,L65EWKN%LT)-:[*HL'`1D/EP[`URF$ ME2867NUT#G=-_>P='KV5JQC?+&`PG,C7KT^.<1MW3D'2G52!O=LIWLH'/3S6 M#&_>RA+B@W[94BZ"+56S0O'5I6-WI_/;XN#HY*>5TI&]D3,*<.[L=@]_7.ZJ M'9?S8@19FUC<&?QI,9N+_6?%?`*O]"?C/G&42&<#]-0C(^*^?X;3A6!.2X3W[P,`7S?>/ M)^-U`VG88#C`-TLGF`?$DXKEQ,3D??I!?L=1AW[WL MC2_P<8?CUL9/S-_W82;HMWB7NXHW;D-K<^--RA\>_[C?,0Z]A?)O%N@Z<&L> MT>=W)1)+B&\)=`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`#L+/VL%& M<3(N=JZGPU'QW/+$S!]'0V7\+QEI(&";D5YLY0RB2W4EI.STR7/-+)@TQ!BS M)FSZVFM,PDJD7'-S-AA=C21'^*J)WTMU,Y: MB>=3J41+3$M!@DY4=5!W,#;IULC8`F9L^1=P(F:(R6W?(GL/3H.H)K)43HT! M6$TZK%+^@J\QD1#EI-"KUK3(&\M*\`J62B`%GR\ M+X4"__=B5OU[LIA^%C=9ABTRM;,:9(_?\[@M][@ MS\@0/(W0HDS0(DICB."O2=#/)N.UBA]OFTY2/UN<_0G>$Y5[Q7AA.2"H.!W. M?N;'X=60-(&SP`16XA>/4&:J&11+M06IM@T)/!;V&I[KP]&=F=@4U1/S2=*"O5UP.+RZ1Z6EYX;FAHAR_ M&TXGXS1>U!KC<`DGD[.Y0LE>E7RJ/(LQ";793)J.%\_1E_R/&8P0)J`LEI*& MO)2K98%8"5DFN9<]+.Q968X!G<2Z%!LH1*WU9M#35`Z&F\I<^"-C;Y0)5$-1 M@8`%(BVE?V$VBF=FHX13FT(OE5?7"ALT3QE'J<@G+O!@AUU(CGNC8&?U4^;C M:YQ"EMFY.XCZ.7H/2HIK-;9[-0R!EJLL]!(V2'`NY&DR)FKL#1F")$(X[R(O M2FP@-E8M:3Z$+6\*\2;#1-[R'#-E6A;'1CGCY3D.`X4)UXJ!)RL,].&'`NY5 MS5+,.JAG)M>*"TN$:'E$)X:%PL`U3/4!0VCVX?Z3M!D&?$,]_:&UR2,PPRS=H9)42BAD+ M>FE%UE@^&M7-81\3VB-*MG!$VMNTU?OAK&QLH!!L,#8Q?)0&_FTV3C;]&LY# M0"IQ[HU0MW(5"./6X$<4)JA$*MCA&1J!L<@<:Z/03'XB0<,FQ4Z52I`^8)\1 MIL_+_&`B8PWE^J,%[H!H!`+7:&ZYF+PQ6CNT:`6)2F)A!D6YY?HAX7D M7&IK?O-Y_0-NT-&>?HCN,]Q^U@-Y;-0Z!Z1%X/E6`:&0>)J:&BBQQC!3Y+T% MF7K]D;SM2K6Y?-2PL1C'`5\`2ZV`X!9AQ>AJ;>VA4FI)PN:74^0I*`&IJ]FM M.L'4"$7<1U^PJ@G:.4):R?4=%['51.28WK&\SY`T0";AXF_(#T&>FGS'/U^*"`,Y; MG%W^ZL@]-6ZBFD^>I6=._MN-SD;QP\[.&_RNAT:8N,T*PGS#HI)!(P0V2R9FRLB5PL2<`P[^[MW`V0# M;U=H`0NC&^,'XJB&'+N=9=IN!QJ"JJ?PFU9Y>3!8$NQDY-8Y)<1O\)\VNK=6V]\*ZR!JZF:G`+08QT!KC=34R%-'UOS6V\I?^\X7]F?U%= MGIZYS7O?O/R^/QDYDU_1G+>E)],#]+"_TAW*-S\NWQ>G$R12OY[W"+1NP@QZ M$U-:KU\W\ZN2>\E\>G_-F^LQN=+,1X]!HE5T,I)X04<&U6: MOXN[WU/]'MVL3][+>,C!'@Z&!#3H-=26YZ,J-1?H`$93ZR#_GK\\K5+O2K/_]\!_PF#HJN]:W"_9)!H4@DT'R^(!/+OVI?]Y_0GA"'TFR,KBFQ`A-->RM0[T+O"$+A;49\4@[X8!:ITZ& MN[Z*DC],)@/%.O]\$NXLLQTM7+JIC#XO*+L(&Q"Q\+7!L7FV0EF6W$GB>_A M=DMMDPE1J:\<>`#!TX1T-""*-=2C-:'0BSP-IR'Q,"8O@H+@\?M+HDYJ,+R- MW428X;A4=BOZPRE]+:A<_',E=RXHQRE6@6T$7Y_"]HU%6.HA,M[`>U,M#]_@ MQJ`T!=\G[SI56-D(6;U@SLP)!ZL@#9[=.>$CV?Z@L$/:RC1.E371OH""LKKT M".ZK9S*&.`]CWV4QH5N';!=[91=807#7"]LV#9+O>HUMR__0*X.R/U(C<(`F MMRK64R+WE$"&>7L@0*OWR%@-V#QV,OA_86S,05`7L<@^&1@SBY!6#7@_*W@T M\1;!<=H6S"[$URLB>D+N)G3;TF`]A_P*T]VI"#2"7W"BJ09,?$=&$K>K8T[ MEECT.\<2I+'(-&./1+;WPN)5CUCRSOF.5?)\6/$IPG%$MN]7DNR7ZZV%SC"= M0_[[C['&+X\LCMW):M\R__\L#T"H7A\92"'GEIF71.E@"23K>9$[L2$5=B> MHP5TD\&\40>9"KHFAV0YM4P9;10_+=%`N0`&P9&;;+IE-C,EALP:PR&8J#O4 MF$0YR'/*%4@+5/P41$]:QY25]776=DQ,I.+)5%U(1)MQ5O)ORFJC295IF5DT MRA]F03W4CLDU"ZLDCR3M1N!`J317B.4'%=9-))7<.YM,?I:#!B3L`&S:(*7C M?'L#U,??)ZMT^;BD?_J8XK1_=+IXX7R9'*M.&-=^EJ$OIH,RI&E[WJCOJ7J;*'XGB/7S[?AG:=\S8]R?XS-A_S]R3"Z; MB=T$>)1O?SG$KIF""#*5`57T2?'**,O@#^1Z6MWT MK/),?@$P4&8)@>K8:9`K4H4\&_J1B">'T4DDT1^OJV(RN2%C:-,M:]UBYA"' M.3/)BNM!GCX3]U\LZ%50DA6L'*1:3M:*E`_Z!5G3?LODDOUN+_JJ*9T?^ MS8CJ`5X"$U#G7^`&S M2C-;:AC=6+46!2U:9\]0\\D2J)X8-\IB'I*"R1['H$G:R5([XMGS]&:6ULM< M3/.P!!6>DK@&)]!55CK8I.)^O>O4^+NX?#9`*S?!1Z6S8P)'GZFA M&:0UC%E'%GB#2ZI);A^BZ"M'F0&*.;^_O?;DR5-+S(2$SZ>/'([]]%$'!-UQ M23A)WO&4<[[N!B]%YAH$5?E09!10,0%E8:AZ1C(0<"(J]796]GMX93;(0P@+ MU)584-6U/B[.>F5]%BR)_8YOLLMW/1I*Y&,+!Z&[)..Y5?II#R<@G'+[;Z>2 MHNFHG+'!!/,A/U!80T5'T+.-BE6`:Q/3DD!70EMU:,W\X)_@=-]`/]>`HBECVA_./*3U MU@F]$QZKDL)J^?`0@8*'1@X,#9>&VK=A8;A;&(5_\7(6I+_ MX@N=GQ.2JU!U.P2NWEH;M:6D.=SR&[\DH*5!GSS96GOT](DQY//MI_[O.V9X M45%JQ@&X$?6-+B"S!^3O)E?=$L0DKO+>5%IU]`0-*-2N*]QERC0(1XT% M*XL@8>A($BK>SI6&6(TE0Y>3?-7I0`(US]6UE>)4KD&(,<$!#!W*R-^J!L/! M4AK7G!KE;>"[8%O2/VHVDIZN.-K^M*VE6AC+9YX`H[-Z!M.4!'A9JC/&2H?& M=$A1OKL*9BS@:FWENBDI%%=:+2\^-J\[*3("H"M]!NI8=^0.=IP+/-H&?@%9 M[%W(F(R!-SO\ER&LMK_0_@YFK64X2'0P'U`^A4/URM<>4A=.XBGHPV3L$P'. M0_?]/],A1VV#B7?#R<)JK(@">E<8B291:3W7S>)2,1IZ;M5^T'H;E8V#=ZRN M+X?')ZVR.AR]67#(G?8DQ4;+(^.WUY8ETO3K6YO%@YW.6[MZA#\> ML@=$"G>*H,U)'-JV+4T!N\ML&PVJ,-VUTE+(:D&XF\@76T^TY&[!/Q[2.[64 MPK&=U92_01-=MTH[5):/$("H$AV&Q)Z5\_=J$%T!=FR]]'1Q-87MB1^7>&'S MEQ`[EFS6R"`D;!6IF.NBUO(N;@$"67RPI8-2)DX(B]J"E.:;3SR)E_?UP!'B MK;JV80C=;;A$T7%2Q(%'8M;13V\G9^;!]D/ZA;%*-D^%PVQ&>)1S]`@[BDS5 MHXHN.=77B@>/'L:8"_^7%V=DJ@QTC128[;'67(CN5A9,GHF:9/1FX"1%$>,+ M6(L$GW;PX'&V1-C[^7"*TVUM#RNF((,LYY\LXFKP617V9@)L',K(DX:4H"YI MZ["&O;!::PN!+ZHK?=XXX3R])*"S.+3&!T$ZG.%#FC0"&EYTGTX(\5WVQJIY MAB0)<.%@FK'MG>/+5>V&6T3\KB.JZ";6$=W:&%M.RR'W"^WWIJ.A<#,(F>!` MK#&]&"GA)H\JB*;2CDQ"?[)TO;F$ZKQTR'BMOI"]X'1=RES6_Z"PX$;E!,EG ML`B:V#16/W4Z.U=(%EM=9#7M2D+2RAQ(DFU*'`7[NNL!1R6?*S7HT`PC-6([ M9WL'H;GF=RWB'NP<@MHF*[$2 M@,/E.=-LF==<=;)`9R)"5P]#TSTRZU%5*+KG488=:@M&#OH:*R!;-EY([2/1B+B#P2';( M4(>[8JQ-7X\L9#+=1/>O4IGP2JR9Y662%@-\^G]-PA\)XF+K6P*VZT7R\_^\ ML!9\]H6Q]1;J&+N*LXF+L)54%S.$A0WQ:P2W,CL5G_ERVV$YG$^VH_((RX00 MHUHZ@%85_^MO")"8;ZCHM@*OVHE'*H$::W&]^GY6#X]4-$TK,DGLPYQ`XAL9 M"HG23FACO3/!99^^\^R(VHBLLQP7?SHYTX$R*(?+F+WDBQ3X,;T6[1P=CY93 M*JV8-W'!%>*6S%,.RK&%KCK5@B6+F\S@$\H7UTHO.>A-[F@!W740.!H)QSA> M!)(27&YBT%=)6*P""$]("]?Q2+F0YS5D+L;9WR:`ZG[022`7^2@/O@P;S]`0 M[!/5:_53_&DQN)!66:*7!Z7:HZ19XTLITC72:2]1MP!#7%/:.%N./3(-Y,;2 M&[M5*7AXPJYPLQHB,QB120P"2R9;54AEIS1&)K-2_V'?V5K4WJ;J@J2--,.L MX"1R%P`^F!VIL\_P[&3A]=MY)^@^PU13BW0S/,CG"%8PA<]P8LIF>4AOWAPT MM>)C2I\&_R4P;M9Z96WC1YQLZ=\4/X4TC?5L)\;/LE$99EQHMCD$%M`"8M/9 MKM##75&03!1\O11J,'U2749(>O:M![Z@9Z]*H#L3@QCZ(7,,%L MVY4I5K*+1V;MC3>*;/H<.PYOY/NS,[#IA*W,F7M&2V'L.Y. M1_-6K=:U&&F0I_:;FP\2WKK8,3QO7348GC]JSG.`Q_;IHQ7XFC\=57?+M:!K MR%!SZ/WF`_J2FX_JG+.*>YNC[#*M**9#DY/JY[$^MY+)6O)N,L&IJR"4G;D<. MD8/1\!S'$(`&.G-;\@\Y&#/TG?+KN;,HT:U<6@.7MF+,T[[MQTUUIF0ENN@UO"7UI#;4V"O:WH@OI MPGO9#"6_.HFE>[8VGCW]JGB`?;F&8.&LPPJ6T/N;&R^VOPK;CV*5KOY[F#.- MS;[YO#7YUN:+VR9074-U%2N+ZB)&%GT:4@T/..(]27^Y\EP&1#C,$E0NPE%+ M*2SAWJ;"Z,(Q.3EB]%/3#+^$OU;`C.CY^4RQZEV%EN;QIM"2-.7DF?F%NM2' MNQ^??26-MK6Q_>RK&G%J[SU[XF]M/>$E@;","'J>[')M^.;&UF.M\EC_;TDA M&MS\S/K=26"UD]:HB'`OEB477K`$A]AL=_4:W$)MC5:_:]12Z-NL43^VTQ0D M@XRY:ON"/N^YST(,KN=@6*40O$'F#=.D\)VD=154*-:'8V)/)Z_K">=FN8LC M#V'E-JC]QG,+.:AA[SC=9!XVBKT%(;J'->$<'',"$UHSA"WB8P%913GSLG]I M=VX7W,+"R7IE!'U((MQ_L4-%G'9%.,12CK"8/@K>G[%RB#9KXI(3+\'F&;#/ M0Y@)2.5P-T4X\X^:/T658>Y`\T=SIUKNP:N418S'.?[VU_\H#E*K0W.6ZA=Q M3MIAY1LC81S&LYR[*?^Z?0HYO>@N-V>/]Q#F]342JAPI2:+OA(!5,G72G&;? MS\S?;4?Q3DUC$&;1#AG[36P3 M^F299"8M:/JYI*%5T0A,XT7Z2)CX""WZ+*?F(+94M3ZN'X/ M;E`C6.6M0?LP9Y.!NO45Z94$5:HBIV4<_*?F?IJ6 MR)"K3!B9!AQW+#?_E@D#\W;XNL++EFY#5F+>RSSR>.&'1LS=ID&.?P]9<]38 M5=N:"A8C\V&0,*D5(:S-"8H\Q["&^[N+!05SC,F`EE^3?^A9`6N=,U:34A+, MPWW&9P0S@U>':&]A,;_1[]9;!NH^JGA;F8C[6]O/(Q.G;80FUMAI1MXF^"AV M\C(.S9*PP2FTVFO\'$,#6=D^/2]JI!38^7XLK6/)3#A;UZ62T7-#F&,=WLBZ M3:I3Y%4DD4(4@B'O,)EQ4`.K+,R&#K)X>^&TY+,6Z=(WT@1:$$H*MJEZ[2U0 MUU\)AB)<\5QX7 M+@#L>D\E64C.W-@Q>L:(G+,&TJSB`9(ML)8HI%V$)RT7&#\L>%G9A>: MH#\9&Z2*T83^U4722]5XC?!(\FB!#F>.*`:ZUF4QMF\5)`&2>^9!N?>>TBB& M2P=60)%:AB(`B5[>-`?6[/2>N(?*1R!*U;XJ4!P'I@C<*%E[`5/KQV7HHU2D MXTXZ`&6:8CS!14X4CQP%1\"!9R46AM^8"K5D_IVI*6.;@+1E:\`QYV@+3Q=O M;Q'ZVOU'+AV:3\U75%7BRNLE[-FQ6@1'.3,T!=P=@$.*<+'K+A",%72 MY'@A2["%59D%$HU2):7]2.?F2FIGYB@53.Q7Q8O4P5UP_J2TRUUM<3@S?B&? MAA`C*/D[L6A+X9RP;"B<$1*);^U4B`X.5>5MRRE%0N1498AZ"F09I#T"\U1O M@"(U'N?B5[=0X6BQLQ5"FKA2.I7I(NKXIX[A_HE8"P7'C&B^EB\FFK2P6`'S M+>/H039(N1L#%[87-=WY:PUZE+4`WP5"2QT:@X$"+ M+CIC'COL^1U[3`Y:9<_U,N2OO#H&U/ZN;,>L-@7OF5+1S52H'^OB;X'\G7P- M[VR):3JS>J3;N(483M#Q+,$LJF@E(*Y4^G?N+H,..-*<*J+]>#.69ZH8UCM7 M/X!,22!KE!>/XMY7=WX8C`.Q-S:QROA!)4T>0IW07BU!`M3"]U:G?EM:]8$VL) M(PN_)2@,"*00(P>?T@J;`X!C9D""]!7?2KJDJ-5%[%5(S2K`]30(BOZ,PN)S MM-0QO*O;BOC.DVK.*&`(]*\+D*=24$LQT(=IS*-LA3B`&Y5[NC[,S]N[%'^1 M5<4(N%G]$GU5^$680)I0C[XJ#8_T8%QXE2=:+JPU#I,C"9?0/(@S6F'5!A9\ MORD$!7CHOAPJW/?0\Z5E=8N$$'*N+O0E]CXX![QARBINP,1/.@=% MYZSE6(TQL)$'N[YD1N$UJE0_Y"Y&M1/(IG+S=>S:AGB)0\9,W+%DJ$X75$2Z M@:#DU\=G;L6UK&,S5[B#\,$^LR+:C+^2YDW8UK>8.$O"99CQ$W\L5=53O?R4 MM3#&'8IBFM;3IG+9[,H@:WED4?_PE.ZGT%M85,0=Q6/JSF`*R12];Y8AD#K3 MDJQPV[[.:/.CWH:04T"3>W.N[[X!*=31C%K9-J*K9-4I*UX'%HID"P!!:=I& MJS_/>N.?IXOKN7+'<6D0,1G!HSP+H9`6Y><8CO)/^K```N-E0OA=I5C=7+HC MPC#3S[II0"TKI'RVO'3NK!#0VDH58(&U(L?&^9*7?5U+MD*]4*%_A442,X:\ MK=[POI+@"+9DH+:FFTA?15H*'/7].CQH(EF<3HAJ*F->&VP`1^%A=`A9LD0( M0E`Y35B^E)2W@);Y8]('G(B7*PXP^YU+E>-"3^`WN\I8-#4/SPB:>G%JN[^_ MY2FZED4$YX*LHR)F\28>JOHI=)%\W_BF99=E4P;0PECXJWV\Y?ZV9:RP.!B" M<\0GOL+?WD,A-ZZ1(7M!SO33Q]H*LD9AJ+>)Z>1!UAP!--QY3%#L08<$[LTIA&JPYYKUG<99.@#\Z9UTPW?A\#- MK,[U:)ZY?>$O.-21?G!,MD8CA2%.K,#F()+.O#$"I[3AJ("$,%.VXT0L\QC$ MWQD^E27S2B[*GAZLF2L(%)5;1K4!5O^NY_Y,*\F==Z=IV9*64.)#;5SZ9OV0 MT`X]Y1>AM?@PHWL$,9[8@E*?/@I#%2X#!N'\FF19K*XS4\T47$*#."K#^Z^7 M@(L<%-W97Y1^:TZ2,F5W3+[%%CRYY#%/6*&FDI,4S[@TM0H!JP\KQ:ZGYM%* M2ZER@29!A3.,&0RY)>C-[&LK*I\?RC0$1K7DLRK<)N(L\= M'=9T0B%6B5HOZQ11I9X M:VO3GFY^E1+0YG;K3;@`TU=O;G@22^;2HS("L?LH6#`\A822-J^%7#-4JBOX M%>8PTR[HPGE+>1QP<6/U<0$<(7TA(+@[(M==F`W=Z3F%R)_Q<'EBANR\.*KL M_J.U9X_MR'H*PYJ,BGX5,SHXDCE7],N%RHL.>(BA'JH`6W>?R%)J#YD1`,6) M_V/67G&5W8/!(BGV"M60=!D']DO=R183:$ZK.S$`!4TMQA-`#ITJ4*KF_Z(* M#9F(<%#S&C;(+H;?LGH-X.N2#K_1P+^1ZQ1R%/E.,NJMQD2+$4[WJ?9V]@O[ M$&71>". MJ\)0GY/^E2T'D[EN\W.6\,MK\FC;VTO*IN:IUH:D')/JB83#_DWIR*DJ`MM] M.A:\D6G,/_:"P-AQ&S0$IR+M"D$K50FL3$FVW7GT.D,DH:AN/[FW]2V'$EEU MZ]OM3;EE22_/>&UV+O?$$G(*V/W&)ZW`F<>(AUL7#")TO-/9V_D='P:_ML\# MO[:&>#,#U4D_S0/39S(A!_](/]0PQUO^N3,/QWW/=41(_!U'H:?E\RY, MTI71Q"@KF#YV*Q3)#&*.JDRE+EVDO4>M4R&<,C$+-(QA`$1YL/.0M%BJ6TES M/^#PJ';6W$.%("VQSG>MCI%5(NXX6K+G#!B![3L&*_9'316( MVE^VJW`..C1]&&JJ4WW!(]1GQ4PCI4M*D7`KX>M+!'X(0+"0D@:7C@!$1,"` M7[(&_'';QMUN2QNZ24IZ;FL=#W8=%56G:-AZ#:\Y*\?6DZ.@KTX#CNQS@G92 MPT%+UZ=F4E7)_@JZPX"94#?5`"W.42YM_\JQVD1!Y.L-$O;)C(-X1+)0U3`J M^:!.EFZA98>7?0BZ:=(Z2CD$KYQOA+L%/E:[]%XZ9'FK.7U"9:);?6=U:>/D_-/'SO691-O4:@.$1ZJ7DT,_.GC6Q1)^_?] M#W9+"K]KEN8*)U5+0?O'5:BKIFQ.]T97KC0?[NL4C?GGGS[N(8O-WU->2(+< M;M#2$?K;ACPBC54_,\1!^"\;H"[)U!!6['`>(-X'5^%9WUZSKXD$/S-:+C:>;S5,M>26I?-C\).BK;P00]BC<8Z=*72MN M9/-+KM+23VVL;"]7P>M\L9J/6.L+UGP#?>G74#-ER_YDPN(]N<5I2.KOZFOE M:X5IG'#'YYOX+=W5(=/?._$MA^6?!LU_A^WM.%KE3PFO9G367Y%$]4\3QKTN M(_\MUB#6"_LH86ZPD!6(L;96L3AAV6VHL4RB]^/5J>*)Z$Z&CK]P6X-=K@DC MF-L20FK$H"E*MEHXJK/R1DZ-4FJ!0N.L=>ZMJZ\^??KXVGJ?/GWUGSU>%/DOH)?6%?\YW"/TKLHB=&FMX/.;R M"PMH=SDA<%Y@5_G*G'PP'`(T$%?A>3>KQ?[6AFM=W0F6%T]O`P7GF7I;O94X M>J8[G#Y9'U"_MK39B$(H]#++^@5=159QL*CJ\DU`ZW;KV(VPF@6J09='/2 M_G;).9NK]&(4=87WRG6%6ZXSX78S$=F%US*0+;@8ZWX$52K8'WP=CU&%^.9S MMT0K0#1""0("O7!!]$E64_O[3D,#AW*ZP55D"?5=@DO*B'7^`17VK:ZLQ&?Z M"KB4%9+&<7M=132!@[(JC)"SC`$-4Q8%(WN$M]R,]?C9XT`SLJZH]O`M1[(B MDB"J2_$RI\I1V\F.>+Z5WD?4][([]`_2[2YUGNC;)4CJ6X5JZ/G]6O@'8E5@KI^5[1O>A4( M8IO\MN>DGE2@<8 ME5@BT:O[X%`&NLI,-,A5<79T\%W:'XTB:N]I=8^FVIUW4ZH^7-WNH]O+R+(, MN:J*M;+)*A!YGD;:%8.#Z8)^9I(K\?Y`J6W.1^"[6\P>&U9"CT@X1A$$.FJ. M%J%.EQ\U=VWQ#R=:D/Q5%3WX-)%'Q+`O)G95S%],;XJ;H3[63CL5/@1V,>:Q MO)A@U1]PZ!H"5)'P8I12AJD`+%/G%V[IW"FAT\*/_U0L6V?J_?S]7Q=#=5#9 M5UTSQ9OJV(;)N./<_T9 MM1O?T_!EI!9$I1:L>AA6QK`U(CS]:)_A_,^9;L0\/\^O>'Q%`XRJ03,^&?C, M;"^E7)M#PS)YU)I<"F*2Z!V-]6\IUN`Z*XE,=0PG>%/YIFO`ZRK"\$42^_@, M_K,F:B$!OPS3$-'$QY[]LK$6F:S^85%Q%%;1_YA60UR M".$UW8Z!@[OYE9<^*CE5=6U!>R*7H%3QKQ`2'4#/3\0$!FDB5;"P&82MUJP7 M]<%MGY:WM36I),RN^_322\J%<@&.A>7R2M]R7EP=K_&"JH")2+$L($O^7D/& MHVK7BI8Z=.*&P,2(JQ$5QR8;-W_9!<(LHFV6"6+WSWK4,M8]XCBJK&>XF-#6 M#V%\-$^HAX19^I'3J0Y1!]&.*9RHEQ-'$!&B.AG7S;)'0LCVX:XN,\;A22W2(27-4]?5X-9]UC)EG M+3'(O6KY9H1SP:$)_4#RTY!<`R:P:D6$CIFI$T][**GTCO:>YOYVT"VZ!\,Z MV'-O2=K%1IC1UL:5PFGG#:MZ5'/JCE6GFD_KM:GFKQ'=JDPU?\OJ4JV?7(*: MCR,G-9_O>`#3?%PM3@FE7;,ZC=\::8[;#=Y).V':Q6#S9;MQ<\3O]=&RYL.= M>'U>\X=#G!^;D_QHMF2M7@)MOO0VF)S/O!:H9EJ8_=ZZKC1W.F^+_@QXK:0N M.G5Y6A+CG?FWE3/&7/9)825GW>Z:8QW;F23`E=%'2:^;<6GD4&IB'3P##)^D M6A-4AC2D$DR%V-0UQ13?7ZA6Z%_="5L)21S4355GXL9L_S6E]_!GZ&%!G5!5 M25QL]`[[!?CS`U@*U7NMD\M"\R.9"NU[^3;K'0%K5_@PJ]6 M%D)/1!WXPE?R2I#''[N6;>!LJEE`0VL"HPWT)GEM72'`)ZF?>5.6T9>S$X]L M,\&R8#(>F_/SA*`.YN!O>F,JWH@?\&@NOOWLT=K6YM-J@Y%0;%K>3?0@8F3W MZ2-YT5H?'-@647-QR.9(18?GX'_S2E-_=(.ZI'Q_T]BAXQIW24EDLTPUVGQSLZEEG=.*5'[C_>\CM(ZLE1 M=DGLX,&"/FE>^YYDG"]XH3H7:8D'$1?'7AB*$*7X-88`/1$#1)-B+9>/G4^?K+QXGF#49MR?GA,97J_ MZ.[\^WZG]9M]Z:#H]C[4^H%VSI1`[L__>,?W;ZDB/]LH8/I;0.AFI`CE>7<" MU0A+Y_J\]X&@&_IY)<)NB4BL$>^8T:==5"@0;L,D9('HK2X)UBAN:!8EUDH* M&,0C<9AREI(^%N*V9UZKV9X5)B?<%-&C$5--;FJ6-5I4\(9SYH+%EQ2=LS5= MQ^C[O^&[-B2L[+LX]ODU`A:J8P."O`?')T>SAUE6A2.LGB=D-THA$G"F'6;+ M1^9GIYPF+<_Y#`.\FO;6K[[L+CDP&'.LT.*H-E>/>J2^_5]UM3'@Z'*48SJT M['B&?]Q54\5E%7R=<__,M#?213N`K%]Y2@2B,Y,9A?6JP)G=>DN1AIM_?Y9] M/RY*LG2+]NX).%#.Q3)0&*>>K`\H`P/@(>3)<;[,I]TH7H6IH)<`X$OL=J=7 M11O/[Y$H4-IG.%XHP1CF=@FF:JQSQ/3V+]-?GCFJ,DZL(<+6;<,:YP/&Y/R- MG;214`P1:NWX'3'1Y+UQ?T_?4L*V"-AT;D)Y?[\6A4.[#9YON0-=1D:DV;V9 M-<'3O*3(TIZ0O1JE,L.N5X,FMU*IT)'=TFWB:*AW/T[5LM[/5."AH@CES&SG M[/RYQ#Q?C#Z9'XT!6YE181G>RM890)?AY4W9,:B+8D?#`4-+"S$I'!M27; M8+7O]%X-75P328XCG+WB2EUU$7,U=E,M'^]WBZ.33J=XLW]:=/X_>^>V&]6U MI>%76=I"@DAV@H&PLZ5NI+)=)F[YU*XRJ)N+R-@&+!ELN>S0;/6+]%V>)4^V MOW^,>5ISK54N0Z&^R56":\W3F.-\FK^.#L?U%SQ2HH=.9LT!SBM30.O[ M>`Z+_X4#W+F!=6CO!*<;K9VLW1/;,%U5G"FS7\HPY;,0@:5/B4D+S:)P3<&Q M3K`;^F6FPH;/:98Q"JF)(C?;5"(&/#\MQ`\+[LD\_U[6*&]BV&&1L'__S1H6 ML3M/#^'.K\C#X[X1,ZU#J4(#HN*17G=TRR48 MGT=6V8E)YOJ87.2GN^.]Z:09[2E;QW55+-R#C<\O;>@/4OC:W(>1Q. MC%Q\BCF<3=7RRNM:`!7:P#HZMG4E:P=Z$8U\#`V+U;,*'%!PON% M2@612ATVOS[:U>&EJM:S;TECDPX@ZG2'Y,T';W,#'6'_*I,:SFL&!)E&."3/ MP;KP.)A$G)"JC.J+F[H*T%!=>&K/@[R'7HZQR\GV*N(Y>ETT^&T5T@BQ-508 MIKRF#(PK$X4@,KW_AXY^?G)[00\5=:*2IF$"'C(5\?ITYK^E9Q>6F^5\A*U! M`NSU4$V1CHU$^9RIH"3]R;N%,5\G.4*W1:>;(5N,57\,=Z$SHX^7UY?G'ZF M(U/<4,"!//TCM>Z@.5SDE7&)+5.DA5L_"`@PYU:RMWFF4*,D/*TIU,S\9D6B M1G`XZT(8CZ(E-"/50&AHC:7(;)CP>!=VE(ZXJ42/T2F]!-0;S#FJO1VR.?)R MFBOIJ$`65*D`5-Q]O-H2MXJ-@`?>K,`N5GUUK*N4U2>RPUN",;1FFLW0@9L# M]&)RT]'AV!(>0]0N72S+\V4?DJ8[DRGU:O7Q8])=P$NL`<-,M;FXMD#Q[*-" M#KAC+QIZMKQ/6#E*'?L*A2\<]Y->8A&(D7+Y7GR*P`K)[_\DMWMA$R3!^ M`KZF0HV"VU`KQPF]4P#'Q5(&#+M,PVJW>H297(M;$YO7,,=;6AKRG(-AL!+S M@1!HIZYCJ=]*4+7(XN=;@YP`E3>6FUJ@WE-=*<6_BY6,NB,-I)>_F2F6/?CA=U?6M M$('+?W?\.SL4$@>!Q!Y+W.O?ETC%50'H4*WHF,PHMG>+Y=9^!#G\<2VM#MJ$ M';-4C@/!G1U?5,,\GKX2 MAUD>M7]H8GZ/1 MA@LR^^:2U/?`,+(%Z;M.SK/6]#P2B46`GP:'V/M;D7BP/3DBV0(W;H/.3GC^ M5E=I!W7R"<#!?R[])$(FH"/89BS-;3A9XCB+@+=#H6W7BV)MWT!$P/`I.EK0 M:_043Y:1#N^O.?"]A790K&CC'#2PH$;!)D'FD%B3.-[Q*98-TB1DZ[$E+5F" M,/C,L[LO0M3\K>1<&VD4+U.#U_G%V,ZV#\>3Z>'1QO3H$+47I7(R[7AC#_%# M7%.-[-%N7>MAB*&,/%0LR3VL\BXT?#,[+M[,T7Q)0:>-PIT[WO2MRE0KX0>T M>2U7];?@4W0W@@I24+W2N91H.NA9JL+(;C`Y9V3V2%;IXBT=S@^)6U`'3Q,3=J%=$O;6 M?T03*FJ=B:LOZ:V)I[[E0$!RFYDZ MK4O+_G$VG0FE0QK;7656]UT\ON>BA'6O=`/6!$BT$&!1HL$K%5$<\*6]$*HO MO%'XV4KC]3[^3RD]H=['^&=(YL4#]&AC:Q\MT7AJ*(#79C9#DE">45,@%]&C50Y4N-W-YR+SB57H0JW6MQ(3YC^]3,I__HTWBN>+H MI\K2#>$7;GD?Q&+OB_!`M-T0W#ZE&S"VF'VKEW#!5Q$'W_4[: M`>[#FP^S=DB-)XLL-\<84M*)[5D"?5`^34U$[=W:]V2E])B( MD3P639P+/"N"(@H=:B..H9Y:"S!B]#"OP(W$<\JMR7;>#AF6"X M$?W<`P>U]@:+'.8N*AGUSP.4C@(;C0!V(%6ET`GD:8DM1IQ) M&?D`K$":A4`1-%N(V;G:L6W^9_H,GSE.D9V9S#EKS&V>4$EQOT@QQM M\,'A40LI*`9MUB,&\;G1UKG M-6V?+TJ;>]@U"/7J]H6>=Q#U2&BI\IRT5U2I* M.;OH3I^V=VHM;,72;3#YX_6?F936I7V-C\8.%DF)$A^+D%W<1O M]4@O<2Y+0D2:=C!^NQMH8=UTYYOYVF?/-0^ M?W72VV_Z4TQ+KN!8:%40ND6B)F!JMOOP1]"%%C,/4^H@=F75F`DEP=:J;12] M'):Z9L\4"M6+(@GIKP1A]#("FM[Y6VXNPQ$5%_?6`-VPRO MK#16N*ML+HOU\KO^7=*E>^H(5M9-V6.9LN+I&_#;UJ>-UQEMP4Z+PIC]3+6<>CQCBR,#59A>%ZH\1CK3B$OS]=7F3U*&`X6"3=T M9LON:`%L!9GP&:$76Y@1X$M(JW'^2`+6;(DUZ4&'SDT]Q[4ATCJ^^?,/?HSY M_PD`TKB8]DE`#94#?"DP(EQF?M/XP=-?C%;__",^M!8^*7!"K/'&D,!%O(`E ME`C(;.XW^$'+%:S?X=K7]DR`JZ&+('F;TUR^#;W1-1LK6,/RL'@,Y_%/V71% M#%)?EC%#MH'58I84;FWO]BPZL2WJ3?88U],?[*J%/1EA(18NUUJO]MYPE.7] MRZZ$=/.B@/#\IQ?_-ONG$B?^_6]KC__&OTYP<-J&/I[Q)_WE>@L&ZY],K1\; MAE5S2(O=3_KUW?%'Q4Y\!OWA)ZNTN7E!8..M'D^V]\62RTNP?OASMA=Z-%J-[N>^NBKV-\>%> M\^@`S5L!N$Z=P4;2RC%-5@A!\]V7YDWX[QP^OW$\0P+!<.U_U)TJA+97L*RP M,5U6S?EJ\:5>$M4PSJCME6<8'%MSI1?G"(KXGQ0R-FV7!#'MGS(YQ(+T-GIH<2=8F+ M3[^52O'%2K(YO$U.T;5[_NX#A$TB"'1#8B=838ON0N+[11[)A:2U_W])A\?& M6[(@OU*=+`SI5*@1X="PJK1U\2+\HQ1ND]QDWAISMR>GH+`D5$6KTG@FA?57 MG@Z"7Q*:00DG0H(J&AHJ,EE*_STI\UK,UWGJ+M#[-XFVY::Y/V[F4^3J0 M.!#)KYQ$8GUZ>87R'QC_UFBRWHPF&VCXB.:V6ZC(<-3)\.H8VQ:`M!+H0:J- M=Z15Z.?"<]TDWU3QC.(MN1#TAF/BMF`'"O"?AV.MB:7LYA9P/W_;9(0LRZO7D<=)6M MUE0H9*XJ2N#AFL#H.@N>@$XFDP#A)H>.V=I4:\@`M`IBF!W:4.GNNM^(@5'/,]!ZAA`:B$VLD!IIB#:.L9]6<]?(^3MP M#:MS4%M*;-AM2,.7=%R%:'[^>6WEZ?.?#2%_>?+<_[^J0;$?-_%E6:PF5C&V M73B^/F>P2JP"5T2(B5RE&8L(A?;`J0:A_IUAU\E&]T-$%,RY3R*&B1YNS+A= M,@VA6M`DT2H\1`+*`?)B!5.BL^Z:G.K<8?%5'@Q1@89%>W;EC(K_6/8="G3& M:*[9$0&RR.=PPMPI60V0H MGD/2UDLKF:.1K;)`0`5:"S M$?+(M^F(E!9K7D?YM1%OZ[39T9&1JVIRO,`:T]QOE)ZE_WFTC<-MZ)AI0S`P M2T#K:W9*\";NBHLZ]$=;%]Q(3_N[A393:F[8[\3MQ=5+W2ZT]VM&$OBA]FE% MKM8BRE5^WYD1;OS%U+]%@!HO3G`J%,RT"=@NKBS/X7,]$WG[*G5F0HTE2*`4 M@WNA2;5:>83.8B'(B>5P)QIV\XT7NI,1A)82+8.31S0Q;J57:I/*<^.L$HOC MGM3INS?X%?85_;)XW&QFY$>L[H?FT=%DLWG0,;?VB^>(B6HEKJW]2G$[<$:6 M#I!5?-B-1TQ:290:,R&OQ[+B4064#'L+I!""QI$$H3<[/`S5;#-ZUBD*VB,[ M8-M+.1[MD-S]`SS8W9,Q$_@`&?<)%_-4L217\',5]08RUQ/R60=X;Z+WX>Y% MP[S!+KR^_J*-"!$[28\E'E>8Y266H]S7V16,$KW=<%I1`T`2!)$%!Z8Z'8H6 M2:^Y-6U"]U^$3`)A=(Y0^#PV>3MCI62(V7T_J\>5;#S<_N"MEPU[GW:Z[R;^ M]F;7U*#.)85^LW=^ESGY"I<*'<`%G'VO-4-S+S*F^=_\%)6E"]3]@Y>R,U;Y M]H,^^8J#YC'?\Z"M5;[]H$^_XJ!YS/<\:&N5A0]:*$61E](];8"+TD]ZUV*] MJ%^GW6+[$J<75)]6:"3MCU`:WS/JD8I%YTE[#E?\>1X?73_#WC;;(WJ#5YV/ MX!3K,C]V+<:XR*<];"8)F0Y+.GO[(QF&'MNH?R1+[L-LU?QX;>.W4^H)5JG+H&+"_[3YFU&) M3,[/T4;)&9ORTZ&*<=TR'O"'?&._+MINKV^,VXVQ^O3YE%DE++YYBF= MC^=S2W$-E3L@VI_5\)-&)#75POAW\$#_S"O.-*Z>J_H=K=*B2R-82**&Z66. MYJ(6JB#0]+YZKFCZ;`':_GGK$045IGAQ"A$+H<@]=;5[LX?K&!RVD[M8F8CL M7N&NA;XNMFA:?P2GJ:WU3BN8QP'"I'('ID'/FFUS8O3.47[=XJDRWS@DY@;J M,_>`(Z.>X.6U2CT/KB]/SLY.9_!E:I0FU"[*>9!!68_J@*E:=FSO85GD8W#E M>+7[ZD+LKX_SO^N\_&,OV'7XY!P>7)D'F4_#!*(OH3Y"0D4$2GB%8^".?6]F MW0@JPSNL+C0B;.L^W4K*A##G6AV9Y(H>0HW11W&>^F3(Z56+QZ5+DZ6+"A](>.@]+E+OHH,B1Y_(6,6,_"?PB*O7 M@TH#ZEESL'TPSI"*4JHS)HF+`45A,[18ZU4S'H;W&^M9)RD'P=]3'U3#%WW( MKLO&ZR47GFF>@MKG7U.D5ISH++B.[+6E>O6'.&4EX?YZ60]&Z4FG`L=?+^LI MJ?^OE_5:^3.>Y8/7):F#LH]."@_3*6PT1!:R%ZV/-BW_HY=`(].WY!LLG//+ M#LG&5]CJ'TJ-*CQ7,VNRHVW>Y^YXED9`R_'+VQD1H>&!Y:MC.0IPEYX!I=/=7%H^T_D-FV_AC4X+I8C,*;]/-?@B!359:6!=[H&QXZ( M]EY8L>0]MCBH",[UW`1GL=1:=SQ+\S(GT-$5UD=2(?E@/[?KR.K'(X*J,QO9 M=*Q:M-T[K#6X%/J$VAX:9F=-E%G'B.GWEC67215>M91Y[YS(&N.TV=< MOG"4*@U:+OTAU+_'4%PDY)Z1VZKD:#AO&:Z-NNYREGE)F7/C'.)#6FQPY=]I9?0<7?8=JCT`1X MZ?LMXZ;+AD6).:NJ87K_0;`);:>SP+V/A,RHMISY"A1;SH0E:BUGQH12RYFN M0*7E3-A&H>7,.7SFU'Y<3BM+(`6E%,E1SEMO0_$<#'G6&P29!Y"O6.T?(?3R M--9)]J]Z!]3NOW`"66J@KO`:>6/JD^:^RT()[:B>!12^;H+V@;YNCKO%Y5T1 MD+6Y$1"\X(1HJ!`Y.6M(I@-SAC2LI%T-?>"%EQRZ_2[EX(1)%1Z:<$C6W[74E;G&3SFJ5"86GCW6->#S,!YLQ4+`DZ12_8480FTWVY(!S(-+KH<# MA>]:!RJ6+)"+-,'YDF3I^P@5'<1&TGLVLUY7X.#Y7NO(/=,O4:\Q-6H#AA6K2K(5L1_ M%6X)C"WHGBU]M&!HLR,3>-/$-ZYG%>E"P*&E!SY_;C%:4?'\,YRQBI(UOP MML+$]'_UG7UJ_001+:)YP9,T@-BZH:%&' MQJFU%TPY$ATBC<":AB8%"P^,X692BT&%HLE&1"K+T2G^7@.W[B^P.*"ZX=LY MI-()59MK6%KB0DD?6[CD!ZBDFCEGD[CJ5)_W8:CEK_^>TC.\299Z!]"YY(L\ M-O6GU8K*=[R5IINR%LC7OCH^L5J6FK)_FLUN7OQ+`````/__`P!02P,$%``& M``@````A``];^MOR#```/GX```T```!X;"]S='EL97,N>&UL[%W[;]O($?Z] M0/\'@FF+'E!'+\J2?)8/D6*V`=+T<''1`KVBH"3*YID/'44E]A7]WSNS?,V: M(KFD5EJYZ`D72Y0X\\W,-[.SR]?U=T^>JWVQPZT3^%.]][:K:[:_#%:.?S_5 M_WIG7HQU;1M9_LIR`]^>ZL_V5O_NYM>_NMY&SZ[]^<&V(PU$^-NI_A!%FZM. M9[M\L#UK^S;8V#Y\LPY"SXK@8WC?V6Y"VUIM<2?/[?2[WI3S["6J6SVH2#>>Z45;;1GL_&BJ][--6OS-A]54O]2U MV.1YL`(0O_MY%T3?_B;^\^8/;]YT__7-M__XP5[]\\??%[_[\1N]DZHA,B$& MU3+?=BO%PM>QY$YBP4Y[G.\N8\;&#&2WWD.A`DW M=F(-I]6S0#2I36.$P=DTP"W4)@],LG!CM4W63WMLXG0-ZW4=XC].%[.BVBYI MNHJ\*/CP$%U9K(B>\'XQU4T3:DBOVT6WTH`=2=EDW@5])U-V.3R990-S8(ZD M6L9QL1@W5#@P9;JR1J'Y;O3^9.Z4KZS,NJ0,GRH#,.'D>M&!U*W([Y&)KU/P MY,0#VG$BQJ1R19^E7EX;[QS/WFJ?[*_:#X%G^>A8.JBQ7W-C,D>\XXCG*"!? MQ9'%ESDH&Z"*&=,J"#N:*/*]!'.`Z)WKW/MQQ[;=;6!2L`R=380A7M^;\ENDER$11E`@US?GH"$)O9Y.Y?*3S MR42VT+X)+\E"WPWQ)5FH"?_-I?DT221#%LA,GA8Y.$_MOAU-)I-Q[W(\'D^, M0<\PF),7":,=?V4_V3AUE>:F(H(A()@,QI/+/@#I&F.FZJ0(!@!@-!R.A[U) MWX#_V5!W?`2R?0I3=<51)0@4194@4!15-E7J2*C\2:;`JI'BJ!($BJ)*$"B* MZDAR!1XICRI!H"BJ!(&BJ+(%/HFY"JNQBG.5(%`458)`452E-9])!9XHCRI! MH"BJ!,&IHYI,J["Q-MER3[$SD]8?IU.X^>UM^Y<+;3KI'^K=B3S@, M!T?O7)V7M&Z M3/=>7H(;T;?UAA,?^IF2A`[Y2F,'HY"$3W`/%FH6:<$=@!,I)03WD&%CONHN M:B/90\Q&LH.@C60/41LA=?8E5^K)5;"#(\`O`VR:XVXW7N`4U5,MD`#?PYC] M(,@^17_6[K+'H[7[-+45ZDLA-V9]?+'N>(^E-7L4[:S988^5-7N(VLCS)HTN M)SQ;NL#RO`?)"W]S/V\'`Q3%.Z9X7A3!I#[A,G)\Z$6XW.TWMU;\'JMK]VEG MNK#%!!(8U6P$;:,DW>=%M&6'HE8\L?L,(34.18'JM0ZHXE72/4$SMK1=]S.V M1W]?9QT9+'+>7#^MR6DT<&X3GF>"9^G@6SB2D+R-NZ_X`T`LVZE?NI-F;3;N M\Z>=M[!#DYWPQ%2PK7C$(O\T8VUC_ID=F4U7YE#2-$%#+E'H`Q4>40>*TG-!9TY@&J/S"3V(804 M6(I40P`X2B"00/04C;^P"IF5Y9ZB$9BR0=$03"%P8_`),1 M[;*E1PA0.OU_&:NG=>U":J]LT@2RTMWCV5,\U M)LJE^^<`+`*1KG%$K>6XKE*[+O^"&/S:=BU!:C&PA075(-#7"0;I%)"4(IBY MJMT$@Z1R##14,%<-&U:R6K%0Y.B-9\(;-7`/3JI0V48Y3&67*A767CAH' M5,6>;+J7X<+50'.`L6;)4"1ATOR[` MT$*>.^"7,V!QO*6932F+)RPU;+](<@].@B[/_K1[;91@)\=[KNC8J68'!/O( MU?-`*IX$G40J'AFO:+`!1MHNTF&[9JC33@5* MT_L$X^>!E.6JYPG@BKJWC!,U>)N3HE73(FI%&4F.G'A%3FAX#7&<&7#^7*=J M8:4\!?&`I?C8W\JQ1>1G#5>4!V5LYGA0=.\9L_G_4X::137:X,:5T^DA>LJ.HT6M4^T6)"!Q62AK!YP2;@R3G35101FI>U8FT9 MH+K6HI7'VB#$P]I2E\0.3?120&?C,B2L\^4NJ8#VA)=#U"J@;1#280&\M)#:%_^TVT;.^IF> MP-+\!!+9?08=2.,4R->)&Z-3>MCXJ+$K5H=L92R^#YSPRA@W=A0S\=!EZ`J@ M]>=&41?R)6-/AE8@;96O1>0'+.$U`MPS M:]S*G,ZWG\=?FA%T^KG`/933O'L+)%'5LY5QN@;N*^$T-Z`4)R.JG%[&Z5/# ME9>\@M.EPQ4E25F)YDE=2$UE>,5(7<#[*DE= ML$*ZUP7K=QE)^!P\/MP6I#[]<1'BK#ZR5>CH%Q_9TD,>M4>$<(Z^3J::^%9( M^?[D:`^"8.@#*<1`'.`!=JD;7-Q&;A7&WR@LNQ1.PV?EP+/]NK_5+K1W2UP> MS&8H>";[8N>X:R@()\;C< MQTM7"2Y8_6LJ*\O,`5A+9,%=U!K+ROH;>'P+)PO&M*:XLF%PP/M^*.A[8U\< MV27XQ%]@L@@N*BN/(WB.^`M-;BHKCR,$CLH"DYO*RN,("(DL`Y0TE97'$:)` M90'=FLK*XFA`X(BLH:#O+_?&D>G5FK M=&3A"8/CC`@,>`KLB>.#/A04]\<@R'S$2^C#1Q%`?X(G(<-#EC7P M2S*(P3;I/S_!/6!3)^(92:088`,O`OPONXBX$?%%1!&7\S0I]S!8N=5]PM,2B_"X7T/VOGO(;!#._1_BL<';K MX&P^`(Y:V6MKYT9WV9=3/7__9_:,`B!3\JOOG2]!Q$1,]?S]1WSX`V0Q')V$ M7DR&L_<70V,^>__>G'3[ MW?E_P&7X8/4K>#+W`0\N9P]8A_M<](RKK0N/-P\38Q/PG_-M4YU\B.&S.[X# M;+BF(S6BL\T>_'[S7P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL` M`!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6* MV+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5 M_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU M>[66\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0 MVJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG M9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4- M?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC M>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG M%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>] M;=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM M&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P M68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/ MC^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9 MF]B(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP M$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/9 M9/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2C MLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1! MGS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I M!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW; MK"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,< M8[Z4%3]F\=%]UI]>J])XH4(R7B>F:SFF0>N49ZP^).:OGX]W MD6E(1>J,E+RFB?E&I?EI\_'#^L3%LRPH508PU#(Q"Z6:E6W+M*`5D19O:`UO MQ0 M*,AV"`'IN%;9VP.5*1@*-)87:J:4ER``_HV*ZSVQ3!6)Z2^L<.GX M+L"-/97JD6E*TTB/4O'J#X+<,Q62>&<2N)Y)7,_RHM`-%__!XI]9X'IF\9:6 M&S@S.&R,JC7I@2BR60M^,J#P0+=LB"YC=P6\%W\V2F$O3 M`"4G/F.TUQE^.,#O$P'_'XW4L-BCN9(.1?=FWDWE1I\%: MG4ZNEKL=#^QPH+]NX#BW5P:3YJ^LP5`PO7B">-GQHAC$!#U,.$3LIA`#5X!D MOC8-3DR(O/,ZB*/AREO$3&E#Q`)S[D9!W#$,E,%6F:],@\?*WGG1-<1,*4-$ MU"ISG?9W6]MBJ$UO`1^.F>F:TI.&&OUHE+!8SLC=W;_?#[R#;37? M.PT>Z@I[E8S>(6;*NQL(Q[WMGFZ3O0-DVC4-'JM[W^&H#C%3ZA"!MB[<93_` M@7'Q4-J\Q.I)8XE^%SI*1,R41$1@\?F1=RT1^Q4>Q145![JC92F-E!]U+_*@ M9+K1KDW>>_H(&XUOW16<9[H#=B^@?37D0+\1<6"U-$J:`Z5C+6%'"&R`^*!X MTS:`/5?0N-K;`KY3*!R1C@7@G'-U>=`+=%\^F[\```#__P,`4$L#!!0`!@`( M````(0#^/R,DN@(``"0'```9````>&PO=V]R:W-H965T"<8VJC$6D*;]][M`XL9) M5F5[L0V<>SCW7+B>W[Z(%CTSI;GL"AP'$4:LH[+D75W@GS\>KFXPTH9T)6EE MQPK\RC2^77S\,-]*]:0;Q@P"ADX7N#&FGX6AI@T31`>R9QVL5%()8F"HZE#W MBI'2!8DV3*(H#P7A'?8,,W4)AZPJ3MF]I!O!.N-)%&N)`?VZX;W>LPEZ"9T@ MZFG37U$I>J!8\Y:;5T>*D:"SQ[J3BJQ;R/LES@C=<[O!";W@5$DM*Q,`7>B% MGN8\#:-P,7?^_.)LJP^^D6[D]I/BY1?>,3`; MRF0+L);RR4(?2SL%P>%)](,KP#>%2E:136N^R^UGQNO&0+4GD)#-:U:^WC-- MP5"@"9*)9:*R!0'P1(+;DP&&D!?WWO+2-`5.\V!R':4QP-&::?/`+25&=*.- M%+\]*-Y1>9)D1Y*"^MTZ3+T?''HA+J][8LABKN06P5F!K71/[,F+9T"X3\AO M/Z3XMPPA-4MR9UD*?(T1B-=0E>=%-HWGX3-827>8Y2GF"+':(VP%0-Z@$;([ MU'C>[+T4"[92K/E6V])/`/>@+1DK6YTB\ND`&2D!ARY78L%0X(.-L^G1UDN/ MR0XPDV%G)W_U'F*D#4@.M=E*IG#`WW?+!A48#!C,R:;I6,'28VY<6=,TBZ)H M#%AY`#P'DK3`YL]B;ZKN1OKV"J9BO6MAI1N;$=)X'DA]FA&=XE]B(< MS2^A2;J6$@X+T*1Z4K.O1-6\TZAE%5!&P37XIGR;\P,C>]W*?#?R- M&%RT*`!P):79#^PU'OYOBS\```#__P,`4$L#!!0`!@`(````(0!AII\ND@,` M`%(,```8````>&PO=V]R:W-H965T&ULE)?;CN(X$$#?5]I_ MB/P^!(<[(HR:M'IWI%UIM==GDQBP.HFSMFFZ_WZJ8DAB!T;I%R!P4G5]8ES$T"$4L?D9$RU#D.=GGC!]$A6O(1?#E(5S,"E.H:Z4IQE]4U%'D;C M\3PLF"B)C;!60V+(PT&D_%FFYX*7Q@91/&<&_/5)5/H6K4B'A"N8>CU77U)9 M5!!B+W)A/NJ@)"C2];=C*17;YS#N=SIEZ2UV?=$+7XA422T/9@3A0BO:'_,J M7(40:;O)!(P`RQXH?HC)$UTG=$K"[:8NT+^"7W3GSQ7A"`0_V7)L7@2%)D)ZUD<5_%J+74#9(=`T"[Q?[>_3Y M()-K$'B_!J'1:!K-%LL!*J$=5EVQ9V;8=J/D)8#U"N*Z8KCZZ1HBWR\+U`/9 M)X1CLH")BXF&N7G;CC?A&U0_O1([2\!K0U"72&X$3B`X-")0F^$B"*,(SA>: M[>P7W;R1E[=/3!K"$8$J#!=!&)9$9[S3)JHUL\2T0\Q<(OD1X9A!D.%F",<$ M1MW,Q-S-N[-$UVSA$DF?:-T=,]@*P\T0=LV6;MZ=);IF*Y=(^L0#L_EGS!!V MS:B_P"W25:/^"N\C#]Q@(PVO&L*>F[?$=Q9QW-HU7J_&I(\\<,.'YN!S`6'/ MS=\&%G')K\^.S"FSQ'?T-8I.O8"EA%2\SJHR]: MSE>+2;LP'44*/L/K5].>G+<7=U>F:T>]?9/<8=H1N'YX#`^>7VH/[>YA0MN! MVW/NRG3](F_S)'>81WYX7`_WLX=[UR_R=N6.6F9>S]V4+OMR%N@.X)$SY[LCY.Y?VGP&1OW7O,(_\8`R?\$/:77R1OWNAK4.F6YNH36[WQAVF1>SB MLQV;[3\*KHX\X7FN@U2>L0.C,#7-MTU+>>WUFA^@.:O8D?_.U%&4.LCY`6X= MCQ;P1%"VO;,71E9U=[.7!MJR^N,)>G<.W<)X!/!!2G.[P%ZD^3>P_0X``/__ M`P!02P,$%``&``@````A`%H:TA@+!0``K1D``!D```!X;"]W;W)K&ULE)E1CZ)($,??+[GO0'A?$1H<->IF=3)WF]PFE\O=[C-B MJV2$-L",,]_^JKM:I1LLX&75Y=?%OZNH^@.S^/J1G9QW7I2IR)>N/QJ[#L\3 ML4OSP]+][]^7+U/7*:LXW\4GD?.E^\E+]^OJ]]\6%U&\ED?.*P>YY97+D65R.Q)GG<&0OBBRNX&=Q\,ISP>.=6I2=O&`\GGA9G.8N1I@7?6*( M_3Y-^+-(WC*>5QBDX*>X`OWE,3V7UVA9TB=<%A>O;^6.8$=R8_/=YS,O$\@HA!D% MD8R4B!,(@'^=+)67!F0D_E"?EW17'9VO*Q>4AG2=9*WLA+9 M+X1\'0J#!#H(?.H@/GSMN9CIQ?!Y6SP*II$?3;HE>+@=E9WGN(I7BT)<'+CD M0'!YCN4%[,\A.^0]T*,+1)L^P]3"3<55-D*&T486B;#=$F M83-OS9HBHVO:;-;ZX?!AI_K0EOU3IFA3%PO#VPS`>FJ(2AJ)&%GSA_D#CG:8 M4_]+3KIM9UTU%*IFM=OTP4%3DYS3-4UR_(8P M>^@1Y^-TKWL$"RUW6FNH/3%H$B1BZH0P=9T=^B3=U:\^0J0^"C'UR7E=RV.' M/ISN]?PU>U;>\<$F'M2V_:"IR;*&?M;J-SV"A1.[;Q$B$>",IVNJH8@8]!=JR%2'\9I1TQ]P-3SV*%/TF;^FA,Y M0*A](C\X:&JR7*+?1)9/S)8V%LZLB:RA]L3H[KAZQOV.Y^[9ID[+.3IRAY.^ MH[:4'6A]%&+J&^08`4[ZCNY%Z''WUH\3W3O(*X*F5[#&/:B&R,I>':.[LH-\ M(\!YWU%9RA1T92G$J*Q\]._?M8KNZEH-40^T!D(^T3++-_I-9[7*U,DB^V64 MAJ@ZDXB91\M%Z`YF./7I.FN(U-?;/9B=>DB0M<9 MMEG7UV]2,[G*U,DB^[V4AL@\8IQVQ*RSY2@==48'Z*@S91/8SXQ"3'V#G`1> MJMOY:ZDS0OCRT;YWUA'L@Z@)7[CC*^5S?.`_XN*0YJ5SXGMX[!V/GF!;!;YN MQQ^5.*M7R%M1P6MR]?4(?Q;A\'YY/`)X+T1U_2%?Z-_^T++Z'P``__\#`%!+ M`P04``8`"````"$`++(\5G0$``"+#P``&0```'AL+W=O6:&0W+]];5MC!?4DQIW&]-9V*:!N@H?ZNZT M,?_ZD7^)3(,,97-N7/B MPG%-:[MF`?J[1CX01!OR1#/PA/$S-?UVH!`X6YIWSC+P M1V\G"D=/&(7G MXZG@5S85C,+A\506SPE+<5H.Y7;=XYL!^P:B3BXEW85.#&PBMSRB4[;_*]F0 M94JRHRP;$_PACP0J]&7K>=[:>H&JJD:;1+=Q9(N]L*`E1&E3%!8@98 M(''2"77S"3HI"]4I5I@(X%VXJX@2%L(E58%,!7(5*&:`)`J*^A-$41;8D[/D MN9$MJTBXC3\W"F23_60R*=603$-R#2GFB*06-N(GJ*4L4.PPRZQ6?5E+PHT> MRIU,)KD:DFE(KB'%')'D0AN9R[W?;<4&I,9,E5A-PA$?ADFG&RDZ]Y.1<$LU M)-.07$.*.2*)@([V<1'46!;!$1`AUK?7D%1#,@W)-:28(]**H8G-5\P;XH*> M%<.YKIX3S(^J.^GPH/'Q=D@Y9"$C,A.B(2E'/"B(6<:4799-1B(BN88438G.50_E."GFP4>2O'5=7/ MG23U#ESOM!S#=6LLWQ_X`KI^II89H1R+$7+G/=2-0B48PLJ?IM0(Q*\=P%1(GZ14:(Y9O/R)\4_+[9HOZ$]JAIB%'A*WTNK(!L0OE3)EW&T,\@L`H. M3YP=>^$H>$*?/G?L$S>&2Y/.DW@QW"]T?.?'._Z$4B?P8SBA=8[Y8XI_#./6?,(#/(+8+CW#HQ?! M1=BF^_>(\2`^Z`33,WK[+P```/__`P!02P,$%``&``@````A`$@8##P*%P`` MAWP``!D```!X;"]W;W)K&ULK)U;;QNYDL??%]CO M8/A];'7K9@E)#L9]OR\69W>?'4=)C+&MP/9,9K[]%ILL%5G_CFQEYF!PY/Q8 M5[_:/[\^CB]GYV>[Q=O_I[O'+^_/_^7?^R]7Y MV?/+S>.GF_O]X^[]^5^[Y_-_??C/_WCW??_TV_/7W>[EC"P\/K\___KR\FU[ M>?E\^W7WZ22S_NGAYL7^N?3E\OG;T^[FT^CTL/]93R;K2X?;NX> MSZV%[=-;;.P_?[Z[W:7[V]\?=H\OULC3[O[FA>K__/7NVS-;>[A]B[F'FZ?? M?O_VR^W^X1N9^'AW?_?RUVCT_.SA=EM]>=P_W7R\I_/^,UK?WY[]&VV%]=7[YX=WH MH/^]VWU_]OX^>_ZZ_UX\W7UJ[QYWY&UJ)],"'_?[WXQH]WOS^_ M[!_^SPI%SI0U,G=&Z)>-S"X6\7)]-5HYHKEPFO3+FM[ACRA2Y<9ZTZ]3C.D4 MCBBLG`+].H6KB_AJ&2U7YD2/**Z=(OTZQ6A]L8YFF_GZN")UL;&*]/NV*FZ< M`OTZA?GQS0)ELW;?!AQA)@_W-%6%]%B M]IKS(PX0\\<;J\FA8;J!4YD?#\=+VRG&/I;>O-Q\>/>T_WY&`Q?YYOG;C1D& MHZTQQ[W+ALNAO_VHNU$_,U9^-6;>GU,`44]ZIC'BCP]QM'AW^0?UZULG"!2_+UP>$46?^$PXT9 MXW!VU34#KP64=UF"55(-,@UR#0H-2@TJ#6H-&@U:#3H->@T&#P3>IYD1[=S.ZYMF1!]CW'KT/')P!"VDA<((+C73H0DM48%ZIP#P(L9]3(!F0'$@!I`12 M`:F!-$!:(!V0'LC@D\"K)J/UUVK'N[N1#KUJB1^80%(@&9`<2`&D!%(!J8$T M0%H@'9`>R."3P(64>)S@0B,=NM`2LZ+P1LR-"LR#T"$P@61`B"#3P*OFN3L!+>.XJ%?'?)C$U&**$.4(RH0E8@J1#6B!E&+J$/4 M(QH"%+K4Y`]O[^PFQU6AZM!R(?,0HE20%]'Q+(SH3*0XI'-$!:(2486H%N17 M(@XKT8@45Z)%U"'J$0T!"AUO4@O?\38COC!;(2]?[VY_N]Y3UR=W3XR^<\I\ M73YL$Q1:TW)=K\WF`C51T!Z`4B'S6&"]G#(6Z>9%,3T(D&I0_.EW=28 MZ5V-3`38"SF;&3=%QW@H1&K<&YE%\S"X2Q%@,Q6;D=K4(N7,J#V61@383,MF MI#:=2$W7IA03N0AZYATQFRQ[:OS=97Z/<$4:W&R22R M0K%,Q"DC&F\.>M%237@92ZW&L6>QCM>JN^SU5K;KEA$ M;->,CMIN6,K9CF;KF7))RR)BNV-TU';/4M9V',6K2'EM8)'1=MC>)K,ZH;UM M(A:TMT4KOU>M5062R`H%G MJ&Y>L9;TG9J1&&I"0_/5;+-2.YPM:XFACI$8ZD-#R_4JOE(^&EAKHE.:W,UO MI)];?]D,,&@[B\*^JCR51%8HZ*L6K61(R9S4&RQC)]:L<%0N6$L62D2A6J%BSE"@VC$2Q1<6.I42Q9R2*0Z`8 MNM2DX3KXXY6Y,6$J7_16Q6:A9I;`XLIKA]023K5OPE)>'V`D/25C)`-&SD@4 M"T:B6#(2Q8J1*-:,1+%A)(HM(U'L&(EBST@4!T:C8NAPG:V_$L.8EIN;*LCQ MX;2@9N+$"?G3`B-IL(R16_AL]*R7LX!TCH*1F"D963/S>:1J4[&`F*D9B9F& MD:O-:K51@U7+$F*G8R1V>D;6SF(>Z[FO0)`+=(5J>N)="PPMT#8N. MK\.<'O56GC!21M*9,T8TRWM+<34'YRPEM@I&8JMDM!G7!?.E7C]5+"!F:D9B MIF%TM$HM2XFMCI'8ZAG9*D6SY5JMZ0:6&.V$S:<3^Y]:BE&G@>:SB([,+9,X MJ:"'6:F5)-&9DUJYLYGH8XH>#0FB:EPV@4QZK+)D[*AH/=MF'%<-FN MANJ,I1;C`!6OYZN-VNK/T7;!6D=MERQE;<_7ZZN-&D4KM%VSUE';#4M9V\OY M*HY4EVW1=L=:1VWW+&5M7\WFZXV:<(?`=A@4)K$_UOTX*EY9E]C]@:#_6>1? M$8L!I8@R1#FB`E&)J$)4(VH0M8@Z1#VB(4"AJTT>KET]IUM>,-1;%/Z MP-T6A5=V8Q5DB5/T&B5%E"'*$16(2D05HAI1@ZA%U"'J$0T!"EM`I_:O!#7F M\+%%GO\21"FB#%&.J$!4(JH0U8@:1"VB#E&/:`A0X%*3=@1!?=REHWB8)3H4 MWBL3JZ5^(E*\H$D198AR1`6B$E&%J$;4(&H1=8AZ1$.`0B_KM/P5+V,N/K?( M#UQ$*:(,48ZH0%0BJA#5B!I$+:(.48]H"%#H4IUXF]50O#2KH1,'8_,$@-KY M<.C*G[CC6&W:)2(E,6UMD2*C#*5R1`6B$E&%J$;4(&H1=8AZ1$.`P@8@YYPR MD1#@$(OFRSR M!"\;<16X%@6!"RBE6S:,HB>5(H1#0$*7:I3TU<" M%_/.N45AX,Y5;IB(E`3N09%1AE(YH@)1B:A"5"-J$+6(.D0]HB%`H9=UKO>* MES&GFT,"ER!*$66(D1#@$*7_G,YW1QS.H=44*OD M/A$ICN`4488H1U0@*A%5B&I$#:(648>H1S0$*&R!TW*Z.>9T#GGC;((H190A MRA$5B$I$%:(:48.H1=0AZA$-`0I0'].(4D09HAQ1@:A$5"&J M$36(6D0=HA[1$*#0I3K=.S[W+3"GH1#0$*77I:3F>VT;1++?+NCT^.>("D2E MH"/F*Y%B\W6`0L^8_,@/MI^ZNFOZLW:819YW$B?EH=0ADR<>KG1%"W6E*Q,I M/J,<;16(2E$4\_%%H: M13?(0H!99&Y<\-RHM[R=HG^1E)&W/A;`7(6"`\&?G15DAL&2E'D M-JL8V8/-+C9JW5:SP(\.%CI2)T^OS,F8("TL4O&H]UE92F(D9207SC-&\1B/ MRC\YEXI"P4C,EHQ$JF(T:;;FTE$A=,YI>1'F35/ MERK-`S=J6R47!3^>E0L+EI(CE8SD2!6CR2/57/JF^*);B<,)XGA\C>)ALN)0 M&%\+=?H)2TD@I(S\`06?CV`I&QOK"S6ZYUPNX50PDF.5C(X>JV(I>ZQH<:%Z M2JR*I>RQHE@?K&8!WTR\D"H%O7QY6EHRBBO70G:1."E: M"/#IIH@R1#FB`E&)J$)4(VH0M8@Z1#VB(4"A2\GQIT2K$52A%E"'*$16(2D05HAI1@ZA%U"'J$0T!"EVJ\YE7AEE,7)86F93)"UPUJR0B MQ8Y/$66(D1#@$(OGY8$+3$)6V1H52.J$!4 M(JH0U8@:1"VB#E&/:`A0Z.73LJ4E9DL.>B"U#@^-5IF=DH'J[1'/(=CRAEQ>"<%VJC M)4/%7)!_SFJSOQ`I/N<24>605X-:O4J-@(\BJQ M4NEJ*U)-/2_3H(6MPO$6>EQ,GY:&4%4/'J\Z:H6+.2)+&`E')2,:[ MRB'E936XU:C8,)(CMH@Z1N,10Y>:;,O?_S^^7E[9Y,R_V\TASW\)HI05`YX-8L4N4`Q'"Y/(G3!: M&''E<(O,7?H2G2LUCR?TE@"CZ&]B,K(/(-/7%V8P>(!2SDHT%!R.-N%OIVAW M(V$'N60K?L@?5-AK-4HUC&1GOF4D@TO':"*^3\L)5Y@3.F2FU(,#Z.4P83PE M3LI_1MHANA1EXON7>+:$U\^A5L[(/]R$OVT]Z8GQ\<5C\PO]`HV2[4B'JQC) M"P%J1B+5,)+-_I:1*':,1L4PP'5^^'-C-Z:-]/RRB6@5]VH9E3BI(.ZM(EU8 M&!LB6BST.YHRU,H9O1+XUK:[(!6IVI1LQ(_[@X;$O4,BU;"B'_>@V+'41-SK ME/+G6@$S37ID?!Q7_/B,5VJ9E;"4Q%7J$%V6&(?[:+/28U:&6CDC_W`3W<%5 MREU46NN+2B6;D?I4C"2H:T8BU3#R>\/A8-R`'4MA;Z`'NL/A7K?#VYYK'J05NXA3]L=VAM9M*5XNUWL'(4"MG MY!\.@YFEW-BNK< M.M$?R?P_W*K&HFI5BU3?5+TA,6=J>K!$=NK0E9WN::DVT3=!*V=#K_1-I_BC MO@EV*[;[X[X).@V?P=&ZM"Q%S72L%7WS8=\T.:>?B>A1]8U3DTM=97"_I@YE M&L7?X$>4(LH0Y8@*1"6B"E&-J$'4(NH0]8B&`(6N-AFB[^KC6T3F%=FZ-U@4 M7IE:J_PM<8J>XU-$&:(<48&H1%0AJA$UB%I$':(>T1"@T,LFHSS!RS8!]3?B M:#YW@2M=*H;WT(H4KZE21!FB'%&!J$14(:H1-8A:1!VB'M$0H-#+.J,VP\;/ MO3[$+#YTG%NDXESMWB1.,8CS@R(W2H92.:("48FH0E0C:A"UB#I$/:(A0&$+ MF$3PA#BW>6,0YQ9Y,[O]:J3]HMW#[NG++MG=WS^?W>Y_-U^$7)LW:AVP_5SE M]7I%WZLT)F3W^SM[*!#?J/-U2D=\IO=K02=#95LIG06 M,SK3<96E=6+2H1>S3!V'=&B[9JJ$?$WOQ)@J(;_1RQJF2LAO],Z!J1+R&SW_ M,%%B`G&*DP,FXX9.9?),(CH3^L;(Q!%B.@2]:VFJA`Y"[P#"$MJTWYI=>BRA M2]5;LUF/)?1QV%\GO4*.G/0CN7%2WCAQROYB^ZO]^*QN7O+M5(6N34^>,'1- M\3C5C>G"WM90B531Z<;"[;F.@I:HSL'MN9""9;0#01; M6$(?\MB:;W5@"7V; M8VL^OX$EU^2WZTF_T?-H6_.(%>K08VE;\]#95,F22J9TZ(FTK7G("G6NR0?F M,S98DE!),EE"'Q@B'TQYE#YU0R53UN@305OS61H\#GTIB+PS98V^64,EH\[E M82B@ST!_N_FRZVZ>OMP]/I_=[S[3HF`VOG[VR7Y(VO[CQ;VZ\>/^A3X`3?D\ M?0>7/OB]HV]8S,P;C3[O]R_\#ZK4Y>$3XA_^7P````#__P,`4$L#!!0`!@`( M````(0",;8KO$PD``'8G```9````>&PO=V]R:W-H965T:GF1'GSQ$YNMS_]OE\FGPJ;TU57QZFSFPQG927?7VH+J\/ MTW_^3CZLIY.FW5T.NU-]*1^F7\IF^MOC?_]S_U[?/C;'LFPG$.'2/$R/;7L- MYO-F?RS/NV967\L+''FI;^=="W_>7N?-]5;N#IW3^31W%XO5_+RK+E,9(;C] M2(SZY:7:EU&]?SN7EU8&N96G70OC;X[5M<%HY_V/A#OO;A_?KA_V]?D*(9ZK M4]5^Z8).)^=]D+]>ZMON^01Y?W:\W1YC=W^P\.=J?ZN;^J6=0;BY'"C/>3/? MS"'2X_VA@@R$[)-;^?(P?7*"8NE,YX_WG4#_J\KWQOCWI#G6[^FM.OQ>74I0 M&^9)S,!S77\4IOE!('">,^^DFX$_;Y-#^;)[.[5_U>]96;T>6YAN'S(2B06' M+U'9[$%1"#-S?1%I7Y]@`/#_R;D2I0&*[#X_3%TX<75HCP_3Y6KFWRV6#IA/ MGLNF32H1?Z=^LQ03P5!'Y_?B0K%01^ M51!GMO9];[6^^_%T[E00^,4@WFA--BH(_&*0Y;1K=X_W MM_I]`M<1S$)SW8FKT@D<*!6<;#DU_?1_;?9AVD64)Q'F80K9P<0V4+*?'IWU M^G[^"1F)&$D921C)&5'!9$=:=&)C$5A(/XFMY-@LJ M3]@;H5O$2,Q(PDC*2,9(SDAA$I([["`CZ-^DAF)&4D821G)&,D9*4Q"=THCD.W.:O4+F/',4<11SE'"4V([LJV,APZK8*^=!F&-?UTKJNTLO%JT7+%6^=DP0Z9TWY2A#I!USC@J"J`RB:1HA@^RQ(!Y.Q-:1B,B@D!Y4 MI*S$+;UQ&=[9,C#'!,.;,B@KC3*TTF?,.2H(HC+`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`VT3X)(SUB*Z"N;)A[607*%^@IS'6NF"N)$*TPTLR/TDKTO MT4LB6F%VC8=B$Q9UJ*^O4YFZ*ACY0KU!;BTMZ.".%$U13MN%N#/J2F;>E*7JL\W5S[' MMZ[)T&5W`Y%"OB.[ULW*6ZPMMYB[)8C,TE3!]0.@#*W,6F16!;&BH((AJ(1II6XO5 MLGOR\)UF3+;@)'V)?/W>-W05DHO$!ZMAB/`P3)]QN>BEEXQU:;?7HLRAQ+YS M9]*YT39;(7.@B-1`]1#D33$>I@/5JR0=J.CY3%&_K21\V&*WM0IUZX,,+3]= MD=\QG,O;:QF6IU,SV==OXK,46,D>[WLLOYG9K@)X704+G,WO`GB5,\#7`;SY M&.";`-X*#'!G$8AGYP-'7`@%-<>/P$/F0#P/XD?@67.0#QZ!Y\MPGB$?^"KH MJ5L7[`R%P\`YMBX,:X@OX>NB`?[D!4_RJR/[!%X`KWMY$EL_@%>A`QQ2V`ZF M$,(1\4B.^\"S_4`\<^-'X!%_(![@#QUQX`^. M=".8]P+`5T_7W6OYQ^[V6EV:R:E\@?);=.O%37XW)?]HU1KZ7+?PO5.WG![A M^[82[LL7,]@=7^JZQ3\@D7G_Q=SCOP```/__`P!02P,$%``&``@````A`#$" M9@2D`@``OP8``!@```!X;"]W;W)K]?MQ=S2ISG3<%KT\B&+'5LO&!Q,J:>_#O*M6Z`YL6Y]!I;A^V[84PN@6* MM:J5?^Y(*=$BN]LTQO)U#7$_)6,N#MS=X@V]5L(:9TH?`1T+1M_&?,DN&3`M M%X6""##MQ,HRIZLDNYY3MEQT^?FCY,X-WHFKS.ZK5<5WU4A(-I0)"[`VY@&A M=P5NP6'VYO1M5X`?EA2RY-O:_S2[;U)M*@_5GD!`&%=6/-]()R"A0!.E$V02 MI@8#\"1:86=`0OA33E,05H6O8Z8.#Y@ND1#-STEL#&T-+I]!R4$8S*F"ZT#*_.Q%(*/I<+.N+N573!A8(1;J:7=R"^RKAT1 M9HO#((7KU._V&PO=V]R:W-H965T&ULE%==CYLP$'ROU/^`>"]@)X$D2E+=]71MI5:JJGX\<^`DZ``C[%SN_GUW M;2`82`,O2=B,9SW>]6!O/KYFJ?7"2I'P?&L3Q[,MED<\3O+#UO[]Z_'#TK:$ M#/,X3'G.MO8;$_;'W?MWFS,OG\61,6D!0RZV]E'*8NVZ(CJR+!0.+U@._^QY MF842'LN#*XJ2A;$:E*4N]3S?S<(DMS7#NAS#P??[)&(//#IE+)>:I&1I*&'^ MXI@4HF;+HC%T65@^GXH/$<\*H'A*TD2^*5+;RJ+UUT/.R_`I!=VO9!Y&-;=Z MZ-%G251RP??2`3I73[2O>>6N7&#:;>($%."R6R7;;^T[LKZG2]O=;=0"_4G8 M6;1^6^+(SY_+)/Z6Y`Q6&^J$%7CB_!FA7V,,P6"W-_I15>!':<5L'YY2^9.? MO[#D<)10[@4H0F'K^.V!B0A6%&@"%+FM+4%N.+G%_W6A2'&CFJ"+M9B'!E79!RQZ]'Q!L MIM*1N:_LI-WMJRF\"#9Y=01XVQ69#5>$0-W&:U!H,UD=ZA>%X.YN+0]6A.HMG\9I/A1NTJJD*FHBO> M0":9@T)WUJ\RC`%%N'N[BLC*N:T)!W:R5"%3DW^E2I.L@/2]H`X-:!IP@[FW MT(5ZIC"Y7ULV"F=9`H*;;9" M'>H+H;B5.PU'@M4(JU8C.VF0#$)FQUW>P::H2;Y`^[Y0AP9$#?@"\:@3W-Q& MM&\-=<@0M;R\W4U1DZR!5C[0,KLZ-"`*MW.G4I0$MZT!W[H=:ZA#IJ8KAP0Z MR1H4NM,6E5L,:!JP!K*8C2E4WQOHD#.#VU4*6^T^@'R0N8)UQ+N(2KB/IYA+LG@V.WAZVRYUS6#Y#9;6ZS MNW\```#__P,`4$L#!!0`!@`(````(0`ED185FPX``&Y.```8````>&PO=V]R M:W-H965T&ULK)S;TQBWB3;&`73WS-M/EJJ2.ORR#+U]T[0_9?XJ91V461+<_O[GYN7B^VJW M7V]?[P;>Y6APL7I=;A_7KU_N!O_Y(_[M>G"Q/RQ>'Q"OU7[P^_T_ M_W'[8[O[NG]>K0X7I/"ZOQL\'PYOL^%POWQ>;1;[R^W;ZI6./&UWF\6!_MQ] M&>[?=JO%8^NT>1F.1Z/I<+-8OPZDPFQWBL;VZ6F]7(7;Y;?-ZO4@17:KE\6! MVK]_7K_M66VS/$5NL]A]_?;VVW*[>2.)S^N7]>&O5G1PL5G.LB^OV]WB\PM= M]Y]>L%BR=OL'R&_6R]UVOWTZ7)+<4#84K_EF>#,DI?O;QS5=@0C[Q6[U=#?X MY,V:X&8PO+]M`_3?]>K'WOC_Q?YY^R/9K1_+]>N*HDW])'K@\W;[59AFCP*1 M\Q"\X[8'_K6[>%P]+;Z]'/Z]_9&NUE^>#]3=$[HB<6&SQ[_"U7Y)$269R_%$ M*"VW+]0`^O=BLQ9#@R*R^+/]_+%^/#S?#7SO\GHR":;75R3S>;4_Q&NA.;A8 M?ML?MIO_22M/:4F5L5*A3U:97DZN1KY')SU5Q%Z\44$>QROE"-]*L?@)#^: MNVU3Z9-/:/99SQEOE"=]LN=I3?5H8,IQ(D:H'`*G-=8[CC#Z#Y_TQ,AZ/*[$ M?]CWQ`;S:/+T<#JQP3R3AT*8N;),!G#J+?!0SD?V^D=+@Z+^]O=]L<% MK9D4K?W;0JS`WDS(\L26O7NG[O>?[M\/O MM*0LE&"T@65"VH7-`884JR/ M`:J"S`6Y"PH7E"ZH7%"[ MH#&`%5V:A;\BND*&;E'6<`[L<#Y(F\`TFM@F\Z/),>1`(B`QD`1("B0#D@,I M@)1`*B`UD,8D5OAI*?L5X1].SWC1%M9MF#D\#Y($I&\$?NJ,ZJ,1NX5` M(B`QD`1("B0#D@,I@)1`*B`UD,8D5E0IXSHCJL+:CJHD@#=LI,E'(57G0>1!5) M33>G%:(0480H1I0@2A%EB')$!:(2486H1M18R!ZU(E\T0RJ&P'AR27/LW#)3 M9IY6M%4R:MT:`K?V$;FDW249(95YJA?28JIIW6F?G9.X=K7A]"1%%B&)$":(4488H1U0@*A%5B&I$ MC87L*(M<](PHR]35BK*9S:J!"RCT`$6(8D0)HA11ABA'5"`J$56(:D2-A>R0 MBAS:#*E8C+W)I7@P+[\^;`7HS#E]VJU6>]@J$S=O>PH9I;L'*%3(I[L? MG49M?P?.?E6DK7C4QX@21"FB#%&.J$!4(JH0U8@:A6@]IM9;P1]WU21G![]5 ML>^"C(S@(PH5\D57Z^`[>U:1MCH&G[6NCUE.HJU,+6>;(=56K)6A5JZM3"VG M-"FT%6N5J%5I*U-+UXCM^*VU%6LUK-71:Z)R,J=,?THXQG*,D=D]RDJCD*UT ME"-$,2/MF##2CBFBC)%VS!EIQP)1R4@[5HRT8XVH8=0ZVA/AO,IQC)4C(UIB M]%B>Z,):KO7*BOJ6^SED)!^7BRW&B-'X:!4STHX)(^V8,M*.&2/MF#/2C@4C M[5@RTHX5(^U8,]*.#:/6T8ZR6TQ^,'"Q8AQ+)#Z,*.OM`!5E9:5W&\)N1Z?4 MC-C*6I`F3O(>LY663QC9[7+D4[::MD]9QY.)LSQE;*"5]^9 M<)%R]&FY-N2A7T$^8<=>^92M1![Z_;YK/H-RSCZ]R@5;*>7NC@?QBMUZQ6NV M8O%@!"M1HVQDR.T)[1;O[H3^8_OV7L).JIRQC[&H5\C2WFRXLD9 M:T=&":(4488H1U0@*A%5B&I$C4)=M9&HP?__&Y>LY*T;ET)F\`&%8XD^JHV. M5ASI6#E2Q>Q\&":->^92M9(D1^%-'.6,#K9PSZE4NV*JW MX25;:?F*4:]\S5;O-;QA@U;9NK^+O-3J\Y^ZO[\9JMCN(WL!(URJ:C-A*I M.5@<<'3F'CM`J1I0@2A%EB')$!:(2 M486H1M18R.X`=Q^@/]/VL=Y7R(C?'%&(*$(4(TH0I8@R1#FB`E&)J$)4(VHL M9(>TJ][_N3&--;\OD3.FG<)MKJUX`(>((D0QH@11BBA#E",J$)6(*D0UHL9" M=@>(4M-<5#X8T[(R-8M[7R)K3`,*T2I"%"-*$*6(,D0YH@)1B:A"5"-J+&2' MU"W(Q3JMWM(]\PU"'XMUA9Q![>P@S+65'M12R^BG"*UB1`FB%%&&*$=4("H1 M58AJ1(V%K!X(SJO?6W,[^5#("-8<48@H0A0C2A"EB#)$.:("48FH0E0C:BQD MAU24VJ>O$X$P=T(JD3UPI\ZSG;ER-`(?(HH0Q8@21"FB#%&.J$!4(JH0U8@: M"]E1%C7E&5&6):BY&@<2&?&;(PH118AB1`FB%%&&*$=4("H158AJ1(V%[)"* MNNB,D,HRR@JI1+3<\%HZ%]_CH^%MH%`CH[B<.GM1D;9BK1A1HI`8)[I0G3KE M;*JM6"NSM.PP?%2GG?1@17S7SIW6$AFAF"LK`X4*T?K2/C<<>EG&A$CZIOW+RQF*ZV5,-):*2.YWSFYHE]S<=])R-@& MMSR#SA*'X.GO>K82SMU4UC;.H'.>5,Z5HS7HE*/>#8S82NX&_C;QKN#Z8K;1 M^XH)(ZV4,E)*8W^*6Y09&^'&8B#J!G.M_JG=X5;%B98L2)R1Y3P.G"M'&DE1O&$W:QEWIW_*5L=]^>Z0JJNKV/TF<4(+9MN1$_;GJ,? MZX%53Y43XJ8HEP3Y\`/01C M^B&@]F&1>\2?SL2V`8G#D2LZTHXY.')-1]IG?G#DAHZT]V_W2#"B%K0C$8Z( M'REJGVVY1SQJ&WTOH:-M'K6-WJ7O.D)MDP^H7;4QJ=$+$1T^?D"M;KO4]?$G M=*1];ND>H09TGI].WQD9CWJ`O@O7<7;/IR/M*NB>PZ-VT7>-NGRH7?+%`L>' M[MPS<5]&'\I99N+VC$?H5Z(^=;>,3M)A_T"7TFE/%])U'9^"V2?Y*U1.8Q_H M^KH:]$!7UQETZL&N#J0W&F81/;C'2Z/W$V;B[0,\0F\;S(K.(_3NP*SN//)` M(7SH#"$EJC.1CN%Y*%^=B6RTZTA`1[I\*%6=B:P,?2ACI>[M5/-N9N(-??2A M=^$I.EU3C]YLI^AT':'WU"DZ74?HK7.*3M<1>JF'CK238GCL:/JUK[?%EU6U MV'U9O^XO7E9/M$2-VJ]@[.3OAK;:_42E75C^=L,!!M$J,X[,>_[]B.0^S8D+P@F!W/F>,9'\]Z M\_VS+()W6O.<5=L0S>(PH%7&]GEUW(;__/WR[2$,>)-6^[1@%=V&7Y2'WW<_ M_[3Y8/4;/U':!!"AXMOPU#3G=13Q[$3+E,_8F5;PEP.KR[2!G_4QXN>:IGNY MJ"PB',>+J$SS*E01UO68&.QPR#/ZS+)+2:M&!:EID3:0/S_E9ZZCE=F8<&5: MOUW.WS)6GB'$:U[DS9<,&@9EMOYQK%B=OA;`^Q,E::9CRQ^#\&6>U8RS0S.# M<)%*=,AY%:TBB+3;['-@(+8]J.EA&SZB]5,2A]%N(S?HWYQ^\-[W@)_8QZ]U MOO\]KRCL-M1)5."5L3?A^F,O3+`X&JQ^D17XLP[V])!>BN8O]O$;S8^G!LH] M!T:"V'K_]4QY!CL*869X+B)EK(`$X#,H<]$:L"/IYS;$`)SOF],V)(O9?!D3 M!.[!*^7-2RY"AD%VX0TK_U-.2":E8LG4GM,FW6UJ]A%`O<&;GU/1/6@-@75. M*D*7I2])R$X$>111MN$R#`"?P\Z^[Q#"F^@==B-K?9Z4#WQ>?3J/"++I4H(T M^BFYMT!++9+I/*D#'V8:R(&##%A!//$6PT-)Q;!OO=)(-+14!DHGZ3G M,^\\C`S`93Q1X0Q%,J&3+K""5DXCH(%H'UJ0QPO1=IYNU/S%.IE%M]^M!4[# MM:[(0WAAHMZNK'`VH5J+:NA^QT#CV6Q0`BUP&T"L,@%:2[]Y$%IT>VP43ZAR M[^#N/)2&\33)N&=!`DT`\] MNM/D0@M%Q`*3R>G!PVF2C*!6-LA52+3)P4F<\%[M98WPPXCC(XZO52=M,DFM M/*0F20;J-*,[K=KD(.60!')?$,4%9C-J308C''L83=($-!0%;7(P<&LR.5WO?9/3)'G`0WG0)BQGQOX5*T8#NTYX#O/GW3J)A=;. MM2:3DV=FP),$0GI;:*UF..KD$`CT&($"] MW_2W%4EZ6V@B`)@IR(D.-T":S4)X1@DS2".EM<6IE0_VSV]<(XM`( MM%B.Z#ZYTH)QB03Q3!%DDDA(;PO-*Q+$)1+S4=TWU`D93/9#[X8BGC&"3-() MZ6V1\NH$<>C$B/^8Y#(+PS5'$,\<`:\K$\Z3]#;16E-RO9[4:XMZTBAI?:2_ MT*+@0<8NXB4%PUM$9^U>>1[E]6;;D_6C>OV)NK_`Z\LY/=(_TOJ85SPHZ`%B MJN&D5N\WZD?#SI`GO,&P!MY=Y-<3O+-1>(^(Q0UY8*S1/V`4C[J7N]W_```` M__\#`%!+`P04``8`"````"$`BV,7V^$%```&&```&````'AL+W=OET>MDOWG[\?KA+7:;O\L,[W]4$NW7?9NM]N?_WEYK5NGMJ=E)T#$0[MTMUU MW?':\]IB)ZN\7=1'>8`GF[JI\@Y>-ENO/38R7_>+JKTG&(N\*B\/+D:X;N;$ MJ#>;LI#W=?%\W'N3%*7;_XBQ\519-W=:;;@'A/"1ZGG/JI1Y$NKU9 MEY"!DMUIY&;IWO'KE>^[WNU-+]"_I7QMC?^==E>__M:4ZS_*@P2UH4ZJ`H]U M_:2@W]?J+5CLG:U^Z"OP9^.LY29_WG=_U:^_RW*[ZZ#<(62D$KM>O]_+M@!% M(^!`/QVJE*U!BB2O_5_7\MUMUNZ?K0(8^9S@#N/LNT>2A72=8KG MMJNK_Q#$=2@,(G00']CKY_#6]&(/B?1YW>==?GO3U*\.-`M\5'O,5>OQ:PAX M2@@_?DCQ4H:0F@IRIZ(LW=AU@'P+97FY38(;[P64+#0D.X=P&[$Z(50!@-U` M$9(S*7ZL]8F)`BLF2GM%+<,W(/9`39#//4=$Z0"QF(!`)A,EE@\]-,U(+0*< M02`)A_#($2&!`2&(U13"H@A!3(K3U!1XZ4+^@S9)1*@A).EK>A4RD8I@%*=G MO[(A(4_\8"RM10YZW"0W3S^UB.@7$Y((`1Y#'E2_*81%,;(I3NNGP$2_A%!# M2-CKQY/$-UH+U3,!@J=I-$:PB,'F,K6;)J;`A!BI6H80)!;ZD>"D\BL3D#`_ M3B\45],J.:RW-4IO:M&8*3"B-&>,^ M10A2$L*H%);2?!R$W!\2LDAQ<(RO"]:OLNG%=!MH#/*[@HV8,%I4&Q)%D6\8 MM4U3V;%1UVGQ.)JW:27QV,BHGL;0BJ%V^B%RCX,@#>!?\CO^I1'1H^U]FXX9:V+F#+@*(B;\X*RX%L9/A0C32SN$ MC(J9+8A^;^T44KR,(V9RITQ![`*3P?%)@3^8&,3<,FZ.C"L>HM8B%2D MAH?:Y+XT.O@'LV,LCBXR8BZXGSDZN."Q,5LL7N*GAD>_BC0A=6>-P>[_4#P+ M(9*+!P)!)L>\_NM7V>>\E%J@QDSUWR3$EE+9_I==4*A5MI2U@,R2S9'J'B/,9PADU:`TZ55E$Q"17!,"-*6YS4TYOJ/<)-YP+ MICUS1OPW$P@Z<>,A:=&5!DQK1L;&S.8['Q^<$6DR]14=2D\_7M?3&AYI'/)P M7&\K]Z7Y(=#W;>7H`-&@DW*Q"!BQGY4%B5EH'"]L=F1X?%)7='N;'9T:`D'( MSD]$R&-2^I4%">'H$O(Q1YL?F1HSZWL^/3@]&V?"&@YQ*OR0&-#*@L#AAL5L M;%*;)QD@,WF>#Q).2YD)G$X5'T$?^X]^B&*',=P+&U/)9DBFRDR&'TP73J<+7+VJ M-/"V2(2!>;C7!3<18X)($*]=\7JRDLU6KN1^WSI%_:RN5`5\TQ_>':Y[[X2Z MZB/O9W`-W-^9>L,#N(4]YEOY(V^VY:%U]G(#(=DB!MMN\!X77W3UL;\4?:P[ MN'_M_]W!?;N$JT2V`/"FKKO3"W51.=S@W_X/``#__P,`4$L#!!0`!@`(```` M(0"QT:U*;`,``-@*```9````>&PO=V]R:W-H965T.AH@SM"^C[Q9V@I.5N;@;T)4D8Y303%M#9 MJM!ASW-[;@/3:ID2Z$#*;C"<1>:#NXBGIKU:-OK\(?C$K_X;/*>G+XRDWTB% M06RP21JPI_1)0A]3&8)D>Y`=-P;\8$:*,W0LQ$]Z^HK)(1?@=@`-R;X6Z>L6 M\P0$!1K+"R130@LH`'Z-DLC)`$'02W,]D53DD>F'5C!U?!?@QAYS$1-):1K) MD0M:_E4@]TRE2+PS"62<25P(?3`Y/"?#M4NVO%G@!N%X";9JIU%GBP1:+1D] M&3!Q4#"OD9Q?=P',4A8?Q%5-=$*]IQ,()$D>)$MD3DT#TCEX^[SR_6!I/X,A MR1FS'F+"61^R:2%2?LF[;0,77K>?LFL1;4JL`HWN-O38-0I"7S?ZMN]M/Q(L M^VE9URH`W%V#7K^0S1`1SON0[1"BD>R&")TD'D*\:?>>7L=^OV-I;0C6WNY< M)L$(7#7J^V''W[BR5IC)%4;S>C.*V(XB=J.(^!:BIP24>NU].^2WE9!)D0ER M=Y;[_D5II83"S)J)O_.<63#3Q=IHD'`R"377MSU(X'AS;Z*-SJX/"=R9/]%6 M0JP@\-O5>W&EIP9\??Y?#9FDJZ$MW[7"!(T:0>`X3G]N-NKYVQ6J]3["L!ME MB-]GZ&D`GSI=@_&U(9-T#32CU@K3:N#ZX<6$IL6-`MP288QB-TH17U/,O/"Z MBIX,\,7699!?_]L+0R9I,DPTJ]<*HQ:&%P3A6&)VP!M<%-Q(Z%&>!GP8YB[:'50>/+DS:/&UNX`-;!C?N@O8I2!N M=PEPL*C1`7]'[$`J;A0X@U^Z]7-:WS[)! M3UP;H=H<1T&($6^9*D1;Y?CGCX>K:XR,I6U!&]7R'+]P@V\W[]^M#TH_FIIS MBX"A-3FNK>TR0@RKN:0F4!UOX4FIM*06;G5%3*'?1SX4)PF)R= M?N@[\$VC@I=TW]COZO")BZJVT.XE.'+&LN+EGAL&%06:(%XZ)J8:2`!^D11N M-*`B]+F_'D1AZQPOXB!*PA6@T8X;^R`<(T9L;ZR2OSTF&I@\1SQPP/7(L0J6 M:;B(_D]"?#Z]O7MJZ6:MU0'!S("DZ:B;P"@#XLM^P(C#;ATXQRE&D*N!)CQM MXG2Q)D]0.#9@[CP&?D=,-"((B([*H#9?V8&=LJNL2^7.!TYEXLLRB[?(.#"T MYB3Y.$U&7J_L,HN4`T^EAD@_Z9/JP92=6G`O7+RZ#B"UUV?4G9M*#)')K*3I M93=N7\]^'1QX*C5$SMW<3'G[]9%`1J][<:>F`D-DZN7ZLA?8AV\PTZ.G8D,H MZ3=C_^KZ_>@7B.2ZXA]XTQC$U-[MOAA6PA@=]_(V=N?_C2?9UN]K,CZ!?=G1 MBG^ENA*M00TO@3,,4FBY]AO7WUC509ZP-I6%5=G_K>'+R&$MA&X^2J7L\0:4 MR?BMW?P!``#__P,`4$L#!!0`!@`(````(0!MX@F`)0,``.<)```9````>&PO M=V]R:W-H965TNM)!E1'W' MHX27L4Q$N8WHG]]/=W-*M&%EPG)9\HB^B,*W`T\;^H63)34,BS4$`Z9IB+F MCS+>%;PTED3QG!G(7V>BT@>V(AY"5S#ULJON8EE40+$1N3#O-2DE1;QXWI92 ML4T.OM_\,8L/W/7#"7TA8B6U3(T#=*Y-]-1SZ(8N,*V6B0`'6':B>!K1M;]X M\*?472WK`OT5?*\[WXG.Y/ZK$LEW47*H-O0).["1\@6ASPF&X+![LEUN?LG]-RZVF8%V3\`1&ELD[X] M(AJ`L$A,%M'1U)G,O)$/<++AVCP)I*0DWFDCBW\6Y-=)6:XZM4=FV&JIY)Y` MOP&M*X;3XR^`^'PND`1BUPB.Z(P2D-%0P-=5,)\MW58!XN!SQ;CMP@7 M1%ME4!NNC&!4QJI@*@\VT)4)SLN,^C)8]!&T[KI1/`2XCHE@/F_Y;086,^Y@ M)BVB9Q0@PXTB&'K1EPY;8BMM00.D82ZZTF@^F.)TW?"/Y^HLVGHW$:AH:G?=7KI49P7ZJ)V+GM3@P,7M?-=5X$]WEM9-XM6Q!>&$Y\YPZ^%@CN M2S614PMAGW=P0_!<7Z*)]&Y`>.$.^-"VX79J=%_L$#HUY.-]'URI&GU$C001 M'4/7.Y,U.C]9_H=>&C7Z2*UY;YPQ@O>Y8P1;,_9"!_*Z/FAX5X]ZJW5T%5UO^A>>Y)K'&ULK)Q;<]NXDL??MVJ_@\OO(XL7 MD9(JR:F(]YNTM75V]UFQE40UMN62E,G,M]\&@68#W;1L9>;4U''\8_/YXZTVFMS>[Y_O#P_[YV\?;__EW_MO\]N9TWCX_ M;!\/S[N/MW_M3K?_^O2?__'AY^'X^^G[;G>^`87GT\?;[^?SR_+N[G3_??>T M/4T.+[MGN/+U<'S:GN'7X[>[T\MQMWWHG9X>[_SI-+I[VNZ?;[7"\O@>CSYKD>/N<7N&_I^^[U].J/9T_QZYI^WQ]Q\OO]T?GEY`XLO^ M<7_^JQ>]O7FZ7U;?G@_'[9='N.\_O7![C]K]+T+^:7]_/)P.7\\3D+O3'97W MO+A;W('2IP\/>[@#%?:;X^[KQ]O/WG(S"V_O/GWH`_2_^]W/D_7OF]/WP\_B MN']H]\\[B#:,DQJ!+X?#[\JT>E`(G.^$=]Z/P'\=;QYV7[<_'L__??A9[O;? MOI]AN&=P1^K&E@]_I;O3/4049";^3"G='QZA`_#_-T][E1H0D>V?'V]]:'C_ MR5Y>W/_XW0^//V?-O*,E!8)C`C\-")>>-$! MKO:MPD]T@(2\T`+TI7>`G^@PG7CA-%*]O.`7&3_X:?R"R7PV"Z-Y?-DQ-H[P MTSC.)_Y\YLW>:A'NH^\I_+RJIPOC!S_1+YS$WG01O-%3#W*F;U']X[J;]'#T MU3^PU7?%U8-\T8U2XH3O"Y"'V:+^81KUWS?-["(08A.+UNU)'I+I8(S34L,<^^UJ0=S3JE\5C(? M;R&M8%:=8+WXXU/@+S[<_0%S_-[8K*2-YUHD:*$FM))-.<@XR#DH."@YJ#BH M.6@X:#GH.%ASL+'`'<1Z"#ADUC\1<"6C`HZA6B&@$?!9=-$"75(.,@YR#@H. M2@XJ#FH.&@Y:#CH.UAQL+.!$%R:?B&X(:3W^X,#L55[PB+"RU_=F;O16VB:T MC9A),I@,$18D$R07I!"D%*02I!:D$:05I!-D+:H=4CF++X:Z.+\1],AO@+D@F2"U((4@I2"5(+T@C2"M()LA9D8Q,G_A!J M$7]_-KE^!)10/P(8N94F:NH,8^)[;$5/!B-T2P7)!,D%*00I!:D$J05I!&D% MZ019"[*QB1-PV'`Y`;^\K"AK-ZJ:0%0Q8(D@J2"9(+D@A2"E()4@M2"-(*T@ MG2!K038V<4((>X0K0JBLW1!JHHN/?I.0")(.Q$I>GRTHV6"$8Y$+4@A2"E() M4@_$;IX]C9O!")MO!>D$60NRL8D3:%4+RYW=1.V[S]_W][^O#KH"&LGA`'9P M>E^G1-SX:V+'7Y!4DP#6+5H\?+;9RP8C#$`N2"%(*4BEB=6A>K"YT'PS&&'S MK2"=(&M!-IKHYIWX0\GS]^.O1-SX&V(M(8*DF@2S?B/N3[W0?99FPW6\]]QH MS(>%J1ALU&8>-`)7HQRNHT9E-*AG]6!C-%@_FN$Z:K1&@_K1#3;C_5@/UU%C M8S3Z?C@CHDI)9TA&4A\J;\S]WMP-/B*ZQT2B%!'=1291CHBT"D3D6$I4(2+' M&A$Y-A*UB,BQ0T2.:XDVB'I'-Z2JS+%7F3="JJLBV.KA:*U4D0XI[L,/:[%@ MV9:@57]L9&K#P1&U,K3R!_D<$3D6B/1ICZHS2T3D6"$BQQH1.3:(R+%%1(X= M(G)<(R+'#:+>T8VR*G>NB+*NCIPH:Q3`#!BB'+,5.5'''VHH^H,]$V2#[+VY M-V//L@P=HW[!"6,_9C,]1PN2+A!=E"[12DM[TRCFVA6:D':-Z*)V@U9&VYO& M4Q:2%DU(NT-T47N-5EK;]_S(8U';H$FO[8XW:%\SWLJ<+50:1?:LBED'$E5Q MJ?&F3$T14:9F!H5Q/[A>',WF+$HY>I%0@8B$2E?(CT(_9-.\0B\2JA&14.,* M!=%T$;%2O$4O$NH0D=#:%9K%D3]G,=J@5R_D#I(JR^Q)J8_.KMQ@J<,_/G8: MN7.512HQ?LY%RKDEHU.E*? M&H->[U,K=3JILT9TL4\;1\L=/U7E_?WQT[4BI`D^A5;J!$1-*TJT!!&E8VI0 M1"M+ALCLVV(OGL[=75(>DVQ=4:$`R-2*2:1"9WD31 M@BU6+5J03H>(=-:(M$X8^.)9;@?''1U5,]JC\VO/.CC/% MU-/A[T^Q7H6-D3@'2(P5=`:?*ZE!,:$,$2WIN70LT(H<2T3D6$G'&JW(L4%$ MCJUT[-"*'->(R''C.+J15C6[6,S@_1=8.-3![[\/+Q!!\\N[3H%]?0I@/XT, MBN'*L!KY/INRB;&R'T?HZ&[;V5*=H578+U!^'$0+=GZ?2^T"O2YJEVBEM8,X MGB]8551)[1J]+FHW:*6U9T'D>VS*ME*[0Z^+VFNTTMKS:1`OV`-WXVB[20': M,BEF5*UB5ES>E\!*R,M5@_KUT&URO$"^^N-AR![3)J4:;#;YXZ'J4GM=>&.H=1GK3'J- MW$^%`S9Y$E5#0/UK?R#8!&5GA'>52OI"H)$WA4H,".K+)$,WUT;HX[4,5MRVVH2C0BMHJ M49C:JA!A6^P1[2BQDI$U%B%2# MR%R>K(&L4@QB6<92/T$K&O@4$0U\AL@,O+O]S/'J:Z/>?YQ:H!6U5"*BEBI$ MHRW5>/6UEMP0@M4U^:7,67YIY.97R(JQ)#!6E`@I(CLQY4?':*5S(YZPU3W' MZY1.!2)JJT1TL:T*K71;7CAALZ1&@Y%4Y+7,&ZDXE"SX3%JIAR2$UDW%D%4Q M"5I1@J2((,+#!!^)HY'7.0,'^3P_A^:Q1P4*4ULEHHMM56BEV_)\WEB-!K:, M'U*7W!2]KBR!MYI$BIJ"0Y5PKC3?B^OMT=45*#RS39LT!$%`]]-/[I6QNEB! MD@T.0RI1)E$N42%1*5$E42U1(U$K42?16J*-@]SQN&XC'\B-O$%N!:R,HA%F2UNM71L$%&+K40=HKY%-Z2J.+DB MEY4Y6T0TF,33>G=L8\>35R*_B(52^)<;0_ M,S<(=IKJ;R^B((17?]VR,I->.7K9D1+U:H%6YC@2OH;`52ZEAMH+/Z[!3*2+] M!A-\Y\A4+!["*4F5([IXUE2@ ME3YK\H,)?P.W1`LZQJH0T1N%-2*R:A#1D5B+B!P[1+VCF^"\/ORUM5N6C:%& M+._9-BHQ5D[>:T?S2OAO7ACR/_+(I%>.Z(W$U]KP@:U:Q/B?]9C.EEW,>`07#BB]U($%$>I0;!G^6B52:M(R*I& M1%8-(I)O$9%CAT@F,^3,Y2"^ZS6S7H7%4%>,+)G9!CA-^:F M<7QM;@K="G5?GYO"I\$[N-B7%JU@F"Z-HBWOSDVGR`8SOD5XYZ-)5ME02ZO1 MM!)'?Q6?_FJPI]WQVR[9/3Z>;NX//]37[,U4B@_8?`>@'RX_PZ=Q\-AB5^!= MS*5Z#W'LR@RNC/M$<*6OV9C:YR!:?M;%/[L"G[@MU:=-(^T$,5SI_[I`^,SA M2E\(LBM0J2]5:2[5X'QZJ2IT>06^!_%SOSUA6BOX?L1^0\*Y#S*Q#*XCO:'@A4F.!@M.\I3J^D[<&AU)P9:Q3<(@"5\9:AT\3 MENKP1*K!QP5+=3HBK\"G!DOUF<#(E7`*`]*O&^SNX=P5KHP%&,X*XQ/J?0_%@;!0ST M&*\72_A6#]ERMUC"-W5(OH)HK4:C!2]H+I/1*_">YE*]A2G5X(5$N#)V'_"* MYE*]=2A]5M"!,9Y`\V,\C9?P)4!2)YTOXCB<\1?5P/"MN)_^7P````#__P,`4$L#!!0`!@`( M````(0#N!9D$7@@``!(C```9````>&PO=V]R:W-H965T:AG03#1!$TM,S_W[+ ML2NVJY@/1C,70_.DJFR_+MN5A(<_OIR.D\_UM6O:\^/4G3G327W>M?OF_/HX M_?NO[,-J.NGZ[7F_/;;G^G'ZM>ZF?SS]\Q\/[^WU4W>HZWX"$<[=X_30]Y=H M/N]VA_JT[6;MI3[#E9?V>MKV\/7Z.N\NUWJ['YQ.Q[GG..'\M&W.4QDANOY, MC/;EI=G52;M[.]7G7@:YUL=M#_WO#LVEPVBGW<^$.VVOG]XN'W;MZ0(AGIMC MTW\=@DXGIUU4OI[;Z_;Y"./^XOK;'<8>OK#PIV9W;;OVI9]!N+GL*!_S>KZ> M0Z2GAWT#(Q"R3Z[UR^/THQM5WG(Z?WH8!/IO4[]WQM^3[M"^Y]=F_Z_F7(/: M,$]B!I[;]I,P+?<"@?.<>6?##/SG.MG7+]NW8_]G^U[4S>NAA^D.8$1B8-'^ M:U)W.U`4PLR\0$3:M4?H`/P_.34B-4"1[9?'J0<--_O^\#A=A+-@Z2Q<,)\\ MUUV?-2+D=+)[Z_KV]#]IY*I0,LA"!8%/%<2;^5ZP7-T3Q%=!X//7>Q*J(/"I M@KBS51#XX6KY\\-9JB#PB4'\NS59JR#PB4$6,]=WPA_K.I=S-$QYLNVW3P_7 M]GT"ZPAFH;MLQ:IT(Q=2!2=;3LTX_=^:?9AV$>6C"/,XA='!Q':0LI^?%M[R M8?X9TFRG;#;40(M$"7A(*4@HR"G(*"@I*"R@"6$+`(?X<0(@QL!D:2N"O?'OE& MVOBF46";Q*/)J`XC*2,9(SDC!2,E(Y5)+)%@D_D=(HDPL!BA&6,IK6P)-M+H MNRJ-)J-*C*2,9(SDC!2,E(Q4)K%4@BW34NGVH8+;BK`>Q,!!;"3QX6.4QUW3 MY3,:H5O"2,I(QDC.2,%(R4AE$FOL<(+<,79A;8]=$A@[#BMF)&$D921C)&>D M8*1DI#*)-5`X!^X8J+"V!RI)`-N1,PW$RL@?U4A4(-#?<",;3,K0\ZX:C2"0)9HHGPV3^+OKPQA;8LF"8B&/8P5,112 M7K9"9']-F5LV$G-@#E%H-,+V"T9*1BJ36')`D7.'',+:ED,24PY%##F4ERU' M:(\K96Z9(GH=YHP4S*MDI#*)-791B-TQ^,'<'KU"YO`1&>-'1UL`4K>EW#%# M9$C`48%(MUAR5%G(ED$49N:2D,7I3-3=_:'9?=JTL-#!Z,9264`1JDI36=[! MB8J)N7$E"C2*$>F^)@JYL,T9^PDYBE/NF"$*QQ9SC@I$NL52H85&E65EJR.J M-5.=&RK`C<$H@RSN+!D46HW]C%V%],0FB+15BDA;98BT5&R&S.#4AS.5IY0VR/Q"WPLNY-J9"_DKU9!'0(E>5DBRB*LSM$E+4TJZQT-B>(PJ';07!+1.:5H9?N08Y(Y/?G)Y(9+:YWHP4``4:F/FFVL9\:1E@OTT"V7"HWIYO@L MWFYX?DI.C MPF9XCD$Q<(]B@[F]\RM$8Q6>J(31#+'W$5(AIJB@?;)$!D9AN@;AR9> MUD%*A<8,\UPR4Y7E9&682(P[,FPP)WK),MW.,)KCL7*$CF!]DBBD,BSP:,&5 MRAU:\"H6Z9S%'"4 MAB+)6"YZZ[7[*NI(VE=(L1_1BS? MGF_""!Y?#:_4A-+E2+"/QL(:[E,M(/++A%ZIE)![<\`OPZO[CL!A) M$QMXI7_+?N-!GV[$V2PB>!%U([X/\8<\HPW`X&Z-;1-$\+Z"!]HL(_&4C%^( MEY%X5L8OI,M(/`OC%[)E!$_/;_!5E`\/?4A7LW4$SU-OV+M.E,/#PEM77+@R MM#T?@\$O$B[;U_K?V^MK<^XFQ_H%$L(95O!5_J9!?NG5KO;<]O!;A&&#.\!O M3VJX4W9FL)A?VK;'+]#T?/PUR]/_`0``__\#`%!+`P04``8`"````"$`;D&/ MUAL%```/$P``&0```'AL+W=O&9>G[:VA977$A==[-Z)4T\)<3;>N\ MAU_;L]5=6Y(?!Z>ZLES;7EAU7C8FBQ"V[XE!3Z>R(#$M'FO2]"Q(2ZJ\A_EW ME_+:\6AU\9YP==X^/%Z_%+2^0HA#697]RQ#4-.HB_'9N:)L?*M#]['AYP6,/ MOVCAZ[)H:4=/_0S"66RBNN:5M;(@TG9]+$$!IMUHR6EC[IPP@M:\OC][(AD&VH$U;@0.D#FGX[(@)G2_-.APK\T1I'ON-E.=+#^7V01$*"X\O,>D*R"B$F;D^1BIH!1.`GT9=XM*`C.3/P_-6'OO+ MQG2#V=*Q5_,E1#F0KD]+#&D:Q6/7T_H?9N2,H5@0=PP"SS'(?#'SE_;<@3'? M=/!&!WAR!W?F!K[C+_YG*)C((!2>W//MH>"O@P,\N<,[AUJ. MGO#DGG>'LE@MAM+&>9]OURV]&;!?(-O=-456"J\G\5&:J+0788 M96."/]2O@Y7YM'67J[7U!*NI&&TBW<:1+?;<`I<.AHU5D*@@54$F``LD3CIA MO7R"3HR".OD,(PX$X8HH;L%=8A4D*DA5D`E`$@5K^1-$892-"3]?BQ?8LHJ( MV7BBD2^;[">32:E&$HVD&LE$(JF%C?@):C$*+'8819"KK,2(&;TI=S*9Y&HD MT4BJD4PDDESH'J+<^UV6;T`T'E3QV42,>!!>T.DJ-9N,N%NLD40CJ48RD4@B MH!F]7P0:RR(8\=AI@BUAKY%8(XE&4HUD(I%F#$U,G#$V1!^:R@<;(D:1I3`" M4L1ZS)5Z3$93/322:"352"8221W>Q81V__:B0F-9!"-B/302:R312*J13"32 MC%L%,9FBY/<.2, M2-C:.HI'-)>[F'+R)*]6/'RJHTP*+VO$\_6G-;)#6M(X(E&CAF)G1$MV;[(= M974FW""8LI=R-/DHC23C!L/0LE@\7W]:+#ND);$,N5#7Z&]T5@O/#K0*:V[I&(F[!?.5XVI9$-WD+."QJV8!7B3&5?V# M7H=5_8$ESLYQ*2,,N3")*2-NL%`S,EIY4W5CAZ&E-V1D`2E9*,J2T<1]]4IE MK[GC^8%RW&>2EYP//,$_-1\84.EA#$DKQ%,6^QY?*-4%PE!@#^GP;/PG)S'1 MO=(1!;"[INP[OI+'3'*4,X(W!#4C_FOCXTOD3N.#U\.I\[%[AK0LQJL'UIN- MR-ZXV6M93=HSV9.JZHR"/N+;-/ANUQ-FK_I1$,*)"0%4O@KA$+K#'1N^#0R; M3O&`%AMBM]1]X'/"SKW#(_S,<(^[(;RHZ'&B>0AW>IWOO'#'/EGLNF,RIR@@3;0U%;]D&# M_=*/^_]`>_@0,;2""WQX(G`#M;%)G"CM^2\XP/0I:_LO````__\#`%!+`P04 M``8`"````"$`RZ]$BC4+``!0-@``&0```'AL+W=O/NKCU]-;59T'H'`X/0[? MSN=W=SP^;=ZJ_?HTJM^K`QQYJ8_[]1G^/+Z.3^_':OW<..UW8WLRF8_WZ^UA MR!7;;OCJH/:S1]$?K_='.M3_7(>@=R8 M7RB]Y_OQ_1B4GAZ>MW`'+.R#8_7R./QLN:5C#\=/#TV`_KNM/D[*_P>GM_HC M/&Z?L^VA@FC#.+$1^%+77YEI_,P0.(^)=]",P+^.@^?J9?UM=_YW_1%5V]>W M,PSW#.Z(W9C[_-.K3AN(*,B,[!E3VM0[N`#X=[#?LM2`B*Q_/`YM./'V^?SV M.'3FH]G=Q+'`?/"E.IV#+9,<#C;?3N=Z_S]N9`DI+N(($?@4(I8UNK,F]\X= MB/0X3H4C?`I'>V0O9M9LSL[>XPA'F\N&3SSC9&1-)Y?\YL(//M'ONBN]$X[P M>=N5PD1KKA0^\8R3T6(VF\X7%X)S+SSA$SVONU8+LJ@Y)_O/;5=K83ZP_^!9 MKXJL!1G$3RI3Z<@S]]V5OYJ4L)L9"J?F(#*N/B$!\0J)341( M3+P28I,2DA&OG-@4A)2JEY;HK'V\(8:-N1Y$1'`*F;"SB3ZJ*V%E-SL=HFEA MIX9=";[/P/H8'ZV:S93&*D`D'4-$TC%")!UC1-(Q020=4T32,4,D'7-$TK%` M)!U+1(VC'F76Y:CK27^FLL;<2%6!;+76LV:D,>2.]K1=!;QN1Z/G\=%*6W5F MCCZ(`5I)^1"1?EV&?(16\Z;EM6(D&C;(^YJSW4L?\M[ZPV9:+F0HW7O$"K5!\.B$K42EL M>,CU"4%_5[+!]6G/:":24?&@ED2>0WO#,S!I<6N%` M!A2%%$44Q10E%*44913E%!44E0+!!UR]'GS6@O;E^77!YXVLEN8"R4BO+((\ M@2XT0-)*!E]HR5(]E%;*,C@UBH](6J%6+)`EM1)II6J9;9"T0JV,:N722M4R M.R%IA5HE:G6,&NMEU5&[4&**UE==A=1NN"F^5Q9!'B(9&9^B`)$$5/2I:D@%NM`;<2NM5!-(-AP^ MY&)3"\B&(T`D*Z`0D72,$$G'&)%T3!!)QQ21=,P02<<J-A)5:2W4ZDEI*6/6V&(%%Y$-$4*XH19@A'Z$5;S&FSMRH MTF(TD!>>(.I53M&J]\(SM)+R.:)>^0*M?G7A)1HTRMI7#*2Z/N:_U1LU*GI9 M+="%W@BM9!9[B&3GX".">:<,GS$Z`5I)K1"1U(H0]6K%:"6U$D12*T7$.QK' MF M"*WZ>R,J'Z(CG%A)"',^HQ5O,CKF,U5.T*=7.44KKOR+@2=1R=&M5[Q`JU;\ MGJQ$I;#IZ(ULMD.@+N)F+ES7&S4R1C+PO8>.-81U@?24-_^$Q[XV>`+*475L MH]A?"JO>GU&E#=9K'D4^10%%(44113%%"44I11E%.44%1:6&].7`;(_["U!( M(C+OVS98CH0U-[9]5L)1:98]BGR*`HI"BB**8HH2BE**,HIRB@J*2@WI468- MK)KU%Z(L^EVE6F)/W4&^*_%;4>11Y%,44!12%%$44Y10E%*449135%!4:D@/ M*>L;;PBI:#/5D'+DW+=;.BN;($\B-;V-+7Q?6N$B$E`42J1JD:\BU_3;M*P72HL.M%.0)J^F$;RE.+&-#VY<&,C!$)I16:F",HBV2 M5J@5"\0O20\,:[QNR`_>IZD;'S9'[.M3%@YSXP97:"5K-D\@!\91.LZ,8?;1 MZJX)76==$%#Q$-UZQ2.TNE"YBCOLJ!)97Z1&CZ65/6=/*O_B`6;\O=;F'946 M2-%D:8W)W-PU%XZPB.+H>HCDI/41P74HL34R)4`KJ14BDEH1(MX*S>[@`7GS MYXH8;6@EPPI=&B+([>N?ZV@D],))("/IC+IFA59*TB&2C8*/B#<*GV;6';F_ M`&VD4HA(*D6(A)+MS&GW$J,1S296VI-06;,;'\QH5(QHB;I9SRQCIW`E'-7, M$HA]*&ED3E&TPE\>.G[/"JAXB&Z]XA%:M:5[5TC%_75DWY\IW>$%"+.>$T@Y M)7_%@3]8O:^.K]6JVNU.@TW]C;V^`/?Q]-!B\6Z%[;B?^F<*0Y+3DR@R/-3I]Q!+XX7/:U0-7@*]-EWP[T"+SW\;G9XC*TEO`^2+,; M9G(;3MZALX0;Z;J/SU/0[W2`^^N\/;B[KIM;SEUXKHS>`.RUNSYL*=,CL'/N MLGUQ>@3VP=VT\PCL:KM%YY$EA'#9&4*HD]Q5YQ$HEUQ6#-$K@%(!CG0-"%1* M;M!Y!`HF&-Y.M3L7'@SK.,O"A:>L*`\7+CPT17FR<.$9*,KSA0N/-%$./S)! MM#I'RX+AA=_&P&?<9A"\S_.^?JWR]?%U>S@-=M4+3)A)L^X=^1M!_(^S^`WR M2WV&-WE@C8-7%>#-K0J>KIFPYUM?ZOJ,?[`3M.^"/?T?``#__P,`4$L#!!0` M!@`(````(0!]#HLOH`(``.(&```9````>&PO=V]R:W-H965TRYG7])%OTR+41JBMP$L48\8ZI4G1U@7_^N+NXPLA8 MVI6T51TO\#,W^'K]\:T](=D2](X7A!)18<#0ZZG<*BJ$HS?*K:7O+.!1/.66O#?-*(W+VR2 M3:&35._V_053L@>*K6B%??:D&$F6W]>=TG3;0MQ/R8RR%VZ_>44O!=/*J,I& M0$>"HZ]C7I(E`:;UJA00@4L[TKPJ\";);ZXP6:]\?GX)?C!'[\@TZO!9B_*K MZ#@D&Z[)7PX!N;CR M\OF6&P8)!9HHG3LFIEIP`%8DA:L,2`A]\L^#*&U3X'09I5?S9+X`/-IR8^^$ MX\2([8U5\G=`)0-78$D'%G@.+-DBFE_&6?(V"0D>^0!OJ:7KE58'!$4#DJ:G MK@23'(C/1P2A..S&@0M\B1'X:N`6'M=9O%R11T@=&S`W`0/KB$E&!`'141G4 MIBL[L%-VN76NW`3#L4QZ7B9[CXP#%QC6T?DLB4?>H!PPLR/,?$2*0<^E1HLOM)/L@=5 M=AR":[DL2UU_O5&D[N"IQF`Y+I8LRM04SMW;Q(H8E&ZSC*-JD[_Z]]EF_\B"/C!Q@Q/:WY`]6UZ`QJ>064 M<70)*=)A2(6-53UX"7-&69@M_K6!?PF'/HHC`%=*V9<-")/Q[[3^`P``__\# M`%!+`P04``8`"````"$`I0A(C`0#```:"0``&0```'AL+W=O:XK\L25%K)):30**>%-)G/1;%/Z MY_?]U34EVK`F9Y5L>$I?N*8WJ\^?EGNI'G7)N2'`T.B4EL:TBR#06R MY0W\4DA5,P.?:AOH5G&6VT5U%<1A.`MJ)AKJ&!9J"(MHU4;%.![^=HPK(C MM_TXHZ]%IJ26A1D!7>`2/?>A2[K\JD7\7#8=J0Y^P`QLI'Q'ZD&,(%@=GJ^]M!WXJDO."[2KS2^Z_ M<;$M#;1["H[0V")_N>,Z@XH"S2B>(E,F*T@`GJ06.!I0$?:P+]!K1N&4Y/M`#B MR[E`$HA=(SBE'A-Y1`"B7AG4ABLC&)6Q M*IC*K0MT9>++,N.^#!9]#*U[VR@N`ES'1)S,/;_+P&$F'LW3&! M:>M:L)LF>7=2<55?X!#I3LPX#"][P1-W\*9`<%_J$#GWDO1YT4L,:>QB>+M;L9 M`_\+W$PMV_(?3&U%HTG%"^`,;>>5N]O&PO=V]R:W-H965T7#BZS1@6LC M5)/A>!1AQ!NFPJ&* M0C#^I-A>\L8&$LUK:L%_4XG6G-DD&T(GJ=[MVSNF9`L46U$+^^I),9(L?2X; MI>FVAKA?X@EE9VY_N**7@FEE5&%'0$>"H]V.5_!-`L7.`7BV[Z`$PZ[=N`,SS$"&0/Y.ZR2:+(D!PB:G3"/`0//#A-W"`*B MG3*H#5=V8*?LLN)<>0R&OLSXMDSR'AD'AK3VG$^B:<<;E`-FTL/\0UP$")#A M`3HPU.!2>O9&.H`&2$,_#)=V8"_=)?=D@0[OBIA$\\Z9BRAG[Y%RX$NIDR4T M:;\]H,OZ(?AAF4&__Z]'W;U+B9.EWRM)M+@=C5NU@\?!@2^E@F7B)\X'$Y9! MF#C)=NSNO[5/TK7?3:3[`+NAI27_1G4I&H-J M7@!E-)I#BG38+N%@50M>PH90%K:"?ZW@)\!AC"*7ST(I>SZ`,.E^*ZN_```` M__\#`%!+`P04``8`"````"$`LZD`G)`$``"$$0``&0```'AL+W=O.9@L_K^F6?>!R]E*HJU3R:A[_$B M$;NT.*S]?_Y^_?;D>[**BUV^;GW]:743Y+H^<5QX@%'+M'ZOJ M%`6!3(X\C^5$G'@!;_:BS.,*'LM#($\ECW=J49X%-`SG01ZGA:\1HG(,AMCO MTX2_B.2<\Z+2("7/X@KRE\?T)!NT/!D#E\?E^_GT+1'Y"2#>TBRMOA2H[^5) M].-0B#)^RZ#N3S*-DP9;/?3@\S0IA13[:@)P@4ZT7_,R6`:`M%GM4J@`:?=* MOE_[6Q(],^('FY4BZ-^47V3GNR>/XO)KF>Y^3PL.;,,^X0Z\"?&.KC]V:(+% M06_UJ]J!/TMOQ_?Q.:O^$I??>'HX5K#=,Z@("XMV7R]<)L`HP$SH#)$2D4$" M\.GE*;8&,!)_KGT*@=-==5S[;#Z9+4)&P-U[X[)Z31'2]Y*SK$3^GW92%04: M2Z7V$E?Q9E6*BP?[#=[R%&/WD`B`FYPT0IOEK20A.P39(LK:7_@>Q)?`[,>& MD>DJ^``VDMKG6?O`9^M#6H\`LFE3@C2Z*5VGIXF,SA@9Z<)4GK6A&X9>#\/L M,%CY].9N-.%P$?#>+8*P%E]GH'VF'9]9ZV$5"B[C"T5GV*1N:$8,L`ZMG4:$ MAD*[H;'X93A9#-:/ZU06+=^U!6@W^TH-)5;!W<`#9:.WS:<"`/7H-29.ZP/(6CB<$7]R"1TM+P35P"&4/,$>#Q2(RYP" M:Y--IQD:FTY4A$[8@6BU?G0W3YNNT/F0?I!60(PR,;)TZ6Q$Q3C=:A-'9E`S MV8+@;_40HZWFM*I):I/-J!D>FU%'9088[6L+T:8KC#ZD)*25$D,6HZ'+:",O MQND&H]31&V243MF(GR&UTN[1QF0S:J;'8I0Z6G.?4>7M1-.:TV>4HCR,[G[E MK9`-68R:N,P11VM M&8C6EQ@%<$U#<;P>(+25$\,5ZQQ':D(;A3%.MPAU)`<))?/%B*&GK?P81FM3 MEU'"S/S8+>K(S0"C?8FAM4F?_[OG)>KHB2IJ-FKN^MJBP(`4&`AS`&2FA>VB M'M(;VNJ-H;`V]8MB5\2$3"&K^\2I9?9L-R:[HAN-#Q?&!]I3>3O1$,!J?'V! MU+>TG)<'_@O/,NDEXHR7PR5C*UD1!F_4%;<7>PYOGG!-T+Z"._`I/O`_ MXO*0%M++^!YHT)>54M^B]4,E3D`MW(1%!;=?]?4(_W9PN!6&>(K<"U$U#QB@ M_?]D\S\```#__P,`4$L#!!0`!@`(````(0!92HDH,@$``$`"```1``@!9&]C M4')O<',O8V]R92YX;6P@H@0!**```0`````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````"&>PM=-S-)RQ(U.[G$Q!F--X1O&[%0`FBW M?R_MNCJC)X_D?7EXOH]RL==U\@G.J\94*,\(2L"(1BJSK=#3>IG.4>(#-Y+7 MC8$*'<"C!;N\*(6EHG'PX!H++BCP22093X6MT"X$2S'V8@>:^RPV3`PWC=,\ MQ*/;8LO%.]\"GA!RA34$+GG@N`.F=B2B`2G%B+0?KNX!4F"H08,)'N=9CK^[ M`9SV?U[HD[.F5N%@XTR#[CE;BF,XMO=>C<6V;;.VZ#6B?XY?5O>/_:BI,MVN M!"#6[:?F/JSB*C<*Y,V![=]/=J=DN?B]FZ] M1&Q"\FE*YBF9KB>$S@HZNWXM\:DUW&`*SW_OGG[`L``/__`P!0 M2P,$%``&``@````A`.``-%()`P``I0D``!``"`%D;V-0&UL M(*($`2B@``$````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````G%9=;YLP M%'V?M/\0\=Z2-M4V583*`;=!(\"PDZU[L5SB-*@$(NQ&[7[]+M`TI'&HVC=_ MG'OON?=R)-BGN;W0V-*KT]^&#VI>#[G69&+ MH?$LI'%E?_UB166Q%J5*A>R!BUP.C:52ZTO3E,E2K+@\A>T<=A9%N>(*IN6] M62P6:2+<(GEK0:#Q>;M1GGR(2![+5#W;? M\$P*R]PM6&/!JZ)%/"VE;6W4Y48DJBA[,OT'93LW>G=YMSS:)AW!#:JLA0/F<8$;1'TRT@`!3YH=0 ME`C'C(Q1?"SGR<2C$QQ04JB,\CLX<=IR:31Z%WXH M59?)H2"=Z,[N/M?FT,K4%8JGF3[50QA[MW(O_AB%Y^*1PYW]>JE4=VAS(T'K M[!T?MF>D->D^3'I6.J6ZTJWQ&JD:&RVM;I,.6D?#Z`7KCC/0T3O[]HD24OQ1P> MO^W^;L$:P^M>9I439\GS>S'?8@XWJ@_)K/EUV6<7I_U!'_X:K37+W/VO[/\` M``#__P,`4$L!`BT`%``&``@````A`*GZ,`_F`0``S!<``!,````````````` M`````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P M(_4```!,`@``"P`````````````````?!```7W)E;',O+G)E;'-02P$"+0`4 M``8`"````"$`\*#N9/0!``#)%@``&@````````````````!%!P``>&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`="/-FJ(#``"> M"P``#P````````````````!Y"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``& M``@````A`#SLVB36!```AA$``!@`````````````````2`X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`-B8U-#0`@``Q@<``!D`````````````````FB@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/F>)>3%`P``T`P` M`!D`````````````````A#H``'AL+W=OA\&``!$(```&0````````````````"`/@`` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,Q(E4#8`@``T@<``!D````````````` M````-T@``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`)[BX-;.`@``#0D``!@````` M````````````\%```'AL+W=O&UL4$L!`BT`%``&``@````A`/MB MI6V4!@``IQL``!,`````````````````K+(``'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"+0`4``8`"````"$``)&%=1D#```^"0``&0````````````````!Q MN0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&&FGRZ2`P``4@P``!@````````` M````````LK\``'AL+W=O&UL4$L!`BT`%``&``@````A`"RR/%9T!```BP\``!D` M````````````````O,@``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#$"9@2D`@``OP8``!@````````````````` M\NT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`*#Q4/RD!```_A,``!@`````````````````MP,!`'AL+W=O&UL M4$L!`BT`%``&``@````A`&WB"8`E`P``YPD``!D`````````````````014! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`&Y!C]8;!0``#Q,``!D`````````````````8#,!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%E*B2@R`0``0`(``!$````````` M````````N5$!`&1O8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A`.`` M-%()`P``I0D``!``````````````````(E0!`&1O8U!R;W!S+V%P<"YX;6Q0 52P4&`````"X`+@!T#```85@!```` ` end XML 15 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK-BASED COMPENSATION (Details Textual) (USD $)
1 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 12 Months Ended

Feb. 20, 2014

Jun. 30, 2014

Feb. 05, 2014

Oct. 31, 2013

Oct. 31, 2013

Performance Based [Member]

Jun. 30, 2014

Employee [Member]

Oct. 31, 2013

Chief Executive Officer [Member]

Dec. 31, 2013

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 81,805 264,278 96,278

Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 29.00 $ 15.00

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Rate 2.00% 0.00%

Employee Service Share Based Compensation Nonvested Total Compensation In Current Year $ 1,096,000

Employee Service Share Based Compensation Nonvested Total Compensation In Year Two 570,000

Employee Service Share Based Compensation Nonvested Total Compensation In Year Three 203,000

Weighted-Average Grant-Date Fair Value Of Vested Options Outstanding (in dollars per share) $ 16.66

Weighted Average Grant Date Fair Value Of Unvested Options Outstanding (in dollars per share) $ 5.98

Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares) 273,106

Estimated Stock Based Compensation Expense Up On Vesting Of Options 418,000

Anti-Dilution Option Reduced By Expiration Of Warrants 14,474

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 10.00 $ 20.00

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 275,000 1,964,085 96,278

Anti-Dilution Option Reduced Rate 19

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized $ 1,869,000

X

- Definition

Number of shares reduced during the period as a result of expiration of warrants for anti-dilution option.

+ References

No definition available.

+ Details

Name: clrb_AntidilutionOptionReducedByExpirationOfWarrants

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the rate at which anti-dilution options reduced when outstanding warrants reduced.

+ References

No definition available.

+ Details

Name: clrb_AntidilutionOptionReducedRate

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in current year.

+ References

No definition available.

+ Details

Name: clrb_EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in year three.

+ References

No definition available.

+ Details

Name: clrb_EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate value for unrecognized compensation cost related to the unvested stock-based compensation arrangements in year two.

+ References

No definition available.

+ Details

Name: clrb_EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the estimated future stock based compensation expense up on vesting of stock options.

+ References

No definition available.

+ Details

Name: clrb_EstimatedStockBasedCompensationExpenseUpOnVestingOfOptions

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

It represents annual forfeiture rate of unvested options.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresRate

Namespace Prefix: clrb_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of outstanding options Unvested and expected to vest held by the Employee Stock Option Plan as of the balance sheet date.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted-average grant-date fair value of unvested options outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: clrb_WeightedAverageGrantDateFairValueOfUnvestedOptionsOutstanding

Namespace Prefix: clrb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted-average grant-date fair value of vested options outstanding as on the balance sheet date.

+ References

No definition available.

+ Details

Name: clrb_WeightedAverageGrantDateFairValueOfVestedOptionsOutstanding

Namespace Prefix: clrb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Unrecognized cost of unvested share-based compensation awards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE (Details 1) (USD $)
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Fair Value, Inputs, Level 3 [Member]

Dec. 31, 2013

Fair Value, Inputs, Level 3 [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Beginning balance - Fair value $ 3,355,000 $ 0

Fair value of warrants issued in connection with February 2013 public offering 0 5,720,000 0 5,720,000

Gain on derivatives resulting from change in fair value 573,751 660,341 518,806 666,384 (517,000) (2,365,000)

Ending balance - Fair value $ 2,838,000 $ 3,355,000

X

- Definition

Represents the fair value of warrants classified as derivative liabilities during the period.

+ References

No definition available.

+ Details

Name: clrb_FairValueOfWarrantsClassifiedAsDerivativeLiability

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the fair value of warrants classified as derivative liabilities, outstanding as of the balance date.

+ References

No definition available.

+ Details

Name: clrb_FairValueOfWarrantsClassifiedAsDerivativeLiabilityOutstanding

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENT (Details Textual) (USD $)
6 Months Ended

Feb. 05, 2014

Jun. 30, 2014

Subsequent Event [Member]

Subsequent Event [Line Items]

Debt Instrument, Issuance Date Jul. 29, 2014

Debt Instrument, Face Amount $ 1,000,000

Debt Instrument, Interest Rate, Stated Percentage 8.00% 8.00%

Debt Instrument Maturity Period 60 days

Proceeds from Notes Payable 617,500

Debt Instrument, Unused Borrowing Capacity, Amount $ 382,500

X

- Definition

Debt Instrument Maturity Period.

+ References

No definition available.

+ Details

Name: clrb_DebtInstrumentMaturityPeriod

Namespace Prefix: clrb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

REVERSE STOCK SPLIT AND RECAPITALIZATION
6 Months Ended

Jun. 30, 2014

Equity [Abstract]

REVERSE STOCK SPLIT AND RECAPITALIZATION [Text Block]

4. REVERSE STOCK SPLIT AND RECAPITALIZATION

At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt. The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected and the corresponding reduction in authorized shares of common stock by filing an appropriate amendment to the Company’s certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on June 6, 2014 and effective at the close of business on June 13, 2014, the second amended and restated certificate of incorporation was amended to effect a 1-for-20 reverse split of the Company’s common stock (the “Listing Reverse Split”) and reduce the number of authorized shares of common stock to 20,000,000 from 150,000,000. All share and per share numbers included in this Form 10-Q give effect to the Listing Reverse Split.

X

- Definition

The entire disclosure for reverse stock split and recapitalization.

+ References

No definition available.

+ Details

Name: clrb_ReverseStockSplitAndRecapitalizationTextBlock

Namespace Prefix: clrb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 20 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B M,#8X,S0Y-V$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+2$],1$524U]%455)5%D\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE. M0T]-15]405A%4SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DY%5%],3U-37U!%4E]32$%213PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/34U)5$U%3E137T%.1%]#3TY424Y'14Y#2453 M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY3/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-43T-+2$],1$524U]%455) M5%E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DY!5%5215]/1E]"55-)3D534U]/4D=!3DE:051)3S(\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9!25)?5D%,545?1&5T86EL#I%>&-E;%=O'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+2$],1$524U]% M455)5%E?1&5T86EL#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+0D%3141?0T]-4$5.4T%424].7T1E=&%I;#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+0D%3141?0T]- M4$5.4T%424].7T1E=&%I;#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY%5%],3U-37U!%4E]32$%215]$971A:6QS/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T M/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!296=I"!+97D\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO'0^)RTM M,3(M,S$\'0^)SQS M<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6%B M;&4L(&QE'0^)R9N8G-P M.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y M-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T M.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO&5D(&%S'0^)SQS M<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO&5D(&%S'0^)SQS<&%N/CPO6UE;G1S(&]N(&-A<&ET M86P@;&5A3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y M-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T M.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^)SQS<&%N/CPO'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2`Q,2P@,C`Q-"P@=&AE(&YA;64@;V8@=&AE($-O;7!A;GD@=V%S($YO M=F5L;W,@5&AE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2!F;VQL M;W=I;F<@=&AE($%C<75I6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!I#L@1D].5#H@,3!P M="!4:6UEF%T M:6]N(&]F(&%S&EM871E;'D@)#4L,#(Y+#`P,"X@5&AE($-O;7!A;GD@97AP96-T28C.#(Q-SMS(&-A28C.#(Q-SMS(&%B:6QI='D@=&\@97AE8W5T92!I=',@;W!E2!P;&%N2!P=7)S=64@9FEN86YC:6YG(&%L=&5R;F%T:79E2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6EN M9R!C;VYD96YS960@8V]N"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q M,RP@=&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E M28C M.#(Q-SMS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<&]S:71I;VX@870@2G5N M92`S,"P@,C`Q-"!A;F0@8V]N"!M;VYT:',@ M96YD960@2G5N92`S,"P@,C`Q-"P@86YD(&ET"!M;VYT:',@96YD960@2G5N92`S,"P@ M,C`Q-"!A#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS($9O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;F0@=&AE(&%C M8V]U;G1S(&]F(&ET2X@06QL('-I M9VYI9FEC86YT(&EN=&5R8V]M<&%N>2!A8V-O=6YT#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE2!O;B!A;B!I;G1E28C M.#(Q-SMS('-T;V-K('!R:6-E(&]R(&$@;6%T97)I86P@861V97)S92!C:&%N M9V4@:6X@=&AE(&)U6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5D(&%S2!D971E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E+"!N970@;V8@97AP96-T960@9F]R9F5I='5R97,L M(&9O'!E8W1E9"!F;W)F96ET=7)E2XF(S$V,#L\+VD^($%S('-U8V@L('1H92!#;VUP86YY M(')E8V]G;FEZ97,@97AP96YS92!B87-E9"!O;B!T:&4@97-T:6UA=&5D(&9A M:7(@=F%L=64@;V8@;W!T:6]N2!S=6-H(&YO;BUE;7!L;WEE97,N M/"]D:78^(#QD:78@#L@1D].5#H@,3!P="!4:6UE6%B;&4F(S$V,#MA<'!R;WAI;6%T928C,38P M.W1H96ER)B,Q-C`[9F%I2`D M,BPU-38L,#`P(&%T($IU;F4F(S$V,#LS,"PF(S$V,#LR,#$T+B!4:&4@8V%R M&EM871E M&5D(&EN=&5R97-T(')A=&4@ M87!P6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!D;V5S(&YO="!U'!O6EN M9R!C;VYT2!T:&4@;G5M8F5R(&]F('-H87)E&5R8VES86)L92!A;F0O;W(@=&AE(&5X97)C:7-E('!R:6-E(&]F M('1H92!W87)R86YT&5R8VES92!P2X@5&AE('!R:6UA6EN9R!R:7-K(&5X<&]S=7)E('!E6EN9R!C;VUM;VX@2!M965T('1H92!R M97%U:7)E;65N=',@9F]R(&5Q=6ET>2!C;&%S2X@ M070@2G5N92`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L('1H97-E M('=A28C.#(R,3LN($AO=V5V97(L(&EN($IU M;F4@,C`Q-"P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E65A2!T:&%T(&EN('!R M:6]R('EE87)S(&ET(&AA9"!B965N(&EN('1H92!D979E;&]P;65N="!S=&%G M92X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQD:78@#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^3&5V96P@,CH@26YP=71S(&]T:&5R('1H86X@ M<')I8V5S('%U;W1E9"!I;B!,979E;"`Q+"!S=6-H(&%S('!R:6-E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-EF5D(&EN($QE=F5L)B,Q-C`[,RX@02!F:6YA;F-I86P@:6YS=')U;65N="8C M.#(Q-SMS(&QE=F5L('=I=&AI;B!T:&4@9F%I2!H M860@:7-S=65D('=A6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@=&AE($-O;7!A M;GD@:7-S=65D('=A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#4U-SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#4U-SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO2`R,#$S(%!U8FQI8R!/9F9E"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#DP)3L@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S93L@1D].5"U325I%.B`Q,'!T.R!/5D521DQ/5SH@=FES:6)L92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/DQE=F5L)B,Q-C`[,3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DQE M=F5L)B,Q-C`[,CPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DQE=F5L)B,Q M-C`[,SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D9A:7(F(S$V,#M686QU M93PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@1D].5"U714E' M2%0Z(#6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M"!S;VQI9#L@1D].5"U714E'2%0Z(#
6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/C0L,S8S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2 M.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$U M,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C0L,S8S/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/D9E8G)U87)Y(#(P,3,@4'5B;&EC($]F9F5R:6YG(%=A6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,34Q.SPO M9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/C,L,S4U+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!787)R86YT M'!E8W1E9"!L:69E(&%N9"!D:79I9&5N9"!R871E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!O9B!R97%U:7)E9"!F M:6YA;F-I;F=S(&)A#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPGF5S('1H92!C:&%N M9V5S(&EN('1H92!F86ER(&UA28C M.#(Q-SMS('=A2X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q% M1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;CL@5TE$5$@Z(#$P M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52+5)) M1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,RPS-34L,#`P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,3`E/B`\9&EV/B@U,3"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,BPX,S@L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2`V M+"`R,#$T+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@=&AE('-A;&4@;V8@=&AE M(&1E8F5N='5R97,@86YD('=A#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4 M:6UE2`V+"`R,#$V/"]F;VYT/B!A;F0@87)E(&-O;G9E2!T M:6UE(&%T(&$@8V]N=F5R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6%B;&4@=7!O M;B!R961E;7!T:6]N(&]R(&-O;G9E"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"P@=&AE($-O;7!A M;GD@86-CF%T M:6]N#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E2!N;W1I8V4@=&\@=&AE(&AO;&1E2!S86QE(&]F('-E8W5R:71I97,@8GD@=&AE($-O;7!A;GD@2!N;W1I8V4@9VEV96X@=VET:&EN('1H#L@1D].5#H@,3!P="!4:6UE2!I;B!P2!I;F1E8G1E9&YE2!A(&UA M:F]R:71Y(&]F('1H92!D:7-I;G1E3L@;W(@96YT97(@:6YT;R!A;GD@86=R965M96YT('=I=&@@'1E M;F1E9"!T;R!T:&5S92!D96)E;G1U2!N;W1E#L@1D].5#H@,3!P="!4:6UE2!E=F5N="!O9B!D969A=6QT(&]C8W5R7,@869T97(@=&AE(&]C8W5R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!T;R!O8G-E M2!A M;GD@:&]L9&5R(&]F(&1E8F5N='5R97,@;W(@=&5N('1R861I;F<@9&%Y2!H87,@8F5C;VUE(&%W87)E(&]F('-U8V@@9F%I M;'5R93L@=&AE(&]C8W5R&-E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS(&-O M;6UO;B!S=&]C:R!B96EN9R!I;F5L:6=I8FQE(&9O#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E&5R8VES92!P&5R8VES960L(&5X M<&ER92!O;B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B2`V M+"`R,#$Y/"]F;VYT/BXF(S$V,#LF(S$V,#M4:&4@=V%R&5R8VES86)L92!O;FQY(&9O2!D96)E;G1U6UE;G0L('!R97!A>6UE;G0L(')E9&5M<'1I;VX@;W(@ M;W1H97)W:7-E+"!T:&4@87-S;V-I871E9"!W87)R86YT6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E&5R M8VES92!P#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2X@26X@;W)D97(@=&\@97-T:6UA=&4@=&AE('9A M;'5E(&]F('1H928C,38P.W1H97-E('=A2!W96EG:'1E9"!V86QU871I;VX@;6]D96P@=&]G M971H97(@=VET:"!A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2P@=&AE(')E;6%I;FEN9R!V86QU92!O9B!A<'!R;WAI M;6%T96QY("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!;06)S=')A8W1=/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQD:78@6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!R M97%U:7)E;65N=',@9F]R('1H92!L:7-T:6YG(&]F('1H92!#;VUP86YY)B,X M,C$W.W,@8V]M;6]N('-T;V-K(&]N('1H92!.05-$05$@0V%P:71A;"!-87)K M970N($EN(&%D9&ET:6]N+"!T:&4@<')O<&]S86P@87!P&5R8VES92!OF5D('1H92!B;V%R9"!O9B!D:7)E8W1O2!F:6QI;F<@86X@87!PF5D('1H92!R871I;R!O9B!T M:&4@F5D M('-H87)E6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPGF5S(&EN9F]R;6%T:6]N('=I=&@@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M&5R8VES928C,38P.V]F)B,Q-C`[/&)R+SX@3W5T6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO&5R8VES928C,38P.SQB"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO2`R,#$T(%!R:79A=&4@4&QA8V5M96YT("@Q*3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO2`V+"`R,#$Y/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@/&1I M=CXQ,"XP,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#(S)3X@/&1I=CXS."PT.38\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO2`T M+"`R,#$X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#(S)3X@/&1I=CXR-2XP,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@/&1I=CXR-2XP,#PO9&EV M/B`\+W1D/B`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S M)3X@/&1I=CXQ+#,V-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@/&1I=CXQ,"XP,#PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S M)3X@/&1I=CXU+#(U,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@/&1I=CXS,C$N,S`\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO2!W87)R M86YT6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U=)1%1(.B`P+C(U M:6XG/CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!72414 M2#H@,"XR-6EN)SX@/&1I=CXH,2D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X@/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`P+C(U M:6XG/B`\9&EV/B@R*3PO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^5&AE(&5X97)C:7-E('!R:6-E3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q M,#E?86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O M'0O:'1M M;#L@8VAA'0^)SQD:78@ M6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF5S M(&%M;W5N=',@8VAA'!E;G-E(&9O6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI M9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E"!S;VQI9#L@1D].5"U714E'2%0Z M(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,#8L-S6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXQ,3`L-S`Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR,3(L-C$R M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXR-C0L,C0S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXT-RPX-3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT-RPX-3,\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q M-C`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXQ+#DX,CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#,Q,3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXQ-BPV.3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#4Q)3X@/&1I=CY'96YE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PY.#(\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,W-RPX.3,\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!G&5R8VES92!O9B!O=71S=&%N M9&EN9R!W87)R86YT6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5R8VES92X@3F\@8V]M<&5N&5R8VES960@86YD(&%S(&$@2`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E65E('-T;V-K(&]P=&EO;G,@:7,@86UOF5D('1O(&5X<&5N'!E;G-E(&]V97(@ M=&AE('!E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2X\+VD^(%1H92!#;VUP86YY(&5S=&EM M871E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6EE;&0@8W5R=F4@:6X@969F96-T(&%T('1H92!T:6UE M(&]F(&=R86YT(&-O;6UE;G-U'!E8W1E9"!T97)M M(&%S#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!E8W1E9"!T97)M(&]F('-T;V-K M(&]P=&EO;G,@9W)A;G1E9"!I&5R8VES960@:6X@=&AE(&9U='5R92X@ M5&AE($-O;7!A;GD@87!P;&EE9"!T:&4@65E(&=R86YT2!F M;W(@=&AO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!F;W(@=&AE('-I>"!M;VYT:',@96YD M960@2G5N92`S,"P@,C`Q-"!A;F0@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M M8F5R(#,Q+"`R,#$S+B8C,38P.R!5;'1I;6%T96QY+"!T:&4@86-T=6%L(&5X M<&5N#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`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`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E#L@1D]. M5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3@N,C`\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^)B,Q-C`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`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXQ-RXX,#PO9&EV/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U M,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY+C(P/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY+C(V/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/B8C,34Q.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO&5R8VES86)L92!A="!*=6YE(#,P+"`R,#$T/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5R8VES92!P6EN M9R!O<'1I;VYS+B8C,38P.R!4:&5R92!H879E(&)E96X@;F\@;W!T:6]N(&5X M97)C:7-E&5R8VES92!O9B!O<'1I;VYS(&%R92!F#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPGF5D(&-O;7!E;G-A=&EO M;B!C;W-T(')E;&%T960@=&\@=6YV97-T960@&EM M871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2X@5&AE($-O;7!A;GD@97AP96-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE? M.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4 M:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!M971H;V0@;V8@86-C;W5N=&EN9RX@1&5F97)R960@=&%X(&%S"!B87-I2!F&5S(&9O2!H87,@97AP97)I96YC960@;&]S M2P@8V]N=&EN=6EN9R!L M;W-S97,@86YD('5N8V5R=&%I;G1Y(&%S2!A;'-O(&%C8V]U;G1S(&9O&5S(')E;&%T960@=&\@=&AE(')E8V]G;FET:6]N M(&%N9"!M96%S=7)E;65N="!O9B!A('1A>"!P;W-I=&EO;B!T86ME;B!O'!E8W1E9"!T;R!B92!T86ME;B!I;B!A;B!I;F-O;64@=&%X(')E='5R;BX@ M5&AE($-O;7!A;GD@9F]L;&]W2!I;B!I;F-O;64@=&%X('!O"!P;W-I=&EO;G,@:&%V92!B965N(&ED96YT:69I960N M/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H M.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!D:79I9&EN9R!N M970@;&]S"!M;VYT:',@96YD960@2G5N92`S M,"P@,C`Q-"!A;F0@,C`Q,RP@=&AE(&EN8VQU6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#8X M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PX M,SDL,3(S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,3`E/B`\9&EV/B8C,34Q.SPO9&EV/B`\+W1D/B`\=&0@3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B M,#8X,S0Y-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T M9F)?9#@T.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E&ED:7IE9"!G M;'5T871H:6]N92UB87-E9"!C;VUP;W5N9',@9F]R(&%P<&QI8V%T:6]N(&%S M('1H97)A<&EE2!D979E;&]P960@:6X@ M4G5S&ED:7IE9"!G;'5T871H:6]N92!C;VUP;W5N9"`H3D]6+3`P M,BD@87,@82!T:&5R87!Y(&9O2!T:&4@8V]U2!S=7!E2!H87,@;W!P;W-E9"!T:&4@;6]T:6]N+CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD M:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E"!M;VYT:',@96YD960@2G5N M92`S,"P@,C`Q-"P@=&AE(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2!I;F-U#L@1D].5#H@,3!P="!4:6UE65E2`D/&9O;G0@#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T M:&ES(&5M<&QO>65E('-H86QL(&)E(&5X97)C:7-A8FQE(&9O&5R8VES86)L92!F;W(@='=E;'9E M(&UO;G1H#L@1D]. M5#H@,3!P="!4:6UE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2P@:7,@82!F86-U;'1Y(&UE M;6)E2!O9B!7:7-C;VYS:6XM36%D:7-O;B`H M)B,X,C(P.U57)B,X,C(Q.RDN)B,Q-C`[($1U2!W87,@:6YV;VEC M960@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,RP@=&AE($-O;7!A M;GD@;6%D92!C;VYT&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;F0@82!G2!T M:&4@0V]M<&%N>2!O9B!U<"!T;R!A;B!A9V=R96=A=&4@;V8@)#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!O M9B`V,"!D87ES(&9R;VT@:7-S=6%N8V4@;W(@=&AE(&5A&ES=&EN9R!O2!O8G1A:6YE9"!T:&4@8V]N&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!4 M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD M:78@#L@1D].5#H@,3!P="!4:6UE2UO M=VYE9"!S=6)S:61I87)Y+B!!;&P@&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T'0^)SQD:78@#L@1D].5#H@,3!P M="!4:6UE2!A8V-O=6YT M&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!N;W0@8F4@2!T M:&%N(&YO="!R961U8V4@=&AE(&9A:7(@=F%L=64@;V8@=&AE(')E<&]R=&EN M9R!U;FET(&)E;&]W(&ET6EN9R!A;6]U;G0N($YO('-U8V@@979E M;G0@;W(@8VAA;F=E(&EN(&-I"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"X\+V1I=CX@/"]D M:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E&5D(&%S2!D M971E2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF5D(&]N(&$@2!T:')E92!Y96%R'!E;G-E+"!N970@;V8@97AP96-T960@9F]R9F5I='5R97,L(&-O;6UE M;F-E'!E;G-E+"!N970@;V8@97AP96-T960@9F]R9F5I='5R97,L M(&9O2!T:&4@<&5R:6]D(&1U6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6EN9R!F:6YA;F-I86P@6%B;&4L(&-O;G9E&EM871E;'D@)#(L-34V+#`P,"!A M="!*=6YE)B,Q-C`[,S`L)B,Q-C`[,C`Q-"X@5&AE(&-A&EM871E M&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T2!;4&]L:6-Y M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2P@:6X@86-C;W)D86YC92!W:71H M('1H92!$97)I=F%T:79E2!U M;F1E2!R96-O2!R96-L87-S:69I M97,@=&AE(&9A:7(@=F%L=64@=&\@97%U:71Y+B!!="!*=6YE(#,P+"`R,#$T M(&%N9"!$96-E;6)E2!T:&4@0V]M<&%N>2X\+V1I=CX@/"]D M:78^/'1A8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T2!497AT($)L;V-K73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE3PO:3X\ M+V(^("8C,34Q.R!);B!P2!H M87,@2!G=6ED86YC92!U;F1E#L@1D].5#H@,3!P="!4:6UE2P@*#(I(&QA8F5L('1H92!F:6YA;F-I86P@ M2P@*#,I(&1I2!I M65A6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A;FYU86P@;W(@:6YT97)I;2!P97)I;V0@9F]R('=H M:6-H(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@;F]T('EE="!B965N(&ES M2P@=&AE($-O;7!A;GD@:&%S(&5L96-T960@=&\@861O<'0@=&AE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C$S M9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE?.#EF M8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@.3`E.R!"3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@1D].5"U714E' M2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#
"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXR+#@S."PP,#`\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#@S."PP,#`\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0Q)3X@ M/&1I=CY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-3$[/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,BPX,S@L,#`P/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z M(&)O=&@G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T-, M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DQI86)I M;&ET:65S.CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G M/DQE9V%C>2!787)R86YT6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z M(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXT+#,V,SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H M)SXT+#,V,SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO2`R,#$S(%!U8FQI8R!/ M9F9E"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,34Q.SPO9&EV/B`\+W1D/B`\ M=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,34Q M.SPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78@"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/C,L,S4U+#`P,#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C,L,S4U+#`P,#PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E1O=&%L/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C0L,S8S M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[0TQ% M05(Z(&)O=&@G/C,L,S4Y+#,V,SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/ M3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,RPS-34L,#`P/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I M9'1H/3-$,3`E/B`\9&EV/B@U,3"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,BPX,S@L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E+"!787)R86YT'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@ M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@ M/&1I=CXT,#`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@/&1I=CXR,"XP,#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#(S)3X@/&1I=CXU-3`L,#`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@ M/&1I=CXQ,BXU,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#(S)3X@/&1I=CXQ,BXP,#PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(S)3X@/&1I=CXQ-2XP,#PO9&EV M/B`\+W1D/B`\=&0@2!W87)R M86YT6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE2`R-RP@,C`Q-3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0R,R4^(#QD:78^,2PY-C0L,#@U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%=)1%1(.B`P+C(U:6XG/B`\9&EV/B@Q*3PO9&EV/B`\+W1D/B`\=&0@2<^(#QD:78^5V%R6QE/3-$)TU!4D=)3BU43U`Z(#!P M>#L@1D].5#H@,3!P="!4:6UE3L@5D52 M5$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN M)SX\+W1D/B`\=&0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE? M.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D]. M5#H@,3!P="!4:6UE65E(&-O;G-U;'1A;G1S.CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY297-E M87)C:"!A;F0@9&5V96QO<&UE;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXS-C`L.38U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#4Q)3X@/&1I=CY297-T6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,S"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-3$Y+#4Q.3PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^-S@X+#@Y-#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY297-E87)C:"!A;F0@9&5V M96QO<&UE;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#4V-3PO9&EV/B`\+W1D M/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,38L-CDW/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY4;W1A;"!S M=&]C:RUB87-E9"!C;VUP96YS871I;VX\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C4S-BPR M,38\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`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`@("`@("`\=&0@8VQA6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,3@N,C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-RXX,#PO9&EV M/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXY+C(P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXY+C(V/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,34Q M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R M8VES86)L92!A="!*=6YE(#,P+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78@#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN M.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@ M5TE$5$@Z(#8X)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9, M3U6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^ M(#QD:78^,2PX,SDL,3(S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,34Q.SPO9&EV/B`\+W1D M/B`\=&0@3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E? M86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D('5N9&5R(%-T;V-K($]P=&EO;B!0;&%N&5R8VES86)L92!/<'1I;VYS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-3$L,S8U/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO2`R,#$S(%!U M8FQI8R!/9F9E'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO2!787)R86YT'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B M,#8X,S0Y-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T M9F)?9#@T.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS M<&%N/CPO'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^ M)S8@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO2!787)R86YT'0^)SQS<&%N/CPO&EM=6T@6TUE;6)E2`R,#$S M(%!U8FQI8R!/9F9E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!6;VQA=&EL:71Y(%)A=&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO7,\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'!E8W1E9"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)S$@;6]N M=&@@,C`@9&%Y'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!787)R86YT'0^)SQS<&%N/CPO2!787)R86YT M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^1F5B(#8L#0H)"3(P,38\'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@3VX@1&5F875L="!/;B!";W)R;W=I;F=S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2`R,#$T(%!)4$4@5V%R'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'!E8W1E9"!6;VQA=&EL:71Y(%)A M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'!E8W1E9"!$:79I9&5N9"!2 M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A(')A=&EO(&)E='=E96X@ M,3HQ,"!T;R`Q.C(P(&EN(&]R9&5R('1O('-A=&ES9GD@28C.#(Q-SMS(&-O;6UO M;B!S=&]C:R!O;B!T:&4@3D%31$%1($-A<&ET86P@36%R:V5T+B!);B!A9&1I M=&EO;BP@=&AE('!R;W!O'0^ M)SQS<&%N/CPO'0^)S$M9F]R+3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO2!!=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-3`L,#`P+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!/9B!/=71S=&%N9&EN9R!787)R86YT'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^2G5L(#(W+`T*"0DR,#$U/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^1&5C M(#,Q+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^1F5B(#(P+`T*"0DR,#$X/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^2G5N(#$S+`T*"0DR,#$W/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^1&5C(#8L M#0H)"3(P,38\&5R8VES92!P2!E>&5R8VES86)L92!F;VQL;W=I;F<@8V]N=F5R3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y M-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T M.5\T,3`Y7V%C-SE?.#EF8C`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`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N M/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E8W1E9"!L:69E M("AY96%R'0^)S8@>65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C$S9#1F M8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE?.#EF8C`V M.#,T.3=A+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO&5R8VES92!O9B!/=71S=&%N9&EN9R!/ M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`\ M&5R8VES92!O9B!/=71S=&%N9&EN M9R!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PT M-S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!O9B!/=71S=&%N9&EN9R!/<'1I;VYS/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3DL-C8S/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0&5R8VES92!0&5R8VES86)L92`M(%=E M:6=H=&5D($%V97)A9V4@17AE'0^)SD@>65A&5R8VES86)L92`M(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG M($-O;G1R86-T960@5&5R;2!I;B!996%R'0^)S0@>65A3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y M-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T M.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI("A54T0@ M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@ M8V]L6UE;G0@07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO2!3:&%R92!"87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!% M>&5R8VES86)L92P@5V5I9VAT960@079E&5R8VES92!0'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!3:&%R M92!"87-E9"!087EM96YT($%W87)D($]P=&EO;G,@1F]R9F5I='5R97,@4F%T M93PO=&0^#0H@("`@("`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`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO&-L=61E9"!F&-L=61E9"!F2!/<'1I;VX@6TUE;6)E'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C$S M9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE?.#EF M8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)S8P(&1A>7,\ M'0^)SQS<&%N/CPO2P@06UO=6YT/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W M.5\X.69B,#8X,S0Y-V$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8S(Q,V0T9F)?9#@T.5\T,3`Y7V%C-SE?.#EF8C`V.#,T.3=A+U=O'0O:'1M;#L@8VAA M&UL;G,Z;STS1")U&UL/@T*+2TM+2TM/5]. M97AT4&%R=%]C,C$S9#1F8E]D.#0Y7S0Q,#E?86,W.5\X.69B,#8X,S0Y-V$M #+0T* ` end XML 21 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCKHOLDERS' EQUITY (Details) (USD $)
0 Months Ended 6 Months Ended 6 Months Ended

Feb. 05, 2014

Jun. 30, 2014

Feb. 20, 2014

Oct. 31, 2013

Jun. 30, 2014

Warrant One [Member]

Jun. 30, 2014

Warrant Two [Member]

Jun. 30, 2014

Warrant Three [Member]

Jun. 30, 2014

Warrant Three [Member]

Minimum [Member]

Jun. 30, 2014

Warrant Three [Member]

Maximum [Member]

Jun. 30, 2014

February 2014 Private Placement [Member]

Jun. 30, 2014

February 2013 Public Offering [Member]

Jun. 30, 2014

February 2013 Public Offering - Placement Agents [Member]

Jun. 30, 2014

November 2012 Private Placement [Member]

Jun. 30, 2014

June 2012 Public Offering [Member]

Jun. 30, 2014

December 2011 Underwritten Offering [Member]

Jun. 30, 2014

April 2011 Private Placement [Member]

Class of Warrant or Right [Line Items]

Number Of Shares Issuable Upon Exercise Of Outstanding Warrants (in shares) 1,964,085 275,000 96,278 1,365 ^[1] 5,252 4,570 400,000 ^[2] 550,000 ^[1] 38,496 50,000 149,069 462,411 302,922

Exercise Price (in dollars per share) $ 20.00 $ 10.00 $ 10.00 ^[1] $ 321.30 $ 1,989 $ 2,019.60 $ 20.00 ^[2] $ 10.00 ^[1] $ 12.50 $ 25.00 $ 25.00 $ 12.00 $ 15.00

Warrants Expiration Date Feb. 06, 2019 Jul. 27, 2015 ^[1] Jul. 27, 2015 Dec. 31, 2015 Feb. 06, 2019 ^[2] Feb. 20, 2018 ^[1] Feb. 04, 2018 Nov. 02, 2017 Jun. 13, 2017 Dec. 06, 2016 Mar. 31, 2016

[1] The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as a derivative instrument as described in Note 2.

[2] Warrants issued in connection with the sale of convertible debentures. As described in Note 3, the warrants are only exercisable following conversion of the associated debentures.

X

- Definition

Expiry date of warrants held.

+ References

No definition available.

+ Details

Name: clrb_WarrantsExpirationDate

Namespace Prefix: clrb_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 22 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

REVERSE STOCK SPLIT AND RECAPITALIZATION (Details Textual)
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

REVERSE STOCK SPLIT AND RECAPITALIZATION [Line Items]

Stockholders' Equity, Reverse Stock Split At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt.

Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio 1-for-20

Common Stock, Shares Authorized 20,000,000 20,000,000

Common Stock Shares Previously Authorized 150,000,000

X

- Definition

Represents previously authorized common stock, shares resulted in reverse stock spilt.

+ References

No definition available.

+ Details

Name: clrb_CommonStockSharesPreviouslyAuthorized

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: clrb_ReverseStockSplitAndRecapitalizationLineItems

Namespace Prefix: clrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents reverse stock split conversion ratio.

+ References

No definition available.

+ Details

Name: clrb_StockholdersEquityNoteReverseStockSplitConversionRatio

Namespace Prefix: clrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK-BASED COMPENSATION (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation $ 273,690 $ 377,893 $ 536,216 $ 803,791

Employee and Director Stock Option [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation 271,708 371,017 519,519 788,894

Employee and Director Stock Option [Member] | Research and Development Expense [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation 47,274 106,774 110,701 212,612

Employee and Director Stock Option [Member] | General and Administrative Expense [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation 176,581 264,243 360,965 576,282

Employee and Director Stock Option [Member] | Restructuring Costs [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation 47,853 0 47,853 0

Non Employee Consultant Stock Option [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation 1,982 6,876 16,697 14,897

Non Employee Consultant Stock Option [Member] | Research and Development Expense [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation 1,982 3,311 16,697 4,322

Non Employee Consultant Stock Option [Member] | General and Administrative Expense [Member]

Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]

Total stock-based compensation $ 0 $ 3,565 $ 0 $ 10,575

X

- Details

Name: clrb_CompensationCostForSharebasedPaymentArrangementsAllocationOfSharebasedCompensationCostsByPlanLineItems

Namespace Prefix: clrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 24 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK-BASED COMPENSATION (Details 1) (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]

Volatility 108.00% 109.00%

Risk-free interest rate 1.76% 0.92%

Expected life (years) 6 years 6 years

Dividend 0.00% 0.00%

Weighted-average exercise price $ 7.40 $ 14.80

Weighted-average grant-date fair value $ 6.20 $ 12.20

X

- Details

Name: clrb_SharebasedPaymentAwardStockOptionsValuationAssumptionsLineItems

Namespace Prefix: clrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 25 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE DEBT
6 Months Ended

Jun. 30, 2014

Convertible Debt [Abstract]

Debt Disclosure [Text Block]

3. CONVERTIBLE DEBT

On February 5, 2014, the Company entered into a securities purchase agreement with certain accredited investors to sell $4,000,000 in principal amount of convertible debentures and warrants to purchase 400,000 shares of its common stock for an aggregate purchase price of $4,000,000. On February 6, 2014, the Company completed the sale of the debentures and warrants (the “February 2014 Private Placement”).

Debentures

The debentures mature on February 6, 2016 and are convertible at any time at a conversion price of $10.00 per share into an aggregate of 400,000 shares of common stock. The debentures accrue interest at an annual rate of 8%, payable upon redemption or conversion, in cash or shares of the Company’s common stock. During the six months ended June 30, 2014, the Company accrued $128,000 in interest expense, which is included in accrued liabilities as of June 30, 2014. The debenture conversion price and the common stock issuable pursuant to the debentures are subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the debenture holders after such event will be equivalent to the rights of debenture holders prior to such event.

The Company may elect to redeem the debentures prior to the maturity date upon 30-day notice to the holder. In the event of any sale of securities by the Company resulting in aggregate gross proceeds of at least $2,000,000 (a “Subsequent Financing”), the holder shall have the right to require the Company to redeem some or all of the then outstanding principal amount of the debenture, plus all accrued but unpaid interest and other amounts due in respect of the debenture, in an amount equal to the amount of the holder’s investment in the Subsequent Financing, by delivering notice to the Company on or before the consummation date of the Subsequent Financing. If, within 21 months after the issuance of the debentures, the Company raises gross proceeds of at least $8,000,000, in the aggregate, in one or more subsequent financings (the “Minimum Proceeds”), the Company may, by notice given within three trading days after the receipt of the Minimum Proceeds, compel holders to convert all or part of the then outstanding principal amount of the debentures and accrued but unpaid interest and other amounts.

Other than as specifically permitted under in the debentures, as long as any of the debentures remain outstanding, the Company may not, without the consent of holders of a majority in principal amount of the then outstanding debentures: incur any indebtedness for borrowed money; grant any liens on its property or assets; repurchase shares of its common stock or common stock equivalents; repurchase or otherwise acquire any indebtedness; pay cash dividends or distributions on any equity securities; enter into any transaction with any affiliate of the Company which would be required to be disclosed in any public filing with the SEC, unless such transaction is made on an arm’s-length basis and expressly approved by a majority of the disinterested directors of the Company; or enter into any agreement with respect to any of the foregoing. See footnote 12 for discussion of the security interest extended to these debentures as consideration for the consent of the holders to the issuance of the promissory notes in July 2014.

If any event of default occurs, the outstanding principal amount of the debentures, plus accrued but unpaid interest and other amounts owing in respect thereof through the date of acceleration, shall become, at the holder’s election, immediately due and payable in cash. If such amounts are not paid within 5 days after the occurrence of any event of default, interest shall begin to accrue at the lesser of 12% per annum or the maximum rate permitted under applicable law. Events of default consist of: any default in the payment of amounts due and payable that is not cured within three trading days; failure of the Company to observe or perform any other covenant or agreement contained in the Debentures that is not cured within the earlier to occur of five trading days after notice of such failure sent by any holder of debentures or ten trading days after the Company has become aware of such failure; the occurrence of any uncured material default or event of default under the other transaction documents or any other material agreement, lease, document or instrument under which the Company or any of its subsidiaries is obligated; any representations or warranties made in the debentures or other transaction documents being materially false when made; an institution of any voluntary or involuntary bankruptcy or other insolvency proceeding or similar or related events; default on any borrowings in excess of $150,000; the Company’s common stock being ineligible for quotation on a trading market for greater than five trading days; the Company entering into any change in control transaction; the Company’s failure to deliver shares of common stock as required upon conversion of the debentures; or the Company being the subject of a monetary judgment greater than $100,000.

Common Stock Purchase Warrants

The warrants have an exercise price of $20.00 and, if unexercised, expire on February 6, 2019.  The warrants are exercisable only following the full or partial conversion of the associated debentures, and in the event of a partial conversion the warrant shall become exercisable only for a proportionate number of the total shares subject to the warrant. In the event any debentures cease to be outstanding prior to the associated warrants becoming exercisable, whether by reason of repayment, prepayment, redemption or otherwise, the associated warrants will automatically terminate.

The warrant exercise price and the number of shares of common stock issuable pursuant to the warrants are subject to adjustment for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.

The Company determined that the warrants associated with the convertible debentures meet the requirements for classification as equity. Therefore, the relative fair value of the warrants at the date of issuance of $254,000 has been included as a component of stockholders’ equity. In order to estimate the value of the these warrants the Company used a probability weighted valuation model together with assumptions that considered, among other variables, the fair value of the underlying stock, a risk-free interest rate of 1.52%, a volatility of 110%, a 0% dividend rate, a contractual term of 5 years, and an estimate of the probability that the warrants will become exercisable upon conversion of the associated debt.

Following the allocation of the relative fair value of the warrants to equity, the remaining value of approximately $3,746,000, at the date of issuance, was allocated to the convertible debentures. The resulting discount on the debentures of $254,000 will be accreted to interest expense over the shorter of the time to maturity or conversion. During the six months ended June 30, 2014, the Company recorded approximately $51,000 of non-cash expense related to accretion of the discount on the debentures.

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK-BASED COMPENSATION (Details 2) (USD $)
6 Months Ended

Jun. 30, 2014

Share-based Compensation, Stock Options, Activity [Line Items]

Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options 634,658

Granted - Number of Shares Issuable Upon Exercise of Outstanding Options 20,000

Canceled - Number of Shares Issuable Upon Exercise of Outstanding Options (20,521)

Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options (14,474)

Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options 619,663

Vested - Number of Shares Issuable Upon Exercise of Outstanding Options 264,752

Unvested - Number of Shares Issuable Upon Exercise of Outstanding Options 354,911

Exercisable - Number of Shares Issuable Upon Exercise of Outstanding Options 264,752

Outstanding - Weighted Average Exercise Price (in dollars per share) $ 18.20

Granted - Weighted Average Exercise Price (in dollars per share) $ 7.40

Canceled - Weighted Average Exercise Price (in dollars per share) $ 23.17

Forfeited - Weighted Average Exercise Price (in dollars per share) $ 15.00

Outstanding - Weighted Average Exercise Price (in dollars per share) $ 17.80

Vested - Weighted Average Exercise Price (in dollars per share) $ 29.00

Unvested - Weighted Average Exercise Price (in dollars per share) $ 9.20

Exercisable - Weighted Average Exercise Price (in dollars per share) $ 29.00

Vested - Weighted Average Remaining Contracted Term in Years 4 years 14 days

Unvested - Weighted Average Remaining Contracted Term in Years 9 years 3 months 4 days

Exercisable - Weighted Average Remaining Contracted Term in Years 4 years 14 days

Vested - Aggregate Intrinsic Value (in dollars) $ 0

Unvested - Aggregate Intrinsic Value (in dollars) 0

Exercisable - Aggregate Intrinsic Value (in dollars) $ 0

X

- Definition

The number of unvested equity-based payment instruments, including stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are non vested.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice

Namespace Prefix: clrb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise prices of unvested options outstanding.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average of the remaining contractual term for unvested portions of options outstanding and currently exercised or convertible in the 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm

Namespace Prefix: clrb_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average exercise price of options canceled.

+ References

No definition available.

+ Details

Name: clrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice

Namespace Prefix: clrb_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: clrb_SharebasedCompensationStockOptionsActivityLineItems

Namespace Prefix: clrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)

Jun. 30, 2014

Dec. 31, 2013

CURRENT ASSETS:

Cash and cash equivalents $ 1,626,025 $ 2,418,384

Restricted cash 55,000 55,000

Prepaid expenses and other current assets 334,979 294,687

Total current assets 2,016,004 2,768,071

FIXED ASSETS, NET 2,185,087 2,360,534

GOODWILL 1,675,462 1,675,462

OTHER ASSETS 12,009 11,872

TOTAL ASSETS 5,888,562 6,815,939

CURRENT LIABILITIES:

Current maturities of notes payable 41,330 0

Accounts payable and accrued liabilities 1,195,418 1,162,098

Derivative liability 2,840,557 3,359,363

Capital lease obligations 431 1,694

Total current liabilities 4,077,736 4,523,155

LONG-TERM LIABILITIES:

Convertible debt 3,796,781 0

Notes payable, less current maturities 408,670 450,000

Deferred rent 145,993 143,234

Total long-term liabilities 4,351,444 593,234

TOTAL LIABILITIES 8,429,180 5,116,389

COMMITMENTS AND CONTINGENCIES (Note 9)

STOCKHOLDERS' EQUITY (DEFICIT):

Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of June 30, 2014 and December 31, 2013 0 0

Common stock, $0.00001 par value; 20,000,000 shares authorized; 2,869,739 shares issued and outstanding at June 30, 2014 and December 31, 2013 29 29

Additional paid-in capital 53,548,170 52,759,089

Deficit accumulated (56,088,817) (51,059,568)

Total stockholders' equity (deficit) (2,540,618) 1,699,550

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 5,888,562 $ 6,815,939

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of capital lease obligation due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7501430&loc=d3e39927-112707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndInvestmentsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature Of Business Organization and Going Concern Disclosure [Text Block]

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

Cellectar Biosciences, Inc. (the “Company”) is a biopharmaceutical company developing compounds for the treatment and imaging of cancer. Prior to February 11, 2014, the name of the Company was Novelos Therapeutics, Inc. (“Novelos”). On April 8, 2011, Novelos entered into a business combination (the “Acquisition”) with Cellectar, Inc., a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers.

References in these financial statements and notes to “Cellectar, Inc.” relate to the activities and financial information of Cellectar, Inc. prior to the Acquisition, references to “Novelos” relate to the activities and financial information of Novelos prior to the Acquisition and references to “the Company” or “we” or “us” or “our” relate to the activities and obligations of the combined Company following the Acquisition.

The Company’s headquarters are located in Madison, Wisconsin.

The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.

The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its efforts toward research and development and has, during the six months ended June 30, 2014, generated a net loss of approximately $5,029,000. The Company expects that it will continue to generate operating losses for the foreseeable future. See footnote 12 below for further information regarding the Company’s cash resources. The Company’s ability to execute its operating plan depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The accompanying condensed consolidated balance sheet as of December 31, 2013 has been derived from audited financial statements. The accompanying unaudited condensed consolidated balance sheet as of June 30, 2014, the condensed consolidated statements of operations for the three months and six months ended June 30, 2014 and 2013, the condensed consolidated statements of cash flows for the six months ended June 30, 2014 and 2013 and the related interim information contained within the notes to the condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions, rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments which are of a nature necessary for the fair presentation of the Company’s consolidated financial position at June 30, 2014 and consolidated results of its operations for the three months and six months ended June 30, 2014, and its cash flows for the six months ended June 30, 2014 and 2013. The results for the six months ended June 30, 2014 are not necessarily indicative of future results.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 19, 2014.

Principles of Consolidation — The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

Restricted Cash — The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2014 and December 31, 2013 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.

Goodwill — At June 30, 2014 and December 31, 2013, the balance of goodwill resulted from the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore no changes in goodwill were made during the six months ended June 30, 2014.

Impairment of Long-Lived Assets — Long-lived assets other than goodwill consist of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore, no such impairment occurred during the six months ended June 30, 2014.

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable, convertible debt and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The fair value of convertible debt is equal to the fair value of the underlying common stock, which was approximately $2,556,000 at June 30, 2014. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivative Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 551,365 and 826,365 at June 30, 2014 and December 31, 2013, respectively. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2014 and December 31, 2013, these warrants represented the only outstanding derivative instruments issued or held by the Company.

Development Stage Entity — In previous filings, the Company has reported as a “Development Stage Entity”. However, in June 2014, the Financial Accounting Standards Board (FASB) published an Accounting Standards Update 2014-10 (ASU 2014-10) that removed the development stage entity guidance under Accounting Standards Codification Topic 915 (ASC 915) Development Stage Entities, thereby removing the financial reporting distinction between development stage entities and other reporting entities.

In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.

Presentation and disclosure requirements under ASC 915 are no longer required for the first annual period beginning after December 15, 2014, including interim periods therein. Earlier adoption of the new guidance for ASC 915 is permitted for any annual or interim period for which financial statements have not yet been issued for public business entities. Accordingly, the Company has elected to adopt these changes effective with the filing of this Form 10-Q.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

RESTRUCTURING COSTS (Details Textual) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Restructuring Cost and Reserve [Line Items]

Payment Of Lump Sum Amount Related To Employment Agreement $ 160,000

Restructuring Costs, Total $ 204,934 $ 0 $ 221,815 $ 0

X

- Definition

This element represents the amount of a lump sum payment that may be payable to the executive upon termination.

+ References

No definition available.

+ Details

Name: clrb_PaymentOfLumpSumAmountRelatedToEmploymentAgreement

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 30 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

NET LOSS PER SHARE (Tables)
6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

Six Months Ended June 30,

2014

2013

Warrants

1,964,085

1,839,123

Stock options

619,663

314,582

Convertible debt

400,000

—

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Related Party Transaction [Line Items]

Amount Invoiced Under Clinical Trial Agreements $ 334,000

Payment Towards Clinical Trial Agreements 264,000

Related Party Transaction, Amounts of Transaction $ 62,500

X

- Definition

Represents the amount invoiced under clinical trial agreements.

+ References

No definition available.

+ Details

Name: clrb_AmountInvoicedUnderClinicalTrialAgreements

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the cash outflow arising due to payment towards clinical trial agreement costs.

+ References

No definition available.

+ Details

Name: clrb_PaymentTowardsClinicalTrialAgreements

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of transactions with related party during the financial reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Liabilities:

Warrants $ 2,840,557 $ 3,359,363

February 2013 Public Offering Warrants [Member]

Liabilities:

Warrants 2,838,000 3,355,000

Legacy Warrants [Member]

Liabilities:

Warrants 2,557 4,363

Fair Value, Inputs, Level 1 [Member]

Liabilities:

Warrants 0 0

Fair Value, Inputs, Level 1 [Member] | February 2013 Public Offering Warrants [Member]

Liabilities:

Warrants 0 0

Fair Value, Inputs, Level 1 [Member] | Legacy Warrants [Member]

Liabilities:

Warrants 0 0

Fair Value, Inputs, Level 2 [Member]

Liabilities:

Warrants 2,557 4,363

Fair Value, Inputs, Level 2 [Member] | February 2013 Public Offering Warrants [Member]

Liabilities:

Warrants 0 0

Fair Value, Inputs, Level 2 [Member] | Legacy Warrants [Member]

Liabilities:

Warrants 2,557 4,363

Fair Value, Inputs, Level 3 [Member]

Liabilities:

Warrants 2,838,000 3,355,000

Fair Value, Inputs, Level 3 [Member] | February 2013 Public Offering Warrants [Member]

Liabilities:

Warrants 2,838,000 3,355,000

Fair Value, Inputs, Level 3 [Member] | Legacy Warrants [Member]

Liabilities:

Warrants $ 0 $ 0

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 34 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE
6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

2. FAIR VALUE

In accordance with the Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

·

Level 1: Input prices quoted in an active market for identical financial assets or liabilities.

·

Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

·

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company had issued warrants to purchase 1,365 shares of common stock prior to the Acquisition (“Legacy Warrants”) that are classified within the Level 2 hierarchy. Additionally, the Company issued warrants to purchase an aggregate of 825,000 common shares in a February 2013 public offering (“February 2013 Public Offering Warrants”). On February 20, 2014, warrants to purchase 275,000 shares of common stock issued in the February 2013 offering expired. The remaining 550,000 warrants are classified within the Level 3 hierarchy.

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2014 and December 31, 2013:

June 30, 2014

Level 1

Level 2

Level 3

Fair Value

Liabilities:

Legacy Warrants

$

—

$

2,557

$

—

$

2,557

February 2013 Public Offering Warrants

—

—

2,838,000

2,838,000

Total

$

—

$

2,557

$

2,838,000

$

2,840,557

December 31, 2013

Level 1

Level 2

Level 3

Fair Value

Liabilities:

Legacy Warrants

$

—

$

4,363

$

—

$

4,363

February 2013 Public Offering Warrants

—

—

3,355,000

3,355,000

Total

$

—

$

4,363

$

3,355,000

$

3,359,363

In order to estimate the fair value of the Legacy Warrants considered to be derivative instruments, the Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 6).

In order to estimate the value of the February 2013 Public Offering Warrants considered to be derivative instruments as of June 30, 2014, the Company uses a modified option-pricing model together with assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate of 1.76% (compared with risk-free interest rate of 0.92% as of December 31, 2013), volatility of 108% (compared with 109% as of December 31, 2013), contractual term of 6 years (also 6 years as of December 31, 2013), future financing requirements and dividend rates.

The assumptions used to estimate the value of the February 2013 Public Offering Warrants as of December 31, 2013 include the fair value of the underlying stock, risk free interest rates ranging from 0.07% to 1.27%, volatility ranging from 75% to 115%, the contractual term of the warrants ranging from 0.14 to 4.14 years, future financing requirements and dividend rates. The future financing estimates are based on the Company’s estimates of anticipated cash requirements over the term of the warrants as well as the frequency of required financings based on its assessment of its historical financing trends and anticipated future events. Due to the nature of these inputs and the valuation technique utilized, these warrants are classified within the Level 3 hierarchy.

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

June 30,
2014

December 31,
2013

Beginning balance – Fair value

$

3,355,000

$

—

Fair value of warrants issued in connection with February 2013 public offering

—

5,720,000

Gain on derivatives resulting from change in fair value

(517,000)

(2,365,000)

Ending balance – Fair value

$

2,838,000

$

3,355,000

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)

Jun. 30, 2014

Dec. 31, 2013

Preferred stock, par value (in dollars per share) $ 0.00001 $ 0.00001

Preferred stock, shares authorized 7,000 7,000

Preferred stock, issued 0 0

Preferred stock, outstanding 0 0

Common stock, par value (in dollars per share) $ 0.00001 $ 0.00001

Common stock, shares authorized 20,000,000 20,000,000

Common stock, shares issued 2,869,739 2,869,739

Common stock, shares outstanding 2,869,739 2,869,739

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 36 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENT
6 Months Ended

Jun. 30, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

12. SUBSEQUENT EVENT

The Company and a group of lenders entered into a Note Purchase and Security Agreement dated as of July 29, 2014 providing for borrowing by the Company of up to an aggregate of $1,000,000 upon the issuance of the Company’s secured promissory notes (the “Notes”) bearing interest of 8% per annum and having a stated maturity of 60 days from issuance or the earlier closing of an equity financing with gross proceeds to the Company of $1,000,000. The Notes are secured by a lien on substantially all assets of the Company, now existing or subsequently acquired. The Company borrowed an aggregate of $617,500 at an initial closing on July 29, 2014. Any borrowing of the remaining $382,500 balance of the $1,000,000 is at the option of the lenders. In connection with the entry into the Note Purchase and Security Agreement, the Company obtained the consent of the holders of its outstanding convertible debentures in exchange for the extension of the security interest on all such assets of the Company to the convertible debentures, pari passu with the Notes.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
6 Months Ended

Jun. 30, 2014

Aug. 01, 2014

Document Information [Line Items]

Entity Registrant Name Cellectar Biosciences, Inc.

Entity Central Index Key 0001279704

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol CLRB

Entity Common Stock, Shares Outstanding 2,869,739

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2014

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 38 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies)
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation — The consolidated financial statements include the accounts of the Company and the accounts of its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash — The Company accounts for cash that is restricted for other than current operations as restricted cash. Restricted cash at June 30, 2014 and December 31, 2013 consisted of a certificate of deposit of $55,000 required under the Company’s lease agreement for its Madison, Wisconsin facility.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill — At June 30, 2014 and December 31, 2013, the balance of goodwill resulted from the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount. No such event or change in circumstances occurred; therefore no changes in goodwill were made during the six months ended June 30, 2014.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets — Long-lived assets other than goodwill consist of fixed assets, which we periodically evaluate for potential impairment. Whenever events or circumstances change, an assessment is made as to whether there has been an impairment in the value of long-lived assets by determining whether projected undiscounted cash flows generated by the applicable asset exceed its net book value as of the assessment date. No such event or change in circumstances occurred; therefore, no such impairment occurred during the six months ended June 30, 2014.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable, convertible debt and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The fair value of convertible debt is equal to the fair value of the underlying common stock, which was approximately $2,556,000 at June 30, 2014. The carrying value of remaining long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivatives, Policy [Policy Text Block]

Derivative Instruments — The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 551,365 and 826,365 at June 30, 2014 and December 31, 2013, respectively. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At June 30, 2014 and December 31, 2013, these warrants represented the only outstanding derivative instruments issued or held by the Company.

Development Stage Entity, Policy [Policy Text Block]

Development Stage Entity — In previous filings, the Company has reported as a “Development Stage Entity”. However, in June 2014, the Financial Accounting Standards Board (FASB) published an Accounting Standards Update 2014-10 (ASU 2014-10) that removed the development stage entity guidance under Accounting Standards Codification Topic 915 (ASC 915) Development Stage Entities, thereby removing the financial reporting distinction between development stage entities and other reporting entities.

In addition, ASU 2014-10 eliminates the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.

Presentation and disclosure requirements under ASC 915 are no longer required for the first annual period beginning after December 15, 2014, including interim periods therein. Earlier adoption of the new guidance for ASC 915 is permitted for any annual or interim period for which financial statements have not yet been issued for public business entities. Accordingly, the Company has elected to adopt these changes effective with the filing of this Form 10-Q.

X

- Definition

Disclosure of accounting policy for development stage entity.

+ References

No definition available.

+ Details

Name: clrb_DevelopmentStageEntityPolicyPolicyTextBlock

Namespace Prefix: clrb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph a

-Article 9

+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for its derivative instruments and hedging activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41620-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579245-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5579240-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41638-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph n

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=35706170&loc=d3e41675-113959

+ Details

Name: us-gaap_DerivativesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6390181&loc=d3e202-110218

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

COSTS AND EXPENSES:

Research and development $ 1,380,798 $ 1,648,838 $ 3,096,105 $ 3,239,450

General and administrative 959,885 1,073,749 2,046,921 2,195,452

Restructuring costs 204,934 0 221,815 0

Total costs and expenses 2,545,617 2,722,587 5,364,841 5,434,902

LOSS FROM OPERATIONS (2,545,617) (2,722,587) (5,364,841) (5,434,902)

OTHER INCOME (EXPENSE):

Gain on revaluation of derivative warrants 573,751 660,341 518,806 666,384

Loss on issuance of derivative warrants 0 0 0 (744,957)

Interest expense, net (113,970) (2,216) (183,214) (4,866)

Total other income (expense), net 459,781 658,125 335,592 (83,439)

NET LOSS $ (2,085,836) $ (2,064,462) $ (5,029,249) $ (5,518,341)

BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share) $ (0.73) $ (0.72) $ (1.75) $ (2.03)

SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE (in shares) 2,869,739 2,869,739 2,869,739 2,717,966

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net amount of nonoperating interest income (expense).

+ References

No definition available.

+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_RestructuringCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

INCOME TAXES
6 Months Ended

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

7. INCOME TAXES

The Company accounts for income taxes in accordance with the liability method of accounting. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, (NOLs) using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the six months ended June 30, 2014 or 2013 because the Company has experienced losses on a tax basis since inception. Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax asset.

The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions. No uncertain tax positions have been identified.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK-BASED COMPENSATION
6 Months Ended

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

6. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Employee and director stock option grants:

Research and development

$

47,274

$

106,774

$

110,701

$

212,612

General and administrative

176,581

264,243

360,965

576,282

Restructuring costs

47,853

—

47,853

—

271,708

371,017

519,519

788,894

Non-employee consultant stock option grants:

Research and development

1,982

3,311

16,697

4,322

General and administrative

—

3,565

—

10,575

1,982

6,876

16,697

14,897

Total stock-based compensation

$

273,690

$

377,893

$

536,216

$

803,791

In October 2013, the Company granted options to purchase 264,278 shares of common stock in connection with the appointment of its then Acting Chief Executive Officer, including options to purchase 96,278 shares of common stock at $15.00 per share (the “Anti-dilution Option”), exercisable as shares of the Company’s common stock are issued following the exercise of outstanding warrants to purchase up to 96,278 shares of the Company’s common stock, in the ratio of one option share for each 19 shares issued upon warrant exercise. No compensation expense was recognized related to these options as the Company was not able to conclude that the achievement of the performance condition was probable. On February 20, 2014, warrants to purchase 275,000 shares of common stock at an exercise price of $10.00 per share expired unexercised and as a result, the number of shares subject to the Anti-dilution Option was reduced by 14,474 shares, according to its terms.

Assumptions Used In Determining Fair Value

Valuation and amortization method. The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. The estimated fair value of the non-employee options is amortized to expense over the period during which a non-employee is required to provide services for the award (usually the vesting period).

Volatility. The Company estimates volatility based on an average of (1) the Company’s historical volatility since its common stock has been publicly traded and (2) review of volatility estimates of publicly held drug development companies with similar market capitalizations.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Expected term. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, as described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. The Company applied the simplified method to non-employees who have a truncation of term based on termination of service and utilizes the contractual life of the stock options granted for those non-employee grants which do not have a truncation of service.

Forfeitures. The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. An annual forfeiture rate of 2% and 0% was applied to all unvested options for employees and directors, respectively for the six months ended June 30, 2014 and for the year ended December 31, 2013. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.

The following table summarizes weighted-average values and assumptions used for options granted to employees, directors and consultants in the periods indicated:

Six Months Ended
June 30, 2014

Six Months Ended
June 30, 2013

Volatility

108

%

109

%

Risk-free interest rate

1.76

%

0.92

%

Expected life (years)

6.0

6.0

Dividend

0

%

0

%

Weighted-average exercise price

$

7.40

$

14.80

Weighted-average grant-date fair value

$

6.20

$

12.20

Exercise prices for all grants made during the six months ended June 30, 2014 and 2013 were equal to the market value of the Company’s common stock on the date of grant.

Stock Option Activity

A summary of stock option activity is as follows:

Number of
Shares
Issuable Upon
Exercise of
Outstanding
Options

Weighted
Average
Exercise Price

Weighted
Average
Remaining
Contracted
Term in
Years

Aggregate
Intrinsic
Value

Outstanding at December 31, 2013

634,658

$

18.20

Granted

20,000

$

7.40

Canceled

(20,521)

$

23.17

Forfeited

(14,474)

$

15.00

Outstanding at June 30, 2014

619,663

$

17.80

Vested, June 30, 2014

264,752

$

29.00

4.04

$

—

Unvested, June 30, 2014

354,911

$

9.20

9.26

$

—

Exercisable at June 30, 2014

264,752

$

29.00

4.04

$

—

The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.



As of June 30, 2014, there was approximately $1,869,000 of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize approximately $1,096,000, $570,000, and $203,000 during 2014, 2015, and 2016, respectively. The Company expects 273,106 unvested options to vest in the future. In addition, there are outstanding options to purchase 81,805 shares of common stock that vest upon the occurrence of future events. The Company was not able to conclude that the achievement of the performance condition is probable; therefore, the Company has not recognized any expense associated with the $418,000 fair value of these awards. Recognition of expense will begin when and if the Company determines that achievement of the performance condition is probable. The weighted-average grant-date fair value of vested and unvested options outstanding at June 30, 2014 was $16.66 and $5.98, respectively.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]

Net Income (Loss) Attributable to Parent, Total $ (2,085,836) $ (2,064,462) $ (5,029,249) $ (5,518,341)

Certificates of Deposit, at Carrying Value 55,000 55,000 55,000

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options 551,365 551,365 826,365

Convertible Debt, Fair Value Disclosures $ 2,556,000 $ 2,556,000

X

- Details

Name: clrb_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesLineItems

Namespace Prefix: clrb_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CertificatesOfDepositAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Convertible Security

-URI http://asc.fasb.org/extlink&oid=6509036

+ Details

Name: us-gaap_ConvertibleDebtFairValueDisclosures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 43 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE (Tables)
6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following tables set forth the Company’s financial instruments carried at fair value using the lowest level of input applicable to each financial instrument as of June 30, 2014 and December 31, 2013:

June 30, 2014

Level 1

Level 2

Level 3

Fair Value

Liabilities:

Legacy Warrants

$

—

$

2,557

$

—

$

2,557

February 2013 Public Offering Warrants

—

—

2,838,000

2,838,000

Total

$

—

$

2,557

$

2,838,000

$

2,840,557

December 31, 2013

Level 1

Level 2

Level 3

Fair Value

Liabilities:

Legacy Warrants

$

—

$

4,363

$

—

$

4,363

February 2013 Public Offering Warrants

—

—

3,355,000

3,355,000

Total

$

—

$

4,363

$

3,355,000

$

3,359,363

Schedule Of Changes In Fair Value Warrants Classified Level Three [Table Text Block]

The following table summarizes the changes in the fair market value of the Company’s warrants which are classified within the Level 3 fair value hierarchy.

June 30,
2014

December 31,
2013

Beginning balance – Fair value

$

3,355,000

$

—

Fair value of warrants issued in connection with February 2013 public offering

—

5,720,000

Gain on derivatives resulting from change in fair value

(517,000)

(2,365,000)

Ending balance – Fair value

$

2,838,000

$

3,355,000

X

- Definition

The tabular disclosure of changes in fair market value classified within the Level 3 fair value hierarchy.

+ References

No definition available.

+ Details

Name: clrb_ScheduleOfChangesInFairValueWarrantsClassifiedLevelThreeTableTextBlock

Namespace Prefix: clrb_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

RESTRUCTURING COSTS
6 Months Ended

Jun. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

10. RESTRUCTURING COSTS

During 2013 the Company had several changes to its board composition and executive management, including the relocation of the Company’s principal executive offices from Newton, Massachusetts to its corporate headquarters in Madison, Wisconsin. During the six months ended June 30, 2014, the Company incurred approximately $222,000 of costs associated with the closure of the executive offices in Newton, Massachusetts and accruals related to severance agreements. This amount has been classified as restructuring costs on the accompanying statement of operations.

In connection with the Acquisition, the responsibilities of the Company’s Vice President of Finance, Chief Financial Officer and Treasurer (CFO) and those of the Director of Financial Reporting were transitioned to the Company’s headquarters in Madison, Wisconsin. As a result, the Company’s relationship with both employees terminated in June 2014. These two employees received lump-sum severance payments totaling approximately $160,000, which is included in the approximately $222,000 restructuring costs presented in the accompanying Condensed Consolidated Statement of Operations. Benefits will continue for these employees for six and four months, respectively, following termination.

In addition, all unvested options held by the former CFO were credited with an additional six months vesting and the vested options held by this employee shall be exercisable for eighteen months following termination. All unvested options held by the former Director of Financial Reporting shall be exercisable for twelve months following termination.

The Company does not anticipate any further costs related to the relocation and restructuring.

X

- Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

NET LOSS PER SHARE
6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

8. NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options and warrants and convertible debt. Since there is a net loss attributable to common stockholders for the six months ended June 30, 2014 and 2013, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

Six Months Ended June 30,

2014

2013

Warrants

1,964,085

1,839,123

Stock options

619,663

314,582

Convertible debt

400,000

—

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

COMMITMENTS AND CONTINGENCIES
6 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

9. COMMITMENTS AND CONTINGENCIES

Litigation

The Company is party to the following legal matter.

BAM Dispute

From its inception through 2010, Novelos was primarily engaged in the development of certain oxidized glutathione-based compounds for application as therapies for disease, particularly cancer. These compounds were originally developed in Russia and in June 2000, Novelos acquired commercial rights from the Russian company (“ZAO BAM”) which owned the compounds and related Russian patents. In April 2005, Novelos acquired worldwide rights to the compounds (except for the Russian Federation) in connection with undertaking extensive development activities in an attempt to secure US Food and Drug Administration (“FDA”) approval of the compounds as therapies. These development activities culminated in early 2010 in an unsuccessful Phase 3 clinical trial of an oxidized glutathione compound (NOV-002) as a therapy for non-small cell lung cancer. After the disclosure of the negative outcome of the Phase 3 clinical trial in 2010, ZAO BAM claimed that Novelos modified the chemical composition of NOV-002 without prior notice to or approval from ZAO BAM, constituting a material breach of the June 2000 technology and assignment agreement. In September 2010, Novelos filed a complaint in Massachusetts Superior Court seeking a declaratory judgment by the court that the June 2000 agreement has been entirely superseded by the April 2005 agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied. ZAO BAM answered the complaint and alleged counterclaims. In August 2011, Novelos filed a motion for judgment on the pleadings as to the declaratory judgment count and all counts of ZAO BAM’s amended counterclaims. On October 17, 2011, the court ruled in favor of Novelos on each of the declaratory judgment claims and dismissed all counts of ZAO BAM’s counterclaim. Judgment in our favor was entered on October 20, 2011. On November 14, 2011 ZAO BAM filed a notice of appeal. On November 1, 2013, ZAO BAM’s appeal was docketed with the Massachusetts Appeals Court. BAM’s appellate brief and the Company’s opposition have been filed with the Appeals Court but oral arguments have not yet been scheduled. On April 14, 2014, BAM filed a motion to modify the record on appeal. The Company has opposed the motion.

We do not anticipate that this litigation matter will have a material adverse effect on the Company’s future financial position, results of operations or cash flows.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS
6 Months Ended

Jun. 30, 2014

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

11. RELATED PARTY TRANSACTIONS

Jamey Weichert, the Company’s Chief Scientific Officer and principal founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”). During the six months ended June 30, 2014, the Company was invoiced $334,000 by UW, of which $264,000 has been paid, for costs associated with clinical trial agreements. During the six months ended June 30, 2013, the Company made contributions to UW totaling $62,500 for use towards unrestricted research activities.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

NET LOSS PER SHARE (Details)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Convertible Debt [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 400,000 0

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,964,085 1,839,123

Equity Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 619,663 314,582

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

ZIP 49 0001144204-14-046802-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-046802-xbrl.zip M4$L#!!0````(`(N&!$7LT2S.6*0``.:&"0`1`!P`8VQR8BTR,#$T,#8S,"YX M;6Q55`D``X7RWU.%\M]3=7@+``$$)0X```0Y`0``[%UI[)@'I6;B[\CKD7VW/I=SOM M-W?=H5O$-]AL+)B%JIU[S[LM*BSA.VQK2*V@R6['#O5HX(OI$;R/.[+\T`O$ M-"\VR:S-D3_9BBZB9K:;K79SNYW<%@H!N)MW7W15J31_H\UX^3UPH:0YN[6N MR]OCE9(;N#=A,BB_15\K68U'N27+[U&7\)9V_A;)K?(;X$)9\V`LYK2'*R4W MA+(YHG2X-L04?:2>S[7L!N`W+) MK`!\CW(0,(1V$59TD0.<":*FS7++C$6^?_S3QL<66'#GS;LWK>[[K>+-\5!;A;%R,Q@SP7V[.`.P M:Q&`JV4?8YBUVG$_Z;6XJ\QR[,Q-KYO;K71P.[HE.Z7,X/%'D0RCON\3;+MS MM=U>-\&V.V`NRQ1L-X/8;AT%VWV*8+O+0VPG(UAXO5-GP7:>(EBX:6?Y@NW4 M&K%/%&QG&8C=DV=>[9"JZ6A0`KGXRN(D4R^H%2638F:!DFEU7Q#AZ5:)\'1? M4%Q^O&"7%Y>5+==-H'E;SDIFT5[N;0R[6DKF;09H"Y9,NU6SK",C&4@?6IGT M8=&2J5L^EI=,9P62Z=1/,IVE2J9V7"&'F3_O@;&L=,!=YJEB]OV%I7S4NCJB M7/Q,G9`=>^,PD"=LPISV%^8.F`@EUMB2!I^FR2KQGQ?HJ,@LVPHDEXT47;)C([=CA M%@_T0H@="_?#1E1VW'V83#8^SK2?%?+[K=)1,_-]S,3ND3?6)G>+FIH_@VCT MK3*!59M[W(WOCL'W\O'=,?A^+GQO&WPO']_;!M^KP/=:X=*H?UGT](@-1$C% M%$GW>3@`09T-AS`_;Q3)4^;@%0XDMSFTOZ0..QM>!K[UK=[0JBYEG2]KA?>' M:F[][.`I--;8066IK;&#%=)=8P>5I<#&#AYB!^N.7P.3%=+G^L)D);3WI2+E M"01SO9%R+S%\J4AY`@5;;Z3<2YUJBY1T#]_L+58V8KWHXN2*3F*4X]OL+58A MSAI\+PO?9F^Q"NS`X'L1^%XK7!KU+XN>KGTMKKJ4M-'526`AL[>(@=K#M^#4Q62)_K"Y.Z[RW6C6"N-U*>J-P^5G\4V:5$6S\44[\QK.N`O#TU@#^&0&?%;\!_/SO^+Q"E;(_ M0MRUG\`_171G+O6GXQ<`W](%S6GPW`2A4M]D.H>)IA;?/>=C5N8E#1DM=Y$E M`C-D].XGT;KG@D]@E'.'6NJHD=DGNDB)EM MYD?*Z66#YM2?J.68$)/#R-UB>=F0^&?H,1-6,F"8)Y"7#8.OGLW$C>!!P#P# M!`6$^2)YV5#8&PONF`B1P\(=,GG98(AR]_Z-;Y[NR3[=DPAD/=1_+9AYO"L/ M@%0D+PP"#RF#FNA0U1)5E8N>]R/+5+BJ6>%Z4:@R!;):%,AJB#E37ZMT?:V& MB#+EN-/&=N#D;A@5N`+10S.QOC;H5E,Z4^.@7#> M,KOO'TL9,B&U)N(#VE<73#(\38O=X7E:?ZS4=3L&5>80>NQ9OLL2A9[X%L7N MZXW/AX@H@NE#Y#X?N$^9W)T23Y[0N%]_SV1.3WQ(H][F])EY3%`'>MNS7>YQ M&0A0VH09@ZJ+03U(@\:D5AJA`A%:08BEDGU?YG=.C!55RHK4G.9IS%C-RJS& M8/]>[!O,79WZ7BS#?=^3H8-G>4PVL0+H/DSR)I^HG4DM)@%8N&4:HS(Y19W- MRMC#,]C#6N(N7Z\WU=8Z4OLU9$=5W;Q8JCF9:FO=#:K*S&@M3<;:T0 M="N6UE:?'6TW6]TJ;5ZLQ)Q,M;7N!E5E9K26)F6JK36RHBI66]?1:@SVG_WD M1@TP9ZJM=4V$33Y149,RU59C5":GJ'RD,O9@&%(Y[LS9UBI`MV)I;?794?K,=A_]I,;-<";^O75^=,#'WA4L]BGZAD=A9G>S=4 MV/4'5&$9"CGERWZVNGR[]82Z/-RTW5X=4O:O.1L>WC(K1,]^-AQRBXDL7/H\ MP-\#`,OE$VZ'$`YJ#9LYRXDOWR$.`Z/XMS,-?"H-G\P/:!9PL(P?T$1WTDGP M$!0D\WY[P4[[OJ-U9CM.XY[GX]0-+K@[XW'RV4L]JE7\C6_2S#3D: M"RNVN:,<[24X7,$#SN3AK>6$-K./A._B#T"$@ M]\3W1@$3+GY>_UI"^6H24E\F!@.<^W]XROB\*OB\*H3KJK+,/&Q-N*X8=*L2 MKNL!7Q.N*Q>NZP$<_.U?]D>(!R8F;/:7CC.7ZH^=N0N:T\#`)U_[-["I)&PR M-?^"_A=8\R_H_POWN!NZ6;U?4&^DC]2MV6_/)@M/$9$3SV)/[U3]EVZ?!8WT MUJ!Q2?A8E$5D551_-(8>UU"4F-$4X>(R*D/!/D:K4$WB[N)KV2&PMSG]?[T\ MF-,YEWZWTWZS"RV>WO<5+/A*966%4=2>%2N*$V\]#5TF:."+(CP?/+6LP(L] ME@QXP#S?Y=[=0]XGZN*8LYW&5S,K?X`,Q^&,Z/)3P@8/TL_[OS2;AXXR70)) M,2:^S:9NFNPO0TYSP*7E^-A-'U#YR8$LF400O6##N41_0\WVB$*_]E5[X^-W M3M"#E1(93!WP6U_V+CX?G^Z2UCB`O[<]*72W?W*X=[$[\(-KW5/S:._+\NK:Y?%_'^JA M>D^>1CJ+`;[:WOR.NN/>7]NO6SVR?W;Z\^%%__C3R2$Y./S4QU9;JIEZ!=.N MTA*2>5=P>FL@0X!;/)#LZ^;[0Q_>-[R7>_7TTRW0FJK\C-A`A%5.RTR"( M4;5B[!PO-DAPS0B&+^I-"1@%$\PFW`M\0HE,BD8$[,NZII(1.H)HIJSGA@?7 MQ&(BH-PCU++@1AZHFR=,@L%+`IU(YCCD;XM<3KQ+=]U M?0]&0P`37.^Y0RT%KJ1EN_?WS0J:*,Z"*]^6 M=R2\JOXNGN]!HI]JS[?*_KF?Q[E+\?_$7Y+7U@;X.N]$T+;`C>3<&PT(VF8` MPZC7T47,&9;D/]JMS:)W&V.6AAXNBB%9;P;#K]*]9EWK9E%I&*]"-4D(>#+0 MPH,_7@CA0RQCMF]S\WS5(&,ZI:BW$#)'`L&3N6H;AD`02#77P,!F47F-'Z=K MRSCCV%6VW_1D8)^`7.R>%TP!W-2:@216XA!3W/F@`:#JXU M%W>YE*%2!<1;>`4+!N@6HQGT)L/![Y`RX%5J_Q[*0/$@C-JZ'YW3>#:X"_V! MA+P;@A\VX"YW*&B6CGF`$&.^&%&/_TOMWDDB<4``(8XJ^.@ZD#,1E5S[C@V+ M(708H)6%("4VT4P,2-:`$?9'"''48>D"TJYFNP&!P,20HR4]53+45CT4Q&;C M4B#03H0/M&?F%D&4B!P_5W&#!U-BH[M17F"[U;2A%\\/$*M1.ZVO37+LJ;=: MY:!1'#.F7AFF/ICFC!F T`W0#/^N*1\"7.Q[<8LQ5``'P.),[!8LV^4\[6 M?Z!9,IA6]LD1]RB0>&^498"-C!S0"0+:K^F$I0C7$@?T"Y9;?*H(Z4-41'H- M]T:&!7_!V88!%JAL%%!9_I!3(/AL)Y2JC]@?#<*`A-Z8%A8"MT2WDBKA%2)LX&XL)F#@=W MB&O-0RR6EXX^`P8NC45NTI.AZRHGI7$:3:1L#(#HL*'20IA(IQW'&^VN\";E M9SVK)%G(!R!!N02,K0JC;TLQVHC%F1B-^L3W%(Y<7\>#6`C#6`BSJ4ZT2P%) MCE[(++(S'D3I*5+.")3EQ?(,L(I,`D$55,%+9`4KF,7X.$%)<<2&2MB8D[A^ M4'O$'+5!""`C(GBZ8>AD[U$V84+-PR<'2N(C[\,&4@X^G*K)GBEA`F?PD`>A M7^%#;H$VI\C!71Y@=AYZZ#$C'&>M#6YQ?-`LE2J,S.I3,!?+.AD4S$`58:K- M'5HEWB(*3C'2T&BA\>^^BG1SBC2EH$LGLXM,,!1JIAQ6-("E>0Q<`S*O@2^$ M?P-K!6_#ICUP&LC?L*G#@4^B2T,*!EX$Q`)3P!@@)0MD#]:8U%?N*,HH.IYY MGY*L?!?03@'\AF.5S-+!J#CE'K)^S><3LHAWVOCD/P?#4630]]2-3&TM96)[ M3Q?HXM1JBN[`DU05L74Y3M'WX1`8>?[#_08`RT$%*.:8G03'=-AF>@7`F=ULJ&J"T$;0 MRX!*KCT&<'X0NP3,TC%H:(+.8YH%3`Q,+F-/`DWLZ/FO8B;40TD6)%0H5\81 M.+H:W8_A;N2K"';)\*T?`+89:7<4Q%`RH51)1'1#I))I-GL)=%ZE(ZK,.T>I M3`/4+70DQ5X+!I-&=QE'Y6*X!`FY\)DOE.DQ#/V0_3BZAF;\Z2,G=ZP9=$*G M;3:DP)2);X%N(T+RN"`8T\-'44/_)N+F"33A*E-]"S\<:9N+F1=T#1F&!E$C M8L(#AM\STB!1\EC"$%52HFL)KLML=`T`&N2D.)VX#!'5&9#$:;N.9XB9+^"- MJ)5$;&2GR$"4U`2+T%HFV$8JA7CB(XQ,?ER+B1:`C@4Z773YI=W)UU]4I0KK M/2Z)C-'5>^>Z^E.,H>"?P!DJ03GT9I.H(T@RBQMEX1)7O*O6'W\>15\0LQLG M;IFL(*L!50``SXC"!FDR>S[WZY$AY8XJ.^9]/(C3!U(J)BH@C?6W-6A?IV!G M@9/U,$)B'$Q\(^YL0KC7OA^[2\O$=\T*DE$J'#R8@<,B`G`Z0SXI):H1J_4C M>,4+4`X0O3[,,4KQLN4*%1[!M\ZCOO'"(09'ID#H#14SX_3FP#3T]*(@QP'X M@'4G?D#,^@:-!=61IE^9T&?[5NAJ4(B,P)-^$VDW5`X#%AO?@3?@.0FAW^E! M=+#.)6:L:\!0_O&"P(4,J0.![@:9&_:((ZN%\"`,HFB)G; M`?6^B7`<6--T:+C?=T#N\%F4^>&@F0H:O!3,P95J_8`M)"K3Q$530I6+P1K9 MK8549>&U[YW9E+'WH+IL)$,+#>V9D%ZE(CJ`$GU1MK+PVR%[V25/'_BL95"+U'U8$Z%'4E.PBA5,2M3 M>YT)E;W8Z<83UC)1W"HJLNK,`4B]@LKOH:T.*>6EL.#=C)*]T`H2ETJSJF2C M<5]C0SU?0L[C)"DZ$F&QX#^D<7_I.Z+N"@:;*2E[E9(1<()JC8EF^AY'+=QS-O%7^%Z9%,`S5LYZ+ M0MIE<15T[7,16Y!\@Z MJ-1"`_ZA"2\D19G7^6W.I%[2F#NDVMJB8>!C#5J7M_"Y)#Q2R(QS?KKO*+H, M@$`Z=51&BKDY\7[NIFG.\IYERS1>XY_:,"UV8K9+%[M=:C-MR.H06:3&%#H9 M5Q`7'N<0HV$>IY:476_.!\C,\K-0UZ)SB>IPLWI12;(S MQ6"D%@ZW@^W*;\TAEDJ22M-23O*T-W<*Q20<'=):6+@35:T7.V"[-3O>(DB1E)>*W3'N/6*727.U/72K4``, M<*$.=[OQIONZ9/=_CL,'ODMEO,YDOV=.<-+'T=(C.+B3I/<.9FMOJX@C,>]1 MI_6CV1TVU%QLO/2XL1IL2+`OD^;J;]1GQ&WP=*.\S4+'WPT9K(U[/#;>#Z]UV MJ_6J1U2;ID.GD([M#ODMLWL;D*8YCAQ3/%2B[L/W8VK;T?ND?Y&\LI."2O:E M2%_B,/CN_=8]SSK%CV'EOB8D(A?ZB<=3/V"+>$BJ\X(?DI*!`$JC`+A)+OMG M^S_]>'9R<'AQF>5GA__U];C_F])/VKZ"CK[242@O[?(BY)S:XW*%WC_\M=\\ M/CTXQ-6T-G>XUR,O71$+X[TYA]U7!S42LJ&\JCJ;*/B_U%D(];WTZ5$8/+,G ME"O/UKA*'_HJ[F/,G"HWR(@GO'=R_/ET]X0-,9O/K0#G_\OQ0?]';-YZE6HP M4E7!N1>:]\BGLPMPCX'2U>2X,X2AQ:7OW?3F#N'F+1R'L`00_7?C"7T MB'JJ=G_O)!X--!?X;M3PEV@A;UJP:$4I/FQT7K_*14)U7'`X5!N"LU1%4X7" M^K.KL]1F8H76UYY=WAW(+U_@XQ1<.1%TMF=E<*HJMJDD_&'Z6GWW@,Q+:2"V M]$&HJ)";7OT*J7)YV\.H:EP^2K;E6>ITRQODPK%!9.T1V7VU@2X;G#+XWKH5/GZSO<.#HY//S8%]3+5:$/_PY M*O48_K!-SO6#]/$6#/FA\VSLX<'+KI(=_TFWO$!5E]CVSLZSLH?J*K1B9FKP MJI?7?DX:45VT+H9&+%=UF:BB>,3;=59C17C$ZNH0LSPBDM1.JYR-V-,V MU5\,PWQ9:=_VVT;WW6NCSXI;[_^S=ZV];2/)]OL"^Q\:P2PF`6B-WH]D=P'' M<69SD=B![KF4Y+CQU)F4RI@'I9$-KN[3E6= M*I)5!->$7G1;`\I2-#M+T:^779@@14/8Q6ZS%&?!C>XM!=+N;NG!<,#L(0NX5K=T`IBH:F*'*7HCC$Z)"E:`B'V&V&0KTGI?E#.3MQR.QQ MST*Z_L1J#P_ZIJ4)R]LC^K#C!R7JI`_FHK4)*0CE33J]>KF#"2(TA#OL-O_P M@3M9_J'#OF%%I]L0BV[[M;,($_CC?@5U_6'7ZGNVN->EV2:"&:RCA-6$0 ME(=H:A[BBQTZ<];KU,L?3)"A(?QAMXF(S_S:=E9Y;3AZ06.?`CFK-QR0.`U7 M2T(KO9[1\+2#;L4Z4ISAH`V.(9QAMSF'--$DPR$3Q.>6NFUJ4->W!B,*ZDQ76C-=T*Z3 M8Y/QI`4:=\2Z5KLS:0T)IXT49/;,0W+3@A(0]?.)W28@KK`-]"&SQ@=91`]8 MA!O$4[R^H;'>4RK4/L*6#_M6>WS0H80)RVLHT]AML-L@^3648)#\7I99Y.TT MV<8Y;L7]X8[:K>ZV#G'Z_[IY'`[PMHI><5L:MFD/]:26=.E<,[<,9S^JJ>D: M;2OBZ/=81F*VVA1Y%"RW4;JDP9S>/'7`4_"Z>781,<^K`9ZL8&.TM!N6ZC/, M7294KVJ?.WE#0]58U_94-^+[V@T?2_@HG5!,]1AG0<19SUIK91_"&+ZW*K7' MSELK/M0C^_ZNMX]3%(+7H^#UK&>0[H,7-L],I(W]TX7#92)JRLV"D*5-:[OM=VYPZQ^%0>R[,ONV\T[U:R\A;6[?<#;EW,=VRM@\ M&1"$0V$';8"2>E8;>X,+7T9AK*YD;T-P]]E@JZH7J1HZZQU=G$T.:5-[/#^Z M>?-ZU^?\D/,9MNOFOE0]O"YTF^R30$92=19\;TON?K57*$'Y_%[0O8/H!3U, M>D$?O3^^//W`3LZ_?#T]NSR^^G1^IB1(7:"KV>=C;7+0I:'-45IPI)#*BF!^ M@3UO7*O?IC:!MA%U)A5I77R%KV#+4%"R`O]>;^`S9T7>D:? M^F#H\/"T:2]6Z\A_[K4MPLE!X.12W!%*ZKLW:=QFD//8'Z/P[*:PG>^W?\=8 MOT%(J+,W[L$#I=<@H!`2R&20R:@=*`=N,HA4'I2XS5I@G8:OT>MO[\D&D(1I M_83P1B^0$$X()PG3^@GA!_V>T;:@Z_2Q#T1L/KYP0`^&F["\@W_OI');1?`D M>!(\"9X$3_/E1_`D>!HLOX:6.TA?B/]\^A''ZM565V=;:'+!)5>5NE5HPF^X M%RRI M7QZOO6';FM37IXSP2GA]$EX'P`>ZXX/NDV-P.+/SVRY1&#M1'.IR@9*Z63SG M-3SS\S/4SN.^VS?C06W4DB!/D']QR"?;,NB8GX@FV!/LR=+7+7&"?$,A3Y9^ MU[&=,;>E&I27V5<+]V(-@_;)`+[2:8/@.:=%=IQ!HD?0(W@9O`W!NX'AU6[O")YM[TQ( MU?X,7)Y)CZK7LSXC;17!D^!)\#1^>01/@J?!RR-X$CSIM;/R_E"U/S.79Y*M M,OK1ZHXUJ>^-64(KH?5):.U9O0Y552.T-@.MG:$UG-3VC"G!E>#Z)+CVK5[W MH*F`P5$,U0*DQWWI-=.7R>74^)HIP9Y@__)EWJP!%7DCQ!\0XLG0$^P/$/:= MMC48';2E-^2!.7H?:<^M6Z,>#3;%^-7Z0#'=!R-](7UYO+X,K?%H2/I"^D+Z M0O<"26%(82I7F+XU/FR%,218I7J/!MC&'FB1&\13O'[]$C;0.-ZW034]0[Y? M[[J2BI"*F+-#I"*D(J0BI"*D(B9M$*G(GJC(RST%VQT:]2[?51#9GBXK9$RR6W)]QN;>U$T+.&DS8I M"RD+*Q/D0U[F'\LGC,+5"U)M1&E)?ZXML8?K1\E#\7LQXUUJ2FJ@7&PXGS3@4\^ MGQY?O`51S\O[N+Z-ZQOVY?CBYT^P3_`W_)L@4/^V+@)+?V&Q2YQDLFOW;U7] MD_ODLW,G"J8\9-UVIV>Q:,[9"43K'3Y7VY+]W'GWQF+\ MCH>.D*C/S):%1130DY[1&;V3:XN#:PHI8T#6+/"\X!9W'\],AN4X4A!',K)] M)9E;.U2594NBB9?X\04%])BU(9[4@?CB=J#6X?.T/*[>[5D0,FX[\TJGGK2$ M6I]ULLOQ$C5%;V*VR2UV%I1R:_`+_LWA2,E"[@37OO@+S@ZY9Z,5@-V&E4F> M*8HM2]8"3_.#B"E41#BV4BWX>PYP5CKJ@!;>\%1'\2M`X0Q=F^^HLL*NT%H- M0RW#8(I#M=BYSS[R:1C;X0J,E(6&JF]M!T6U5FDTL-KK:G._PMI^#N!E"-8% M#ZI6B]O?T6*0G@A1V'XZ"U>7$@!!@0RQ8+.V[GZ\0',/DTO6(N/I[V!.$P&S M;>J?8,*-'1AUNJIVGT&:_5%_VS9;`!DG")41@-DIH\[#A6SMPI,J`O;I[,,I M^L]V:R"`4.VSZ\=9R"@,_&O\>`RF8I$H]C?$#C"##QQW6_BX_1]M$;)?;"_6 MU2CR$TD4U8A"X%^XP=H8*]5=!&$D_M)?+'@T#UPU>75HBUV!LLY0+#]9SM_'%TZ\\!#ZZ:`<(16 M#`]8!"[W6OD.JBOGXZ[-(:T27RP-CZXH78YV):FSR:>`U4XP$CSR!/A,O5P6 MW("IPE]O\'IP)!@\$;BM[TY!6;EBP?J')I%=18_.W#A4O&,NL*AD>2R!AO#/ M6-E:=#UA<"/`R8&%NP&;+Y5_5\Y.">!U+&/;\U9;UO"&K%BEJA,`31&>B%:M M7$D43%*"DL)%LIOL6*;O,2J%8S;`P+Y6$'K=>7,OX9L+@#:HANT5!P(<@\M' M%U4B!D!+V)1#(+*,IYYP$`FA[2:^^77W#8#I1L`"X9J%P?*IPO?9F7/N`3;# M^+I8Y%1Q.-L7<*P*AJ18",\.V<(._^#PJ[T4D>TE5H0\9Z68NQ#RCZ-9B%8! M`F4@+!$2?[YNI,/MAZ$IR>"'8/O6NH030F[+&*CN2J"XG3B\P?,8G\V0I"54 M&N"A<*J-.2(.#%FL1LU"8K1NCF+NX,6!!Z8.GC!0)09.B[N\+OFR")!REYQB MFF`I`@'#B$3[\81;3&*DQ]\*SP-KPG*&GX2;LSB*0]XJF3M[N?0$7AI]JP#W M)6;X,76LL_0R>?2]-E?\,KFRA6&$RZ43BFE^U_L1F6(@;I=@4@EB!>RDUQJ4`6KLTS(PLA*YAS M)P(?GT0F0)[UAL*0Z>B;NRMP-S6YQJEE'*C@@38)@]I`_+IX55A(=OA6<#T% M%+#V(M:N2G/W,0AG7*#"R2+/RB=?1!MFD4)7WOLX5T[` M?:`WN;P5=T[T+&"KET0X(MN"68#&SYC/@:]+ M.URIK)V,IQ)X/3(JK6X2CTG`FE\,%%>`)P[9+`Q`CWT1";1?*5^#F:$)]\LG MZ1G"1*K-3Y52)O]0ZZOR`NVU\3$'5+"2$-:`445Q%&X1J.QF9CY4/7Z(E!RP M\X`GV#V4(]CT3-IHA>X@P/2C.&2`]=<3"Y^J`/(#N5 MQNIUU(&]8GCZS=/2\%96DG=40DS!5LAMWA->9HX6KZRPJ7&9),P4+A4.R;14 M8UHJTXD29%6")+_#H!+30((A,E(>Z99CNH&[1ZG750D$F61-\W18+!-GM.Z@ M,(.08MW*@:X&R'ODR92G9&9%4QON;G;*,T`:.X5*X2;W9W6/NPQVA/JOGSY< M_06F[;OH9HN9K_U^O\&9\82;/>AC;X1CXO?S3 M'Z5;^J/"+?U1O^(G[XU;XAAGY$M,3MJ*ZVAG; MO&9^WZ&N!_U,>%_-A.69\+ZFH15J*ZT)U!XW!@I/D?4_C%\5Z2_I;Q7Z.VD, M%*K37T.X2'4O3V_C(M^['WV@;R"8L#QJ?O98T]1J0#G;1G$+4D%2P2>I8+LU M,;\"^][2@]VF*K)'E=2S%Z_Q=JI\8SP7;*9E,JNUCJ%AS9,LT[!56T4382/@A\K\5WC2>#S31*%+E4'KGLI2@I<]!`H9'^[8TH M*6WP[M?UYV3+90Z,9X+--%`[);J/K>2U#\'*J-4_Z&C%A.61"AZT"G;ZK?%! MZZ`A/&&W&8,-GJ#>DSE2E4;R`AW&L\1FVJJ=DF"S;-5NPYAAJ[N?D4R#,$HJ M>-`JV.GNOPZJ;W?SVNNCF.[X0GQ2G6-@N3ZN( M/?(E=WQ=B-URK';PIRHGHJLQ)F6<2K7-'JRPFM03A,D:5J5]+)G'XZ0&P&J]P`_6B5"24^6` M9%(Z0-);^O26_@LRB.*KEX,>O9#\\`*;_D+R%@9\IFHTYSL1S/#']*7C2U6& MIOC-)RECQ>6R,[XM=;>\](B4L-PWYGE>;[WTM2YY0E#;#Z@]\.Y[FL$K(N!8 M)_.^CZ6OS[P1:-X.$4BVV:-'`N."+VQ5+KSXY4E2]*]\]A56R\QV5I1LU?_A M@^F$IOU`TP,FY_CZ.N37R4N*F3L#Q`A?"J?XY2_/O'M@WI8T_392=7?4MA'< M`A/!.HX;E?[J2@R:>[/;H-O"5;ZH/NSUK>'`_&(3S;Q;46=9!K-N9M1;C6%< MX[T.G=HK3.1_G-Q6@U=&*WDFN0$I*-(7@: M++_#I+.[33F?8/]IKSX^:T(L8U2H^B3E?0WD==#M4"4K0](LS66ON\5IM]?J MC(R7(ID8(_F!N?(SW\@0/,V1WV'2U]UF8Y.>G)2/?,%4V5[Z&J>>>P)?@2?(C^9%Y M(7B:`D]#B.QND[N_`T_;=BL>V=2W-(TJR+;;^@P]D#-F[$ MC=\:V;H)^F((6]]MZCNIFJ]ZI-!SS4;;A$J>:WZV3:`,N1'+:SYEIPSY7G%V MRI`;Z8;,J65\,)R]7O]VTAV)STT[LP3DNF]H2_IMTDUT&4D3BAC-7S&8\Y+[# MV91'MYSKW[F,Q$*=MN3AD<0>=6QFBS"_8*E'+81`ZBS?3=O:AEPNN:,N`2.( MP%5]<=5!I6Z[Z?&Q[_+06^&TDZ6T"OV58?DP@;E]@[.$*?I!VN8S'4UBCUWL MD=M*.NIMS%%(&<-ZXF6R!=D\"KNGEAD&"V;'T3P(Q5^X;W$$LTO.5CLA#6N_ MF[;-_#T&J>!X[P&"-W.P7TBXD6I_3QS><3#A?#1D>)>/F M?>-7>Z4\X16_B]Y[8!+^_?>__?UOC/TS'>Z3#P:#7]EW^;C9L8B\"#Y<\-F_ M7GUM=WZ#?Q`35T%[^%NOK?Y^Q80+LL(.\.YO_5?_7J,ZSZ8L[)5!S`EG,<6_ M1B5?<'9R_N6471W_[^FEDM8TDYM9Q,]H5EIT.;;C("V3#&P?^&!$)FC:'0P! MUA1_#%UE$3,/X`E[*CP1K=B"0Q"A(J)D$%"Z%OO`(>`*D3K:=^A".(P-0Z>G M":[#$"20\4;<=D^X-A,^3$(`B02C&6FKK8Q\-E\<1BAGG%P2?RY<4],@GX.U M!SMOXU09J!Y&D&&X@K4K#V.QUV?GG^4;%DL\0,=\JAVPN@:(UL;4!(@R#(E.6J.Q5U9Z;`L"261QJB_RNS`%6[FKD/P*^B8 M;H14SC"_+,IQQL&.VIZEMPM_1>*.P8$)II+#'%AQF5W!$=A M+U.X@F/'DF]0"%Q[*%!HKMI3)$6`G8)88#<=#.L=KMQ?B[U/ADI+58'``CU]6S5F`4)%:N9=+3SCZUGEF%]EU++0AA0N"2I0%IC/3'"WR?3N>WQLG;N=VB'VC)=?>:@8W_.)VV"/B9N, MPL"_QH]C0-+I%?M\?GG)OIY>L,O_'%^<*D'DQQAHC8PVE1!E"$=Q&<5@P`#H M7(1*B&>T"OD">#.T%MFA\&54"&%9&L+ZL>I:#J;QGJ1&,5Q-4DQ)R*Q8R@?A MJ8L^8TY@UL"ENYC;Q9<#DAG*>)'Z[:=/-LW$NS@KE:$/(K130!]+Q_$_8P'. M'&,U/-XOKK*8QOSZ\.F@_,!SE'-)-BS-N,-<;E5^-.&D<"2L(Q)H$%T^C8H7 MNE0T2:>X8-_L?#_M*`K%-([RQ%`^D7G@@5E]-)M+TH$]G0H2F&"2"4VZ=WD) M;=*"U*Q*7RV0*0@DNPUBST6_"6L5Z=ZWV+&*(6!+/6!S4P5=G(+[71+!>H9=KBP?6DKT(!'2!`@5.U,V;Y5KH.0.6`T5_.7L M@=^IY*:K8Y]U@`$>OX,1F:J*^'_VGK2W<1S9[POL?Q""7>PLX&1T6#ZZ=P9P MYYC)(AT'2;H;^[XT%(EVM"-+'E%*Q_OK'XO4:#AB MA!ID`-DJKM8$P>#7G"?3S00LM/4]QVMQM\+#M\#@#@4JP0&P`"%R0L?:`CZ> M[/<4)9_IN9Q^OX8#.OT*)W7ZC1S9ITTCNX?:;O$ MBL8M71#'=L2Q3>GX(Q(-1Y=T570.?(O\!%ML]=%$ZAYK`/>VC2.45K_3;LD] M71"%((J4*'I:OZ6H)]U/A),C87_%"8J.A*>L,[FNW>8AZYI#$5!O,G[-'84$ M37!($YK2;NF]VI*Q>:`)3DZ%:@V%R[D[Q%-6`S@4`O5F?)+?DZ!Z01.")C)X M$UG`F<_+LX";$[FV-!IM/FSMTIM,[("F)0QBJR$/2`;/H3PX%($R,(D%])C%4^%N5"A_"28T8[ M0&'#IT^#SQ(1MA`*2<&T!1%O#MP-A(K9-"0Q2B8A].M[X?@5@AKEEG3OO2%R MG-$[%^ M0+"G1Q1/VV4AJ`)[IID.@1$DTP< M^#:;WB@FX@0DR&_[>B[+ZC]IV'4$W8RBW/7<P034FSRG!@!R%-IC'@ MN$,4N!GD,8X^^2,#OV`T"7Z@P%G(8(A0H:> M/Y/^&UIC.FT4)V_29Y/J`"G`"5@TL8V%VQ*EWX>*&AAF(D*-1>3#>RGC9EYD M8?31R-Z+$ZEB>!$[V.(E\>D)MN*J0`XRP`!CC.E%1T$!=NF4 M,1!2E(=&ECTG+I7N1S+4A$79SX$Y=*6A&7A`"DJW%<&:;ID?.HS31\:;1Y,9 MXG5`T9\,#1;#1R>)XNCQQ,9P1*T&-0OB!=F_:#0X^4(_@@3.31HWPA)7XS6H M+'U`H0L#4"F11T5&E&0[XTV(>!`DTG2*#&?NM5:4@5"(3_H"A<,BMBC*Y77F M669`'\6,8RX*1W+@M")L;:-1DA<2*<&Y9[UI(EA2&F:K22;/34?K)GD^U+7Q MQR&UK-F;9.G2#`5L!$Q$EP5;31'`V"Q"&OEO%F,1V1*JI*)OEN0Q^G0?8C1F ME7C@;`IWQ#YL")$8L2%PWPB3>:SL"I&0I@T:32SXB)WD)$9H9!6Q_R9=#I^>N75;K:C]QA6L%(JKI`"7-EB7:TY\A,6HAVY#JKT3Y@/>^$<:#!$CW(E[^ MZCQ$I@S!GNTM*>V2DD.\NJLJJ:2T\%YJ",3U!@`I,$9&K$8@1Z<7 M%!R@6(1?TLHKN=-)J!L;`G>[Z,&@RB7X27!:Y8X6SP*F2JKFE'#X5U"V'\@; MM"`#/'E#M0O4DBY?0?6]292-(24PG]+1L\_J8OC23YYF&R0D0XSY*<<#(]A\3SE)6F42DO M5L&2FN,5UJ;L%)6-9-XX&T>2/_5ASD$2R:!"=DZ2II-WLXQ-]#`+:A=9\(F& MHU+,/67Y?9CRN_2)%1K"3`^.ZO.@V&L'*G""6_@;'`/4!0`V)CL/\I7A6IG; MAWCGA!VSE6!)ZV2",V"AZ.`K\;%)CDC[>2,,M*QH.A6>I+# MB)0/(EMZZ0R$8F,Z@)1M6J`QKDE,C12@#5;:@1Q)T>C%A"`-UES,*G&U%([@ M!W)`T2J#@L,=YYH<K^\&S]=7TL/@\?D_TO/CX/YI MTT-5M''KWC`[%^ M23B2R'C#9P4=#AY6VP8SUT49NW8=7&KY7$[,2Q:RYD53XI+ MA'_YENKS>UU^1VWI"^6LR7)IT4R/5ABE=?>)_+=IG4'0RPV?[$)Z$=SLDVWM M4VDA0-'`K^`3)O^[3@M/#8)+*,]*@/Q*BV[FCK(!'KI+CK#^&;2T8,]]>;HZ M@ULT8BDY&-;ZJ])1.[*J9_S2ZTR^)X@5];M&#V`M![$BEX*LMI6>UFOO"/)C M0GG1Z[=4J:8\=DDKU`=KHUA12@'6"2/("=DLLZN5P MR>3,EC,,M0L(RU#3*0>AV^G)765-$!Y\\+D&LP>'V%`$;\#U-(CH'FV`E&XY M1$I/E_.[M7S2W0!.8!:1]:U]G8`_N9Y5N*R6@M;JXZ1KM[NJ"DP\03K M3[P$"VKY8;#VQ!G>NO?8/<@&'*262WA%E>6,&"J<:TN`EJ&E7(HK2J^K;@@0 M^WU]E)2+9KW7Z^G9C6'#KSOILF672]A.3]'[6G_EI%$Y[0=C!HH;X94!W"(A MZRXMDK^IC%7+9:RB]'6BMV0@6Q^&O8*_#+'E\EDA>J+*-1DKN@ M>X7T[K5E7<]([[))=P-P&4++I;>F$4+M:-L!>&E,;6*SW4%H]3`-1MP8A^4R MO:TI61V[;,I=`5R"0VV5[.^WMX5P!]+3RL^"MMSM=K5."MCJ_=R!S+3R_V.]U>EK:6S;@#:,O057Y^R%L`=>>YXV?D M3^Z]`,7B<'U4E9\:;;G7Z6:`*IIK.WB6X:?\&&B#<;@A/'&'F$>"NTMZL;8- M296+>Z6M]_LY8;I\SMW@6X:WG(A(!M-OPP-*_PP1.72>OVUIB^) M)5T?&PM"^QW;'US;^>4L('K=F?3S3K,N0\*"/%XUZX,?\0XM![69*[1=+FWE MG&MF?I:M`%FV['(QNQD@E[13P3;H6*%#][.G87Z.S6%8AHD53HX-8!@D01H/ MAFW=NI%"N#XZRD6EKNGMGI(]C9=,N#5<2U"DKY"7:E?ORUE)L29+DK/]8[L]U1=;[ M>J>W"[A/F78DX(D+9NMCLUQ_/E?UMMS)^A(6Y]H&FF7(*E>9B1'6UW5Y$V`R M)QDY.'9!5+D\7W!!K9IX=T"7X;!*(QNSO-,J54*$S.V?Y\#A\P;9E&_Z,125"&C#MW$?3*"&W32:E/Q(V"FRT#-YE$;N>1@'.LKG_K#8BYT6A$`F MBQ?3HLSEN-\;8MV/:0$1UL"3IDY8B&9RP<>_Z7H4EA^5P6"1;,L"XASPY&;R MZ6E39K+PQ5P)"&6CG8,;+2IV8/]EMZPT7B,PW#&X,=E=6/S3MG*C+^1&?7(C MWKQ5`F.P%N>R^,`7PV&]>$?2.+Z<9UE'V6YTF92L"RFYQ+>C2/8))!7\C_:L M#"-9%+$XZQZ,H$^T$4LFF_"Z[4=U-=R0EOJ!:@NOR(5L(_(T551`OJ6MPDW; M)R87M*2$E$`>G\U!"@$;O"-K` M.S23*LZW8HT$R19#;_(_(,&*'BHN[;YNA:SU(!'!MI\BG^4LQ+DF8/H0]#O> M#Y9%&^\52\:D_97IRB*4^,L0P+!%)OW(L`6-W`D<63))MH\F\M"85VO=6.0F MGQYK2_SYH^(V(?&A#Q79/&PXPQ%<[-Q!)B`;8E>3LB.+4Z.^4R/=8F!-V-JB M\^-\\45*`1(C@55'#@Q[[M`7#!;3DU%`QYFHK[@W,&6/Z-E$U,0=="'TW4G% M,A7&:>?B5"Q?2-\*3HVYV@+!"F^G61T97,0O MG(9PW49&+GA@(1WG$]1/A+,:N9@:8D.:P$F%-G0H(Z-!].:V1GU'$6*V/C%+ MW;3G=(NE[!YO8MV'&+&&WY\<@PSV9+YZU!-(R>0<=#G@MHEG(8>V/C<-9=NP2P;-O6'J+]/S67)\"C`1-C0BO45%#7D?OL=^A1&R MH6039LE+;#"FAAL^*_@55;L#R1(5#*4&@>F-75J+$6"0H)@D)#R?4RV6Z<6@ MFC-)@OPWT%K969"(-Y@K4P2`"4V'ZJ,^0M(,&5'G]US;^0OI9OY/+,5J$CV).88>>R,%E4=+[1`L& M%?YT2>MFF@5%2P=/GZ3!TV6NRCB+$R9U8=CVH^J4D8$1LM.HD@3HS`<)61Y MZT(*^V0'7WQ'%<=V?<;#5-ID]G6=$SP16%68L=:HL8)2OW,KO8B8LKA/ M6D@XUXJ)RA5J)8%-E"V;FTT5?\YZ[Z+R7`43QL6^@:<$[.@S>'\_EE0GF7/T/#21H(++C"*$TXLTC1(D82 M.R(3L]?`"R6,6KK>H;.&M5(KGOHWP1]+:^/EWHM'G1C^'RC(/TE6_6;8#CTU M`"?VA'SQ>[)[DXW[8B/E;P,3[&VJ=B.];94=4KJ\X2T0'TR M<%:"$D9_1=88BB=-J73&S!J+'#K@:HGHW;?Q'SEQ][OW`]Q5K41T_X@Z7<,( MT]`W::7XK)1@UE54EG>"4!!IX_2(8/#0N^"HDF':B@%1Y;6U3,G.D!H5KK^3 M%8$L8"=6)+GB@*`#*CJ3`<"#E=I-(,EPH6QUB5EI!CC&%C7D+.8^-(J@B,O@ M)9M`5PG''M.,E^Q_5@*FI3GH_+"E&5/#\GZXYS[4;,D8&QD#$Q;EH\CKYX;T M?@XL=M!5V;ZR(P)^S@&9+=M%=N_GJ$]$]&<4W_N,\F_:8+.\@#>2$FSN_B?R M$J9*A4VV)_(/QCX$(V`#X^@ZA^X&V99S5NH9\%0.`3NK%A9*IX*E,.V)TD\" M-!R/NJZTM(Y.";6G=MCG-6\YLP7VV/RL&`\,%V9DH%T,$%F%RFGR17H%EGDI? MQE'#!<^--GE,F[SX1#7`M,:IE9$&D:V:BR7+J(7YBMQV5*,_P[:13^!V%!5! MS*XNA=F9E4@S%`58YH3:@JD=BR,\KW>136,C7&QR%YX5!&0Y2:5(&-QSX38W M#$"F495IB6@`2@9SW\\5Y8M@;K(ZLUPS66HE9\)8/[/JJM;0?80F,^"2^`1. MOQW4FS:OZDT57;WXLZ2?T;ZK M><8"MOIV>_7\.SR>;?3*Y.B\3,@\W@=)&C65O1S>W0T>GLB<)B%F8XK11VGX M]?KQYF[X[8,$6AH9;*6(C4OS0W_8#"!;-=T&-R3R#]>!O+#M=C?;=GL?W8>Y M7F&%[965Z;M$M:A\=V7N4-#N_OT,6(`0.:%C15E`R`HGU&F30;:=LN#ZAJSP M=+B^J(%Z!L3E&%*R0D%=0-<=Z&,ISI0&4<76*!%$LU^B4071"*+9E&@T032" M:%82#3BB4I11EU2#Z$:HJ4)-W9<[YZNP^[PHEM60Z:6V&[0G;F M8`.K7)X/N7P\K6_?TDB0IR!/09Z"/`5Y\K]_@CP%>7*\?Q62)R>&QFXV5WN5 MH8'&ACF3OD61^G7M]]J+;*8XVM\>%BSO;_N50@^#JZO;^]_.']GD>AR^?/BE M+I=,NL+_5@I*/6E*A9SS+O>[*(CTI(E4B%->EB.')R;8TL+G5BP2V"6[A$EO`8 M"T81C+(MH]2L?0MF$4D4E;Z63 M,_6YE'QYT";5ZSH\)9U`628A=DY5[%11W&T-;(K2I(+DZB6Y$RQL*DBN7I)K MDIHE2*Z9)'<:156%Q?L$^@GT:Q3Y'D2Z^HYE\U$5TJV85#K:_QM7S7J7ON'9?T+Z@?4'[?.R^ MH'VNEB]H_VA7+VA?T'X=N\^):;B;$5V65+Y6J,=QESUN!*_LCP(V7_VIU$Y< MGQ".,:U*V M3[-0=?WY`9R1#G?X:6()R$:H)H*G!$\)GA(\)7A*\-1RK&DM3=>/LI)Q_20C M6$JPE&"I@YODW-8.7P-]QUE:_("BYBBK7N[1'2J*8C;"T!"LR`WY"%:LDQ7% MW8;@0L&%=7-A[2:-X$1NJ$=P8MV?L1S_]&$/\KY]# M?#XVC.D'J+I&:ZUE,H0_(P.'/K*&[B,R0Q_N\3\9V,;/Z#WXY'CF'[_^]2]_ M_8LD_7KX8[1OC630:-;_\O'0-C>V0CBQ86?'[U$7H& M8)(A)=-S`_+E$8U^.7N0E>_D'U56VL^>W/FNR?3SF61;OYS=&&9@6]\[^MFO M<_N[=8%\:16YY,BX@77Z=P3I^15)(\]QO!\0TA%5TP\G$\.W_T?>#@!,D;T1\NO,WWJJTOV(I1\1E4@_7FWS53)\ M,EQ",(2G@]=H5$H\DL9&9\.^VL@W?/-U=L$AWAK:#8')I))V")MW/Y`,QQZ[ MOYS!09&!Y,!E"[=SO&9++W3U/;35X64QA^_*6NMJ2\J3PN=_AR[*5+R56WE< MO/@_TS?@(!+[W.!]+FXJD=GA&AM,U+G71Q?+6B2K/Z&Q[;J@Q;P8CN&:*-YM M728C)6K%T=VO[GQ.U;.W-?1VXS2,8)^-VVKWN0DR%V1^"CVB>:!S3H[U_<6^ M%!WKZ]S;O3*[6U/[-(.]-HDL#.)]'PO3>P=W&&34<'@&\UVN#SS_I2A<$WS\%A0L* M/TX*5UM:1S]Y&N?D=*_6XKYV+6Z]Z#RH>*<9L[>)!U($Y<%GM=73>J=N#PEF M$&)0]Q@^&D>DQF&MZ:A/`?GYU7/(RO'UGZ$=S.Z](!EYZ#\" MJ^`=XE`[O,:AYL,!+W2(\#NYV%3;'0&;IS<_/AH;OB4%GD3H'`<&TV.3*R/R M]VGHFZ\&1H04)A/R&@8*D@P,5TL0)"9IMWY)LV1L6S9)\X.Y*8UORU238ZZNVUC%[CU M#A=P?R,1('98K%]0>*,7*':81YV%LQ"/(I4D&S7>!N/DC>BJTH-CF&A"ME+Z M23GIP`?NLTN6;W8!9Y/?18Y4_Y\+`\D9>U)KTJ M=:H1_%+K?M2(:KMUVKW.V(_.>=>0:Z1>J%>Z,)+T6PO1;M>[8*'7>1$NZC62W'OO=$"B;#; MZN(MQREKE\=E\PD7!0_+.R(=HEIR577AHFBHBR(]4J@.T3WE7>1$AZC60T'S MI)C^D/=.G++V>&0F7;O?DCLG?6G)P_*.2'VH.%"B3O6!7VIM@@N"GB:*5J_N MP,,6_8&'/>1$?ZC6$7&'QH8Y2VO# MB02-8S+DH%:YV$[.V5)0JTC/:+C;X=^A,Y/4+M493EK@<*(S5.MSF-,93EE' M/"ZS36^ING`R\,Z2@EHCIYBJ7&C"R]!(+P,7"@,/6\B)PG!0)\,I*X@5]$;C MVJAKM_2N,.IX9UH^CZ"JG6/]7O^"<-RYI+9DI7_1$73:R(U,8AZB2POA@*A? MGZC6`?'L!89SREHCATW3-M[Q;9NF+9'EG79+[IVT*<'#\AJJ:51K[#9H_QJJ M8(C].ZQF4=:3T=IS?[AS^4(MZA#'_L^:Q\$`'_;1*ZZ@81L[H39J21?#FAS+ MY.VU^DS.J6U9.OIOB`-[-%O<\L";%JET48,YACSZP";TNOAVEF*VJP$>K6!A MM+@;EF1C'")+LEUH4.DB,VUH&+R233'(SG@C^.T-^0'TPI,L](+<(/01OI`& MF'S%IF^_L#'NO0!)6HN^FX2W PW5F$F(]F>AVIZT5V=@8YB4SP9L&QIYI M&P$9,S/9MHPBR&LM\MHJ!FD9>4'SS&BWD32%9ELXVEP\1Q@X?/DOH3KHCVE8 M,!RM*C?R_$AB]%15_FAY/]QSWPM="R=_53Y*AFOE*>W5>$/2"T*N9)@F>1PH M"(8RR%R$E&BLMDT>L5T<^"&=R2BB8'5K8N._.>[.G6SG6^(^^&B$?!]9=)P' MPQ_Z3P$P+VVU^X!\V@PPW_]V@(?NLKZWW3,I=&WVX)>GJ^]3Y'^G0YR1G3)M M?![=8+/^BX.PN#5@S:UUOI8 M[V?`QG24++RW]S=GOW8)O,O`G9]X5S"78+C_"M*MO*XW6@&(O@"]# M<:<>P+<6H-WN:II0F<=-+@1VE6C:",AE6.T=&LA-A><:QY#:Z_2[6K\$OF(9 MM39L2Y#76^/LV1MLVPC/WAHGSVH`UY-,VPO/WAIGT$Y0IHHM>6N*7$S[P%YZ M.+CQ&/]_,C"R'HP9&``#T'+'-'43#XA):M*GB5*W`,]QE4ZD0I MSB]?5K[+=.GM9V_99FEGO\YY;N9\+>O;IE+._MJK(RCR]6P-VMF"9;0O,'<$ M"2S4U`<1^0C"R<0`N4;,Q0F8CU@R"1F,B9`@YBEZ!S)`U*#$0(GG+T`>9.=3 M^I!\Y%"_!3P_F3K>#"%JIEJV3ZS<^$W)F]*GQY$=3!X@/X.A6.B)R;Z#V4ML M"M=SSY-IR%LX=`(8\0.'""]Q`.Z+:)E3XHYZ._)4##0<^3_`[CXK',W_/9!>K,Q.,A6VN^2X=AC]Y5@>3UX5;CJ(%)ZRW4Y+[]5VR@IZ%?2Z MV7';:;?4]C9AX8)>!;T>GEZUCMSJU]>!5-"KH->-Z%4G^H#:.^D.>!R;,Y5? MNP1^:`:ASRI(8=&G:ILT//[],Z)1U[+KFYY>FVHI2%Z0_,%)/D*+KO#OB!9D M+\A>2/JZ=UR0?$-)7DCZJFT[;JZE&N27.58)=[!6@,U03A&5KJ"8P3'"(Y9[W)%Z;?(OX)C!,<(CEF+8[J]7JO7KRU6 MG0>.X<1DK?;JL7Z3E0?O!`_+XT'T[3]=]7#+YS*;51"W(&Y!W(*X!7$+XF[F M\@1Q"^(^9O.JVAO!^^+.A*+:'X?+XRE4O9[U<2FK!'D*\A3DR?WR!'D*\N1X M>8(\!7F*M+,\?D2U/SZ7QY.LXCJT6FGUZ\N8%=0JJ'4C:M5:FB*JJ@EJ;0:U M*IU6IU];C*D@5T&N&Y%KNZ6I)ZT*<&S%B%J`(MQ7I)D>QI=38YJI('M!]HA%^M`<7B M'DSPB^"7]?FET^IU.X)?!+\(?A%W@8)A!,/LG6':K=YI,PPGQJJH]\B!;-0( M%UE>^`+SU[_#'`K'90BJ*8;\N')=!8L(%N$'0X)%!(L(%A$L(EB$)P0)%CD2 M%CE<%*S:X2J7[]D+#(>5%3E_,3"R)-.;3)&+#2@QB'JEYE[<4%D(-\'0 MWPXN+7EPVJV'K<).!%JKTY<%LPAF$@ED$LZSN/Z!U6JHB M0@X$LPAF6
0_\L9@2)" M$`7F@R++?_\HT6?.'6/FA<&'D?V.K(]GDHDC.\G MGZSXT\_9CW[Z,8;X7S^'^'QL&-,/3^8KLD('#4>7&;OTTL/!C><_O1H^^@16 MZX,Q@PHT`]\WW#&"CWC@.)Y)GQZ.T@?G1\&?9@^.X3[#S,_H/?A$7OKCU[_^ MY:]_D:1_+0*Q..,/P[>>P'P>TJ*<^*OAA'3T`<;AA/TM/SK4\PS(ETW+GNR;3SV>2;?UR=F.8@6U][[7/?HUH(=ZD)^?9(RI%6/-SEW?7@\0/ARM<\R<]3_#QM4R:ZO;^Z MALGE"]TF3+$U:&?%M+H','<$Z?D522./D-,/0MJ,%R2RMQ/#M_]'WOV!0*`B MZ]QX0[XQ1M(;(0'R=YI8G!*!%()W9>3Y4?E6S.JWDK\%GA37>B436[:/S,#S MV0!I[5R*0FV7UCBHG0'A)I?G,W_/9!>K.Q M349;*0Y2Y6^'A8]OX M0P'!`;``(7)"Q^H"/I[L]Q0EG\GA]HK3[]>NA2QX^,7_F;[X[]!%Z<^:W$J_ MP,DG:.9$%BB88FVFV,9;QA_"N+RXUU;T#O[FWR\/_._:H$_PK^W0?_\M\7>?_\RXDNLK^@H")=Y-'& M?YR/?(0D&Y1(A`/)-X+:ZN+QX%GG87FBJ.>ZHNFB`6G:C=(M!`L*%MR(!>6+ M/O^518Y6/:C657']/D4F7%PY]@A)/\V0X>-_Z5P68*)6&Y[-UR.4*W'8$%/H'DRYY81(&EDV#[+K^%>2VRFK*I4">9+ M5E5KQG0NU..T9!I$HX(%3YH%%?7X>9#^=>2Y0;R0'(C_F(/Q'ZU_8,C1_,<" M7)GD6QB-3K*N)G)LF>;[2/)>)X4\FXN>'7U@!O:;'4T;/[X4\4&4 M$#Z3O!&KIA=E>4M&M)F2C24#1WGD6*1LBY3M`QXGV3P\71/9J<>?G5J@#MV' MDQ?DIYCP1O!CG(%*CR6<_&"VR5 M^S,[Y@2I'0>IK4B$CMTY60H8,,]..2T];'DKQ!^&!)$4R:,U">,130S;G1,A MET07]@US[NUGY$]2S-HY6?4?B%(6U'0;H\^79KCCXYM?$A?=6HYZ>QLOP01Q-V;WCZ(5 MD:+5UXJH0$?_C97#K6OO^8TJ:.K]NRJWB#@0^]F\^`*^=.EJJ;3.N&Y^:70_ MZD2U.]<@)A0R1I`GQ_MWFNILM2[G2\,UD5.?/LN#+<.5J;H1\_Y$E%==5419 M(T[<+,W57JNE4U6[4+K<[Z(0,5SJ!_SN'_]"1I`G/_MWFNIKM=[8&\\?(5OX M8[>*F&J">?J3TFZUN^W:-%R^]K=9OA.^--R*L_CT"W&)(#Q@Q[9__`L909[\ M[%]#-5QNG+%S\;_0;D_29!K[NTW'R:,Q;SAL(E]O>+#2;W4Z(AR<=Q[G7B>N MN!!6MPF%L!JJ$PNWFA`R@CSYW[_CUXFK]?#6O]4\F#]3)"WERHLA6Z]S]BG"`K);PZAZ35W_-6KK//`+)]IZM:[OJ&H^[9$BXIJYE@E[B6O> M6B8(#SD7RVN^RBX\Y$>ELPL/.9?'$#^UC$]&9Z_W?*Y?9^>!7TZCJ^AF?3^7 M=Q(=N(%MV4Y(WD)/R`Q].[`1OGXWG=!"UHWO36"F,*`3#4?7A@]ME/`#\BDL M.W06[8C.HH<"Z?D514U#(7=UZ@6([+KA.#,IWGH))WLOO1KD^PM"KH0B,I!& MA`ZD@(QBIL0`74KIZ^1W%P62XV$L31&QDH$P)&R[)H)W;%\B'YT0PSL_O-"Q MR."2D:$[T3_9ZBY#,Y MQEYQ^OW:)?(O_0K.L?2;)K=.FT9V]X]RAPPA$HY')&Q2U6%5I]$MO>&-6[H@ MCNV(8YMZ'T=!$H3HZ$_464%1T)U/"JN8R<((F M.*0)36FW]%YM$30\T`0GIT*UAL*EY[XA/P`'NV2AE^"4U0`.A4"]U_3D]SI[ MF@J:X)`F1.C&_-EP;*$;^PJTF`_EN(1S9F2;1H#P<'2%IAZV@T%P:?C^C`SP MU7!"E`_.&."ANRPHHWLFA:[-'OSR='5&3B_3)J2$`26_ZCHA\G1QZTR]'W`5 M];M&XTFT/+B]JL%=$G`#?\6#,'CU?/M_R/KB$N++1.$\.(:+H[!Z].#;)GHT MW#&Z#R#@DLZ]-,7VEE$=47>_DN63UW//@ M7B'??C-`L-W9QHOM4,EV&?H^R4+;52M*AUH$5;13I=#C"CU8&9-E<$L_-R]"9L]#:2X0:]^*'AS^`T M>"!ZN6T.1R,"E#N.[_)R&`M?,%'2R/-/!@VW!9F^B*T.5YN_+VE1":K*]4D> M4+6-^*@$5>6ZK-K3>KES^C`(JV*A?1X7NA]YDUNH(LO<4_\6@F)NC2O52QZ. MCBV8?&Z9Y1KB`8DVM6ZX49\5N5Q1Y`$O=>C/BERN)K:UCL8!:NI0H!6Y7.4\ M-,GLOIYRI9"3K>9%A59D#A3#"B1&-;@JUPQYP!4O2K0BERN7FC;G$SX,QJI8 MJ5*N7-:TTBK4:*51AC3NKT4JY?LG)\;&S&JV4*XI;$:WI^"\?$@B&HYBG M+AT#8WMD(VN`%\>99;NY+L>#6A$>5OH/=U_50?!3%9V4:X<)G=2.I25I[]JS M5SF*RA5.O:O*NZ"H&KSDR@%4A)>5FN6.&%F43;ZJ$.15(TLMUU(3O]G^!'F,]F2P`<;AA-VS/]KXCQL?D14&R$"387X<+ MY]:4U4>GH8^RBVH3$7,ARWTU)8!U(:ER!?NR0;Y_MEU[$DZR#]/@AH*M5U>C M2>X>*YJ,]W71I*U$DZ+6CZ;EA7P4M;UZ!=U.-2NX?I\BDXC0KYY#)`.(A"UY M6B]9@WKVJW(A]\M74`Q)M6NH@ZL[Y8B2+[KZ,2-J?;[NKJ(HA0]$E7%V;R57 M]*I>PS/R)UOP<__LUX?.?]8##J:H`J0:V%,C2M6#\EF5KXYEZ6LSG*:0I;?_ M4\_B2YA(4W#)K>C!F(&E=>/YA6/-;;2: MV>AE:RAW6B7H7F?V'*1IND"\IL&8Z$KP_BV9SZ9!R5>+$GX=F#O$""-_/9?5 MMDDST8O(2L=BL>BW1)(@2]D"RVOD M$[3GQ,1F,)7O2E;?I[?MU@/RH2R.,2[*6EFRBK:\2BG-ZBGK0Y#CPM]\#^,' MWS,1LC#DZT1'55HXT#/'")0V[H/T(&9BZY)?761;_B#21J6U]3 MHJIYB;H56#GTQ[\2U$772;7Z[L-]M"KE4_+LJ4@'S4T;KK MJ<+54-WZ"?D_Z#MX+1X11C`!LQI'D_E6(S>&0`):.;XH[2`"-YP%?9NW!C">;O7\6M-BRN4N1.C[L M\7WZ5%63%$E)S19%RM9F@5S6(XG-7U77N[NK';U$>"4DUQ8GSYKJ0-SEGABO MB+_B7-BUW-G,Z@T79!UBQP56PZ+[RSC-VGF$A,3:TL=XMM_6&X^(8^*45M>U MF68-"DI&[*0/K@R(1\0DL;,!M74-\Q!0]"&(72%H?>2HHXN,:9BNJM?7'9IO M[(E(Q*2.1C$&N#E3&PR1C!AU>`='UZV9,S@B`8^<#OL/WLK6#D!TLV9HL7!7 MVR)>,=S,=K@H.6(C/]F2I1UO[0],Q"VQ-9]LB=0@P"0$RQ$;\N'D''?.MDCNV&JNS6;-%;I73K*,%HE= MF&VK1EVYSX9DT2QW^$@(IZW3D%S^"-"-,U\^3(901:[-XGD'2>GN,RHBWVT1--,UQ'/0YY_>O& MJN7B]E]@8C(5,= M31\GNFJ;IJT/"$;$F:Z<49U9,\.6!-/NJ?S62X,%+@X4MQ@?+D6RFU#O`#(,;A%;;5G<6N,XQZBX9633D<6M3AW]Q+A%_);=-HJX^\O)SPRW.4'B M]0@6=--OF!ZMG90\7NPE-HWJ#F1?]>"T'[A12=P_8[HJT2Q:G]FN4X]27A&) MWZNB]$8NO=%[;P^-8/!- MM;ZX>"2Z$Q+;W.!""3C[''H+.HUP>-LDO=&23W+#^WERJW7LJ@^OK&Y>6=8? MD%>5@,WO6:_N7'JC'>`>UADST[7/DG/7\2.Q9`A]="1D[&Q%[.]YQ(Y7PYF$ MA3==U7;/DD=T>\83#)"QZ!@NR9QDLG53T\Z22_-U$H0#Z)LF$=@:6&_0SY)- MQ_9QU36)J+AYO<[Y<>?V*>[+'8F`VM*MLY:=VX>$]98>B6#0#6!FSWYFH82@X/O+5+,(_0_RZ^L+XCX]&-7M#CFJ>A)P!0T2-GP1W)IHV MP:U>)T`_2-RFS0KZ[IX26NF M&HY;2U%VOW8X<+^^7ZW#^)DQ*F4F;)'%]:L,ZWSFGUR!B?G._-N8#MDF*6=Z M>?S_5^&9F_IH?)FNFKM/\8(P[YBSCLO)--VNG\<_-X9UG//HQ[*NWL"V/CMC MEFV?8>C')>D[*,Z,02TRQ?M8G-ELYIHGI/4ZCDIR+^,HS<,,C.\K,SGB?36F MH9]2>X:Q$(/SO-4""2V;'AJ?>K@ MNK8"U"!4'G\/)QASW;=S3/+Y]WORDZ&X_?_(2?XAKQ/850JR.J]": M=\:=@(37PS5!@&=UWHO6;6O/AVN'742Y5])$][#MN'%T=!)>"\]$'[O2?6_DX5_ZD=^K$GUF21#[K2/RC6MW>LA9 M*S#>?ZF:.9T=PL7AB'I]_!0)HFQ7&F=JG@D[][V9IR&U_I(WV0-+;A^\2`83 M?8E[O2NUZB&\LJUT-'VJ#V$"AB;YW.9")/BR[8'L/_A4%*^O=2OA)PJWCS_N MN3]9MR7.G-N&:5M#Y&K[X`[-C^9T])`OF;Y'S5X%PT)NG*0Y=NA++UHP/%7: MGR&.3)1@A@R>CY>@CY:/MNQ1.E8\>1-9A!J[KU5N!RL`TG MJAM3S9$U>(,2-;B0[@AQ!F:J*ZOUUO2@$']@REZ-^=S'R/8-%OL9Z1Q6SWLA M\]DOA*JYO8'8JLDJO7N8?(Y*WZ`IZW4<<33#,U>79*X[K?H!G9J:$>/(@9AH MO(R$'L._/HM[TKE3"\T7MO*"B';E15D"3,N]L.=*Y0RO9S9_T=IX//3'T$76X^2+M`":)#PRT!6T4 MM..N['Q,^ES#H[L2JQDS;:9VG@,Z"O?)6:.IFU5N^+NHB/T*OU_&R0IS?AJZ MOB>8QM^]^=>5N57"-G5GP(7#5\S%RX>`+4$/%CGN1[]9+B$.3>JLO`TR[&9X M!5;D,?#!?^U@J<3RB6N?&T=[9Q]#5\5_+ MTS:'LM7LW`TW!DDOP*[=YY0.99CA@\1%<375MVEPQ.-1A>8`CWC[%/>@7IP"6HPY( M?H%R!-*Q/VL/XCL._JK&T,0CSF9OVJX-6C=+GCMM%YSEPV]7>IG!GMI5[^7^ MR`ZEL$IN^M-HJ+(K`-;4G$,5'[LU(=7::'QO7`WRYA&\ M&2]L@V_X]U^8GR_P9H5-]^?J-H8V37J-)AW^V$63S&UL?.]7'T!2UV$TXL?- ML^65$;M*!?NHD=Z9KTX[;VCJ@M6F;<.:1[:Y"./]]T68^\S_D,0KE(`\*UC4 MOBMSOHKS2.K*];*Q>"/#/>[E;Y]W#[`5^!DR=ZQI,\/5]-KFN$%8\W+\WG/2 M^'0\E[F<33.M^CGE,V?Y)09#219`MOF.W35$_5,'G.VLZALP=;>H9 MLVKG-0,O(YDR5[VU+_,\ZYKIVK=(J`V)`X()P6A.'T]IL M9M1OB#P$.(6JD$\OO/2A/-)>A-Q?6.A1;O$N2!)F8EE8SEG(H!L4NF@9QD7&BZW7U[H?]*EHD#'+4=XS_]RKZG+"U%_COV)(E M"?.+&05UHR.#\S1E6]FFS#R("X83S*#UVC&C?KA&I4XT4^**X$0S=$VSQJ=N MOB!M2S][S[A:@S9RL4ARYG\*O#ML(P.NK,?D0;1OWBKAQ6A.4![Y)=I`CE!E&.5 MB'^YOWPEF$!='"A,#%?7K7J;[N,`GH1<'77J4VC/)+!:1!-CSBZT"RM?JM MA^XDM(IFK2N<:*K(L,3",`O&_)2GND?F1QW7D]7D3_#:XQ$*>-UQ&Q@O#_3# M^05".FZ\;I98K,#]OI?>.LB\\!.JV,U=&-SWU8>NB[VT^B:K`Y`,3X2(^1V% M`+U>R3J"B/JD85M0W"IXL[R,5ZLXHJ)>#_Z+/;'I.I96;SO<"6$HS")V2_=U M/0IMZ;(_Q`EE+Q^"")YO&*(>_!;[7D>U#'0PSKKCQB@+,D9+,SL]F"2^DU`KFDRQNS9FN@7S.1:U.!2$P?@?#(4? MO1"%@V^';0=U/6:RXWHGS5(;'<8 MS3V'1:J]K'H+>D>#>]MQ+-/J@MYZ_4"8]PE.Q[U(UDP'M3!Z8J;2^XM\AR]-I&Q\,!C4./2`DZ(X`A*,%@ MF,?&*5BL(DI&$U>)L$7E@]T,.O=UWP8YM;%(@AM$WN37+O1<4")LQB&H>![Q6+FY\3 MEL(SQ3)S$1MX874=1(I+:V&0_:?/_PT__+QZOI'15UG\+_O;Y0/-]>W/RH: M_OLV6$$T?,V>E"_QRHLN^`<7RE9V^4UG"7G][/O_QX%VVWKU?7 M[[]^O5!NOGR<7U_]8WY[=7.MS*_?*1]OKJX_*I:MUF_^#?3K-8*[Q+8\B\Q+E+=!G()T0F()OX"`:JK\.V0S!?J9KJMO<*.% M%SU7GVAO_D,)4L53[H)X_>`E*V_!\@SU#`2;?@H*2G?&\"W@JS4H@I\JRSA1 M<.@,8K6,C)D7^0HH\CW^+EXJ"TQOD^F&<%4V[4%`_ M+FBHR%LQ?!+_+F`J3Q[0'N/[4^46\C)O3>@JZFJ4%3^K4S95;B)EODZ"4)G1 MF^!]Y6B,5M]C,`L=V M`8.NR:6S\%EY8*&O_(P+]Q&\!UZ2K&.>>P"Y7@8\3L':`!SD8L%P^-O21@$,``"Q]R$)5B"M+I&")[^_Y_ M;R=7U^_>HZ"J4RN(WBA_9!W[@HO(I%@@,2BBD"XM2P<"V$H/0A,3Q1FC.:LK M7E,\:O*C).23\?F(IE6H?!GIZ+XR:PM>AP$BU'SVQ_=_EZ?[OXCR1IB^NU5T+0\3-`:AB M:9&6<1C&3VCD6C3^J68#J-GMMBAHSIL4[*?G_Q-\!MALF*J$*2'>W$7F6_G) M\X,4Y;RRKW].Q;!3@1%"FM_]!N9&(6\9\?-/H"-)D/X.7P:K(/0*S8]3+-/.1(\P68HW29AZ73K4*9 ME9?\SK(BF`FR=#,*J.OFG.`\DSMZBB&F1\3N]]X/W MR)0[QB*8;K;V,$!$[Z7<>2GH`(5J'MZ]PHI_-&+5(`PI&PRB'-Z%0?5]7!R< MA#@L*L3"*_)^R+\]"A,>6/E4P*.WS%O@-Q5D''2>-@"L0EH(N+,$ZZG9>0[;6C\`^`'E8A1M$FG(`L&7H'( MHSX7*L&6$`50=(H9NI(4]TS6@]A*'V#`"\6G6TDY].`[!K#9`X;B/KSE[WG$ M%$,M,X)[NM017P_FAF5@\%-RRMX:%/$[G08$,'^Q+E3=O5!5M0F?T:''8I*" MK#4WH&GE\"6S`16^@6TR&_@OT,-P`UJADE.0)_P\SC#`4S0=)`5B`7IBF2=D M[^J!$;8$2OR2X%UN#;?Y(MM@,L`*U).E?8ZPK%(""8PZ7S":B0T5(%518353 ME%W\MO;0#E.4\^.]CX%7R%1(6K>.9%!1?@]:IA*=$.>)1F82FE\E1%%BU`*>O$T>3!E"4^S0/5:[RJIHMI M*P:A(;R.^P7RW<.C4PB5/BF(.)7>!<10!X6WKP(-NOIZ>8T%?WB_??%`W8(0$N["M*4 MBE@U>%_?7QX&;*K,B6W`I?"9Y.5YRP[R>(`#;U*TF<6$T3Y34(5GI>(1O1[U M*&39[FK*5+GBS,?R8Q'C@%WP>`\$+K\;[2LI.416$K;$*@I14;?F3P\!!C() M&6V(0#R*R6M>I(P2O"!!,:O6%5H5S*:[WPUG'9=5DFR'$C4>XIXE+0.PXXW! M!:_;9ND1*LY-8@E-]N&$9*-B:1#RU&Y!?AX)+/*@8MP_'>7ACC)EW;YIIU:D M#W$>^AA<0?Y!%A">^0W"%A+3RE")_&1AL;C-+TPY1FU@SPO+45G67:KR`0P) MD#KY[XVF!2G6#IZQMQ07J"UW?E&H+:X:+(.0U6PJ6#Z,AG^B_$1SN1#^*5-] M5_CPCP#_^+QQG5B3KB^X$OZ@6M"[JY-G:3R2ZQ;%TLUD1=25%Q%)/?,N?4W] M^X",>`R>?!(_1446&_@!&&]P:F#MT\WR+O<:)P![TL3U(Q^*@&799Y,WX)$L6[ MT]4=O-?X/8XS5;XT/]@=0&QG/50EQ_90/+C!9)0T(2._ZS,*2/#/OU@6UE8V MX1ODSBS9:[1#VD7H5?M;*+P$PK:U("GWQ?!%N%9FTNTU,J6$@>*/X9_'^PTPGQ=V@EJJ`)$" M!"#LT0MSKU21`(0N2(JB8I13H@8?/SU`VO8(^.#_D?T'1:-$B,J>BR!9Y"LL M8>+:8YK?P^?9IGZ[*'9#*H^T&Q-5(N*%5L@UG@DE!4*+&'O3W86L56HL`*8; M'NQ#6L0[RQB+A65`4RQK$9\W93FD"Y.H*JGA%>B`P!&52KP`*T&T\G(8;>,H M\K\VU1>XU/'`B](^6X20:XNBKY3.0JRI`R]M,,!R*^Z[`H2X0X[5WD."4.V> M"*DR6P5B%$;"%#,E#'['XAY9-V1I0HW.-CE4Q7Q>*UBC6%!M)7PXO2]*0I,0)4FN30 MHSH86+D"+`IH5;I$(['A7:&1E3J%6Q3?/=->HF1%=V=4HZZ3^#=J%(E.OF@Q M4L85O"RP69*Y>^;Q]GH=`@]PA83;2_8=3]20IN*:S5T<_UX@\:J@O48>AOW' MJ?`%ZC`^O1'V&B_*!_[4XQ/J,1UEFU"/3J7>I/.0D#E/BX71MZ$'@WU=0"*' M`D!MPB;HEW`Z5['/0EI&\L)%SO?UP#/WN$-[XI-"-CP+]VI\$,6C3<7UTE6Y MP;$$3(N(48HRQL@6L**3*NIYV4/[@I2>#U:L#Q>%K?7F!H4)M6GEP;>)Q'I.VC;A3>ZTIJN8(D.0_\,L"N=JLKF\WHN!@1^21Z;V-<@=_Y MU24X*LKNVJL!'^9?W_Y?>\_:G#J2Z_=;M?_!-[NS)ZF"'`R!0&8F5>0U)[N9 M)!-R9FOOEU/&;L`[QLW:)CG,K[]2/^RV,:\$B$EZ:G>&0+M;4DMJ22W)1KN3 MOA)XI"/7-NJ5>LF(1=K@+ST^S'.#X.!E"KB4BLC$A`OEAAB<#I1O.9$-?3,B M*FG/9)C[`+Y"TD0X\"')IHSV,R0BEAYQ!/!!0K)XBE&`YT`0Y]XR!I.W$NRH M8Z=3"@Q]3+SZF,!R*.-WN>\)=RMOUE[FQ(A%A$L$A)NIZ@ M9N(Z$*F0TFPJKN]3=V;QC(<*-LK7TC);G&B@F)_,^B))[5XIB2:->',D5*QQ MQP2>IL'RW=#L0R-/36K-YCQDO*F\!;E;FEDSF4;)QDF^9.*9_*F0SAG+U%OX M*AR`C\=AY-=K6?`R-,^B"9(.@%J>O"*>=B,93W@B2P#+[+E*5J\),NE$U5*] MWF`A+Q%*2T`"$S'Y@]F*:1K&*P?RM73YFU`2(6UID,I0'_-X,4BF@!2J2'6) M;8%A)"Y#OLL+3XQEL$RFU'-R5I[&F!X)6#]9KL?L=J2)2-Y46;B(*F2W]%M2 MS[FJ2I-G:'*,.93P:!ENOY-,K&H7$((!<8"6]-_2K!"^PY%I5 MUK[09_1-2[%:>Y8-\&&&T3@`?XP5AR<2)(I6>"+`$)-:N&7$U">'AP6[17VK ML#VL4"25E689/`G1N.+Y`ABAG'!M+J1:ZO@2.[WMN(86YU<2(%4,KWU^B"/! M1#P,S,,RHP[XK9%'I+O-LSNY598HYR0>!>0`\N($Z*XF-BQ*>9BK=_BK*>/T ML1'O4,#=ACPH#L7-;;P)#$L\$KB5,F/_5>U@I0LT<4L5L\^ASWXYP#(NM3`B M,?81J8`(%S_)].:]?AG<7'WBSRD@2?).*YDVR&P]T?E?QA-[Z2?3N>7IN*(( M"20'KBOZIH2)/V=%?.)0A`EY$@0!:ZW7(RRG<`$$7(]/(,GH."XR(2'CDZP-H0TPL47@'!3469[1C(W&NB`-/ M)2$[26+:+7T4JD+200QS+1JVNRYZ?TP=H7$?8.@$L%568E*,MZP@Y*RZ.0FM M*J.2AUFX&@L*?;')?=QA8!J>ZNLKG!Y*OV&YQ#B8AH!3J8JM\,^N>Z+"0,4N M@1F0FZW-1$)L6JE-N3U2'859FP0S=KD;M[?#@DX-\7H*#'DT660+7+'OQ MR:5CELN"_=#3O#9@%\+(X%*8%!T_<]5$XQ\FYS[("^/')!5UJ6C#/I[$!W`D M@G$;#I@#G3_\ZXA%XW#ZLEDQ]MN=K_*/`VY*@)S1)\'6:N5`R&`G#/:LK[2/VM1>$;CKI'JA9"B\X&@6[>-P]D'B%L>O!K"IBQ$$4TEDS M)0*FJAW(8`5A`T,[<$=J'NKTLTK1*]KZL2TGI`S=:K\/`QV.P?Z1LH2\P78# M\"59*MZ,*7S*O%^\UYXMT#P/QA=EPSQP[4:@V1Q^LR56FWI>R\R*P*F-3WB8 M,PEPI>1$:%:N+,55AMS(.#$CRIA5D-LU9AUF7"< MA#]D;@-_5B2(NOZA<6D%GHN\X]`4,_N`9'P*(!@24N"X$=YH1C*BSM,"&61* MCKL`,O%A9M?>N4==_(!_P%S,.#/ZJ%QU;Y^,'YOWWR] M9%N;_%9`95=H37R='_A2;D-^)1;R99)$K_!J?B#,:%8K:8W3#^AX%+(\C$3# M*;7#R9=JQ7`2/CN/\8[9PQ,9:S'5.ST>7LP8%+D`%L'68ZX M=1/WJG$/OB159#P4-X+CD&M/F;JB^M8[9@]P'2W`^]?UQ>,7G!8U\]G=P\7E M0_G\[N:F?=\!2&SJ>=8H)"NLOHPFYV`$$H;?+Q\>K\_;-^7VS?4O@')$1\HP M)P-J]8>4JLKQSE.'$S\<\J>JY4P%'WN467ILI+IEG@!,XN*GN0BYLSM^!TT%.VG^ MD(@DQKS4P/72&(GC=K7M?/'F;76K7KXO5;$OJ=R^J3T2>Y@DQJ9'L/P9<3&6 MJT)5;>9F]AMD40[N8Q\"O\0)9#0]G2T"[ M-,[34P8)9@2+R](\]CH>J^7+?KPU:G'1S.OI!7I`J4%%;DCO=C@>B=!?=S*E M;UZXNXG%KIQ>!3E.'ZFX2\+LVB1WGV?>BIRJV!IAB8$A=_S2(N.ARY:FY-A7 M_G954Z8DH@_U.7&2)AA*6X_V?L]/D-WI0KZ!"\DL.GY:#X4BH;D$<8 MU/QZ=.`Y:I)]:8D+P!,N7<[F?H=Y&VE!%]9>P#^ M.!9/3E*4QD$>?4:`^,.L>F+"Z1[7. MC4^9Q3Z5/H6XS">!3D8S&NPZ-*5ZY%TJSQA-T@=F]@E4TQ-O2-^R)X9LN9S* M4HP%6KG^5_A6&`()TP+[*Z4U:6=I'GU0L_;[V,B'U\:ME5Z8G5:I5-(4DW02 ME]"8)!SW2V7%>R(`17L]PC(:4QF=J9'W?.2=')E'2=8B57E,!NDVSRW5XQSL M9_"+V"*QNVDL8T*0[R,,3\J4;IF$M5:@Z_7*--#I3(TY#%E3&%)KNO6$J=:V MM:D]9>F'2:=/M`U"S-'!8U>$;/+JYO*S)S!%T)T*IF``N9][@/+#4RFNP=0! M:T9RAM).*)6K.">QX*2(6UET/MN(K'+GZ8;T\-A."2^*KA(:4GPK-7@4XZ4, M;RT()-V!ZW9U<_>O$P/SO6"RA1$CP_+`@/MYSP,X\\)'7RZO?_F"Y*R.ON?% MC11486J\BI$B^/CO&X"-MR1,DR^[+8!2^_R?OSSA0#/R7`/2X`DBQ&Y&?]X[,-82S"HWA.A`4_'1V]_AX]RM`Q]_@9YBC M[P:[Q!'L6U02'!W_L(**%Y-$,\UZF::JF48SS:I,4]-,HYEF(=-@RDA" M,I8[LD-\H\U4;::N2P\4`<&WU(,[C7_EG1!`[[#&7W/X3B.H.5QSN-YAC;_F M\.VZ71Z[_WPE*6R;D,TY73=)6N;T[?GB[=XNAD/7<3R2P?!H@^)<@`W<)'H! M=F@L$G[KUD::/35[:O;4[*G9L_C[I]E3LV>!]V^#[%D01^-U/M?1(D,-F`PMMH4NN:(E@KTJ5` M0:X7$ZN0-K&6%BTMA226CAAK0=&"\E)!>6/K6PN+%I9"$BM?6(XJ'_UDF=7$ M/?N,\RX[:?+GD+L&V^@E^F:-.ZI7]?V.>D#M&72:N>CJIU--'=;@IJZ M-:EFN;=EN0_8V%2SW-NRW"Z969KE=I/E/D9356W<:^/^3750$?`OL(K>:?)4 M/@9]-']H\='BH\5'BT^AR*/%YT/@K\5'B\].B<^[*!=_I9O\KIOH;EI4"K#] M;XA]T;OTO:_=U[RO>5_S?C%V7_-^H=#7O/]NL=>\KWG_+7:_(*[AZYSH>47E M2Z5ZO.^VQSLA*^OC@-6Q_RB]$Y=GA/=85J[%0(O!LJ0X*M4:+TGYTQ*@)>!] M2(`^"+08:#'0!\%N^(^;ZT2]3-[VQVQ4_?;U`05CG<+19Q=;0.Z$::)E2LN4 MEBDM4UJFM$S-IEJM5*O7WV4GX[=G&2U26J2T2&W=)2]L[_`ER/<^6XMO4=6\ MRZZ7:PR'ZJ:8.^%H:%$L#/MH47Q+4=1W&UH*M12^M12^N4NC);$PW*,E\:TE ML:7/Q*6#"_.ZO?>H'\E54Q3XE"'!I]*G$%NT?YI"FX.%$^-D"]!)D7G3?>0W MVN+]E$AA78@^?T^'(\B?&.`2(\(LSS[+_*'?L`?7@ M&SJ*7.H;H\#%=O#&D#K$,RS?,:PP'`_9C_B8%<6KE@QK2&$H$(P@H(&+W"56 MFP9^[,,SW@0G#R-J_U$"I17^4>X%!(&-`(LP,@)`OF0\40^0\-QH4C+(]Q&Q M(\#0JN9)5)Z;7.X'=DH*8\BL6&Z1@AVJ&#!?A?)J[X*/%M=NZ* M:9P$S#"!S&4/@TT5XC(X'+\9@,5-P:("%DAPBP+`GM-"!570@#PAF(?&!:@( MV#6$PK?8+QS6$-7":"R(*745-],C8@]\%R`VQBA6?Q*G)!Y)$(2);`\@Y58? M'O&N+[RJ)[#X:@`S>`R!/9CHDV55X-8I82GI8C)"/8\^,P;B+T4;#X=@:?\I MW%A[`.H$/HO=9`<-_/X'B=+G39[XQ-SQ/'#MP1(\HAQC'YA=UO)2NVR$LT6Z M#9L@LC)4*$;PU)6BX<+SGTOWM1K\#(1RYE@B/CIU("%K]$S+,_M^S_O M8<11H<66^]^_+(-'[>%W7%_#^UF+@LP&WS6[]G=CK`';.>^YP,\8+E%>G5(I MI6G1#3ZS)S"8HO=Y8_L,ZNKN(9Y_&_N>_[9"9$'ST]?Y1O`W3^;0 M;*[9?/-L_O9)O$7@\X(\3F\7-V$57 M.LH_XE%^*J+\[RZSIAAJ<6/-8EZ-7H$RR79,PVF6U2R[$LO62\?5RKM,)-Z] M,WFSKO8O%IR[<-XF.4NA$9!P[$7Q/2B_QL#SN:==[U>$WPK&#=LG0-$;@>/G M_;IYC(KO0'.XYO#WR>'54JU1__`\7I#3?;,>]Z7O%#:*7@03[V,6@ZT2@=35 M7OBY6FK6FA_=']+"HH5E)RZNBB`LRQ8WRC\825@26I=5)K'T+$$@!LP)SQ]C M8\J>-:'CZ*3G?B?.CPO3O.+Y@_B3(S]]5C\&R4<)\4^?QV&Y;UFC$[08?D># MX8(7J(T#$CZ2[]&91^T_3O_R/W_Y'\/XR2'NR06U6<73XV3$4ZYAT`/I_;QW M7S&_P?\P5^>15AK?:A7V><]PG9_WKBP[GK=S+2S5^8`OG3M^M[I;]6\E95IU;4O M_&MDO``@Y+QK5O'W)X\I:: M!N6<8,V`=^T[Y/L_R>0%L!SOG8(R-*O'K>/*D;IT9FIU[?-Q$*0VZ>6\U]P[ M+9?-:KEF\K5G33V-^I7KD>`N;Z]`%IN-UG&ME>*$ M.8M+4*4>OJ41">^M"6IHL9UKW>?6R(TL[Y9$,SBIIG!2 M%M"CN8"6CVHM,P%V>4C6CL,\::C/QZ':J%9?@X/M!=V3!_)$@I!P3AYY;G2% M]58N]2V/,_8+:-]8Q"3+K;P6..?1]W@NG*99;[X(U`LL\*`C/#D[D=4G7&/< M@V%NBW_'5M@+@(;301BWTMI\<7V'L:A/2,J&WT+A3]$J7P"*KK2P7?R@;*W! M]M;@F\N`=V-CO,L?C],(L'W!*"!/+@63K.=Z6/:6[B0PL/`6#X]<;#J!305D M<5&U,GM5.<3\\=#X0I^12TMX[<=:%B3M"JYXV9SE&6W;IF.?'>L=/*VLP`F- M,PK_,?:OVIVS`YZS$PX0"C]_^->1@W8-,X_-BK'?[GR5?QSPE@8!&=(GP@OK M'`7VD,%.&.Q&?^PZ+,;)BG?SESIGC15L7ICW2$>N;;3,.BYYCA\.C!F4<47? MA(!T)QP:5O(UB*LC@11!;.`X8$ZZ/L]BZI+HF1!_%M@NX26#O$E#,H7\\>/5 M;[V^KP>ZO4C[DJ%PDD$\=PA[%8G*O%3Y*;99F;-!$37VS0,4N!!_A:TEO"]' M1,N,=5V_AS$*MN&B*`^FB&1Q:P\?H4-2XI6O/8\^`]"X[<6B*F7U`,CX%$`P)*7`<3#)THTC`AR>D@(P&F878`,ZTN<(W ML)X0;V3P2#`B3U_%YT2&:G<1PHT#4-*%(C+ M\F'2ZV%2+*PKND01<>ASS`&]*]`_!@;-IIF_^/'%58W<^79\VW<>B,V=$_=/ MQM2O,8];[]@\9F;ET:'Q5*MX.$=]U_#?G9A;S)M MD^%*'C.F^TLO+!J2W+8[%^W?#!&D`.IATX7#M'F(XX!"(QK"B)A8W8DPX!1* MXD^NPSP0M$EZPH14"?-L23TM&GP8_I@=;;BA/*``GU*@LLG4HP`4N34&RPX; M2+##@)TLQC,=>WAVPHK.V,:3!I,RS3K+S\7_RSWM!\2*^)+[[0.CF@Q@IMK9 M03Y<0'9LAX-S8(,CM!HCQKZ,#N.X(4ORH.5YLY"B2M!4-D-92`G$DQU-XQ%\ M1[Z3P';1O`U082.5Q2F/ZZH+\/,?Q"III>([XID(&RB`==B->#N;A>+2&P?, M"U.W8("G)7JSL+@#O&E'-&`.@4.P50T<\IP5&*/#;B;&;H8[Y!9*%HEI`V(' M%`&T'=Z8!W98^A$*(#/H!KPJ#`$4<>1@,)91HJ?$/5=NYJ@`3K,$_:+P6P7)0!S($!&B<]*WT*^ M`+@5X<^J"S!&I?RR1<#N%7_Q-4+9'E6MT&/*WNGVEC0QH(V%K9A+"0W8$L(<\H5G1Z/EY93SYS' M4#XPEE]='V""C#B-A-)ZV=(IZ*=NH._%!8,W:2=\MO0]\W%U\3TX<"7_1V"Q M%`A9E7N.3='N>J+CYUWP@#EUMXR)[GH=8H\#%H$YQS0$YVPB.X.*@6$.1E5` M)P^CVA(W^\=UALZ:@-L\KO'N?8NSNZY9)T/65:[Z*PO/C4--NZ#HNC.]8'H'%49WDT*RQF&;-ZD:D MF>FZ]A"O)Z_])^K"*?T5(^OGX,EA6])'\.&\-IS/PKI9_8"8GXA0JQTE.G=Y M.+);_D`\]*;NK2":/`*B(4]AX!,"F93O5L_Y.&[.1:&!.Y-LS`J@3%GLP"ZL MGVQTR9J\OB)6?/SN8\5F]=#H?#WK7/[V]?+VT;C\'?Z]V:#P>PX`*U$IWG@8 M;'(Z'J'MZF'\(6#W1^RU$JZ/5T/\;1_W8S@*K)#[[D+K3(Q83@W'$CD?:^[- M_X^Q!UYEJY2T6HS[3'.7A]6+@QD.;GW`F^(*]T@B"0`!>H@)>%9]`+@O',J_ MK1-.4SHR:1B9MX#0,/\!KPCG>(DADA6H"(@-83QFO_J8@#@5QF%IB:FP39=8 M07Q]B7WBU[P-V5=#8/0&PP)#Q@\#BZ6F6(8(=0VQ3;5X1T6C`KPQ";E'F%"! MN\Y$7*IB?$VXT+!+/"E!Z9/-+B"!34/FY]J$.&$FQ,CVTTQB3=L-8#(>C@"-MNLY?B6*S5=TAXZH0RB%] MZTR[$8!+9`S:#T6#=/Q3!C)$OW2:3H-6O65X"(M`,$!#OHLN$3(6`TMIH^BIP9@1 MR(Z*7W7OM')8:<[Q%&%M#3*?]DSA8L+@(SPS0\VL.JO6C.?H@9^6EXB67(I9]'X`O'O\8 MQP_,9:,D1_>LE1.Y]T`Q#7/V;(GX2#,30_@&=N8W%I7-Z(XJ*(]%,9)%B&V5 M.ID8TDMHTUR2-N:.TR9FH':?O"S,UFPM2ZKJ8;WXI+JE3XP&:Q"P5F59`:OO M`A-A"L:K!:MEOBN:L&CJ!ZZQ"@VK)DV0EF>?6] M6>OH79U*8O3C,WTI/>I+TJ-6-0]KQ2?(KZ[O#L=#E1H/&'%1;UT?,2GCI?1J M+$,O](9;S5;QJ65]WRRUEK>/S=9A8ROL]9K[5K.27Z'?:BZ^)VTUJL?-C5TM M7PY''IT0TB'!$Q"'T?@,7_%XKKP-_18CA&%$G/8S5GH^TLCRU-_/:1B!L_QO M`HC8M.^OELS2:LT/#S4;K90[N#&0TU?(/@#G>F,*D\OI/6J+42#C@-=?!;;5RE'Z<1AH13207[+*2_;M-[!%/PN0LT"O`+!\ M!!88>C`]AH6)7_[:28,!1*?CP"89.*YN`8S3^&W&LU^4P`+L8"WQ;+F\:/FA MT0Y%"6B7S\%VJ%;*O&P57VKJ>Q.96,>B8,EK+M,I=A%_;3.U77;9I"SVT^<4 MP6;0L1W8*2I8@;UGB!B\&1.("CJ(O_'Z*MXA_A4\MV`OQ(C//6"# MS3;U9=FF5@RVJ>V=/K);&)$>.<*#1=ZO9%\^&XZ[_Q$)W9;SGW$8L8MDO,GY M.[_F=.BS7P[HV'?"O_.+SCA?,YZ(%4:R@DB+U][+8LN05?G*[N+`>3).AC]- MVO:8QS2799[Z;.9Y);KU+:*[M(IMK`?='-70V"*Z2ZN&XXWM M[O'VT*TNS'IQC M$+X6X?58,@!5^N1$XQJ^_^DS3N&>X+\9`O\/4$L#!!0````(`(N&!$4L4UAC MX@<``'EH```5`!P`8VQR8BTR,#$T,#8S,%]C86PN>&UL550)``.%\M]3A?+? M4W5X"P`!!"4.```$.0$``.U=7V\B-Q!_K]3OL.6>-T"27B]1TA,'R1U2+B#( M596JZF1V#5AG;&J;)+3J=Z]M(/Q9K]<;PN$E?8(L,[,S\QN/9\?VYN+]XP@' M]Y!Q1,EEJ7I4*0601#1&9'!9^G)W';XK!>]__?&'BY_",/@("61`P#CH38,& M$.".@>@;7_`'U:/JT=M`?JF5\Y.S/X-_VI__#:ZZ M=T$8/#P\',52@M`2CB(Z"L)0W0`1$LN)<;$5ST[.ROK M7R4I1^=<\]_0"`CMJDR]@E0*]5>X(`O5I;!Z')Y4CQYY7)(^"((+1C'LP'Z@ M%3@7TS&\+'$T&F.EN+XV9+!_68HPZVDW5]Z>5!3_FSHE$@Z!>A@V8$^4`B7J M2Z>YIC&A]Q!3[?:R^KV0+WL*`.^/`:TX<7,V!%X)/^$<#1!&NS;J2V M:W;`1P&ER'AAB;K+UN#KE")OC&FT=C.LDAEEZUZ;WTMGK#[@/9VV)CP<`#`N M*V^6(19\<47[-ZQ4Y]GKS?SRUQKG.NQFDC'H0:SO]W638.&5?:A7GS`F8WIF,E%N!20)G,J'*2EW/\`T2#H9#?]X6`&A@U$JL/E>+O`58#IB;J@+&I M3+._`3R!%F0<^;U!;"/6-H%S-,=C0/4DB2*9?.:V-&5%P87.@]D#S8F[*&`Z M&6.&\M@'*-L,C@&*KQ[':F*1^K?$$#+7G.G$710HG8PQ0WGB!Y14EE!BVI;U M@)#JJ^0R5H%X"^T8VMB\`2\=-9OZ'H^\CY3&#PAC"S1+$N]A6*KJ\0A9&="W ME$29Z2V%WGLP4O0V(W.:1$8:5MYXOV!* M6I-X3DTWQ6/0;B@9W$$VNJ4"\C:8@AZV]1;,Y$6#RFR%Q\5O`_:AM"CN2*/J M\A.YC2X[6]%0LUOC<1V]8F5VC\!$[!=2#C-6$5HYJX,_&Q8CM5^X9/1KC!9X M/#/5HHA.B%BH+"M:>85-8)QK..624B@\I\DVFY>_6N^L-6`CM0=@N<-CM,#C;8#B)IDG:UO%F,91*)!2K?"XG.A``1"!\15@!)$!E_7L9*3<#&/Y[(\B M9-\FD#;D_KKS-7D8&3RD9J M#R+>Z/+$$JQ)>:]G>RY4N3G?_6+#)4GJ`2B6T$I.]YOZ9^,2[G.O'93.4%O+ M&E#E)KVY9:Z[?9>=C<\#R-)"SK#%SF:)QX-J=H8&JTY6/$($<<%T5R0;O4S. M`N&7:8O'U;;I.(AMR*6>'2D`3B;U/2ZN;RFAZTD_>UA9>#P`RJFPL)C@\3A: M=H2;1$69KIUOJ6A`C@9$E=0U_@G&`VW4$\%'^;R@?&'?P/H"LGT`/RN8@.>:I;'&:!)!&1RAEDS==4'=DS=V(L(JYME MSA.Q/XV1Y7G(/?1%S(>LVG*XT%AZFJFUK0:)O#"1UU8/V]IZ1EL)]F`T/B<,$A77EF[P>);= MOGNXQUKY!8+>`'5!^G4-.&8P0MH<^1U#C8!\Q!Y1)M#?^KJU1')A/UB?4>J8L@"/(WA8"%.,W@G'8WDZR?4%54+1M*R184WK^TZ4*]Y MW=$&XGK'6XLD7LF2P'%+>0<'\Y;^\'@+T_+AKBNKE59_[8#KT^E66^_84<#! MQ41>!YB#X&VR]>P+[YJ-LD+IOM MK>VXYPD\V`!YKD/,4?/.AT(D:=+\#2F+U/6#AK4SH(]")T=-JB=W>!Q MGTM.GKK`OJ.U2+J'P=37/5G")(\0#T+B989+XOA)#B?XO!\RF1777\&7:U;9 M9#U8]+--STX"WDT@UX@`$NU@`G$6[$&\['`"<7:#Q[L$I4T1A#&_EH[+[K([ M<7D`^LL,",.K%-.M]G@MM".?F:;S32>+-^&DG&&V[M[-(>5@8R"7%W8S9Z0L MIG6@^M<34)\WZXXQ$M<,1+-;Z[4^$[:NC`<'IZOAV9E[?[/^:CIJ@\,\A^T>+W^N:K]X9KFF3+<^#(YQC`$G2:\B(IP\D;TR:MUM M>O'TCW&T1_\#4$L#!!0````(`(N&!$6.!&UL550)``.%\M]3A?+?4W5X"P`!!"4.```$.0$``.U] M67/CN);F^T3T?W!G/[O2BV0[*VY-A])+7G<[+8?MO#4W.B88-`G)Z*)(%4DY M4S4Q_[T/J(V2L)*`<.2JERR7#8#G.Q](`&?#W_[]QR@Y>"-Y0;/TEP_'/QU] M."!IE,4T'?[RX=OSS>'%AX-__]__\K_^]J^'AP=?2$KRL"3QP'!]^_??XIAA+(:X:\N2G+!]^/#DZ.OVX:/AAUO+G'P5=:_W]=-'V^./_^7KW%+V247A(TZ(, MTVC5BPW#ZW?\Z=.GC]5?H6E!?RZJ_G=9%):5JI1R'0A;L/\[7#0[9+\Z/#XY M/#W^Z4<1+^6"-G&Y?$Q]@.['V1\_@+H.#OZ69PEY)(.#2M:?R^F8_/*AH*-Q MPC!6OWO-R>"7#U&2OU2,')V='K%'_=MEEL8D+4@,/Q190F-&[>B6D M+#X\V2&);,Z]\GM)R: MO222_K:D8ZL2J&,T!KU4R!M(*![#M92Z+[AJ$-=RGMB0\\2]G&:?`+VA;*R@ MI+S+BN*!Y$^OL#R;35%1YUU\H2[#XO4FR;Y;^T#5!K0@_R,IRGP2P?:AVB(4 M9=%H'JB'L2)KPI0!V[-R"B<1F&Q1]:%N*+'>8!;DOLJB"2,/=F+7:0F?\-MT MD.6CZE71E%8^A!7=LD,=J=[GIW%"V9,>212.:1DF\YUD0SV;#VSC&S=Y*Y6A:?HSIZ..\S<0*(\F+^1PJ0*+PG)';RMRFI4]J^_28L"E8#!C:4K9I^H. MAEM[$'P-"*S8\>)13*+6UI/*T@//3;)H[6$),T=E.1=6!6D0%B\5KDEQ.`S# M\4?V4?Q(DK)8_*;Z3!X>'<_M3_\V_W6PW&(`0G(+/Q:+IR3A"TFJ9P?BQD'G M?*4O3Y(_AR\KRF525PV#3F=-XA7'O7Q==IAGBU'G4\[HXS[(LY&6^N;/S)12 M3PJ0(!LS6=E"E.5P.OSE`QQB9A/YYRA+2YB7UTG5#UX&,F0_K/X.\Y'$OWR` M+1OQSMI31-(PIUGO!]6:%O:*`#4#OI6".LE+"VWK#H'/ADB3>UK7ELL:1GT]%UR\5EY.< M>8.T&=EH'W0^^2>&HVL9*3P(?&[.?''#C&"]-&;_85;QMS!AQK%>>1GF^92F MP\IM(N%*JW_0/<+"'8\2/H7ZR/B4>MO&5R9$&L%9:`[A-GV#7U56SSE\":$: MO8/N\?[1J8N+3^:%+S(?0J9&[Z![LG]DZN+B MD_D)Q4*HNP`&W=/](V@;@>"H?>3OQ)04@`7''OHC[DF7Q=[JR"G%(6C0)NBZM&HX(61->H'QOIHS:=_8^ M2R/EEXS;/N@Z-6&XH46,1,"1-^/%3$CE\A)TS_>/A9KH`K5[,SC'UC1CB3D$7@27#B!`EISR$`A:] M63KNLY(4#^&4>1746W!.:S@>(MB)*[3.ITJ(1D"2-]M%+XJR25HN9(6I";_) M)R3>ABU;X/1'"3!F7L[BS.Q(6I/^2T.$LU%O-G[QC<(;`&M6(00U<`K>T-Q.(T7O'FY?[ MNAP*L`CX\6;IJ(FY.G*:;3VW^P5G"(Q4=G>?`I`".KW93C:R?+3L)$^P1D" MTY::`\&W4HI*P)LW>\I=E@Z?23ZJ;Z)E;Q^G>7"&P.+5E"TA(`%1WBPP5V1` M`%3\"+@NX;]4[QV3=0O.$!C)FA*G!"8@$(.A18LY;OO@#(%QK/&[)D0DX,J; M.:4FJ1Y#P=F[,WM5D`3$>#.A7&:C$9W%-;#PE2PM:3HD:20G2M(K.,=E(FE* MG`JB@$AO!I)&+@2)9LYQ&4>:TJA`*FZ'D(9^OPI7R MR4S__![!.0*K1R.>9(`$='FS<#RRQ-Z4Q-=AGL+:6O2B:#*:5.GA-+7YD\LOF&EJ\R>A0XLC M]5^IS8O$QD\NOV1M4IL930H^MX"\Z]3F3TXMMRU3FS^)"PM(`;WKU.9/%_N0 MVMR,.K2IS>MV%=@5]/,*=UP=Y!?%V;2M3*(!@N,C!(9?HW70!!BR).EUT2LY MB]ZD?,UR^L=J&ZDD<[,C8$5@]FU!(A\0LBQJGLBW13$Q)F[6"3"BL/FV)*T. M!EF.-$_<_J1D)"BMQ&[+J2+"E2V$ MJ[?,R;H!4`3&X7:4;<&19UKOR`;<_/H)(VOP=I5?]IN@_K25$7KV:-@D%*#K MZG_[@QN:AFE$PV153_N*%LQD".(S.SL=IG"8CEA)@5F:$@C^`..Q8!N9\=B+ M',%QDYA5OTH4V;%W+D-P?.S2:L>UD7N<)>N?%T_:?A>V_?6:X,_P/)5UG]\# M5.(RL%3+P.]I'@ALFC(]8?,?;,NJMD:+^L`;ZM1@J>]`D#&@35H=%#8G@FW: MD'D1+/.'UI.P(?77M2VWFL-9>T"(P<0L?X&T6*OC0>8>8)+2F(;Y]"E,X(10 M'64T%DQN'T#HTKZ\GTNF1%/(O`TU&>_#$?Q8NW9'_1E6=@;,3DW81LNHA!4! ME9KXD#DD=L`IOC76$;FJY=:;U^*>E+=IE(T(NT1-PN=:.T#DT4"*YJ@MT0TV M?P9+;6<82U+T!U=DG!6T-*BHK=$=<'NTP**;$_HJP^9&J8S1GS>O?=QT`7U+ M0O1&>U6HOK'[#)H@5YR&E$'L-T2.XGC*_^8/X7MNF9M9=N$GE M#/,+/])Z4;VO)&0ZB_OI(V$5&H`.:'"?I?GB?^'%IE(WEY/G!,<=;X8D&T!4 MJ1G6GA$>>ZJ);?;1!*"XS1.*`)I[&%V@8V$^(4 MU.OC1N;*\C8#<)GC/$P%M%ZQI="WZ7A2%A7Z8Z5O3-(+T"((2&WPKBJ8%B%% MYCOCR7O2B,^3)4H$,:M.^5Q#BLS_Q9/WM!&?ITN4"`):G?*YAA2;[VMA^)B5 M9&`6L2RMRK1IIGOS^@%2EP9'?+MP#6T@_-!I4[(`)\P-2#YM8V> M`C6.O49JR%^>ZFWYEF8O!!-<&G[THCBL3P.%1=>J[OZ*Z3!P?'9=6DN:'<.M3H9VH1U=\?TI MWF?&;AW[7:>YD-9#.[K"W,@&N/\*[9AI`M?AWL-4V*O0CI:NXRZ"4HT-WM4& MKN.NT%37P!8@LN$L!.@/%K:(RR0LBJHT;Z_8/AI-Y?6LV@\*N!%4`MS5CM.6 MOJR%C%B;)_8F!R#$9#_".2-F2D(6:;*2\S8MX-A2?2?OL_**%'28LG*9O>+O M)!Z"WFH-O@`=+-OTGNB9H1J.#1I#8*O:]='6DMJDH2V>#&*-:O/AR<C0,FS]QAAOX0\ZFHR4C*RU`T0(S#U;4YW/!$=R9+DI7T%W6AS4VP$2 M!(E_NAQL2XZNG)G=U(>S]YC!)SF8RC6!+L_%=93\&9+$/CDM`BXU\?WI\EG. ML"7_N6-7F?K0P#[A/?7A'$'6H.[+Q7-D&@&UE[*R9]&.YW\ND[")6K"EPWB* M;$0.(AW/$1C"&[RM"JI%2`6$ M>C,RV:]BU>TB,'XX)70-J8!0;Q:K^LYF,IH5['ZDQ6\W.0$,)<$ZPJ`,2T(/F?"2AT"_KT9Z*JPZV44=C]_I,/7 M+JP:\X;2BQ7:C1QT3Q&8AG8V>ZQH2S"Y3G<:MKQQ M/83_X&4FQ4RH0C,M7]`C.+[PMKM;%TD5&LQI#<*[-,))@WRE^N2_#T($[R+P MUMYEU1?>;]Y4,B;V3@H1(0N8M7P_\06>^S"%#&B35@>%+&S6.FVX[).V^4.; M96WI6ND+!'FWBA=(B[4Z'F1!N#MS*%ZXM#^Y7/9,`"*+TO7D%KIP:DZR[AF\ M$`;<-<"-+%#8VPS`M?!ZF`IH8Y4=^`4O,%D-]=_5!G[!"Z%!L(&=01W*U7F@ M8V(S)'G[&$"4RPLR&4V&F5I%4(H>J4:#09`G1:`LTY86ZCV`I@% MG#Z$4_:AN,ERKI0B]A3=0'@$=;M,>=("Y3S8>.7=6,R*WC`GU>?\EJFP*OYR MQ?=/FPT`@!#$')FR9`@/6Y`Q@[LJM?,U+!F8J8!/=2<`B<".T]"C(8.$+1!X M7=[:!V*%^R&G$3G6IE$R!J@`0411:U:5"+&%^JXCGHM/XA6BI]<05H+;HIB0 M6,6T_D"@#`1!0JW=DGHPL87RKD_9>@!;59`C?B!Y!'\(A_H?:-D@H`0$!_K6 MK[8:HKT(7\%&Z4N>%<5#GD6$Q,4-0)PG+BWW!Z(-DK(C`$!PH#?=&&G"PA:H M*YY7UX,!B5CMPI:O(&<<4(73]%S:RR_?1SEN?9=YH. M50=(;I_@Y&B_S#*:B+`%NW*#[*Y_P/2A!:FV::MZM(O(.MFFI]%XH)K],NE8 M0&LOZE5>CHL%W-)<:3#@MP91]]"&(\,BCP>UH/;YFS\OY:S^"(K:@[A[:)B1 MHQ$HWUX).N59I!)L,3]F1Q(Q,>9C`?(YNZ)%Q,3IIS5#DL## MUVH\@+M?9W(+:`7D>C3#C+."EO7+'*,HG[#).<,G?6\5?0'R?AWH#9$)R/0? M!K.#Y-N3H_T\R9L!%#",*KW:91KMR?%^F02:0A3D#*!,E[ZB;S0F:=R"Y?H0 MH(#]M`28`10P_"Y3GD^.]\N$8`9,P*2WO*QUV_"W-!QEL.O[@TW"V590VWK. MZ1MT,5S%U]IB+D0F('/GR<(QV\3'\$.1)31F6_GEO0!%?]`?DYE5J_"1.KR4 MY$XC:WB[,;PUWG:D2VE4N<+K#4%DER=]:9JP2('\:9VP*+W`GN>,))M^I1] M`3D"XXK90J@)"EFJ\",I",O/`7FO6%)4-JYN@IJ)+J%0VB\X.4%@-=$DA,^F M!CYD><%?2`IX$Q"X%X]`VPPC"\M1&&9!,&MCS:^RS-UF6=3R:-K:2R+T!&D.-@QIPF*&Q7 M![6^]%UJ)VY[H?S)"0)7O":S(HNR%1U@NYQH!6LA*HME7OQ.=UH(^@)D!"=) M2[1+,=I+$+9#ZR*68`UO71%R9G6Z!R<8BM.V(E7\E+,\&-F!O\`48DF7%<`:@/RF+,DSC>2%R/6*; M#0C*01!0;,9W&Z3R7-\=!4]497->LP2>75S_/F'5)&;%UGV$2G"SP^XTPB;D M'8.3,W_V-9YDJG`*<:?@I.-RTR@-K=!1LL#,IL#S+D(NK-XS?=)!<]NEBCR! M7U@.#5LHAN,KAD\Z3@$%NZ-KE@14*F)#UNDAGM.D<5NN"/702"'3JG1RDQ$ M'I(PJC[\!N5&N3T!"88#H.;KM,Z7$41K81K&5WLWO=)[*3T"CZ(=@B0`K<5> M&-.SG"V](6EQ`3MW&,"&X?CF@CP)7FMQ%$LW[?J:6;?0GDOD!R!-ZD%4SKP MK,59"(CYCTE*3+Y]HO8@+0(?3PLRY,![(2`C=XXIXG9ITK2!81&$+O7@@\E-FQ!$$OCY\P4>)F-QEG*ECS= M_!%>/X#J\O2["V.&&AZVN(0-294'7FY[@(;DFCDU`0)_C!@6MI`#:XPALTI8 MITYEC&@252`O"==/B7P1VVP'8B(XR$HF/V>QXF.PY_F7J_CY>Z:EXF4[$`]! M4&LC%6]@L.?05Z@8&NG-XUI+$!&!$[Z9FC=18/.[/X;I4'5I[[(-0'!I7MG! M+FH#BKU2UQ;94-XZ5FL%,)R:4;1W1QN*E6B_+CBVDM:-](]KK].$"-5NIDG) M:3N$?`4ECB8C)25K[0`2`G/6UF3G4\&1'%NYZ:_A#ST2ZNV"DS,$ABQ=$K8E MMU?JV=I=>?/",B!1%>VB6+7Y'0#_6E47*&:W=@ESSEOL%;<'Z5%3(/T;M.Z(BFE?S*)4S:#R`CB-V0OTU\ M$C5@V:L9;2M[?YSE)5L,[L@P3*[3LJJBJ]Z`!=#$)[N"ZA:;P7XL%6#YBY"RURP MY56"EV&2D/CS=/."*]GIIMW(H"X$UCC+B4.F\+%5G,9Q@US7;6B'EYFA!UI> MM-J>O[7E17+G"$RXYOPH(0FTW]E]UNM+6-4,'[$Z!S,AFV2^"N9`?5Q69>PF MFR6$5P^=WWK98UH:SJJ4]Y)J=&@]SQ[>DJZJ5?9Y^I"$JQ+NHCFUFZ<'ITVB MI00*>XI>23QAH99.A1>EWNYG<\-SK=A]SI^#]G%_4K\6_C* M_6#7E%57"BX2]I_AX0J3CDYW4)9+^YR65J&=%UN,B2G'=(-2Z[T>XXWUWN\_5HG&130JI",3F)H%^U49W) M*H_.)%O31,A MMCK[BEM0E-1J]0?H"#+.&Y-K@-%>YKE@=[Q]_XE\/RQJ#^(B**YL3(D&)FPI MXXN"M>M[.5G`";<#@/,8Y^?9Q*VC&GGB.08/V+$5%]BVRK^'>5P[]Q7LMNC9 M?F1U8[32M]5RV."T21Z)TFG53"I-;U2+P6'*N30@B-U,5FB2^H]::^4].(;, MYO@D/ M:&_C;99H?(KAFM:MJ&VD'E\W35 MI+Y2$+*X6V^6DY3T;-.[;FK$O4U:L/F2^'[Z)9QOUELYE+^HSR4>R M*'UW#P4=>ZR$MI,IZE!OR/Q73A:1*_I&8Y+&/G8`]6>#QCT&(.W5QU2L/FR. M.27L0H1[KO`O5:[(;?I`JK:7TM)F[]J0`&CS&9'F?Q;85B:X&=M/7 M>!8/5[N\NE^^DOSY-4QU-%/]D:5)+;\&+K[4MF4$"CU>)>']7=BMFN4.8PR. MPQ/+CL/Z(^J,]J(2UL5R:N`LU!XJ.#VU%]+-'WS(&Y2DB:0A?#]VK&>KM01W>KV2P0:C@LRV&C,P1N!#P6UK` M=I\.*&SXE65>1'T`(;+;&K;U+R!,#@F9^]`Z:;A:/FP>!?O!8S"R<0MSHY[VX=>^OLR]JM=;MET10A..Q[#V#!.4C/-N;Y? MUJ()>`;O6_I6`=29C#N6`#3J,9P/SS+=4'%[YYA5O(AS7QVSMCG_7&X]"U3J M,>T/XW=1H*)WXS[=/LB["@6P(P&H'T\P*XH9:J2X_^=3>SV('^[-TEW70;J@*U97,PG)T>I`#5OA,CMS?EV;L@&\E'EF/!\/69 M-10%"/FSV="=:-#>A>0X]KL"TUE`V= M/!)&<%6C+"WS,"HG8>(LG]&ZD$#B.W%;8-6MX`5!X&43>V8T$;K:@#27"%3^ M3CP?*!0IB/CVZY5K\6Z+5S8?7_$&T@`M[]%OXD.)@KF]M[X_];K5&PYS,@Q+ M5F0BIVE!(V>IDFUE`HK^;)X5MZH4S':+U3SM+U7Z\W7'$H!*_U3.%5]R)\DOMS=X M<'KA,0-U+0&WD3M/E+!N_1DPU5U:Z;DY[+9I%GP>[*KH/22Z&U:V/G-I`==* M:'?$)7_";"!'EM?>H,+RF5,;;I,"UTRO$N77!4>6H=Y(_;BRT)OP@#;7O&&! MZS,$%]]L374^$QS)D:5>-RQP?>;15FG*P;;DR`I*7CY^PZ+>'(K*R78C@2:`/' M5>02KC3)U0&*+%W7*^VXMBV[X-_!W9N*"\GUKAY?+CP(+AEO]%IQ[,H\;/;R M/-47BVO?(;X4$,%UX;:4+X"'+>/Q\I62P?4/$DW879O]P8!&)%?N,R6]`*;' MV&F++&ICQ98,>$5S$L'82A;7&P(8CU'$#HCCP;.7ZV;K8/??6?X,3RGZ@ROR M4C+_PQ0`0[SI1%E MC5FO@\:6C[5SWG$=0'8]`52'$9NY2GL=?TZNF6%P[!._S3+5E:)*;(=@R M/)!\D.4C5CBC$E*^6>"W!I$]1LJZ?^DY.PJ9(K#E',SB(V_3F/Q@`>6W13$A M>3';0LW^56PR]`8`\"[-VOAV'R9JL1>9[WY.L#=!N1+H#0#@G5K;M;<.)ER9 ML[T)&%OL^P[9QK62[Y)VY:+MS="W&U?1C<4?[A+`7DKMPF/5 MAOV8M4:J%,SD!O9"1U4;:E5H'\/266F&C<>`PK2S"' M[-7J;RTRD_7Y>^9L_LS'#TX_>:P:N@]S9TU1@GG3P.[I=-[`(X1KF+TG@$HP MG`&QSYV5J@2SIX'%53![-G9BU_(CB2<1B3]/03B: M5V+V![^&>65'%4T!PV$`W/LVS332AZ"DCC>+]&42%L52R'[^R);>-?OC"L'\ MKX6LF&6C\4`U",)%W%J+6RA&,&?\96KSH,S6M_Y@E6]S&;);]CY/-U&9SA[] MD8.NSUK1'N>1J8H$,\J>`5CX;93Y!J2=@J[3TH2(EY,5>@%MWD)&S:P[E1Z* M+1O/95:4]UGY3U(^DB@;IO2/5:U<6O(]*>^R MHG@@>05O7C;91[WDU1O]1E9?YNL?43(!1#?`/5/KI)QO%*_#G-U1L93\3J-J MLJU'!)TC?R$ZRP#/EFCT"RC;>!"HS*7M7EI%V2[M@O`&!]IZ#P656VKC\Y0_ M@"J'V]U3@1J7"?P-@[WM33K^]':N4&2UI/GB:B7TJKH"7J=>*OW<;]>#[@"DU'/#'05MN>6PZ4P>UK[0`1`@N,W@O)YXP#!UD);I,,O>W$ MM&X($D)#5Z+[+TF%)\A&K1:21A\=K#K@0YLJ[WI>)-8&L2O>FH,IE MD]\!L.'(?AV);[/=BAE[B>(I*&.&X!XA"E MH'0;"C*KZT+`;VDQ)A$=4!*K2SZ(^@!"'-?S2/0O\B5)(2$SC5HG#=>AP2Y[ M:.V7]Z1D>X*'/'NC,0N%^@:?[-NT#U^DD$7ASN^=9K%2\+6GZ81%YL[^R&ZE M?BG*/(QD.U([#P`=8@B3-5I2;2)'9EP%:+&F3%2'O MFZ"1F5U[\7]/BK(Z$CQG+#PIC6A"UN1^SC2UI/$)S0_ M[E*VN^1V`&P(LL=WS;I,%ZYOFXX':!'DA>^*>0NJPF8M_P+Z9?KIIT\A\ZJ"AD`GY915EB]9A=KQ MW-XD^B+H#0#@$<2T[_H+8:(;;+=@7I&`A*J358(`:=2G<2+<<&E2$XJ^Y^FV%%;>@NYUS"6KTOJ]_ISB1!7X", MX$3L;Z9(U8+MZD_01DY@0W5%9O^MX;\,Q[0,$XVCL/X@H`0$!]Q=SPU3_6"[ M"'1;_EY4[;B*AW#*'#;LX!5%^83$=S1\H4FE&:,)HS-@T#E%<.8Q)5-W2NAK M`-M]H=M8'G(R#FE\108DSTD\W[`#I'[Y2O)>41!I*GBS`4$Y"`PAKJ:'O@;L MW2+J;(EA(F^J1;[KT!\DZ#IU:WN>!G+4V&XI;6=)=N9_@_<$P139B<^FM9:P MW9@SLLEP+Z^%_T^H3E9,PS-;XQ6 M&=[T!P$E(+"6V"24/V5,-6+ONE)7>Y-'4$U.61D_ICJC';7RLZD M$7)L=Z\"J(B0N)CE9:AA0N<`8C`)J0.")<3\3C%5B[_)60;#((X'I6,SNCGT:)[2\ M81BJQU4Q+,)"N\J.0==M(H!O3DVT@.URUOH7B=TX#+H@_<%E-AIE:85%\X/. M[0O*0N`ZV^UG7:((;!>\UL5>G(IOLKRRUW*THSD3-$8*.EV\1P9'\T);+=AN MCVVG)F=G`U`6@C.!^SED0TO8;KEE@'II96IAQK:W,&%OQNPZU$W;C&0"F0P# MBD"P!S$[0IKCPW:!+!]!#V9TGD]AHE;7XQ@SO-$?H".(&K5!+1>8O:M4;=TF M/A[/$LW#9%'%X#8=9/EH5OM9;132'`'@(S@*&F;OFT!S?J]I[0:J16']JAY_ ME1/;*U:Q?HMXG:GHC&<^$D!$L/A>DZPZ(&3U;ZS2A:OVC4W>'%2^$7J2:D)\SMC% MHX,KFI,(!BB$%3%UNP(6E_<_:.X\I2\(USVD"*]X:RL&&K6S)YC[K\C6D^2A4 MWT,B[PA@$61*6"#2!*Z]RB,BBS9,J#\`OV(SNM$,A$/@)++U4G'!V:O$(=#\ M/#2E/[B;C,9/D]&LFOJR5M'L%M;JYM9A3H@@X:CA2$'G`H$?H:FALQ5H;'4U MMKT))G9ZT,\%MG-Y`Y.U")>\OL7._#W5G'H(\W+ZG(=I,8LP1>'UX4JFY_&1 M=P7]H_#V\%7_>;KV%P._C_9XH`"71SB%!TB''+7WQQ#L^_`#Z8!6.H=T!P'% M(;Q^S9AYT5?93`WH'$HK(36<$YN-`1...]=,:5"360>(SJW4FC1<%AB7[.W. MN?0MI56X3CGM#WYE550!??HUC&DAN5]4LR<@07"8%+T?G*.'+B373J79D>*ZGQ/4IKL;P'D[=RW2-*DR_/ZC2;W6O M&MSL$W2=9J!HG:G5M`FL+W)0R$[(=2&5AZWMQH#):;*)^56#?*WSJ1+A078@ MML`1K@.Q1;(<7RNHNZ3-EO]',J0L\24M[\.1:#GC-87OB4?'=M-%38S$R65] M9EQ<`I@\3&YA1_?C/PDOOT[8%C!XM$:T8X,+Q4E4I2X=EY,\!Z%N:`&GMW^2 M,+].XRMX_P6,B)H#$H]IC4U)D:-QTUN:$+R2Y!HF.7REV2M9=`]]A@] MT.X5X0!Q$KVH2P0<;6.:#I^FHY)R$VQH:CQXAF$5!@/6!,#N(17;"-S< M/Z:K]!X($S.!;I)0]%JLM0&A/::G-%4[!X*;V[A,)_NL](Q\X\1M"R`\%FMJ M._TY4-S$[IGR,=O/S<2[@=^I[*U;[0&,QY#TMKP(X+BYBJH9-VROK<_,LC4` M\5BMR@XO&V#D-T#M+(!RHTAG%1T:S>JNSJ]@;A-,J5M:E?-8F<_$?)"@Z[(R M+.?)(L^)V0`@MLMM$M>7TE2YZ_._"G]T1K^5N:$&GL@1'?\;R_ M'I@3ISL\&QX8IG5]H_Z)<)NWOQZ8D\[>>&!,R7+L@6GSA00Y7[,$I"A8K4?F MJMCXNDB_E@-[C)M[.\FD,UW5$X[8@]UE)MH19%8][9"!%&Z!FHP%2C^XX MB_NB-O"1E>+8LDOV)N5KEM,_N.45-7H!2H]>/KMOKQ*F-4^3X*W=$N`A)V\T MFQ3)5,J3?F?`X='_9_&=-$"+(<;Q:?)2D-\GL%6X?H-__&<\;@@D.[ZKN@3= MCK_=R;I,R@1&3G,0WZ4?4)J?*%>I8(\AQ/`N#N0;Z.!YJN,XOP>HQ*4MQBRA M4$B9'L5KD)`=O#FR*L]VPCZ`T*G#2_\8+F-`F[0Z*&1G<>NT(3N96^8/[_%\ M76IE:2!N>T"(X781^0NDQ5H=CY/PR>9,L6+MJ\KLBWNVF$_V6,*7I!>@1%"0 MJ\D61@D*V:EY7=Z;,"*SC"IMWE9=`!^"XEOM2=M$A"QW<&.&P;X7CHCE(\RP MRF8;/\#F#?X0#F6G!?U!0`<(,J\MO(I*C-9B/"47@ZSD^1JR2D;E=!8D(;)\ MR/J`U"CN<=%G1A.2DZA/.Y@VT504ZW)RR1'A*V\Y/H< M^Y:"?/'G+,^S[ZQV6#@.(YARA@N==!10`X),^O9?20V0\D!3KM'Q;Q_9HU_" M@E0*^A]02P,$%`````@`BX8$1=5WX>?=20``D"\$`!4`'`!C;')B+3(P,30P M-C,P7VQA8BYX;6Q55`D``X7RWU.%\M]3=7@+``$$)0X```0Y`0``[7U[<^1& M[ZHH=LCMKFL&EVC^2]"8<#!*I)6&B@%T!S MAGMQW_WJA3?JA4=5M;2.\(I#5A8RLWZ9]`]CF'HY#,##"[CROXO64$/7G_S^IL_`/3#=[^_6)X>+[[_[O7OP:?7W__P^^]^>//V/\#_O?OP M_\!JNP,7X//GS]\$J(><]/"-GQS`Q07^3A3&OSQX&02(L3C[\U=/>7[\X=MO M`]W`/"P`_YRQ'^^:LL/!PCS#CYW5,*]_U<1&GZ M+:;_-H:/>+#P%][B+[S^`_["[]BO;[P'&'T%<,N/]VNN0&\;?3&B;Q&7IOB\ M@VF8!*MX&,-M:O.<;W,OS4?P7JJ[HC.H7.4TX M3+\URJDYSKO<:BNUH\T(__L&\=#@#G[)81S`H.`/4PO\*NF<^&/B(G&WB=_H M,,+..4E[Y25][;WL@71XRBX>/>_X+9Z@OH51GA6_(5/6Q7>OF3?^'?OU?]XD M\6,.T\-E$J/)+@\?(G@%'_++4YK".%_&P6T2^^P?#QF>U/*"#2(\8>X_1_56 M:+/09T/T%&;)*?6AEB[I*#6Y]![&<8EF5=077CS`^.+C]JM_KE$#3`X^%8W_ MXT^4A99,PO&C+NT^0PP4`PYI()M%4?4W-@ MQGQ=A9D?)=DIA3MDA^_0UWX1`)9+81R4?-[;P"-@JYJ"3[@Q(*T=0)YD#-KH M4AH`.IRV84(;..65^K7;AH1(M>:0L,T1#)^2*$!K M$LK1;9)#/>^BT8=Q_.C(UX96G18PG&%J/:\T6D0T'3TDY8)Q=DG_X7=OWOYQ MN+@F#4T;O&T;'(A<@U-]R MRP&M3S(%QSZV8_,+A[&:Z*PO*E0G>U#O$K`^`>ET`4BW%Z1?4'3LU(0S#4HZ M:Y8)(>*@Q;RKD@,N9^8&0^)8MA:ILU8'F<&#*R^-P_@QNX,IF2=4CK"X M).8/L_C<=XZU6%.`VM(%@U/>5S8.G<,NI4&PAR,5IRN@L8XDD7_J@Y(SOG9V M06Q:A=3%*D+*G%V@1?DAS.E&/D;K\3A'[,'8#V&FM?;5[,>X_>C*V;T5+>F! M%^.=7:T'5Y?,@P:W#=D1(^L8C%5\OFY';@)9Y%35D>R4JQTVPH/`;-TIWT-D M32<_/Z6(.\0G.RU9^GGX'.:(5P6'K-&'<0SKR->&;X.6`+@X;*O(G7+"VH/9 MQNS`D70(KGHN>%AW[H%8S1TKX=E9KSQFZ+5Q[I2')KS=>6G^LDN].$/F%R:Q MFF.6D5J`LE2:+FPI2`D-J!,YYGS5QJF+19U!LH\[70^KT8LS:%3UIUQ@.GGV M[(:T+MBDUE0Q$,`FX^P0AWBCL=E?A[&'MAA>=)=D(>938990([<07:U%I"P]6'LI6&R_!)F*H!HMK>'BQ;?'7BP/R.W@AJX!(X^A7,QPM>V M0:@P'C[&V1'ZX3Z$P55R\,)8!!<^C7G("/CGP68!:JW!)]K>!13)QJ*#)+6! ML.!X;L(8KM&/2EZGUMB>RZES+)B.<#-`VKD`&*ZZN3Z'HVMS$%EF&52*9V\W M-`Z-#J=M6-`&TK6MJ8VFG-_M=K7;VH=M/P3:D!6-OVFX7BH_).:TMP3>+M_] M&%X`UM(Q,,OYO_QX?[^ZW0&*[1]<`3<',/T8%Z+%X!6[ESWA.U/T'_QRZMF+ MR"UJ?NFEZ4L8/_[D12?1ME*1WOR%NJ)<'6@A`GJ!CG^HD2Z`EX."&A#R!2`I M-NS:S&A!??P#K$AG$N?8R:(RO4C+[8]@>7L%5O_VWZ]CW87(.[U?UZO0\2J=:`Y]EV+X5CST\2L7 MRN8Z?D:_(K$GS*7++L%EU';NO*4R]5YQ$RI0^I(:8;FZ<,)+CA81>TG[=J6! MOMY[>!WHF;.INQ0>O3!8?<$/R2!B;9,_P;2Q3!+8E!*U<9M2DZD-.$8%&!FQ M*4((6DMVN]8T3CA(R6B<8D*D8QEY@$>ZL&]G&HALVYDV'"UM:U6WL[:WL?+M MZ[P33%[+HC>88\*@L6BJ<&$9F% M.4$H1==?TN8+0`B(NRQ)%@`1.;&TTI3J>OWOJRMV)/=H$L8G"SN?IY?7-C'ZOM,6[CLG^` MS6&PMMJI,BT*`,EI;QR=/+[;2*BOQD'5TBYRE9G?_;BZ!Z[<"`FATL:U`DY, M+Z2E*VAK2V?!FMF1I7+?&GFS6]XX`\[F$/YK^_:DB]E.7N=!@+5BD^IQ`R(BFW8GOX&O M-78OC$!+DB*6H&94#@04R.$D,!!'0@MP#M;LSGO!0='R0\?>UL:-H)_G-F9( M*\":.7(FK\9Y8:H'#S_()!-EL@=(B>V#7P"<-NJEJ#&X*?#]Y!3G!3=H MED*_24\PZ%JF:.>@TXOY[866C)T]"*,N+(>LT5@'H&]&<>)\S+1H*7I-%-]+PVW%DVAHN M26$\+W.=9M3*.TW%_L]>FGK<&#NCF8$5[*!;_435"$S&KQY#?.H$O0QN'J+P MD20B5K!H&:&%B%6))-T(3D(`"`6HD3ABVH,%BHA`245BWUS48-:-9%3'F)6C M"KUR:6(ZFP<62B70ZJ>#%8&+IQ9JXFQNWU_L5OKB4G>96VG3AZT!+B6`@1P2PK8PVK@S[[MB!"4E\=3S&,3)X9["'2 M9G"/%'J)_ANJ305B,@MG!D(INCMMVAS@]H`2.#,G#)6%S[G9O;<<3]V]MRJ8 M+&\D=#<0KFP<9)>@XF#OEZ1>KYO'0CK4H"81K)^=ZIG*^7R="AH4BM^ MT.6P2#U!I(&/#IR'ZL)>R[0=A3983IK>UC1?8/3SW/$IF>T/2C"9V ML?V@3H_Q##=;@/_YW3??H?][#8Y>"IXQU1_!/R[0;T"&:U*A"?&4/R5I^#<8 M_!'$20Q!F&4X"H4\PS[E68Y^(-4*2$S8OYQ0BS??+0"&!&ES!7UX>(`I>/.: M_/:-?=L2X++G7;88E&;794FL9$K=IE968"UN^Y9=24PM:%'D1EH3=-E?=*GQ M+C"B[[_#5L2SI.\7__2'MXM_?/.V^"//JO+S,"D>./N6<7QD&@R[#`*2B-N+ M[KPP6,?LSEU@4UP*\^&47-X[881E2X";@C`&K+$3%Q6#!,%I,BZ0(#YM;!_Z M$BAUHAU5<&0R,U7NA3$,BF*42]\_'4ZDHL(5W(=^*$Y,)2>VD)=*0:)NSB9* M!,HRHZ]J=(`1Q4(C=WN(8#ZYM^!6X[> M)Y=J5Q\<4N>>%8LO2*NIXH7T7(V2X%T,D;W/H[95YD7:.Z=:1P M@+(6-.H)]"70[K9RUI[/7$_VT^'K699:EOPA9F4^027)/IZCX<>O'&@NK>)/ M4G>BT8>U%)/'&C?A,PPHJ^HK[V'=&;?K@5*W05YU`Y(4%!WA/2?N MZH+T52+>99R/04$;\N,A8/!B`-_PO_,R-+LF!YS?GVZ%CVQ_O$;*BW%Z!)P4 M6KXP'M2;^:N%03)W[AYP+Q>D&U#O9P%H3\SOL[Y(PO/,V8EN2I4\S*L2HW<< MPZVCXH>]8?R(EGYAIN*H!_9G#Y&:P&RC3>NJ-T3!+GW M<(J\%`3E7(AW:CY36QB#/5;;P4M_@3E]^`/\2FF?P_P)M7;^PYDQG,KW`ML]F>P8/;DOMN'"!^2U](L$GOP\>G7&GI,:)/\X>X M(^07N9UM)_2:Q97C3A>5_]FD@';LW&)D%LTDZII)M#5C]$AWK-UT#G:G,1I; M+]_OO'23DGC'@'B^.YB2HVJ!FU#MP/+[>(%DDB?S"_QH!..84K.E!Z('I`.7 MWM(/$I*]#"X?!(-7:"40)!%:363@B,0D[WX=")37@ZKX?;P:3FV9(6$E6Y:O ML)7-KTMHV>QZ))%EJ*`DH*)QR<*TY&&6U7E4[YHI\>`F-B$QUNR:#LW-H&DV M!9$3)E-*H&@N+F2C&"@',Y-0((%MVVCB2<4N^L!DUR8V5;(.3<-H4#IA'4U9 M%$VD1N2>G:A*Q(PED-&`[I$1M,\>1QAZAF?;(X5W0 M*/'.9O^C`4Q!,B/7=CXUUC2V/4(JF^:EL$%HFI5CVYU!HKB[T5%`E\!67-GB M=%B2[F^X%/9M@[LCZ+,+Y]+LJZ>IL..VH9&3&;?',0+ M_[I-.+>/&29+TS:_>"7R9(HUHL\V/Q&MJLWH61,[4^`.X$7"=LT\;> M*S%V0)V?!:@X(A?AG/=-I,<,O'LA[W<,O[)@"S_V(9IZG)IY[5L.>]VYE==RA',JSU)8TH1V*HA5 MFMQ([?JTNA.N2['T\_`YS%]&^3'=SIWP7=H:4?57S9?=+8LK>C\+#S6=B@3+ ML_$JLNV'AMF6BN\98U@V_,TRSL,@C$[X?>,6/SPACU%67_SH%,#@&FD32W0J M\DD6><"+"Q<]_S/=QRSZHPDU)O)/]<^`ZCN@^!#`7P*U3V&B,IU^>:?IL-\9QN5#;=Z=HOS3X>/<;@/?0\M'GT_ M.9&JA^31-Y)P5Z^$7G-S%G@P^S;.L'YG20U=L4%H:HR`BA-0L,)LW:*!6P-V MXSV9/50;7`J='C+XUQ/B>/6,_F>'OK?\$HIJ[W(IS"]*N+QW)L2R)2!-`6X+ M/N'6+DQCXC'HS$4J`V`505?)P0L[;VC%$AM5[[;5)C& M.#16P,/COP]`M.T"X-;E0UZGIC/A:/1A26$H#.*I8N/6.Z`?=ZD79YZ/%WOR MN4V!V#S"5"3J0*T.KP7`A/B?-5*7IC[E,>O`3W/`W-^KWX0Q7".J/O]GB8]? MY9Z]KF)-DHC5/JYWQ6:C- M9]MFT-\!;0!>X29?NUO[4RK*:@=N-MNMW=L&%84CC&?VI^]>"+=G:@%^#<:P MPS0GKB"'V69_!8])%N;+_-)+TQ?D%!H%Z7ML4(W/`:&9[%&.$" M>#DH:.D[0_L0TQFX3H2X]JC9KOC0?O?T,0Y@6KN2)VGI5U]@ZH<9O$M#'][C ML,C;$][(;_;L+]COLBM\T9;'%`>.5):80[?JI1G_VPP)F`PXW0_6TJ+%@ M6N]>RA]_+%(`D\RWDNL1U0[L&85,,E$J]I+`F4L3O0'CXE5CM"R`L>YINGQ* M;U8T^[$'344Y!3ZY!E!G;E@,7J?IC:`&PZ_AXRC-B0*^EH0A"*GM@[)5! MY!PIP8)ED7_M4(2"PKAP\28;%+OH^GX0NKYW"EW?#T#7]XZCZWM]=/4.BEUT MO1F$KC=.H>O-`'2]<1Q=;_31U3LH!L^:B^M1F@X?'Y`E,7E)+XFV$M.9/]>5 MR-'&&"N,4+5S9N.@-"*=(T[UX3"'K18OTNT`I[UQ+/'XEF'(H:6]4/5M\"CH M?42(%*NNL8DA=]+BM#,;8M3#9WO`61.`VD@FHKGC`50YOH&/GO]257Z9F>L< MII/S;+,ZF`8FD.D`VLARH!;/WAJ!5&)C&V'MU_`A/7GI"_K+F[O30Q3ZF_T> MXC/48CS%7D"=WJQWT)"KLYQEI`#3`DH,"FI5TS0&']T!;,!JV.B=UP75C2`6 M=Z;OG.5%U8T@EK:^PZ.?()=3\H*JG2LL5F'UQH4XV5E1-L>-%@=BYNRQQK)" MP>_>UL9MHY_GSB*F!F593>^Y%XN#.?_!OBT)$-*V""D\W*PX_C%.'C*8/N/; M97(NA/Z,=(.HR-)4.1YBLD\Y7:=<45L3E.U>@/JWZ$$D:'[-P0"*B0$WIM*W M/MK.TD"UUH.3?NZ<#55U=3BEL;JY2)P!@3-:[8@E(^_$H&!NL^_6]%YF5VC[ M^.SAY$P%\R_B&@-3=&KX;&&D!@1A)YM]=$EFV=UT[E(H]Y_.I?OOI^?TKE;O*B:3O"N@=,Z3B",`3*C&-(L M%I_#_`DTS]V/]-P]8>?1UB[`YM2%U-G-!8*9)H!9O3X(3F3_@+NA$_7Y^?B) M'+NM77C%RCK.\I1`*+M-\BN8A8\QKH:YS'Z$`5JY/=8:O/?"&+\7OX6BP^() M^C:^OYY"'VV#J4T%-1J`>@55M]A*6,?U5@N`^V:I&Q8`?<"&VYQ3.T0^-&%4 M+B(#2(!31/*PD$S*_A-^]HDGF/WI97]+ M98_A(^;\'&4W>6PTF*REL>^-5G;&FQL,Q$;'8?9K])TZ@E2NA*EZ+#D#5 M@\.`%0^H"F151M,-T.Y@>A@(54KJ%$"9--JPQ'1N8[$^3CH([`Z2R7/@AYRF MM3S4#-?F&2OA:+X-54$E2KP:\4R)B5/P+%0A4]5D=$Z/!G-_XP##V,2CI+"8Y*2 M&V@70@]'64ACB3"!>8RP]#OO!6/C.DE[^>#9M)3,K/7*I6CCE%$`1`+Z;=:F M->K+TPH!.S+Q]D@\CATZ%^FE",6&\6CA<(295#6P"V-%ULL)K:3&:G#%/:XT8U!CI*R95E8)7$Y;7B5P M6`GLPARE#=J&:0U$K-E=;!5U\\'+,;LO'"-4(;*RE^5*T+N=K5HO0-%>8%RF M-[3BX>C;TZJ,A2U(U::4:NM-BEZ\5D:8L`_+@!/+)\5?C7Q1/V 2!M'>,Q!F%0\4RKN:S)8Q`99'4ZLGSHIR"IY"RP!"\,&I!F18=H/VY` M6'^`Q4>'>J-KR_76HQ5(&L_@#B),H57>H_KL+N[$LO.52"CUOHW0E04MIQJ` MJ@\WT*LWHF(/K#Z<(S9Z[],DR^[2Q(REZ+\9JP=>[?5L M[^.4,=G8OVD"T@5/O]KO\5O59SC2V??VXY"_[Y=3U^67O9R)UQ>,KKKCEP[M M^+/P37P%]]XI0C^\2](T^1S&C[*#<`Z-E5-P'O^$_!-#!@!_K$B<>``7%44 MSNDW><-()4,.W:^VJ.0-8^TL/$\:MT^V';X*$/N.P150:#!$`#^O+E];;]+[ M\/$I;Y0.K9YBL[]FHDWJP/[,AQL,E+MSDXS[P;@MDVFG@+3NU+M-:BDOBD9S M6:_2H^2I5-"2\U6([#F)(B_-$45O2+^VNZSXZE$+0>P*;/]^7R4&7?B5<;; M\/BB"SBZ-TRE-W:\UE8*,'1Y%@"H:#GGK9M&*0;G>->I!JP%T-62-@KKDO)U\NK`W>NS.-X,A M?9DVD4'RRL*U^VYHF&V5\X7HHF;>I>Z4DM_#B&94X23N8MG<2/ZV5C#77+F' M%#W+1.*77B<=H8EZ0%L5*^I&:-L8E]!R7F/]@4/7TTLROXRZF"Z[<.]*NI)N MX&4T[<#^#E!W'+7OGWL'<<0$?(OD\K*GXM@8/^:,,TB\+`QVR568^?B#FX(7 MP2N6D?V9G8A'R-V&*.KJXA+U5=TYL-X`ZPX_8B@ZQ,?&:D]H#,S)$RL!]P7" M0@F0*2%E2L@3$!1*2&*G)N<)];`L]P$Q[72P0FS/PV,]0V,NGL8MF)R/CTD6 MYO6*0+Z?GK`GIA(()V(IK8496"Y/=^HE-/4*&FBBI62EKW-ARE4$(L7<%G&"5';-F,.X']2.C,I[V5R-$]"J7M MB<'4*`KC6:!M=^Y%=NUFE%!!16'?<)1@ULG\JXXQVD&SSS]\[LD*:H-&4=X&K\WVRV6W!]O_D`-G>K^^5N MO;G=VL>W`"_<73$/+.90?IO$29,;9G<*9TD*M,8M0$6>GEO8I&T2Q66T*T=) M0^3:['Y7FPPJ\8L=)7SMPG*0,NK;A:"+.1DG%HC07?BE5_$ZU9"*7 MUF))1+X\_)*'C0*&^):^_B=$[,0&88B(N!66!T<)DAK5;M?J,R28V7MK14/C M%]I3LC*3UX'TWKSAS^J.3NP]U,@M7!0J2=6]-61A/\7*E%'B,J@UXCF+HBJZ MC[$"PN+8,.9)8O9"5!V$W=M1700ZL+P=LJQU:3FKN(RMV8_US9V.+/08(\F? M8`I")@HL17'"9*304EZ\VC*.E9?&^%W2'4Q)@JYW7A;Z^-(IC$YY[XLA94KC MAB*7I?.JDE'@W"8T+=L"$"IZ-4KIG%BIZLOV;KE=7Y(@@JOUS3]J6(SK:5:4'3G*W]#/%3PD95B M$Q&YD8V&5YB-FW+&G1)M\A%1RCDR8\$V9'&97I!]82&;J'?I1`>TJ<>]\S4APTO-^[.\VK0:WUEE<= M9R.,X%].,=29UOGMS0)?P'<;([BIYNQM!.RZ(E"(FY5#Z6'_5&-A^RV^S!8: M]JEF"",L\V,
@VLR*1D MK!,,#6UNV5CEYM$P5U7;&&&PRV,:1GJ+22&)69,5<]])P();N[F&'"((L5GC MTBC9ZS3CXH3)*AA(PV:5K6-\!N;=YT1LJ=UV5K(NU_GDY"P&J(T3R-5@.4.5"$K=R"I1*;.>$;:>`V85&+S1Y MN##YPB_.DB@,R&BLD/&67M0(W#ATDAK;'H#Q]4&QF2:!IS8&P=OW,!' M+UK%.4ER*$69A,Y"\@:Q'#TYTEE[0`A`0>$0RI3&IILD07E@S*%L>WI@P,^T M%U8*M,;1IB)/)Y"QH@$N+[V4QZJ-/,V!<@1]TK69$K5;".2NV*08=&;UIC%F M6CBTNZ:KG'.-28VYMH?*XDS;)X-@GJV#S\5)ECLD_"E6,AZ6XZIOPA@2T(MV MGA)"-^*KZY)HQ%AC,NK9'`":VA`I!5MSQL`>T:/+R<0]7:49KI/('"!9G(Y/+QB!8Q9:E7 MU*#V]J52B_0=T-Q7O/.IIE7"#9>3N4/,/WE('9>T%/<6E^)VU!'J.P\E3SG4 M;M.Z!O-!S0F`:LPOL1^@ MUNS]%FG8[B5[]W*'1I[W:,H"#V9O[@SKM[.%8I_'/KA.2G*!@GW"'E=?D+X! MXP+4V5B`BA'BR6OM.SUFV*UC?NR_&+.&[L85H3UHF\S%2/:K<0"_X,)'Q*.G MV>JOIS!_V:&/2T[,U,@M9&M4DJJ;OI$>4%`Z7!"+40)*N@"8V)GC,YVQZR9* MU!TX=S`I/4=3[<`Y7')/TU21Z3MX61L92.U!"NI0'#(`N!"9-(5U02)<1Z1(JG1/Q M2SI@;"Q7])$XKDYK\3U\\GV*T`8X5S8:56KC-5C59.K)#P9*>%6D[IG.&`DO MI!*^IZ<"KCQ2TH-HNSRH-CZME;F[85L-R5)=2&6[W%U+!FG)NZ*],VMQA3&1 MU+[C#XAU9$D7W!(Z5]#%75X+\.7,BEII;!0Q9OMJ6E"%2^&*6H':K6IQ@BMK M<M?JL'$!*:_&YA`DM09/LY;9Q-NE;CTI M\0:)W][LEDC`MT*Y,@>PHJ3]QMI?3?4CL##K94(GRJ.-+%-?-XM38SKM/DPQ M>2]WXT*4D040-PS4!H(-1A"SU,I-#@5+$!Z!^3AA'N>=>VT.VN=-"1[`/9KF M\7?>G\(`EV*90A::3I^<(C.)_!J!S9`H]>'@,%\4TK"_T!/;1")"N74=W:]@N1FM!-',.L@)W%I`30:1I M!%/BP_:2K[:$??=2-:E+=NV%*98(UJ3!YQ=^#H.?D@AU$X7YR[V7BU+>&_FZ M(XO1J77:;Y_ONONXVH?!NQ=0;]>R8_Q]8KVP;KD+4/``*B8`YL)N<+D=-5<- M7%V;SF*\:@O=&2WW3%WB?9C] MOK4ZY`(SGF3L9),&WZ_C.YB&2=`JU5ED*[A+P^ZUI\ZX3LF%>VYQ4AVKWGHW M`D-PJ(?@D+\\WF=/+<(84%X6H%/#M\Q001ARW%O.JOFB^87'5`,+U1SYJG'* MG4YO_-J.=2[+=\C%\B2D[T[7,8X+)*K8Y$\PW3UYL8KLY(]7:&HIIZ`Y5J/3 M\^B>>S8X/D.YS1Q+%==MGKHP-+/T3XA?]&.WU+LT'[,EJKD MJG%:S=C.5H!*T:G#D5E:2)!&8PV`P2016++O:D1=:71E*])*1UKUN&0N=EV, MI](><$X,U<#1/H,%/1.DEK>1)N^;8V'._];Y++`%^IIAH5R:6>U[13K2!7@' M'\,XQD_,WGD1CN*?:>%[)$N1;>ZE^6R+7PV]UG.,7M1SL^*.N>4T#T=N84Y M-MOK)-W#,#\A#9 M%KBJN3YD88\WL:9Z7150#&(`/4$,A56!\FM@7?BJJ1W26ZJT&#YZR!'P')(Q MW=$VLWFDT>!22I!G0E&[)PCB4D,9U=`I#O"_&7KR)R\'GR'"F%_B**")-7)$ MG9*J,/A?=,T-O`QXZ+W:/1.9S MG>>S**XML@RLC'N_=G;+XWZ=S1`]5ZZ1:U^T/?F852)K]?=%L=A4IUX92^WT M?!S<3S##]XYQ4(9%)_A7)@^*U5DX.U>HH=W)%^8U_TC9("GNJK<4"?EU[YGS M>1\DC%`Z4]3?G:FN6YC:PP[S"39.);J1'E2"C_$SD4'%DQKGX$S.,8;H=OH# MCKXP-K9K+1AI.(%9?:CP9:Y];9<*^4T>B4RAP>99R:G0)R1=L[N"(\-G6'UI M@?[A1R>B0GIH\2I)$7F8?UVN$,LB<(KYU=EN$/GW- MN1>H?>_7L=Q746"MS=\7]WP3G7H5+['/\W%J-1C,]&O/21/!R,07QG M^8Y3]E2UD,+Z:WE-1MR;S*;6]*QOYDMF[#^;GR:CW-S:KT(,?[6.>!97,?G; M^A%^8LY+`!G;G;@733]KA0O'+@.FUO&0PY1L<,BCFUE)W-!\+5[2J5W"-)<" MBR=8609N5\]LDZ&M[ MUFU"/7SR-[)1&#\"]=#+W^QF8:#;F'R[,,IG..2FAT5%U:Y9+-U.C&7,/1<^ M]TA8"_=LW/\ZN5EQ=HS*Z-!?K;\WXG\,Q8H.)C&59+@[M\2'8P=( MT^MYOD>SB)G"7==C5)STRZYHOQ9C^BL\1II??TM!>.>"_/ZS.'TP>(7?ZCZ% M_A--+`DA.7("GO_74X@`3Q[.TL@J]/\P?48#A&N$ASC,"GWO:_(O6,-[_9DM M>PN,+2=&UD''VOF3K)F<^Z2O# M^AOECBLK608UGL^Y6)R)L>,?9G75R4KOXHU2O?SG7_U/J!VWL&[-R*B,[&A_OP\#L0F56,GQHH= ME*6E"NN9XW"2.7*45;[2)DGJ,*YKP5B-E]5H=4,3U>7D!3;=`@0`]8$Z1M_, M0[Q=0^."O_H/OWOS]H]W\5_B#_'5+OX1_6=+?H6_>?#0LH@>HWF'(]X&T]:O M__*_/KQ^W\ANE\SC>6XE,[ MUR9YM\9!]#EX^/*4F*N482AW$6^K/5?!S/ MT]E=N(S1_YS.O.^\+N\]KROY`R6#9UW`<8:!*0_CN+JJ7]#\"JYE1GL5\PD' ME5R*6Z=KZI[9.`=G?WJFZ77G.RUSS+W:UW?M+&R,.SW;XR]U32T/R2DF)T%! MN-]#6C_A`>:?\<%/52BX.`4C%1NB%Y)B4!#>1=8$S8BQK)'+L.=D[%=XPJ0X M@5GUO&=Y@M04R-!!4>>CYWP>U-6@L6,?)^8H*RIMGN";4+]#*G4KOYHVG[I]MDPU3'#>0!ESNIV88ZY M7Z/5T',8G+QH^27LJ_@N:6_<&GA\=Q*%XW88UE5+\`FW=0"=0MVWD::@>(NH M^3G,G^YA1#"?/87'7;**\S!_N4KP0;\.GF0]V4>:5-8V!NN-\>DO;0X^40(7 M@:@VG%*(ZHSEB#/!U>$8)2\0?H"BRB'M5F;/UCH\=A:^K`'X1)M8A(5`J8W] MN$BC(X;S-HG51K2GH=E![>.T/:[X[:IK8\O5<&-X)>HU-]MCD@,.M0=D:0\,'[KR3=H:]DF_T5?,CQ'2$W#/(299&>DW(-Q[*C+U@85H02$%.^A,#&-9:#%OBIZ9_94FN/8!N.@070* MI=(=ET8?+B*5N\O2P*HS&R_M\1R`UXDW6UN(K.HNQ^QYD)=$[,3)=_514P(Z;E.YB2]VY(:^3SX@F9U]KL5,SEN0V^6D,6 M^>?(Y"O6>F/:55&Y.5]+HP#6<0"_X"!>7-H1IADUC'ZQJM.% M?X.^ZD#\L2$U3A/+S=08*JGQ+#R;W(JG?FHH-6&+CPAKA53NO7RVEX*=SYS7 M<\"NEN9[\U1Z6^?UI$5>'..HUGU)!E+\8J+G+=FYOQ_CV-VD MC\2$1C=!D.(6IL^A#_O9O$W8B.V2W(OJ?UG'ES0C%DY3(@MQG.8;=@(D)](/ M?[--^P=>U%Z8D+<-F3W.OL5.*6@H;GLL> MU:59'SU.>FYZ\B+M*^D/X`X![I%E$-GLB^R,Q2%BK5N+3G@>95PTE'&AI0P' M"T3.I*0BH3TIV'B!2SVV$GSQ<58K%4, M,NK:5[A:!F-%C9,9AB:;/8LTO;.HGZD"%VRJ*2CI4RFLI>+'OP9/,`IP> M>OK#LLF[3Y?G)_-^?%#8Q=1.?,RI>9:'!WQD1@:ZPSMF(\[@Q^.&U(-'W]_L M&;/<4_(1/1H^%1\C>^=DM^B,F4R/"V0=@H]'L(D!ZQ,OG%FO5@]RI]3%?;.8 M'"Q5LS^1T"QR&@MZ3F,AT]#IB(\1GIF&D+NA%(Y$<(VWF>9)[$0&,\(++.,\ M#,+HA'NE?=_#X.3#X-T+^GR8$D8V^Y_):7G.-7WM;LS:N[Z4G1L)U,/%%>NB MF!59)WA54W6#S;KHR*9=CY>Y6E+0Q15(F;S!*<76B2W\2.*3\=+`PXG^3Q&I M%``K;:!_?6:?(-S:]MF/=`(&K8\R@)LI)FN&'Z&5;J4U1<_.@4P MN$8:PK[HE#/&5UZ**Y9E=S`E*QGU7-/3?,ABPNF)-"7*.EW_1#U73_$1@!$+ M:I_!1,6'\#,+MJUR,/7TE#CCYY^>'F0&T[^,X_W=2W\'LF0RC?'4KJT*O9-BP$:C6X4-=(`>)"Z@^EE!\T MDXQSJ3Z44WPXD]KC)HD?<-)+A<2!_RF"[<2B@H MTGP;+G*UVT.,=`G#([".&NYRI1\WSJQ2Q",@PX[=%W-UQW@\-VI.%"UHZF3W9FP6YIB7NS1Y M#@-\L?XQ@\$ZWAPAOEV/'Y<^LAMB,6@9C'YQPA$S](])K`+%J3Y@'+23::83 M`@)SBNJB:QPF^@KW#L+X:U!^`%1?6(#J&Z#ZB-0B1BL)[9;E\]QLFKI<;G\$ MUS>;G[?@^G[S`6SN5O?+W?KV/5A>[M8_K7?KU?8'^[Y@6AMJ>XTY#,C@`CKX MKU.6DP?AN^0>8HV&$40RK6,_.<";)$._5Y1/P=O,\SGSR^MYM-992%:?P4\! MR@\![*+HIP#^%OYCTV.]>P'$8:WC7G_EB&.RH,8\`6FIQABI,<+Z0[_UL?Y. MU,F#I-295W[``40/%2(`[1W2//P;[TA MI?6BEDKDYNN#JDG5J1I:(UN`DI"\DJF3+F@J%IO^80()B5A>K;U]*]9!8Z=R MJC84S5G9>R^,L5O8Q%L/ARD!MF^`0E)HS0C0[I]#+X!6D_ZW-QY?>,42P M4EBEZW1BW!BU).RDT6;$H*!NKI!9!XXLCT=)>OF$GV'B+%\.+%SU4=FVNJ&0 MM&EY2]_'9]/9G?>"0^WQ-.W[Z0GYWM!["".R--:R0K4.';!(1@.L.[I4I1V"6H_SKE@5+Y4F4T8I];$FM<>DCBI2%ZU;!_ER2]>'O4VK MOTOAT0N#*[B':0H#]J`5,;W)GV"Z)&L@+:M7Z]`!JU>47-'J66_E.W(,?](1 MH#TYL4J>3`F%M.Q->$;$38BX1V;?_:6QCVLMOQ_S$.F8Y>.8*JM'^ M@"M^0U\SFOZC_(`+036*._W9=-4.JUG?_K3:GDU8S4`K4O0LHTS(G(=AZ>ZR M7;+T_WH*4]BX)<`9[Q3NPW0Z,>XIM"3L['89,0Z\8.3E;=B"7HN0LQ?;2VK74H5&WNW.^1(TE#G'82.QJM_7J;U(%=>D<:E;WY M&N=S*^C(_.S:_ELJ%KWGPNONM)+$YTIB=\O=#SGY1EN$MW-9-L^V7#Z[9?*L MRV-WM]?#M4,T\^I4:.-8TU%8:N8,-MN:EC+MDM@QKW$=QE[LS[C9UOZ`*UY$ M7S.:WJ3\@`N;[3$O6,9KJKW5OE[?+F\OSV6K/="&%/W**`,RN-5.$Q_"(*,O M11NI($1[:Q&5^^S79(J3 MW(4I70%FG4VQ*L;,&*NQ>8C"1^EZ7:L7X\:D M)V-/-O_B<&JS!R2]$NZ@#`TE78!:'W9WS..$+<_A<$59)F!$!$QD`IJTO0&H M;=OB8,B.J#-P#Y^QTR0)]+;'*,RO\3R)/N%%)'4!M[*``J'96@(JDG0-B="P M`B&$"E1D-,6%)>,Y+YET"B`,$ZI1O\0C"35(W8*4B4OKD61$W'TE+JN0T*F, M8+NT@;+=-8H9:!J=G07NFBV2-OO+Y'!(8L*MXC*70VMULTY\;6TCHC MEI0:\;\TF@]:3LQ34.P"(_U'I8`-H'Z`DG M<<#`1XK]ZFIU>;]:;E=?@_4M_0G]`,@MT?+V"JS^[>/ZI^7-ZG:WM6_40X#< MR9T]&,4&CL>(Y&7THB(OXSK>)^F!.!*5=)NJ/9C/O*DL6R<)9XVR2L() M:L3.!$J/$/+CW=W-Z@.RM^4-N%IO+V\VVX_W*["Y!N7-+3+0Z\W]A^5NO;FU M;Y2:8.VD(!V"5!N5-$E$VLG/R=D?\B#W,,(GKI=X]Z->)E.A%XLU,%5D%!6X M;-"3V93U`$@7+A:N5!Y6?E5*S3$U>?=98PS')4L*"'':6[C/[.>[>XY?AQMN MZ$P!(:'JNU=U4KU;!(VTAA"7PCYPN%6$^J#C3`TAR1!(X3.TBA#W5K?6_[O$ M2X/-_BI,H8\ZR+A%@M1)3=_LJD@CQ@LAPQ->2>A`*2'=L6K=!6H.U`@\?4B" M$][A"&/X;$D8R,W:: MF?4?72X[N:E3P)JX,.FI\/N-(L/&/!X'"@V7)\2!I=TC/@$AYR$93)^5*CVJ MD=O=5_*E$F\:,!T[$R.4CA5>U!DYX0Y4:=A&.$86E;'9WYP.Q^WI0.NAL4.W M7;(Z'*.$M%@^IA!R,DX,[LFL>QTD*R?FG43WHVX`ZH<5VBN/9W<)J/H"968P)J+8#@,>;AF-J62L6=BYG2' M^*AW8F'5I2%A=^W5P*LSUT*Z@]9=:@T;,3O`5+@[ZC:V"C3!C5$#4`Y=%O'4 M+8+.Q%=$'^,0OR4*\Y?-_ND)9T'JW,&)VD`I MSN33'YC0_=LZ?DY"'P8?XP"FEX@J]+UHEX9>5&[CN,^S=7HPZZRU9.L4G*$G M``4U(.2@H`>D@^HPQ.HSYU%R]K]W#@NQ3T1LOQ`[)V)[98>V/;L^?!L>?BAV MS7GZ3?KHQ:R4Y26:@)(H##Q6YO*.#AR[IV8/3;QHBWY#F;Y"DU:49*<4UPO9 MAH\QN=:.DVG2#D'G*E9-_W-Y&NKH[N%C MB/U;G-]Z!YZ7Z6]JU,-PN&UC@\U.53N`&]KU*R)%UWV*7,OS0N$203'UHG4< MP"__"E^$6.BTM0"&+K\<-+"&@+0$J*D+>.!HNPL(H:KG0L0E+4]\C5;77O07 MZ*6K.+A"[HH#"GYSH[@0<-V91%C]9=H6X,9H:1L`W-PN/&2JKR-$3>_SNHWK M,(+I)?KH8Y**G4:KI067T>:5XS!(,U"T<\%;]"JYZRL$&IX+!+O4"\+X$@ZRFM>7=9'6:#(F=<&51)/FC=W<\JSW(LQ M-^*%@I#0QJI!+`EO"5%+2+M@*:%!C=(%'Z$R1CW+"^4!FOO(8X>ZE1QST"96 MCC88=]SC#/QW-\XOZGKL.[/H*G&ND5VBSP7XD]>1QW,3K39&Q[;-7S=X@OT= MX`9V1[=7E_7A%2AR;LNEJ>7$6P1.6RNVW.:7:]0L+:(;&P.AMOL,7:#JN1%! M=R24@6OTN[YS2$E[*\CHXYN+#K9W9"`AS=U`"%?[?2B1J-X,4O#>51TGM=86 M45+G6881)=\(E\-E)6E21V+^,X:.E?0LC@\J8\`'X#*.$%$C?YMXCI!LN M$N;#_E<45:/?A>%@`BWI.@ZRH@:$G`46+&@XWPOXQ/X[?_"-4G#R2&FKT#K\ M%KN*73Q2(7%=IJ"FD8QH!))OV(Y-'H#B9FS%4`A/6:2-)&M@Q?!8!)_4]C0[ ML5R\32)A)UY^]=/J?KL"V]WF\E_!]NYFO2/)T.]7E\N[]6YYL_X_)/FRB>BW M8470-`7>/5�B885-;(*XB&HV/35N^V#7$0J,75T-01/;='-UW>GF(5$V3,[ MIAO!6]0AG;CGH&Y$[U.5G=2-"\]5AX^JMK?B#*G)B$_$W5,2!8A57.4%1XZU MV!:X,"5J"U&@*C)U,OS4J/[A=V_>_A%0V@7HJ>QKW_5I#%PW8E1SU$8XQ^ZW M;I,<=KYWF<0DN4`2WV.[X'G)H;V9=9>#95:%),#]]>*2O)%DO0+2KX4D3L5*:AH;1K<4.%J]G6L9/)*DE;%:5;<'?W_*N`E4Z'%LFW[ M$"W;[$L-JV.8UC-FT00PV69?^YU@]Z?5BRMYM#@R*J?46K"$T.0\K/9[^SO" M`8.JF&A+/J(F*[X^9/"O)V0]JV=L0DHE7GDD%FJZJC(&]F"DDIA$0&,=2*([RQXD.96Z0SH6,C!93W738DB:/+VWN6T,<5.? MM^!C_RI11>T2S-A-L]#D170Y)">Q#1O1Q4\7.DY<\*B.@P1#UB]OKN!#OHYQ M01F21"3+3AZ2&X?IOQ9`24AE'$UB&;KQ?@\XY4O1?`$*`LL/*S1&I`TJY>&P MA:MKSX=T!Z`,JCJ)940UN)?"";=F&SS7P-0=!C&2>&,P*A*Y_H$/.#4DCL$D M;SYX!Y1B&M.QQD+^)>@`!0%[JF,WCGA*26R?LJG@JA4,K`HJ<>(+E#)8.A9)S&U.*( M\S`(HQ-)A4VJSM_#X.3#X+X_.X`*D>&*&Q().GDB:NT!)0",`L=R<6;7T3*H MW'H/$>7BRKPL:A5"-(5IW6ZGJ!7P,+I3GUU\FDQKX%V,=H+.;%`_XW`.47 M`?WDHO%W6F4>?1&\0%S>N_BF_<79['!L+^IFQB+2(=4I,O1?T+_1O]`/>,2( MDO\_4$L#!!0````(`(N&!$4T#%;BP#4``!"B`P`5`!P`8VQR8BTR,#$T,#8S M,%]P&UL550)``.%\M]3A?+?4W5X"P`!!"4.```$.0$``.U]:W/C.++E M]XW8_^!;]W-U6;;D-=EZ6P7=,[L;'!H"E(QFV*U)"4R^Z-_>\W M0;TH"4\2%)*L_M+3XR8@G).)UT$B\;?_>)N&1Z\D26D<_?:A\\OQAR,2!?&( M1I/?/GQ_NOEX_N'H/_['?_]O?_NWCQ^/OI*()'Y&1D?/[T=7?N8_)7[P1[HJ M?]3YI?/+V1'\RW'W8W\^^7ARW.D>_9_.R:_=XU]/O_S?H_\W_/;_CZX?GXX^ M'OWX\>.7$=20Y37\$L33HX\?V>^$-/KCV4_)$30L2G_[\))ELU\_?6+?OSTG MX2]Q,OETZ4LM`3(G=*,N64* M?GD9@V-&$QBJJ#8WTAHLM/"!I%DR#[)Y`O5>QFFFVS!>02OM"=E8/?23[!T& M:G#,@'FF?JM$Q6WTN/ES2OXU!UM,$ M90_;PZ](YM,P?2)OV=P/[??SW?IM]O9EW:;=?5VLAK9T2C:F4TMKS*PJ+&UG M7(0M4T;!Q:_(2$8#$R\QJ[6VF:H$U^(ZZFZE[L"EJJ3N=I[8:.=) M_>TT&Q_TJK*_7C%S45'A6G:2)<=9534U[C)+MEBO,OL[T'*.*J^CKEGA,8-_ MYCK&8#R8,4768%MO5.,A$%SZZ!@M"'CT:-5\]@,5]/G\_`!^,XR#K9\) MV?IQXONSA7%)F*6K MO^Q:>?EG;ST#7(8^C*GCO&_VWVC*,;6RC-?KG;NTM]IDVR;6!,2W\TFC[%Q$ M=A5/?1I)#+S_,1#QQ:5E-2W%-Z$#M^NIP[L6F%9\"[,\(S;ACEGU3BK'P3=A#;$+ M8"#QPUM8F+[]+_(NM>'.MP`,(YN:!KXX3^)GUQ' MHRN8<02&%'T.\)W.EF5M*KV.T\U+ MM0[)@<*WWSEB^STE/HNH?'R?/L>AP');WP!0C`L:IK!/@*%& M6G`?@\!6+F0?75OU`<&(H;@)?5$GW/H&D)XVT5H<$`)SN5!O3+O6D"0T'LF7 MH-QO`7FWB>:3@!&8L0EBS6(YO`OM=\<^[`$1BSBF0#S'S:/0*LZ6B0+&_MT']?W&]2=[UJ%7LG/5== M5;OA%\6&ZW3@BC5[)TX7-Q8-RQ\&;-#3AL&A>,?2P8BP_OF-/32ZNZ24=W+N MJB]S6J73467%O!,4Y_LJOOE=3`FL#?UG]W:PBP6JGT0TFJS;H+-4%13Q3CNN M>L]NDW2ZCK",=^I4UM2BF=]IY)#:T&-D-]<=]!Y)K@X.^NM6*/$H]7ZSW@XR^T@RXU^BG MVG5XIY]=]5%E&\UZ:IGJO%.G<4_EK,7OJZ7A-[S'"C*>..FW_+9H=5=Y4:][ M[*Z7"N[W&79.[5J\KM,P&B.3B+JB&=@VK'=W\_PXZ'\[3=#I=Z(B7N_4F<"R MVR:MTX`Q##JK1\U:91%,.NE2Q69N[NXLV#@N,#,8W-/)A M8^"'FVN]&OW/2OW>YXHW$ZML,PMMS@WUKK>I%!?SSE%T6'N6$6TM%134-BDZ M\!(_?6'[9_@?=A;[ZH>,I'S!3@-V#,/][PM29%Y4H5KO',4BJW8OJTJ1I>N7 M&+SP:QR/?M`P!+RW0<83?U^VE*LG3UGY0NIUV'=XY"FJ[;O\SXL'3G$X,S MW4YG/DT838,$MC6S./7#P?@NCB9W])6,%A3H3XAEJO/.483DU.UBI:G!!`5R2!!23K)083G[B0=XXB M-*UN5U$08.G>;S7_$*5<(DS4F3&D`'E"KO,+=PL4:@\PK<+K=5KM$.7XL'^O M^(`BX&[^=@<"WR9E\OIL0D>WDQ7SSIU)Y^MFW5'_F8;YL>H<-$QE:.XG=J]+RB$7T._L4V`_7QG!PWZ4[YY MX>)<=#7]%J;D89S2W+$TSD@UBGO=4V<2P:IYHB21_`^]+HJ-O3:Y@GW[/J96 M)89\#$CD)S3630I9_-[KHMAKB#;D@%R!^AZE,Q+D\X`R%:2PC-=% ML1426TQ@82D>/!DA+73<.TEF2/''7M=I+L'R778;01N4]\6Y@L;R8/M#KXLB MH%9@&+X5.0A:I&LOT"VSZVG;<^=[KXMB3\NQE,RD/!`M$ISYP0O][!)V7.^P M1U\^"&`8/[)3WNNAV)6*#6H2^,'#AD)AMGBAHAC7K^A+RT MUT,1-63J#+K(+(G)&%QAF)"93T?7;^PPEP#D0?9"DBWB)*Z@4=KKH0CP,74% M7626,F!B<`5=H^^0@"*XQM2\^QAL9;?,XLP/'7?I>$:2[)W%8.0/BL"\EI^4 MW1-Y7Q87\WHH1##S3JR`9"M-)H;NNXHCU(C*]'HH%"]3#X7696I4,19;V30Q6'@!4#FI>CT4NE:YV31OO*U\F>ZGT<*Y M-DP=^WGR-"02W2H\MR]2E1+#C+#92KR)H2L7@.N+9>)"'HXWJXS,J?0('D:! M#S1246,Y,M.A_\YD?_6&B?.UU^N@V#Y3)IG7]6KPS%`)J*8\PA2EPE$8J:)O`9"//D!7SSE#(IZ5<08E+ M8/M&2F:7BU>![XB?DL%S2">YB32L+R_HG:'03$O97P.9($S%6&K#X`%&?9[7 M(YJ[#!"@$5C76%-#M0/<2!-FB_W]K=?2Z81E MO#,4`JS:@H(Q7HI+8/5&ZG;L^O032:;%+8^LYW,^]\Y0Z+)E;2V$)#"SL=*' MP7\+]4KW_+BGEG**39VQ"7%FCJT`*G*"1 M,ERI`SH)JY^Q27!EG4"!4>`#C93CAJL6YYA58WT5)$EAVL\4MX MGU&H:Z6L+(,D,'8CE;0'DODT(J/5VS[]()A/YWDF=-AUTH#*+Q^H"GN?46AK MI5Q`$YW`&QJIL'%>M359KWF?4:AKI:PM0".P;@M#Z"J$SGF?LG%47B/>O3X1YE M/_QDL8Q:I*5.F62R\)\TG4\7?RO1"VS\$-@!A:Q\"/>VQU>+WM;@T5,T0)&> MY8N,[Y5\U:QRX!N%`'Y8_RS#46U/=!SR;;'MQ]H=;LZ3A[2WKC6_TH MHR,:SED8_"-+A9MO[Z_?@G`.%KH!?V<^-U\EP"[SV+O]'P/J4"BG[_9+K$_R>*J,OOP10 MXC1RSY$/""9'&4>MR!F\#U"=,UA4QNNZ`#A0RCL)>6D8N(VI!/F,&#!;R?O#_ZZQ,;C4F`6P9H<:IGH)L&)"Q9 M2F7LUGDVP.[]*?SK4^)'*:S3`)1Z1E`6!J)0''PJ+"DPOR8\2XF/2_J!VTW2 MG20;O9-V@$F9+=1$$\)$WLEX]_6=P#?:6"=0YOS MAT\.._;?%'004<_N<3-B,I(.QE=DQMX4,D@-KU$P30"H=O^0/2UV\D"6A*A@D-R`,+A+B?L]W.8+S\ M+VS&6![6R19VAVD!F,RIL(G.SP_*NZW\W6Y'X^W$&KPG%J57GI2E@:N?1A?5 M&XMU.;.5*KS@7RY>$%Z>\+7E">'.:<=57UVW:_G84%1,=LAY"1<^N(^C9/MA M7$4^&6N_`42A".Q1&Y/?32T3T8:SLC4E%^_K?_T[)0D8Y.4]?SI7H9KJ50"$ MH="\+'N`PLTT*&G#P=D:Y)+`?(;=1ZZ43HWJ`?I07-(U,;;"7?1AM^$,;HWP M-IK-LS2GJJ,\B9.4`FI01)Z5L*?",418VW!2QP-Y4LH-3M;4H+C,6ZL;;&%M MPYD;#^1I*3_S+'?KB6B53?.(H#Y73?)*=5P[H M01$K>)#%IP83;3B.VD&G7%MROP5(3!4!*^.8?-?!0M>NO3(\6QE:LP@-Y)0NAJ^1W@'Y><>!"!VAYSMIY9=>JYQ21:9N]RK@^? MNK@D2'L&YGN2D`-;+[AB6.;6\39;IXM"I!3:CV]N-21;;[1F)'%UTWDWRJ'3 MFC"'[KGS-8%\',H'GN]1_)R2Y)7-8KG6"?\YC@(HM4DWID.!I9\"VE"(1&K3 M*B9[JWS\%?M@U>,(U4(@>N+W(YKI2H<-@>CA4LPTC&TE!*(GE,B: MM=^HX="SAT(3*V'/$H>>/:%`UM`0B.H#LY%N8O'GP!@HE#HG,S_)2LHSUCS-GGL!0[@4/)P^M:#)4B`)+HWO-H(]]3Q?L=S' MV15)Z21BZ4+[Z=_):`*<%S[X"LL7=I/WGN@)@27K!K91J(6'M0C@/6?O,C3LGM\9+L52:,SZ MSK<+1+1!ZZXIL/H,EP!IQ]Z"D"TU$VU0LBT%5I^AT"$U;,8WM@256^'9>F#U M&0K=3L(W9[W&1V%)"JZRS+?3!?-,)8IQ>?T-8,V;_T:G\ZG2:%O?`7P4&LZ>1?B&X[2]#=?&OM%( MSW3%[P`^"DU$UW3[;6]#CD'+EXW.VG8E5+)SD;/0BO2`==\U.D,1`ZBPI,#\ MFO`<7SIS?M?H,PK-2]=:/!G;"*KCJV4-"^'\_/,(72:4M.O"VF&#-S^CD,A, MK*WP%WW8K;@M5D/TYF<48EP)@RH\0X35UBTQ='Y0+8-5#]D9?!U^L(75UJTQ M''[0K'O/GW\>^;@&Y@2>VRQ!L\C+Z@GU!YK^<9,0Z+(9`9?('OQ,-_9`5@6P MAD*]KL$5U#ZG)D;@3LT267F0K]]F),C(Z!]Q"*9F(50E'(I?"3"'0EEWZE(R M:@1.U2SY5P;ZB233DJ[$B@)+N-9;+AUH0XC`;9HE#.=QG.NPSD'R0"H5 MD,W+[I=^&)+1Q?M**%M^*'TGHUK-7N\4A=YX,*>SPI<@PJJ*1GW`\-J=9T+< M!]G>Q=$$EB#3G88M,WHL3!TL_X]&0ASSVKS.^;&KH2%O6][45".M!.=K:#P* M5;@T[_R.*D3:BCA8>V_#GZ/0;X76$I\%"]&T(7[5\BONYR@46:G5M`U=Q-2& M]`F67G$_1R&`*>RE9>0BHE8E1JC[=/<"X6CAFK;]DYISW&I1?KV+'%*>RX4@@ZE2:OCPKI#.B/&T6"<4@`75U1H M6=-J8VU#8/#VM*ES@BHH`92@B/(T7`=(T;0AN'='UY!ILMM?>ITO*#16J84$ M:BD/"VF`AWY->UHM!IOGN+A'(8K/R67\70:1WELJVB`+E49L(-"B#.P M+5B.(V@%AMR'Q M!>A.;]-T3D8J!]&O"!A$(<>5]!)3H*V(+MWN'L68QSP]RVA(DH"9<*(_B\@J M`>90Z'.5!Q(U2,?1HH*UX]$C-(;X&5YI7&]8!*M&94%`34*?,C93OY'@$-G.C">%WY_& M\RBK)-(LJP#6FBSBZ4,4.(;C)WI8G+^?OJPV$>Q*5Y22!Q(R\>`I9EFT&89! M5-`H!2?JE>H#CIHFP5C`*_")IHEULSBE6?%=X"!(YJPC+$B1CA**LL!3T_0; M0VP"'VC^_>VZT@&<'#=5N#&#*'",9FE[A[[8?])IF@)4%J3`/9H5IR<#?45? MZ8A$HPK.4:P"6&NJ\&,&47!/JUE:89VY&TXZ35.,S*`)'*!9MVZW#SF^1_XT MAM7SG\SA%TMJ[8,@3EFOA^/1X\J'/T)L`A^H(B$>,.O!`V&4D#QX]7$&\UX? M!C@2^#.:^2']C\MB;D,Z@QSO2QQ"T]/%Q+=' MA'1P5Y8&JIQ&QY8UKFBHUP3L-KF!Z`;-7NOOXXSL(=AL&!X8,\+K-*5J`WJ< MGL/8\8?*!+0AC4'A`N`B3KP_SU[BA.T59:L#<2F@QNE9C-VQ0@D490Z#O58/ M$_)*XWD:ODO-JU\8P#L]7[$X`AC@M9_5X(!RR?Y(MQ1'FJ2*G)PZ>VF=&UBI MRNXH+N2==%$<0O$(ENZAA%A:H8Y8?0SPI(OB,$EE.,$R60ZK#8I(W:_[G711 MB*$*2PK,KPD/I8*RE:(HH:]^1H:A'^2RD4$B)VY)@(TB,EG70)PECRY(M^*( M\<.-91]L7$/&H6]:L:L$(DI90]STM6?V)Z3"JYS<:H`0%`&EM=A<@MBMZ(:`\,H!32@VNB6%#C6T M5KQIO@-/*7!POP<^<.Q^U4;C6UN""F?*Q)4W1T0^2.]^!YA0[&%6`'Q2*3AG#:P!SG!S/7@#APKU3XZE<619X M0B$4%@"(545G*CIX&M%:GON$#OY\S'B^\U M7/IA2$87[[L)NDW=0[]FX!B%9*?C"08^9$J`K31Z^>[&:8`'COSY/1Q1`I:] M2@^VK9Q[57RIUESZGU$(Q>:V58*RE11O/]#K@/<\80DV8NF%1YNU&(Q[?NA' M`7E\(21+ASF_+R2C@9N<6.O@G<'XAD;0,.J'0Y8&EWF0^DZH3G%OY]4_%^A4 MET.W/_1PO$"G3:Y@2[>/J17W0E>P'@,2^0F-=<,EB]][.!Z0XYA(8$(1/%'!!?B0+%W[Q&IZX(V*M9TA1T<+\N5M3P?3YMNK.Z!54[S@A)`#2Z%K92IBUAL74M%:6:]Z5U6 M#$C");B5,O@>(%O75)V>4N0`G_W\F&+*GD,L/M?AXDR"O8P"+9PG9#`N-FGY M2N-EG&9I;I"\T2@6]S9<@'.4>7@JVW"4,\B; M?PO#U1M[?#6?3U<9<9_@QQ4G.SK%@2RGVPE'WL&?T/0):\.ID@JM\HA)KP(@ M#,6V1=^XY9RCB!9EIM'KZ2R,WPGI1Z,KFI``RN5+FP4P>>X!G;(`'<6FQ<10 MG*E*'RK*G*/W<;1"P*)JYB$LR#-M.^N5!O@H=BL5+6T"UFTF4EM7_&!/0S9; MO.7,J5A%2$H!->X?T,"R>%#RU(8W6`0@E4L%:3F@!T7H@M*"1H8O8G/[](JM M.T$I`3Y?V+Q(F$0RRV_&OK'.HI$R15W:.\7QUKF&/?F.H(W1_N,LAW>'KR0B MB1\"UOYH2B/*!(",OA)=A]`J#W2A"&\H[1(&*"T=?=E=38)+9\D\R.8L;6P^ M&\K7CZ+O`2**H`5C0VJ@LG6"9==RM2Z&[E1/>A[FUX%_]V_ZNEY_'ISO5F28 MS4%?[(*6!=QR"P`C[N730QJ?/\W)R+%U!C@B8YA`635?YW3$K@CA.@GL_'44 M6#@'ZIS5A6XO6T@TDBJVQ`P=E"H6#NVD!BLV.XV7*`JEPCV M]`2%ZK1G$;[A.&UOPXVI MB=0>0VTX9>)O)PM;V(OWS2=%KFY\FN2W"@K\,*DU8+<-8E@$TY!F[P_\1"(' M_'4P%0+ARH:[F>@!-5#8HGMC5CE[H.D?-PDA>1);DF:'='G>;X.UW.MD37%X M,8&6#@[=I_[BRX[[?.U92S9`/)%D*LL/5M^/@G6Q+UK9*Y%U_YJF?JN MZ"L=D6CD8N52_&VPEM,0ST8-XV("VW3G44E9*N)L::RO>8Z[VVA($AJ/?B+Z]5H`)G8K]SON`;2K;=#6T]`"R"%J^C5B@24[R('LA MR=.+'^FPFO]'EAQR/0[5,4O8;B.8'\'9",+9I!ZBVW\9]^2O(_C":>[I<:U' M\,4F%;M+/\A@P9.]&Q^[:U4(L%!H_C:,HWG4;L!+&X[7[>0O/3W%>5I@8$S! MI"*&VX9C=[NI3D]/45RJE]A,8&0Y(I372_5]W."H4+LJ(`:!P&RSPU=CH@U! M`:77STMJ"NEH%H]LU+$I$OT6F`&3)&SH/I8W-'*2+$5!S/+-$(RU2=9,#8"[ MN:O19[=_"&R!2=M%X;`\AE!DII7-P17P7K*P>O;XD,3[ZODAX!:3JEK)^^ID MJ&K`PY>%]T5DPK:IC1XG;^)D3&@V9YD&ZQ\L.;\&%L&D7Z(8,84T50U=:)'C MNEZ7.@U3Q^BT`I(L124LUJ774;.=]A\D94<,T6@=OA&S/QW2EW6;X)UVG8;T M8W1Q,^YP!"C87N3N'ZLMN/D>O>;LZ/CR@5L`YG!ZW(%G65R2.EO!!4A")BN, M`,O("R8WUCY2[_T6&`/!>0RN(5E`4GW'],WSV4*GKBLPS$X+P'28+G2@\&\C MZ@1>;WRFU1@16!5%M^+(>62D44/`F`B.X0[<#VI@4-`=C,_O:GB8NS(=>\JF MH6<[:`48I36'><[H$_AT(Y]SK,P?1R=U-<`;-@6,^?.=$];"H:!#&!\E-G]O MVJ1U?FN.*9U0)_!YXQO;K1;5"\J`H^Y0K6%@ZK\.1FM@5-!Y#OQ0:DVQ)_=Q MM."HO/<[:0>8IC4'J@X)%/CVSW4'?%\9=C3^:YNN]]=):Q7J!%!KY;7M&#B MG'QKLE/7TJE\B\!XI<8501S\@N9I`2K0&3MO-TV06-@IYA M?-*,IF?4&A78GTR2/.3Z%KBD44J#VM*+5&T3F/?G.WNNETQ!7S$^AF[*^DG? MVP_<`C#'3W8`;9DZ@2!6'=1MR!)5XG&F,Q1IXW9L(3%8L=T_\>-,9RB>#=ZS"-]P MG+:W(0]3R<>9SE#D7M,UW7[;W3[.9,=T3S1CL\LM;)!?Z0C6TXH9DOL]T.%4 M6#OH;"EAH`U/*^W!^YUF+_F"E&T[7^CL*;Z.,MCF*K,N&M8$%#I5L#3LJ^D0 M.C@MO4MD-T/C]706QN]$O'#B?`5PG(HSE:S`T1UYZ"R]JF/76/=QI&>OO0\! M%(K7B&V93`#04G86IZ/QY0LEX^LW$LPS^@I6W1]MIH M;24K<>H)5S0A`=2M-/[VA\``"JG+HKUY`&UE\7"\C?K/.'F"7TD'XRORG+%3 MV3RIR2/X=D(S2E+%ZERS!N_T\\^C;AEQ8BNW!G8_4B[>M>L`WE`(9T9F+NTI M1?` M&BB41(Z+2.(X:B'!UN5_N]/+D"3C.)FRY!XY(OG$PO\:\*%0^NJS'6?VD5%A MZ\Z[T]%G$9@$&SSRQJ)(;]-T3I)T,407;RV;E`[]9"5TEN(O%1*8L(RP`L*-=3$BGP_ M4$"T=8W8[?IV_IR2?\V!S^M7^(?&'D=0`CA!(8H>9`Z1F4>BAAYD[+-%EZYI@,QUS>65G^ZVXKTF2UYE66? M51'7NAN"/T<"JG,4@C)NGSMC3."#2.)G'TGR"MV%C_P^7MY,?XHS/RS^E]OH.ULWSO]@D-E0>QY6U0)O.Y0VGVM[@8_ M(9QO[?T"\(A#],'N`1%-]^DJOR(L\QK`88:;OJ5HH1@8\T*PK^,O33=(ULD#RP M)<:6C+V!O?ROJ2RO8:GZ@$\4@67U'CM4H$;@:LW*E<'%OYC`!^/-O:1+G[V# M>?&^2X6IT^G7[/7<9CIVZ'ZF)`D1O\`FL? M6+RW'`FMI?;E'*9[FA_+,7D?9_\DV0,)XDE$_]PD:)5%4MO^3>B,+5[!'X@^ M@7=7.20X8+;?>Y+=Q6DZ)$G.RS+-KXO\OM=^PIZ'6#=%(W.OJ(C7/3YV%N2S M#A']T`'BN,AF;$$FKL8CMLLR2CV MJ7<:5U!M_020CB-XORD[T!WFVI`>NB(C_6D\CV2JII7ZO6X'QIQ46+ MA-G*6NWT!;\'DF;)/,B`"/;<[WNOBRV]N*8% M^8X@P=@&R7H/GG+#*B@!E*`XMY/82]/`13QN%65!>-!6BR]B%F$^7CV+D,I3 MLFH4!>`HSK:D=N'$_VA#ET<.;`G*\`#HK#H5)6X`WO''1MT(UW5QN7+SYER=Z5QP/R@D`0BD,@"^8W`>Q6 MFA5TWRMPW3^A6L6:;.Y].%"+^D`+I%'K.?Q_E/$I+?`1#U M??.:O"Z.;-/Z-N2,"65AM^*QO?T3#I/1`4C%D4ZXK`.HD-7P2-Y!CZ]R'Q[Z M2?;^E/A1Z@?Y?(GA$(O?,JVS*WE1,%P7PY$5OY47[UO_Q>#P2KL^(`#%7EG/ M4.K3*T/@[3C'T@&M/-S2K02(0[%-KV!UT;!N1D$[#L0VR#3.PG8_!B)0[-E- M3:=V@"(^E,=BWR,*6\@4=K&#\>\T#0`MC;[Y(YI*0N\U2P)L%!MYD4$XZW)= M4&VX9"'P=KTMN[PHD(1NNU[GX+X#W.TU#5%^C'R+>1N]QC0@H^^PJD\NH10- M_/`IH7ZXWFF*4T9IU^#U3I'$->B8BS,.F$)U>]`F5VF>XCPI@J&QM0I[71P) M@DO;V0"EI0,R'((MEZZ%TZ>#<>%OYI,`KQ;H)$@D&W,_*0W7_B'=`66?9U%X7A2ZNL)>6D8N( MVJ!_[,#3T3U$18`4'!&EU<;K'3QMR#;!;ES?1NR@E6WEV"OQ?A00]F""+(&Q MI!10@^/<0FHZOKF5L-H0+[P-\L8/U'=V146`%!3G$M5MO8NI#6DE=KPYR@A8 M)V.):Q^S?*=.DH`9:R+;8.E7`L2A.,VPT/&5*-W&%XNB2;=`?/-9X$SVOGAS M6!A:*BD#4'$<4A@85!-4&Q(U#),X(&24L@P`]W%&TJ'_KE!+1$6\7@]%R&"9 MKBO'9"N,&-%`_CT"4*.+.$GB'RPPSI_Y`;BWX20NK06XPZB@E1C*-6#6$$%\ M0!WZ,H;OHSS==Y3&(1TMWO.!?^9',^R^(UF\S.(D[?5M!"TEZ_9HB-*"$MY) MQUT$X:HQ2C5ZZT-H,@IM0\JH8-_+`=(*`7J%ZQ&6HOH>I3,2T#$E([7H+"H#M.#8TXIM)C"R'%$K).<5)UI:Y-[' M0`2.':IYQ]W!T`9Y>;DP65[M6+Y?"2L9G9-K95F@"56!`OKDU8;4H7P6[ M#P2,O@#6*\*6MC-&UA*V-+9&4LX[.4&QG=4T)]\7-!!:4J,Q^,%7$@%7(8#M MCZ8THHP?EO!0[0F*DL`4BJUL)5_0PMBJ^+MJ%R!/3E!$AU3M_UQ8EJ1G#&;> MI45BY-U/@0L4!\J53,P'94F;SM@;;T[-N^9F(4"PA]ATEG2;KX$/%`)*R47< M+A!;6K1[R]['4;R-\HF5U35BVQ&8,P_<52>AKO@[9Z.WI M?9Q=D91.HCP[;OIW,IKDC*P_^.K3B/6)>R(_K*A8-]"-8J^OZ1>BLPPK+-A* MBH'+Z58P!]'F;[I.)2@+=*%0#2PYC12EK2P:&)QB%;"QQ5611+E?Z!3W3DY1 M:`J57$,?J,`[C!5&#-XAI*S,*@7H0;&WK.0'"G0"XQL+C`@6JB33VGQL?0CGLO?OHI#9@RRMY%D;\N+R\)1#5PLZ$%2F#]1@J" MOQ,Z>6'+76B,/R'WZ2NZ*PR=M8K<4H)61Q+5T5DH_Z>((L[1I41W-I2N.S&QD3%9_])_S M-,NW2$_Q`PGB**`AV<+\%&LRK#'XU/%S8!,M!)>F:HT M98=1 M-HA@&(V=/H6;7_YK3F>!!(;,*@#84>_]#CTPF[%0.Y_NR<*J(3)@3(XFLPAC.USU! MH2DM0K,2(!"%%'%HSS)ER%;DH?MUVC[R?I"O4%5<^AQ4#K;$/34RN+N4JJ+J=2OQ>CC"0^IR(CGNRG&: MB!RGVCE';2?3T$-1.-A!3B0K\V0KYM-]V+B`C=OHE:1U!DP8_@#0CBN`JDK` M1"GL`IETTD"I_H',EHO+P?@NCB9/))DN=9H[ MME(8/(=THIP4#6H!`E&<,];O1<:D"+Q*7Z6WLOX2!(`]D%?FK(]9'/SQ.`MI M=I,LGK3UPSRB3?A`$C533B^/HZDVQP?@RGD[C*.=! M+:]F)`-(H]6/T>:(,G@4,V,&DLHZ(?Y7(_S##^?FWK%3'DA# M$?]NPRVXT`3^8)R?9);['#0SR7X*KT!QW%:/5XC?"3)6FQ=><1VYW7L]SF>S M,.?)#U?Y?&ZC<9Q,%P;3R+.D5P.0AT+0,?,+(W`"SSAPQEB!,'/CTR3WXL'X M=W!J']S[,O33-,_JTD\WL>RKJ-!WD5)C7A/0@V(/;F1-CC93%KG`,0ZJ`TO> M1%YHURFT;JEBL^7UZJY,CG>%ELD*W+2!I>ORNFA#_)6,&V(M97ATFAUU/>N[&+O6/[XQ M@3;NN`V%G3-@ZFT^D$)3P<*9S*LL_O@S*L M]M,4'[#7[<43`#,/)%@$F*R2>CGHBDQFR]XU>MGVAUYO)W>BU6`5#C>RCF)> M"30?A1+"(U4G&$6-[6"=Y6^?6'N?_93D;/X74$L#!!0````(`(N&!$4X^`V& M[@X``%:9```1`!P`8VQR8BTR,#$T,#8S,"YXDZ%E^DZM+*D2 M?4F:R60H$I(P1Y$*`-I6.OWO78"D1(D$1%*RS4OY16&!W/P#<72S7[[][ M6KC:`R(4^]Y5HWURVM"09_L.]F97C7OSMOE-0_ONVZ_^\/Z/S:;V`7F(6`PY MVF2EW5C,,HEE?Z8QO=8^:9^\T^#B]$U3#V;-L]/V&^VG]MGEF]/+\XN?M?\, M[_ZK&6-3:VJ/CX\G#O3`1`\GMK_0FDT^#K7G:&%IS"(SQ/K6`M&E9:.KQIRQ MY66KQ>D\_P&YOB!J\2%.WYUSMEVT0!Z[]W6Q]WFK]=.$N''[\Q9_/+$H MBIOSIPY;$R0;OVV%#]=-746_/_2@XV2G6-$8>Y19GKUA(L5T)&+[XN*B)9[& M30/:G%G6!)QB@.6A)D\W4OG5\7+8O8 MQ'<1<&"S)GI:NI9G,9^L;N'W6B&^YP6+[$X<1EJMW1Z^^L-N]P%%SL#[5EP#?A1Z$[1\TXCHHR9JVLT@12EMR[4#5SIH1-;: M@B+191F,.K[G(`]&@`OJN]CAL_;:Z";\N-9[>K]C:../AF&.:]A*PS:T8.MG<\0PL)<7PVTB M-:#G90#5?MH:XN<:X"(`K]5-!]/!DEN6P)%J@4H(U,"^R0?LV(3_[HP^@#JX MU09#8Z2;76A00UH6THY%Y[>N_Y@7T4U[-:!ORP#:T<X/L:4!F@?8L% M!`VFUP'%'J)T0&:6AW\3/(`9\L$'GQ"PLQ&)S)TB!&I(WW&3!U,;^($>X4=? M-^]'!@?N^G[<[1OC\5^UP>B#WN_^6RQ+3>_?:!\&W?X'#GK'&/5K6"6PWEJ8 M?++<`(6@;7ZJ(?G;+B2W>G>D?=)[]T:M:OF6^(`(PQ,7W:`)6^][6S?5:O]F M5^TPO3\9([-[W3.T&^/:K)4O4?X(\3`4&C/?_CQ>NIA[82-P6Y>866ZT*X6( MY&JIANEB%Z:1`2B-P2XT!YU_:N-AKVN*/6ID=/1AU]1[T<95PR>!3Z`Q]UT' MH#%^#<#A#<'*N*^$IGVZ"XV`Y..@=P,`_?E/YQ=_UXQ_W7?-'VLH5%#P@"68 M:HLEV&R)M2-YIH:DG0E)\UH/C;:[(9AO]>I00=+UX!*9UA.*K.GD#;7RSW:5 MW^V#R@W-U'\P:F-8:@PCUO,I'2(RGH.+'QF\.S?5BC]/&;6&J?4&X[$&SJ4V M_JB/:DM*;DDM%I@)QQ!>SF!",?`ED&=CM/8FY0W4L+Q)6UAW=UTS]!3Y*QLL M+A,<"Z/?Z=8+1&%N448"&SQ`X>71.+*:<5^-Q]NT*34V1_<=<`!#]VY>,CHR="*D-]9/ZHF2,=7M>=.CJFM*&" M"46_!B"K\0#_1,;3SDTU#"D/?'Q_/0;3%38J#;R-?NT*'B&2-?1=O'FKE"%4 M@YCRYXM'MK2OX['^4B.^+\AE6A,W1G/WIAJIE$N_"7AI7X<]U/K/[[TG@9`^ M52)REMN3K_$IY]*G,)*U4..4V[VO<2KH=B8!RGZD1B;E^Z==T!J3(UH3-XA9 MV*4F>F)!G*90GER-;3J\4,*RB$;4HB'K2;#7P(@TMF-AQ'?5D*5"#TD3(^JB MAB`O!.UL#-I[0$C%&S)`T-HU#'EAV-KL9`_5D*0"#EF0U%M4L=/G+'C43=0@ MI<(1NR?3-51'/:O.PJ\$G1K45'@B[SEV#?8!OO&6#2%_K(8N%:^0>\>U:5'* M/4[#)&VBA.H\.Y"1Z2#74!T"53L'5GOLP_,"T8S:6CP,KK,<<)WM@2L5XM@/ MUUD-5RFXMDR17"W5T*4B&/NAJXV-8@'$K5>8Y)D:I%3,(BN$6+^U"F=+9)OW M>UJIH"U&9IQ#89?0.B3IX4;-^$C**H; M"*1W]10-''<1?:&NKGD`G?A+'B)#M!4SW]!:1Q0,$"DJV#:(U13+M29%Q0(2 MY%97(E@`127:63/'E2M<;\E*!O`K6>E`W`*Q?,(T+[-RBJPD2%ATI>?;HBL% M"?_5C.F:_%:S?=8\;Y\\46>C_2),;&0LQD1,5X*)[((K.8>/"?BX;_..J*R8 M(AE8#)I)V$(NH_&=YJ:K0O(KJI>H&,H@BZZ;FRY*,9)5%28/)TFZ^,?!O&15 MFLG%3))P_>M0C%)%:?*PLB825X>RD"Y8DX>'#55XV=QT4(J+W2HX>7B(:?C% MP>/O%LC)Q4!,)*Y*L)`NMB->-AZ:<9\CW\[E$K)%Q;>O"[YMMM\=S$;.S3/! M`CO*\.J20WE92O9B;#HIP:&R\%2>F1+3\(L2"U9=&BF70G:I#L4INZI3,4Y\ MKU^:&74]K/)O7M&7'**H%IU@"-Q+&,8)7#28=N:6-T.TZZWS)+ZW"+$\1CNN M1:DH5==#X,":8)"&*7[<:;QV??MS0PL-U["(UB6+[W<96G#?JZ%9$\K+Z;&K MQM1R1;DY7A/N$JQ)[#NF('8"$GW,Z6'7Y?U?-1CAM0$H^,`,LX`__4#\8'G5 M",DQ]!^ZR=P\_N58PDATE;]&$ M!!99<:-[&$Q`Y,%TBCB8\890&9GRLRJ3-=[K!M/T;J?3&^CK`7A\0#UL3;"+ MV6H0,.XN\XJJV_-]X8,A!+P4VL!#WYNE-1`VG83EST!:@AS,"BCF,+F.IJTC MJ$@^2W9TY*#)\ZHHSXIY,\1+5.5UDLF@1*[M_$*X#WLC_SX[)C?]84#LN441 M_W[;]\0A\LY;@!]-TN.LB;S2EF1;HH2AM8H*$6?V6^$9OI=SF8&+[(!@'K*, M]:3/P.3C+;H\;AVF!L!K*1T2WT;(H;?$7XPM;@QO M.GY)?(ON\CF85T_J@1?5UAYXUSXA_B/L_E_`C):PK;;%J/&TQ*0ZI4).6+A7T=""Y[L63Z3@[;;\TBZE`0^855D!9>21 M**?O>[9%YUV/(=B]>7"+U]^,4A5,G[LOW$\9>*FZ=95=S^5%RF.)"0,.#5W+ M%DVJ:8U)F"SLFU51.@F+A65;:T>?H8J:U?DXEJ[L!]&@LC-V'X,2N?X1>*BB MLU3.FD26>\]!Y!',*H:\RDFC8DXBC[XDV*WLA%-RI[;SS$>_,F*D6=K#.P^M M5X[[)%/[ST02Z>,\YQ6\3Y&>+'++(_M=Y_W.PJBK[KK1@0TX+NN&N[W0ZQ5, M`Z]R\,I+)69.&#Y]Q253HU.FEY-R[]Z9'?;2(DYA\E/N;X8$8 M^)J+\%Z%-]6#!)*IJU2?%9IN!PM08!XE)V5R!-UF^"$N_%7UN9-3B+WS95\_ ME9PC!9A6*>!ZMZ_$AG:]VC1)3LEHI`X/#;DN#WL-A9`'GQ`=23_'E>G8V@N+ M!VQ"A30:^EZDYR(G<6#;#Y(FPNL=O+VDK&7538LB^SW"LSGPH#\@8LV0\03[ M#J8(G%-[O?-QDVP9?8=9M9E\9(&?:9,`L_F3@#H:CJOB637_>I.]M,3/I/J, M1;;#QPAQ;R,L;"?T&EBNBG<];DY0;$=_ M!.K%4I`*'NV\I`[VQ$4JXT'O,K0_UE$9UC-XDDU^;F1V8,/][M%G#]OUHSS)]9KG))UVO([X=8S\BBU3X//ZX8CZ7+GGOYJ/_ M>];C6L1GU2$_V/G=:S$44G;NMFWI?>#G73P-*Y$<'!KIT7Z1D?W]>A[(0!5WLP.$$J6P@$FK(-=,738=H2FLV!S,YSD6<2F1 M\,YWQ%=WX3R(%D!E)%-R)Y.(#"UW@:N3H+#+D"P5&YK]YKNH.MI/<;3GVX9I M+U@LQ\%"7_`A4$W7>_#!6W!$3F3'Q1XL6-L?4>?C4OJA""\+N.1WQHR?E(@>Q/?9T;]5*[10B..\ M9D_&WPNHFMP%>3Y$\JKEHA1@^@"Q*Y1U4I!=U0'"UE]0Z/L,I?K>?%G3\8?)X=^P9"@!^P'U%WI`9O[!/^V^_7;ZWQMG8M-M;%F^CR$ M0"OPNBYIG^T30/'!XR;MY8[_;3G^5LA(DWJETW4U@T4#$Z/4A[>O,6/WL,>% M>M\*BTD)^?X'4$L!`AX#%`````@`BX8$1>S1+,Y8I```YH8)`!$`&``````` M`0```*2!`````&-L&UL550%``.%\M]3=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`BX8$12Q36&/B!P``>6@``!4`&````````0`` M`*2!HZ0``&-L`Q0````(`(N&!$6.!`L``00E M#@``!#D!``!02P$"'@,4````"`"+A@1%U7?AY]U)``"0+P0`%0`8```````! M````I(&@W```8VQR8BTR,#$T,#8S,%]L86(N>&UL550%``.%\M]3=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`BX8$130,5N+`-0``$*(#`!4`&``````` M`0```*2!S"8!`&-L`Q0````(`(N&!$4X^`V&[@X``%:9```1`!@````` M``$```"D@=M<`0!C;')B+3(P,30P-C,P+GAS9%54!0`#A?+?4W5X"P`!!"4. =```$.0$``%!+!08`````!@`&`!H"```4;`$````` ` end XML 50 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCK-BASED COMPENSATION (Tables)
6 Months Ended

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and recorded in connection with stock options granted to non-employee consultants:

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Employee and director stock option grants:

Research and development

$

47,274

$

106,774

$

110,701

$

212,612

General and administrative

176,581

264,243

360,965

576,282

Restructuring costs

47,853

—

47,853

—

271,708

371,017

519,519

788,894

Non-employee consultant stock option grants:

Research and development

1,982

3,311

16,697

4,322

General and administrative

—

3,565

—

10,575

1,982

6,876

16,697

14,897

Total stock-based compensation

$

273,690

$

377,893

$

536,216

$

803,791

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The following table summarizes weighted-average values and assumptions used for options granted to employees, directors and consultants in the periods indicated:

Six Months Ended
June 30, 2014

Six Months Ended
June 30, 2013

Volatility

108

%

109

%

Risk-free interest rate

1.76

%

0.92

%

Expected life (years)

6.0

6.0

Dividend

0

%

0

%

Weighted-average exercise price

$

7.40

$

14.80

Weighted-average grant-date fair value

$

6.20

$

12.20

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of stock option activity is as follows:

Number of
Shares
Issuable Upon
Exercise of
Outstanding
Options

Weighted
Average
Exercise Price

Weighted
Average
Remaining
Contracted
Term in
Years

Aggregate
Intrinsic
Value

Outstanding at December 31, 2013

634,658

$

18.20

Granted

20,000

$

7.40

Canceled

(20,521)

$

23.17

Forfeited

(14,474)

$

15.00

Outstanding at June 30, 2014

619,663

$

17.80

Vested, June 30, 2014

264,752

$

29.00

4.04

$

—

Unvested, June 30, 2014

354,911

$

9.20

9.26

$

—

Exercisable at June 30, 2014

264,752

$

29.00

4.04

$

—

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE (Details Textual)
6 Months Ended 12 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Feb. 20, 2014

Oct. 31, 2013

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value Assumptions, Risk Free Interest Rate 1.76% 0.92%

Fair Value Assumptions, Expected Volatility Rate 108.00% 109.00%

Fair Value Assumptions, Expected Term 6 years 6 years

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,964,085 275,000 96,278

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 550,000

February 2013 Public Offering Warrants [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 825,000

Maximum [Member] | February 2013 Public Offering Warrants [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value Assumptions, Risk Free Interest Rate 1.27%

Fair Value Assumptions, Expected Volatility Rate 115.00%

Fair Value Assumptions, Expected Term 4 years 1 month 20 days

Minimum [Member] | February 2013 Public Offering Warrants [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value Assumptions, Risk Free Interest Rate 0.07%

Fair Value Assumptions, Expected Volatility Rate 75.00%

Fair Value Assumptions, Expected Term 1 month 20 days

Legacy Warrants

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,365 ^[1]

Legacy Warrants | Fair Value, Inputs, Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,365

[1] The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as a derivative instrument as described in Note 2.

X

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 52 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (5,029,249) $ (5,518,341)

Adjustments to reconcile net loss to cash used in operating activities:

Depreciation and amortization 188,369 219,968

Stock-based compensation expense 536,216 803,791

Non-cash interest expense related to discount on convertible debt 50,805 0

Loss on disposal of fixed assets 2,268 4,513

Gain on revaluation of derivative warrants (518,806) (666,384)

Loss on issuance of derivative warrants 0 744,957

Changes in:

Accounts payable and accrued liabilities 33,320 304,484

Prepaid expenses and other current assets 132,115 180,024

Other assets and liabilities 2,622 4,391

Cash used in operating activities (4,602,340) (3,922,597)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of fixed assets (15,191) (92,977)

Change in restricted cash 0 121,768

Cash (used in) provided by investing activities (15,191) 28,791

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of convertible notes 4,000,000 0

Payments on capital lease obligations (1,263) (1,178)

Reverse Stock Split Fractional Shares (1,158) 0

Proceeds from issuance of common stock, net of issuance costs 0 4,975,153

Change in deferred issuance costs (172,407) 70,539

Cash provided by financing activities 3,825,172 5,044,514

(DECREASE) INCREASE IN CASH AND EQUIVALENTS (792,359) 1,150,708

CASH AND EQUIVALENTS AT BEGINNING OF PERIOD 2,418,384 4,677,545

CASH AND EQUIVALENTS AT END OF PERIOD 1,626,025 5,828,253

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Fair value of warrants classified as derivative liability 0 5,720,000

Relative fair value of warrants issued with convertible debt $ 254,024 $ 0

X

- Definition

Represents relative fair value of warrants issued with convertible debt during the reporting period.

+ References

No definition available.

+ Details

Name: clrb_DebtConversionConvertedInstrumentValueWarrantsIssued

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the fair value of warrants classified as derivative liabilities during the period.

+ References

No definition available.

+ Details

Name: clrb_FairValueOfWarrantsClassifiedAsDerivativeLiability

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash interest expense related to discount on convertible debt.

+ References

No definition available.

+ Details

Name: clrb_NoncashInterestExpenseRelatedToDiscountOnConvertibleDebt

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the amount for reverse stock split fractional shares during the period.

+ References

No definition available.

+ Details

Name: clrb_ReverseStockSplitFractionalShares

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3095-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfLongTermCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCKHOLDERS' EQUITY
6 Months Ended

Jun. 30, 2014

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

5. STOCKHOLDERS’ EQUITY

Common Stock Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of June 30, 2014.

Offering

Number of Shares
Issuable Upon
Exercise of
Outstanding
Warrants

Exercise
Price

Expiration Date

February 2014 Private Placement (1)

400,000

$

20.00

February 6, 2019

February 2013 Public Offering (2)

550,000

10.00

February 20, 2018

February 2013 Public Offering – Placement Agents

38,496

12.50

February 4, 2018

November 2012 Private Placement

50,000

25.00

November 2, 2017

June 2012 Public Offering

149,069

25.00

June 13, 2017

December 2011 Underwritten Offering

462,411

12.00

December 6, 2016

April 2011 Private Placement

302,922

15.00

March 31, 2016

Legacy warrants (2)

1,365

10.00

July 27, 2015

Legacy warrants

5,252

321.30

July 27, 2015

Legacy warrants

4,570

1,989.00 - 2,019.60

December 31, 2015

Total

1,964,085

(1)

Warrants issued in connection with the sale of convertible debentures. As described in Note 3, the warrants are only exercisable following conversion of the associated debentures.

(2)

The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as a derivative instrument as described in Note 2.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONVERTIBLE DEBT (Details Textual) (USD $)
0 Months Ended 6 Months Ended 12 Months Ended

Feb. 05, 2014

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Feb. 20, 2014

Debt Conversion [Line Items]

Convertible Debt $ 4,000,000

Convertible Debentures And Warrants To Purchase Common Stock 400,000

Payment For Convertible Debentures 4,000,000

Securities Purchase Agreement, Initiation Date Feb. 05, 2014

Debt Instrument, Maturity Date Feb. 06, 2016

Debt Instrument, Convertible, Conversion Price $ 10.00

Debt Conversion, Converted Instrument, Shares Issued 400,000

Debt Instrument, Interest Rate, Stated Percentage 8.00%

Gross Proceeds From Sale Of Securities 2,000,000

Debt Instrument, Interest Rate, Effective Percentage 12.00%

Payment On Default On Borrowings 100,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 20.00 $ 10.00

Warrants Expiration Date Feb. 06, 2019

Default Value Of Borrowings 150,000

Debt Conversion Converted Instrument Value Warrants Issued 254,000 254,024 0

Debt Conversion, Converted Instrument, Amount 3,746,000

Non-Cash Interest Expense Related To Discount On Convertible Debt 50,805 0

Deposit Liabilities, Accrued Interest 128,000

Fair Value Assumptions, Risk Free Interest Rate 1.76% 0.92%

Fair Value Assumptions, Expected Volatility Rate 108.00% 109.00%

Fair Value Assumptions, Expected Term 6 years 6 years

Debt Instrument, Unamortized Discount 254,000

February 2014 PIPE Warrants [Member]

Debt Conversion [Line Items]

Fair Value Assumptions, Risk Free Interest Rate 1.52%

Fair Value Assumptions, Expected Volatility Rate 110.00%

Fair Value Assumptions, Expected Dividend Rate 0.00%

Fair Value Assumptions, Expected Term 5 years

Subsequent Event [Member]

Debt Conversion [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 8.00%

Gross Proceeds From Sale Of Securities $ 8,000,000

X

- Definition

Represents convertible debentures and warrants to purchase common stock, shares as on the reporting date.

+ References

No definition available.

+ Details

Name: clrb_ConvertibleDebenturesAndWarrantsToPurchaseCommonStock

Namespace Prefix: clrb_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents relative fair value of warrants issued with convertible debt during the reporting period.

+ References

No definition available.

+ Details

Name: clrb_DebtConversionConvertedInstrumentValueWarrantsIssued

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the amount of default made towards borrowings.

+ References

No definition available.

+ Details

Name: clrb_DefaultValueOfBorrowings

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the minimum gross proceeds towards sale of securities.

+ References

No definition available.

+ Details

Name: clrb_GrossProceedsFromSaleOfSecurities

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of noncash interest expense related to discount on convertible debt.

+ References

No definition available.

+ Details

Name: clrb_NoncashInterestExpenseRelatedToDiscountOnConvertibleDebt

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the payment for convertible debentures during the period.

+ References

No definition available.

+ Details

Name: clrb_PaymentForConvertibleDebentures

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the payment on default of conversion from debentures to common stock.

+ References

No definition available.

+ Details

Name: clrb_PaymentOnDefaultOnBorrowings

Namespace Prefix: clrb_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents securities purchase agreement, initiation date.

+ References

No definition available.

+ Details

Name: clrb_SecuritiesPurchaseAgreementInitiationDate

Namespace Prefix: clrb_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Expiry date of warrants held.

+ References

No definition available.

+ Details

Name: clrb_WarrantsExpirationDate

Namespace Prefix: clrb_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtConversionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of accrued but unpaid interest on deposit liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_DepositLiabilitiesAccruedInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 106 180 1 true 30 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.novelos.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.novelos.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.novelos.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novelos.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.novelos.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 106 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcern NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN false false R7.htm 107 - Disclosure - FAIR VALUE Sheet http://www.novelos.com/role/FairValue FAIR VALUE false false R8.htm 108 - Disclosure - CONVERTIBLE DEBT Sheet http://www.novelos.com/role/ConvertibleDebt CONVERTIBLE DEBT false false R9.htm 109 - Disclosure - REVERSE STOCK SPLIT AND RECAPITALIZATION Sheet http://www.novelos.com/role/ReverseStockSplitAndRecapitalization REVERSE STOCK SPLIT AND RECAPITALIZATION false false R10.htm 110 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.novelos.com/role/StockholdersEquity STOCKHOLDERS' EQUITY false false R11.htm 111 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.novelos.com/role/StockbasedCompensation STOCK-BASED COMPENSATION false false R12.htm 112 - Disclosure - INCOME TAXES Sheet http://www.novelos.com/role/IncomeTaxes INCOME TAXES false false R13.htm 113 - Disclosure - NET LOSS PER SHARE Sheet http://www.novelos.com/role/NetLossPerShare NET LOSS PER SHARE false false R14.htm 114 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.novelos.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false R15.htm 115 - Disclosure - RESTRUCTURING COSTS Sheet http://www.novelos.com/role/RestructuringCosts RESTRUCTURING COSTS false false R16.htm 116 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.novelos.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS false false R17.htm 117 - Disclosure - SUBSEQUENT EVENT Sheet http://www.novelos.com/role/SubsequentEvent SUBSEQUENT EVENT false false R18.htm 118 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernPolicies NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Policies) false false R19.htm 119 - Disclosure - FAIR VALUE (Tables) Sheet http://www.novelos.com/role/FairValueTables FAIR VALUE (Tables) false false R20.htm 120 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.novelos.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) false false R21.htm 121 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.novelos.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) false false R22.htm 122 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.novelos.com/role/NetLossPerShareTables NET LOSS PER SHARE (Tables) false false R23.htm 123 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) Sheet http://www.novelos.com/role/NatureOfBusinessOrganizationAndGoingConcernDetailsTextual NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN (Details Textual) false false R24.htm 124 - Disclosure - FAIR VALUE (Details) Sheet http://www.novelos.com/role/FairValueDetails FAIR VALUE (Details) false false R25.htm 125 - Disclosure - FAIR VALUE (Details 1) Sheet http://www.novelos.com/role/FairValueDetails1 FAIR VALUE (Details 1) false false R26.htm 126 - Disclosure - FAIR VALUE (Details Textual) Sheet http://www.novelos.com/role/FairValueDetailsTextual FAIR VALUE (Details Textual) false false R27.htm 127 - Disclosure - CONVERTIBLE DEBT (Details Textual) Sheet http://www.novelos.com/role/ConvertibleDebtDetailsTextual CONVERTIBLE DEBT (Details Textual) false false R28.htm 128 - Disclosure - REVERSE STOCK SPLIT AND RECAPITALIZATION (Details Textual) Sheet http://www.novelos.com/role/ReverseStockSplitAndRecapitalizationDetailsTextual REVERSE STOCK SPLIT AND RECAPITALIZATION (Details Textual) false false R29.htm 129 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.novelos.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) false false R30.htm 130 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.novelos.com/role/StockbasedCompensationDetails STOCK-BASED COMPENSATION (Details) false false R31.htm 131 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://www.novelos.com/role/StockbasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) false false R32.htm 132 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://www.novelos.com/role/StockbasedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) false false R33.htm 133 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) Sheet http://www.novelos.com/role/StockbasedCompensationDetailsTextual STOCK-BASED COMPENSATION (Details Textual) false false R34.htm 134 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://www.novelos.com/role/NetLossPerShareDetails NET LOSS PER SHARE (Details) false false R35.htm 135 - Disclosure - RESTRUCTURING COSTS (Details Textual) Sheet http://www.novelos.com/role/RestructuringCostsDetailsTextual RESTRUCTURING COSTS (Details Textual) false false R36.htm 136 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) Sheet http://www.novelos.com/role/RelatedPartyTransactionsDetailsTextual RELATED PARTY TRANSACTIONS (Details Textual) false false R37.htm 137 - Disclosure - SUBSEQUENT EVENT (Details Textual) Sheet http://www.novelos.com/role/SubsequentEventDetailsTextual SUBSEQUENT EVENT (Details Textual) false false All Reports Book All Reports Element clrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresRate had a mix of decimals attribute values: 0 2. Process Flow-Through: 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS clrb-20140630.xml clrb-20140630.xsd clrb-20140630_cal.xml clrb-20140630_def.xml clrb-20140630_lab.xml clrb-20140630_pre.xml true true XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCKHOLDERS' EQUITY (Tables)
6 Months Ended

Jun. 30, 2014

Equity [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The following table summarizes information with regard to outstanding warrants to purchase common stock as of June 30, 2014.

Offering

Number of Shares
Issuable Upon
Exercise of
Outstanding
Warrants

Exercise
Price

Expiration Date

February 2014 Private Placement (1)

400,000

$

20.00

February 6, 2019

February 2013 Public Offering (2)

550,000

10.00

February 20, 2018

February 2013 Public Offering – Placement Agents

38,496

12.50

February 4, 2018

November 2012 Private Placement

50,000

25.00

November 2, 2017

June 2012 Public Offering

149,069

25.00

June 13, 2017

December 2011 Underwritten Offering

462,411

12.00

December 6, 2016

April 2011 Private Placement

302,922

15.00

March 31, 2016

Legacy warrants (2)

1,365

10.00

July 27, 2015

Legacy warrants

5,252

321.30

July 27, 2015

Legacy warrants

4,570

1,989.00 - 2,019.60

December 31, 2015

Total

1,964,085

(1)

Warrants issued in connection with the sale of convertible debentures. As described in Note 3, the warrants are only exercisable following conversion of the associated debentures.

(2)

The exercise prices of these warrants are subject to adjustment for “down-rounds” and the warrants have been accounted for as a derivative instrument as described in Note 2.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

STOCK-BASED COMPENSATION (Details Textual) (USD $)	1 Months Ended	6 Months Ended			1 Months Ended	6 Months Ended	1 Months Ended	12 Months Ended
STOCK-BASED COMPENSATION (Details Textual) (USD $)	Feb. 20, 2014	Jun. 30, 2014	Feb. 05, 2014	Oct. 31, 2013	Oct. 31, 2013 Performance Based [Member]	Jun. 30, 2014 Employee [Member]	Oct. 31, 2013 Chief Executive Officer [Member]	Dec. 31, 2013 Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		81,805			264,278		96,278
Share Based Compensation Arrangement By Share Based Payment Award, Options, Exercisable, Weighted Average Exercise Price		$ 29.00					$ 15.00
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Rate						2.00%		0.00%
Employee Service Share Based Compensation Nonvested Total Compensation In Current Year		$ 1,096,000
Employee Service Share Based Compensation Nonvested Total Compensation In Year Two		570,000
Employee Service Share Based Compensation Nonvested Total Compensation In Year Three		203,000
Weighted-Average Grant-Date Fair Value Of Vested Options Outstanding (in dollars per share)		$ 16.66
Weighted Average Grant Date Fair Value Of Unvested Options Outstanding (in dollars per share)		$ 5.98
Share Based Compensation Arrangement By Share Based Payment Award Options Unvested and Expected To Vest Outstanding Number (in shares)		273,106
Estimated Stock Based Compensation Expense Up On Vesting Of Options		418,000
Anti-Dilution Option Reduced By Expiration Of Warrants	14,474
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 10.00		$ 20.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	275,000	1,964,085		96,278
Anti-Dilution Option Reduced Rate				19
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 1,869,000

FAIR VALUE (Details 1) (USD $)	3 Months Ended		6 Months Ended			12 Months Ended
FAIR VALUE (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Fair Value, Inputs, Level 3 [Member]	Dec. 31, 2013 Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance - Fair value					$ 3,355,000	$ 0
Fair value of warrants issued in connection with February 2013 public offering			0	5,720,000	0	5,720,000
Gain on derivatives resulting from change in fair value	573,751	660,341	518,806	666,384	(517,000)	(2,365,000)
Ending balance - Fair value					$ 2,838,000	$ 3,355,000

SUBSEQUENT EVENT (Details Textual) (USD $)		6 Months Ended
SUBSEQUENT EVENT (Details Textual) (USD $)	Feb. 05, 2014	Jun. 30, 2014 Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Instrument, Issuance Date		Jul. 29, 2014
Debt Instrument, Face Amount		$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Debt Instrument Maturity Period		60 days
Proceeds from Notes Payable		617,500
Debt Instrument, Unused Borrowing Capacity, Amount		$ 382,500

REVERSE STOCK SPLIT AND RECAPITALIZATION (Details Textual)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
REVERSE STOCK SPLIT AND RECAPITALIZATION [Line Items]
Stockholders' Equity, Reverse Stock Split	At the annual meeting of stockholders held on May 22, 2014, the Company’s stockholders approved an amendment to the certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue would be reduced from 150,000,000 to the greater of (A) 20,000,000 and (B) the number of shares equal to three (3) times the sum of the number of all shares of common stock outstanding and the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible debt.
Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio	1-for-20
Common Stock, Shares Authorized	20,000,000	20,000,000
Common Stock Shares Previously Authorized	150,000,000

STOCK-BASED COMPENSATION (Details) (USD $)	3 Months Ended		6 Months Ended
STOCK-BASED COMPENSATION (Details) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 273,690	$ 377,893	$ 536,216	$ 803,791
Employee and Director Stock Option [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	271,708	371,017	519,519	788,894
Employee and Director Stock Option [Member] \| Research and Development Expense [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	47,274	106,774	110,701	212,612
Employee and Director Stock Option [Member] \| General and Administrative Expense [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	176,581	264,243	360,965	576,282
Employee and Director Stock Option [Member] \| Restructuring Costs [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	47,853	0	47,853	0
Non Employee Consultant Stock Option [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	1,982	6,876	16,697	14,897
Non Employee Consultant Stock Option [Member] \| Research and Development Expense [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	1,982	3,311	16,697	4,322
Non Employee Consultant Stock Option [Member] \| General and Administrative Expense [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 0	$ 3,565	$ 0	$ 10,575

STOCK-BASED COMPENSATION (Details 1) (USD $)	6 Months Ended
STOCK-BASED COMPENSATION (Details 1) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	108.00%	109.00%
Risk-free interest rate	1.76%	0.92%
Expected life (years)	6 years	6 years
Dividend	0.00%	0.00%
Weighted-average exercise price	$ 7.40	$ 14.80
Weighted-average grant-date fair value	$ 6.20	$ 12.20

STOCK-BASED COMPENSATION (Details 2) (USD $)	6 Months Ended
STOCK-BASED COMPENSATION (Details 2) (USD $)	Jun. 30, 2014
Share-based Compensation, Stock Options, Activity [Line Items]
Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options	634,658
Granted - Number of Shares Issuable Upon Exercise of Outstanding Options	20,000
Canceled - Number of Shares Issuable Upon Exercise of Outstanding Options	(20,521)
Forfeited - Number of Shares Issuable Upon Exercise of Outstanding Options	(14,474)
Outstanding - Number of Shares Issuable Upon Exercise of Outstanding Options	619,663
Vested - Number of Shares Issuable Upon Exercise of Outstanding Options	264,752
Unvested - Number of Shares Issuable Upon Exercise of Outstanding Options	354,911
Exercisable - Number of Shares Issuable Upon Exercise of Outstanding Options	264,752
Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 18.20
Granted - Weighted Average Exercise Price (in dollars per share)	$ 7.40
Canceled - Weighted Average Exercise Price (in dollars per share)	$ 23.17
Forfeited - Weighted Average Exercise Price (in dollars per share)	$ 15.00
Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 17.80
Vested - Weighted Average Exercise Price (in dollars per share)	$ 29.00
Unvested - Weighted Average Exercise Price (in dollars per share)	$ 9.20
Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 29.00
Vested - Weighted Average Remaining Contracted Term in Years	4 years 14 days
Unvested - Weighted Average Remaining Contracted Term in Years	9 years 3 months 4 days
Exercisable - Weighted Average Remaining Contracted Term in Years	4 years 14 days
Vested - Aggregate Intrinsic Value (in dollars)	$ 0
Unvested - Aggregate Intrinsic Value (in dollars)	0
Exercisable - Aggregate Intrinsic Value (in dollars)	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash and cash equivalents	$ 1,626,025	$ 2,418,384
Restricted cash	55,000	55,000
Prepaid expenses and other current assets	334,979	294,687
Total current assets	2,016,004	2,768,071
FIXED ASSETS, NET	2,185,087	2,360,534
GOODWILL	1,675,462	1,675,462
OTHER ASSETS	12,009	11,872
TOTAL ASSETS	5,888,562	6,815,939
CURRENT LIABILITIES:
Current maturities of notes payable	41,330	0
Accounts payable and accrued liabilities	1,195,418	1,162,098
Derivative liability	2,840,557	3,359,363
Capital lease obligations	431	1,694
Total current liabilities	4,077,736	4,523,155
LONG-TERM LIABILITIES:
Convertible debt	3,796,781	0
Notes payable, less current maturities	408,670	450,000
Deferred rent	145,993	143,234
Total long-term liabilities	4,351,444	593,234
TOTAL LIABILITIES	8,429,180	5,116,389
COMMITMENTS AND CONTINGENCIES (Note 9)
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of June 30, 2014 and December 31, 2013	0	0
Common stock, $0.00001 par value; 20,000,000 shares authorized; 2,869,739 shares issued and outstanding at June 30, 2014 and December 31, 2013	29	29
Additional paid-in capital	53,548,170	52,759,089
Deficit accumulated	(56,088,817)	(51,059,568)
Total stockholders' equity (deficit)	(2,540,618)	1,699,550
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 5,888,562	$ 6,815,939

RESTRUCTURING COSTS (Details Textual) (USD $)	3 Months Ended		6 Months Ended
RESTRUCTURING COSTS (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Restructuring Cost and Reserve [Line Items]
Payment Of Lump Sum Amount Related To Employment Agreement			$ 160,000
Restructuring Costs, Total	$ 204,934	$ 0	$ 221,815	$ 0

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	6 Months Ended
RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Related Party Transaction [Line Items]
Amount Invoiced Under Clinical Trial Agreements	$ 334,000
Payment Towards Clinical Trial Agreements	264,000
Related Party Transaction, Amounts of Transaction		$ 62,500

FAIR VALUE (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Liabilities:
Warrants	$ 2,840,557	$ 3,359,363
February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	2,838,000	3,355,000
Legacy Warrants [Member]
Liabilities:
Warrants	2,557	4,363
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 1 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 1 [Member] \| Legacy Warrants [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrants	2,557	4,363
Fair Value, Inputs, Level 2 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	0	0
Fair Value, Inputs, Level 2 [Member] \| Legacy Warrants [Member]
Liabilities:
Warrants	2,557	4,363
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrants	2,838,000	3,355,000
Fair Value, Inputs, Level 3 [Member] \| February 2013 Public Offering Warrants [Member]
Liabilities:
Warrants	2,838,000	3,355,000
Fair Value, Inputs, Level 3 [Member] \| Legacy Warrants [Member]
Liabilities:
Warrants	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	7,000	7,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	2,869,739	2,869,739
Common stock, shares outstanding	2,869,739	2,869,739

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2014	Aug. 01, 2014
Document Information [Line Items]
Entity Registrant Name	Cellectar Biosciences, Inc.
Entity Central Index Key	0001279704
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	CLRB
Entity Common Stock, Shares Outstanding		2,869,739
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2014

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
COSTS AND EXPENSES:
Research and development	$ 1,380,798	$ 1,648,838	$ 3,096,105	$ 3,239,450
General and administrative	959,885	1,073,749	2,046,921	2,195,452
Restructuring costs	204,934	0	221,815	0
Total costs and expenses	2,545,617	2,722,587	5,364,841	5,434,902
LOSS FROM OPERATIONS	(2,545,617)	(2,722,587)	(5,364,841)	(5,434,902)
OTHER INCOME (EXPENSE):
Gain on revaluation of derivative warrants	573,751	660,341	518,806	666,384
Loss on issuance of derivative warrants	0	0	0	(744,957)
Interest expense, net	(113,970)	(2,216)	(183,214)	(4,866)
Total other income (expense), net	459,781	658,125	335,592	(83,439)
NET LOSS	$ (2,085,836)	$ (2,064,462)	$ (5,029,249)	$ (5,518,341)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.73)	$ (0.72)	$ (1.75)	$ (2.03)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE (in shares)	2,869,739	2,869,739	2,869,739	2,717,966

NET LOSS PER SHARE (Details)	6 Months Ended
NET LOSS PER SHARE (Details)	Jun. 30, 2014	Jun. 30, 2013
Convertible Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	400,000	0
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,964,085	1,839,123
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	619,663	314,582

CONVERTIBLE DEBT (Details Textual) (USD $)	0 Months Ended	6 Months Ended		12 Months Ended
CONVERTIBLE DEBT (Details Textual) (USD $)	Feb. 05, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Feb. 20, 2014
Debt Conversion [Line Items]
Convertible Debt	$ 4,000,000
Convertible Debentures And Warrants To Purchase Common Stock	400,000
Payment For Convertible Debentures	4,000,000
Securities Purchase Agreement, Initiation Date	Feb. 05, 2014
Debt Instrument, Maturity Date	Feb. 06, 2016
Debt Instrument, Convertible, Conversion Price	$ 10.00
Debt Conversion, Converted Instrument, Shares Issued	400,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Gross Proceeds From Sale Of Securities	2,000,000
Debt Instrument, Interest Rate, Effective Percentage	12.00%
Payment On Default On Borrowings	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 20.00				$ 10.00
Warrants Expiration Date	Feb. 06, 2019
Default Value Of Borrowings	150,000
Debt Conversion Converted Instrument Value Warrants Issued	254,000	254,024	0
Debt Conversion, Converted Instrument, Amount		3,746,000
Non-Cash Interest Expense Related To Discount On Convertible Debt		50,805	0
Deposit Liabilities, Accrued Interest		128,000
Fair Value Assumptions, Risk Free Interest Rate		1.76%		0.92%
Fair Value Assumptions, Expected Volatility Rate		108.00%		109.00%
Fair Value Assumptions, Expected Term		6 years		6 years
Debt Instrument, Unamortized Discount		254,000
February 2014 PIPE Warrants [Member]
Debt Conversion [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		1.52%
Fair Value Assumptions, Expected Volatility Rate		110.00%
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value Assumptions, Expected Term		5 years
Subsequent Event [Member]
Debt Conversion [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Gross Proceeds From Sale Of Securities	$ 8,000,000